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Prognosis research summarises, explains and predicts future outcomes in patients with a 
particular condition. This thesis investigates the application and development of evidence 
synthesis methods for prognosis research, with particular attention given to improving 
individualised predictions from prognostic models developed and/or validated using meta-
analysis techniques.  
A review of existing prognostic models for recurrence of venous thromboembolism 
highlighted several methodological and reporting issues. This motivated the development of 
a new model to address previous shortcomings, in particular by explicitly modelling and 
reporting the baseline hazard to enable individualised risk predictions over time. The new 
model was developed using individual participant data from several studies, using a novel 
internal-external cross-validation approach. This highlighted the potential for between-study 
heterogeneity in model performance, and motivated the investigation of recalibration 
methods to substantially improve consistency in model performance across populations. 
Finally, a new multiple imputation method was developed to investigate the impact of missing 
threshold information in meta-analysis of prognostic test accuracy. Computer code was 
developed to implement the method, and applied examples indicated missing thresholds 
could have a potentially large impact on conclusions. A simulation study indicated that the 




Firstly, I would like to say a heartfelt thank you to my main supervisor, Richard Riley. I won 
the lottery with you as my supervisor. You have always supported me, pushed me, and 
looked out for me, and I thank you so much for that. You are a great teacher and I have 
learned so much from you, and I look forward to learning much more and working together 
in the future. I cannot thank you enough for everything you have done, and for always 
having my back when the sandwiches have dodgy fillings.   
I would also like to thank David Moore; thank you for your invaluable support without which 
I would never have been able to complete a HTA report, and thank you for teaching me so 
much about systematic reviewing, and the many other things you know so much about. 
Many thanks also go to the support of Jon Deeks; thank you for your expert knowledge and 
guidance through this work, you have an amazing ability to hone in on the crux of problems, 
which is an invaluable skill. Thank you for looking out for me when my time at Birmingham 
came to an end. And thank you for breaking my computer programs. 
Thank you to my friends for supporting me in my quest to become a “Dr of Numbers”, as you 
say. Most importantly thank you to Kym and Dani, I am lucky to get to work with such a 
great team of like-minded people, thank you for all your help and support in this and other 
work. Also thank you for checking on me after conference dinners. 
To my mum, dad, sister and grandparents, thank you for always supporting me even when it 
makes no sense to you.  Mum and Dad, thank you for always believing in me and pushing me 
to do the best I can, thank you for always being there for me, listening and giving me your 
sound advice. I wouldn’t have made it here without you. Pen, thank you for always making 
me laugh, and grandma thank you for always keeping the cupboard stocked with Jaffa cakes. 
Finally, I would like to thank Emma. Emma, without you I would never have believed that I 
could do a PhD, or that I would actually enjoy doing one. Thank you so much, I really 
wouldn’t be here without you. You are my rock, you have always been my biggest fan, and I 
couldn’t have completed this without your selfless support. Thank you for helping me get 
through this, for always humouring me even when I'm being stupid, for always being there 
to talk to when the simulations broken, and for your patience and understanding. You are 
amazing, and you inspire me every day. 
CONTENTS 
 
CHAPTER 1: INTRODUCTION ................................................................................................. 1 
1.1 Overview of the thesis ................................................................................................. 1 
1.2 Prognosis research structure ....................................................................................... 4 
1.3 Prognostic factor research ........................................................................................... 5 
1.4 Prognostic model research .......................................................................................... 7 
1.5 Statistical methods for prognosis and prediction models ........................................... 9 
1.5.1 Logistic regression .............................................................................................. 10 
1.5.2 Cox regression .................................................................................................... 13 
1.5.3 Flexible parametric models ................................................................................ 15 
1.6 Phases of prognostic model research ........................................................................ 18 
1.6.1 Model development ........................................................................................... 18 
1.6.2 Internal validation .............................................................................................. 21 
1.6.3 External validation .............................................................................................. 25 
1.6.4 Model performance statistics ............................................................................. 26 
1.6.5 Impact studies .................................................................................................... 30 
1.7 The TRIPOD statement ............................................................................................... 32 
1.8 Systematic reviews and meta-analysis of prognosis and prediction studies ............ 33 
1.8.1 Systematic reviews ............................................................................................. 33 
1.8.2 Traditional meta-analysis ................................................................................... 34 
1.8.3 Individual participant data (IPD) meta-analysis ................................................. 38 
1.9 Current challenges facing prediction model research ............................................... 40 
1.10 Aims and outline of the thesis................................................................................ 43 
CHAPTER 2: A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS FOR RECURRENT VENOUS 
THROMBOEMBOLISM (VTE) POST TREATMENT OF FIRST UNPROVOKED VTE ........................ 47 
2.1 Introduction ............................................................................................................... 47 
2.1.1 Aims of this chapter ............................................................................................ 49 
2.2 Methods ..................................................................................................................... 50 
2.2.1 Search strategy to identify relevant studies ....................................................... 50 
2.2.2 Inclusion criteria ................................................................................................. 52 
2.2.3 Study selection ................................................................................................... 53 
2.2.4 Data extraction ................................................................................................... 54 
2.2.5 Assessment of study quality (risk of bias) .......................................................... 55 
2.2.6 Summarising identified evidence ....................................................................... 57 
2.2.7 Relevant articles identified outside of search dates .......................................... 58 
2.3 Results ....................................................................................................................... 58 
2.3.1 Quantity of research available ........................................................................... 58 
2.3.2 Quality assessment and critical appraisal .......................................................... 64 
2.3.3 Update to the Vienna prediction model ............................................................ 76 
2.3.4 Relevant articles identified outside of review search dates .............................. 77 
2.3.5 Quality assessment and risk of bias summary of HERDOO2, Vienna and DASH 
models 80 
2.4 Discussion .................................................................................................................. 82 
CHAPTER 3: DEVELOPMENT OF A PROGNOSTIC MODEL USING META-ANALYSIS 
METHODS: PREDICTING RISK OF RECURRENT VTE IN THE UNPROVOKED POPULATION ....... 87 
3.1 Introduction ............................................................................................................... 87 
3.1.1 Background ........................................................................................................ 87 
3.1.2 Aims of this chapter ........................................................................................... 90 
3.2 Methods .................................................................................................................... 90 
3.2.1 Identifying, obtaining & cleaning IPD ................................................................ 91 
3.2.2 Population at baseline and outcome of interest ............................................... 92 
3.2.3 Available candidate predictors .......................................................................... 93 
3.2.4 Issue of different start-points and the need for two models ............................ 94 
3.2.5 Univariable (unadjusted) summary of candidate predictors ............................. 95 
3.2.6 Development of prognostic model .................................................................... 95 
3.2.7 Internal-External Cross-Validation (IECV) ........................................................ 101 
3.2.8 Comparison to existing prognostic models...................................................... 105 
3.3 Results ..................................................................................................................... 105 
3.3.1 Exploratory analysis of RVTE database ............................................................ 105 
3.3.2 Pre D-dimer model ........................................................................................... 106 
3.3.3 Post D-dimer model: Development and validation ......................................... 107 
3.3.4 Final model: Post D-dimer model .................................................................... 122 
3.3.5 Using the post D-dimer model to make predictions for new individuals: a 
detailed illustration of the model in practice ................................................................ 128 
3.4 Discussion ................................................................................................................ 133 
CHAPTER 4: INDIVIDUAL PARTICIPANT DATA META-ANALYSIS FOR EXTERNAL VALIDATION 
AND RECALIBRATION OF A FLEXIBLE PARAMETRIC PROGNOSTIC MODEL ............................ 147 
4.1 Introduction ............................................................................................................. 147 
4.2 Motivating example ................................................................................................. 149 
4.2.1 Breast cancer dataset ....................................................................................... 149 
4.3 Methods for examining performance of an FP model using IPD meta-analysis ..... 152 
4.3.1 Flexible parametric models .............................................................................. 152 
4.3.2 Performance statistics ...................................................................................... 154 
4.3.3 External validation in multiple studies with meta-analysis of performance ... 156 
4.3.4 Recalibration strategies in a single validation study ........................................ 157 
4.3.5 IPD meta-analysis to compare recalibration strategies ................................... 160 
4.4 Results: Application to the Breast Cancer Example ................................................. 161 
4.4.1 Visual comparison of the baseline hazard rate in each study .......................... 161 
4.4.2 Overview of the model development .............................................................. 162 
4.4.3 IPD meta-analysis of external validation performance of original model ....... 167 
4.4.4 IPD meta-analysis of external validation performance after recalibration ..... 171 
4.5 Discussion ................................................................................................................ 180 
CHAPTER 5: DEVELOPMENT OF A MULTIPLE IMPUTATION METHOD FOR HANDLING 
MISSING THRESHOLD RESULTS IN TEST ACCURACY META-ANALYSIS ................................... 185 
5.1 Introduction ............................................................................................................. 185 
5.2 Methods for single and multiple imputation of missing thresholds ....................... 190 
5.2.1 Single Imputation (SI) of missing threshold results .......................................... 190 
5.2.2 Multiple imputation of missing threshold results based on discrete 
combinations (MIDC) ...................................................................................................... 193 
5.2.3 Potential advantages of the MIDC method over the SI method ...................... 197 
5.3 Software to implement the methods ...................................................................... 198 
5.3.1 MIDC Stata module ........................................................................................... 199 
5.4 Applied examples ..................................................................................................... 203 
5.4.1 Protein/Creatinine ratio (PCR) for the detection of significant proteinuria in 
patients with suspected pre-eclampsia .......................................................................... 203 
5.4.2 Apgar score to assess the health of newborn children .................................... 212 
5.5 Discussion ................................................................................................................ 216 
5.5.1 Motivation for subsequent chapter ................................................................. 219 
CHAPTER 6: A SIMULATION STUDY TO EVALUATE THE PERFORMANCE OF IMPUTATION 
METHODS FOR MISSING THRESHOLD RESULTS IN TEST ACCURACY META-ANALYSIS .......... 221 
6.1 Introduction ............................................................................................................. 221 
6.2 Simulation study methods ...................................................................................... 223 
6.2.1 Step 1: Define the scenario .............................................................................. 223 
6.2.2 Step 2: Generate the number of participants per study ................................. 224 
6.2.3 Step 3: Generate the true disease status for each patient in each study ....... 224 
6.2.4 Step 4: Generate the true sensitivity and specificity values for each threshold in 
each study ...................................................................................................................... 225 
6.2.5 Step 5: Generate the observed number of TP, TN, FP and FN at each threshold
 229 
6.2.6 Step 6: Create missing results for some thresholds ........................................ 230 
6.2.7 Step 7: Apply meta-analysis to each simulated dataset using NI, SI or MIDC 
methods ......................................................................................................................... 230 
6.3 Results ..................................................................................................................... 232 
6.3.1 Base case settings (Scenarios 1 to 3) ............................................................... 232 
6.3.2 Greater chance of missingness (Scenarios 4 to 6) ........................................... 237 
6.3.3 Missing not at random (Scenarios 7 to 9) ........................................................ 238 
6.3.4 Unequal threshold spacing (Scenarios 10 to 12) ............................................. 240 
6.3.5 Extreme unequal threshold spacing (Scenarios 13 to 15) ............................... 242 
6.3.6 Extensions ........................................................................................................ 244 
6.3.7 Summary of simulation findings ...................................................................... 246 
6.4 Discussion ................................................................................................................ 247 
CHAPTER 7: DISCUSSION .................................................................................................. 253 
7.1 Overview of the thesis ............................................................................................. 253 
7.1.1 Summary of the chapters ................................................................................. 254 
7.2 Publications arising from this thesis ........................................................................ 255 
7.3 Contribution to applied and methodological research ........................................... 257 
7.4 Further research ...................................................................................................... 263 
7.5 Limitations of IPD meta-analysis ............................................................................. 267 
7.6 Opportunities with Big data .................................................................................... 269 
7.7 Conclusions .............................................................................................................. 271 
APPENDIX ................................................................................................................................ 273 
APPENDIX A: Chapter 2 Appendices ................................................................................... 273 
APPENDIX B: Chapter 3 Appendices ................................................................................... 275 
APPENDIX B1: Summary characteristics of the RVTE database ..................................... 275 
APPENDIX B2: Exploratory analysis figures .................................................................... 280 
APPENDIX B3: Sensitivity analysis results: Post D-dimer model .................................... 295 
APPENDIX B4: Model checking results: Post D-dimer model ......................................... 300 
APPENDIX B5: Pre D-dimer model validation performance ........................................... 311 
APPENDIX B6: Final pre D-dimer model ......................................................................... 317 
APPENDIX B7: Sensitivity analysis on D-dimer assays .................................................... 322 
APPENDIX C: Chapter 4 Appendices ................................................................................... 325 
APPENDIX C1: Validation performance .......................................................................... 325 
APPENDIX C2: Stata code ............................................................................................... 333 
APPENDIX D: Chapter 5 Appendices ................................................................................... 336 
APPENDIX E: Chapter 6 Appendices ................................................................................... 355 
APPENDIX E1: Base case scenarios ................................................................................. 355 
APPENDIX E2: Missing not at random ............................................................................ 361 
APPENDIX E3: Unequal threshold spacing ..................................................................... 367 
APPENDIX E4: Extreme threshold spacing ...................................................................... 369 
APPENDIX E5: Extensions ............................................................................................... 371 
REFERENCE LIST ...................................................................................................................... 383 
 
 
LIST OF FIGURES 
 
Figure 1.1 - Overall prognosis for recurrent VTE following initial provoked and unprovoked VTE ........ 2 
Figure 1.2 - Illustration of estrogen receptor (ER) status as a treatment effect modifier for tamoxifen 
in breast cancer (3).................................................................................................................................. 7 
Figure 1.3 - Example of the probability of event from the logistic model (logit(p) = LP (as in Equation 
1.1)) against the linear predictor (top panel) and the probability of an event transformed using the 
logistic function (p = 1/1+exp(-LP)) against the linear predictor (bottom panel). ................................ 12 
Figure 1.4 - Examples of published prediction models using logistic and Cox regression model 
structure (39, 40)................................................................................................................................... 13 
Figure 1.5 - Examples of calibration plots for logistic prediction models (71). Where the dashed line 
represents perfect calibration of E=O, and a=CITL and b=calibration slope. ........................................ 30 
Figure 2.1 - PRISMA flow diagram showing the quantity of research available. .................................. 60 
Figure 2.2 - Linear predictors of prognostic models included within the review ................................. 63 
Figure 2.3 - Events per predictor (EPP) for included studies, based on total sample size and number of 
predictors. NB: lines represent number of events required to maintain EPP=x for given number of 
predictors. ............................................................................................................................................. 70 
Figure 2.4 - Final model sample size compared to total & selection sample size. Final model sample 
size=total sample minus patients with missing information in any predictor included in the final 
model; Predictor selection sample size=total sample size minus patients with missing predictor 
information in any predictor considered for inclusion in the model using a selection procedure. ..... 71 
Figure 3.1 – Timeline of patient therapy and start points for pre and post D-dimer use ..................... 94 
Figure 3.2 - Schematic of Internal-External Cross-Validation (IECV) approach................................... 102 
Figure 3.3 - Comparison of baseline spline complexity with differing numbers of internal knots 
(Example shown for development dataset excluding the Palareti 2006 trial).................................... 113 
Figure 3.4 - Baseline hazard within each trial for the post D-dimer scenario (null model) ................ 115 
Figure 3.5 - Baseline hazard within each trial with 95% confidence intervals for the post D-dimer 
scenario (null model) ........................................................................................................................... 115 
Figure 3.6 - Random-effects meta-analysis of discrimination performance as measured by the C-
statistics obtained, for each cycle of the IECV approach for the post D-dimer model ....................... 119 
Figure 3.7 - Observed vs. Expected risk within the validation trial for each cycle of the IECV (The post 
D-dimer model) ................................................................................................................................... 120 
Figure 3.8 - Random-effects meta-analysis of calibration performance (at 1 year post therapy) within 
validation trials across IECV cycles (The post D-dimer model) ............................................................ 121 
Figure 3.9 - Random-effects meta-analysis of calibration performance (at 2 years post therapy) within 
validation trials across IECV cycles (The post D-dimer model) ............................................................ 121 
Figure 3.10 – Apparent calibration of the post D-dimer model fit to all trial data ............................. 125 
Figure 3.11 - Probability of recurrence across the risk spectrum (The post D-dimer model) ............. 126 
Figure 3.12 - Average baseline (recurrence free) survival function for the post D-dimer model ....... 129 
Figure 3.13 - Predicted recurrence free survival for three example patients using the post D-dimer 
model ................................................................................................................................................... 132 
Figure 3.14 - Predicted probability of recurrence for three example patients using the post D-dimer 
model ................................................................................................................................................... 132 
Figure 4.1 - Baseline hazard function in the Rotterdam study estimated using various numbers of 
knots for the baseline spline in an FP model. The baseline hazard estimated using a generalised 
gamma distribution is also included. ................................................................................................... 154 
Figure 4.2 - Baseline hazard functions in all 8 studies in the IPD dataset. .......................................... 162 
Figure 4.3 - Baseline survival function for developed model (solid line) and predicted survival 
probability for example individual described in equation 4.11 (dashed line). .................................... 165 
Figure 4.4 - Calibration plot showing apparent performance of the developed model in the 
Rotterdam derivation data. Dashed lines = KM curve. Solid lines = model predictions. .................... 167 
Figure 4.5 - Calibration plot showing performance of the developed model in the seven validation 
studies. Dashed lines = KM curve of observed survival. Solid lines = model predictions. .................. 169 
Figure 4.6 - Random-effects meta-analysis of tumour size regression coefficient [ln(HR)] from each 
validation study. .................................................................................................................................. 172 
Figure 4.7 - Calibration plot showing performance of the model after recalibration via method 1 
compared to the developed model in the seven validation studies. Long dashed lines = KM curve. 
Solid lines = method 1 model predictions. Short dashed lines = developed model predictions. ....... 177 
Figure 4.8 - Random effects meta-analysis of calibration performance (E/O at 3 years post-surgery) of 
the model in all validation studies split by recalibration method. Top panel shows performance of the 
original model in the validation studies. ............................................................................................. 179 
Figure 5.1 - Illustrative ROC curve with missing threshold results bounded within the rectangle ..... 194 
Figure 5.2 - Schematic of the multiple imputation using discrete combinations (MIDC) method ..... 197 
Figure 5.3 - Summary estimates of sensitivity and specificity in ROC space for all methods. NB: Arrows 
represent change from NI summary estimates ................................................................................... 210 
Figure 5.4 – Standard errors of sensitivity and specificity for the PCR dataset using NI and MIDC 
methods .............................................................................................................................................. 211 
Figure 5.5 - Summary estimates of sensitivity and specificity in ROC space for all methods, for the 
Apgar example. NB: Arrows represent change from NI summary estimates ..................................... 216 
Figure 6.1 - Mean summary ROC curve used for the simulations based on Equation 6.1, illustrating 
the different threshold spacing as defined by the scenarios in Table 6.1 .......................................... 226 
Figure 6.2 - Illustration of the linearity assumption between logit-sensitivity and threshold as defined 
by Equation 6.1, with threshold spacing defined by the scenarios in Table 6.1 ................................. 227 
Figure 6.3 – ROC curves compared to true estimates (base case scenarios 1-3) ............................... 233 
Figure 6.4 – Coverage of 95% confidence intervals (base case scenarios 1-3). Dashed line indicates 
ideal 95% coverage. ............................................................................................................................ 235 
Figure 6.5 – Mean estimate of  for summary sensitivity for scenario 2 and 3. Dashed line indicates 
the true simulated  for scenario 2 (=0.25) and scenario 3 (=0.5). ................................................ 236 
Figure 6.6 – Mean Standard errors (base case scenarios 2-3) ............................................................ 237 
Figure 6.7 - Mean summary ROC curves for all methods. Scenarios 7 to 9. ....................................... 239 
Figure 6.8 - Coverage of 95% confidence intervals for MNAR scenario 9. Dashed line indicates ideal 
95% coverage. ..................................................................................................................................... 240 
Figure 6.9 - Mean summary ROC curves all methods. Unequal threshold spacing scenario 12 ......... 241 
Figure 6.10 - Coverage of 95% confidence intervals for unequal threshold spacing scenario 12. 
Dashed line indicates ideal 95% coverage. ......................................................................................... 241 
Figure 6.11 - Mean summary ROC curves all methods. Unequal threshold spacing scenario 15 ....... 243 
Figure 6.12 - Coverage of 95% confidence intervals for unequal threshold spacing scenario 15. 
Dashed line indicates ideal 95% coverage. ......................................................................................... 243 
Figure 6.13 - Coverage of 95% confidence intervals for MNAR scenario 9. Comparing simulations 
results at 10% prevalence (top figures) and 50% prevalence (bottom figures). Dashed line indicates 
ideal 95% coverage. ............................................................................................................................ 245 
Figure 7.1 - Key research contributions of the thesis ......................................................................... 262 
Figure 0.1 - Box plot of patient age (years) ......................................................................................... 280 
Figure 0.2 - Histogram & normal plot for patient age (years) ............................................................. 280 
Figure 0.3 - Histogram & normal plot for patient age squared (years-squared) ................................ 281 
Figure 0.4 - Box plot for patient BMI ................................................................................................... 281 
Figure 0.5 - Histogram & normal plot for patient BMI ........................................................................ 282 
Figure 0.6 - Histogram & normal plot for patient BMI (BMI > 45 removed) ....................................... 282 
Figure 0.7 - Box plot for patient D-dimer score (ng/mL) ..................................................................... 283 
Figure 0.8 - Histogram & normal plot for patient D-dimer score (ng/mL) .......................................... 283 
Figure 0.9 - Histogram & normal plot for patient Log D-dimer score (ng/mL) [Outlier - D-dimer=20]
 ............................................................................................................................................................. 284 
Figure 0.10 - Box plot for patient lag time (days) ................................................................................ 284 
Figure 0.11 - Histogram & normal plot for patient lag time (days) ..................................................... 285 
Figure 0.12 – Histogram, box plot & normal plot for patient Log lag time (days) .............................. 285 
Figure 0.13 - Box plot for patients treatment duration (months) ....................................................... 286 
Figure 0.14 - Histogram & normal plot for patients treatment duration (months) ............................ 286 
Figure 0.15 - Box plot for patients Log treatment duration (months) ................................................ 287 
Figure 0.16 - Histogram & normal plot for patients Log treatment duration (months) [treatment 
durations > 1000 months removed] .................................................................................................... 288 
Figure 0.17 - Scatter plots of continuous candidate factors ............................................................... 288 
Figure 0.18 - Box plots for patient age (years) by gender ................................................................... 289 
Figure 0.19 - Box plots of patient age (years) by site of index event .................................................. 289 
Figure 0.20 - Box plots of patients BMI by gender .............................................................................. 290 
Figure 0.21 - Box plots of patients BMI by site of index event ............................................................ 290 
Figure 0.22 - Box plots of patients Log D-dimer score (ng/mL) by gender.......................................... 291 
Figure 0.23 - Box plots of patients Log D-dimer score (ng/mL) by site of index event ....................... 291 
Figure 0.24 - Box plots of patient Log lag time (days) by gender ........................................................ 292 
Figure 0.25 - Box plots of patient Log lag time (days) by site of index event...................................... 292 
Figure 0.26 - Box plots of patient Log treatment duration (months) by gender ................................. 293 
Figure 0.27 - Box plots of patient Log treatment duration (months) by site of index event .............. 293 
Figure 0.28 - Box plots of patient age x log D-dimer interaction by gender ....................................... 294 
Figure 0.29 - Box plots of patient age x log D-dimer interaction by site of index event ..................... 294 
Figure 0.30 - Comparison of observed and imputed data for log D-dimer (The post D-dimer model)
 ............................................................................................................................................................. 299 
Figure 0.31 - Comparison of observed and imputed data for log lag time (The post D-dimer model)
 ............................................................................................................................................................. 299 
Figure 0.32 - Scaled Schoenfeld residuals vs. Log time from cessation of therapy for log D-dimer ... 301 
Figure 0.33 - Scaled Schoenfeld residuals vs. Log time from cessation of therapy for log lag time ... 302 
Figure 0.34 - Scatter plot of martingale residuals against log D-dimer (The post D-dimer model) .... 305 
Figure 0.35 - Scatter plot of martingale residuals against log lag time (The post D-dimer model) .... 305 
Figure 0.36 - Scatter plot of deviance residuals vs. patient ID (The post D-dimer model) ................. 307 
Figure 0.37 - Scatter plot of deviance residuals vs. years from cessation of therapy (The post D-dimer 
model) ................................................................................................................................................. 307 
Figure 0.38 - Scatter plot of Delta-Beta for log D-dimer vs. years from cessation of therapy............ 308 
Figure 0.39 - Scatter plot of Delta-Beta for log lag time vs. years from cessation of therapy ............ 309 
Figure 0.40 - Random-effects meta-analysis of C-statistic estimates obtained from each external 
validation of the Pre D-dimer models from the IECV cycle ................................................................. 312 
Figure 0.41 - Observed vs. Expected recurrence probabilities over time, obtained from each external 
validation of the Pre D-dimer models from the IECV cycle ................................................................. 313 
Figure 0.42 - Expected minus Observed probabilities with a recurrence for each validation trial for the 
pre D-dimer model .............................................................................................................................. 314 
Figure 0.43 - Random-effects meta-analysis of calibration performance (at 1 year post therapy) 
estimates from each external validation trial in the IECV cycles for the pre D-dimer model ............ 316 
Figure 0.44 - Random-effects meta-analysis of calibration performance (at 2 years post therapy) 
estimates from each external validation trial in the IECV cycles for the pre D-dimer model ............ 316 
Figure 0.45 - Average baseline (recurrence free) survival function (S0(t)) for the pre D-dimer model
 ............................................................................................................................................................. 319 
Figure 0.46 - Calibration of the pre D-dimer model fit to all trial data ............................................... 320 
Figure 0.47 - Probability of recurrence across the risk spectrum (The pre D-dimer model) .............. 320 
Figure 0.48 - Predicted recurrence free survival for the 25th percentile of D-dimer values & 10% 
change in D-dimer values .................................................................................................................... 323 
Figure 0.49 - Predicted recurrence free survival for the 50th percentile of D-dimer values & 10% 
change in D-dimer values .................................................................................................................... 323 
Figure 0.50 - Predicted recurrence free survival for the 75th percentile of D-dimer values & 10% 
change in D-dimer values .................................................................................................................... 324 
Figure 0.51 - Random effects meta-analysis of discrimination performance (C-statistics) of the model 
in all validation studies split by recalibration method. Top panel shows performance of the original 
model in the validation studies. .......................................................................................................... 331 
Figure 0.52 - Random effects meta-analysis of calibration performance (E-O at 3 years post-surgery) 
of the model in all validation studies split by recalibration method. Top panel shows performance of 
the original model in the validation studies........................................................................................ 332 
 
 
LIST OF TABLES 
 
Table 1.1 – Predicted cumulative recurrence risks for groups of patients as defined by the DASH score 
(37). ......................................................................................................................................................... 9 
Table 2.1 - Summary patient characteristics of included model studies .............................................. 65 
Table 2.2 - Study characteristics ........................................................................................................... 66 
Table 2.3 - Study inclusion/exclusion criteria ....................................................................................... 66 
Table 2.4 - Unprovoked VTE definition across studies .......................................................................... 67 
Table 2.5 – Predictors included in final model ...................................................................................... 68 
Table 2.6 - Internal validation performance statistics .......................................................................... 76 
Table 2.7 - Quality considerations for included studies ........................................................................ 82 
Table 3.1 - Summary of baseline characteristics and candidate predictors for the complete-case data 
used for development of the post D-dimer model ............................................................................. 109 
Table 3.2 - Univariable Cox regression analysis of the candidate predictors for the post D-dimer 
model .................................................................................................................................................. 111 
Table 3.3 - Comparison of degrees of freedom for baseline spline complexity across derivation 
datasets for the post D-dimer scenario .............................................................................................. 113 
Table 3.4 - Model regression coefficients and selected predictors for each IECV cycle for the post D-
dimer model (Hazard ratios (Lower 95% CI, Upper 95% CI)) .............................................................. 117 
Table 3.5 - Summary statistics for discrimination and calibration of the post D-dimer model in each 
cycle of the IECV approach .................................................................................................................. 119 
Table 3.6 - Specification and estimates of the final post D-dimer model fitted to all trial data ........ 124 
Table 3.7 - Baseline (recurrence free) survival at particular time points to combine with patient 
specific predictor values for individual risk prediction (Post D-dimer model) .................................... 129 
Table 3.8 - Model parameters for three example patients and recurrence free survival/recurrence risk 
predictions using post D-dimer model ................................................................................................ 130 
Table 3.9 - Different D-dimer assays used within the RVTE database ................................................ 136 
Table 4.1 - Summary statistics for Look et al. dataset. NB: RFS – Recurrence free survival; * Median; # 
Number and percentage. .................................................................................................................... 151 
Table 4.2 - Transformation of model performance statistics required to approximate between-study 
normality ............................................................................................................................................. 156 
Table 4.3 - Recalibration methods to be investigated ........................................................................ 158 
Table 4.4 - Predictor effect estimates for the developed model ........................................................ 164 
Table 4.5 - Apparent discrimination performance of the developed model ...................................... 166 
Table 4.6 - Discrimination performance of the developed model when applied to the validation 
studies. CI – Confidence interval, PI – Prediction interval................................................................... 168 
Table 4.7 - Calibration performance (E-O & E/O) statistics for the developed model fitted in the 
validation studies and meta-analysis results (Null value = 0 & 1 respectively)................................... 170 
Table 4.8 - Comparison of random effects meta-analysis results for each recalibration method 
(including both discrimination and calibration performance). CI – Confidence interval, PI – Prediction 
interval. ................................................................................................................................................ 174 
Table 5.1 – Example data for a single study reporting a continuous test measured at a partial set of 
multiple thresholds of interest for meta-analysis ............................................................................... 194 
Table 5.2 – First and last five of the 56 possible combinations of the imputed TP values for thresholds 
2, 3 and 4 in Table 5.1.......................................................................................................................... 195 
Table 5.3 – Probability of each TP value being imputed for missing threshold 2, which is bounded 
between 35 from threshold 1 and 30 from threshold 5 ..................................................................... 198 
Table 5.4 - PCR data at each threshold for the 13 studies identified in Morris et al. ......................... 204 
Table 5.5 - PCR example sensitivity results for all methods, including the summary sensitivity, its 
standard error and the number of studies reporting the threshold ................................................... 207 
Table 5.6 - PCR example specificity results for all methods, including the summary specificity, its 
standard error and the number of studies reporting the threshold ................................................... 208 
Table 5.7 - Apgar data for all thresholds for the 11 studies identified in Malin et al. (242). .............. 212 
Table 5.8 - Summary results for the Apgar example, for summary sensitivity and specificity using NI, 
SI and MIDC methods. ......................................................................................................................... 215 
Table 6.1 - Simulation scenarios including base case and sensitivity scenarios.................................. 224 
Table 0.1 - Summary of baseline characteristics and candidate predictors ........................................ 276 
Table 0.2 - Inclusion and exclusion criteria of trials within the RVTE database (15)........................... 277 
Table 0.3 - Percentage of missing data for candidate predictors........................................................ 278 
Table 0.4 - Correlation coefficients between continuous candidate predictors ................................. 279 
Table 0.5 - Model specification including an Age x D-dimer interaction effect (The post D-dimer 
model).................................................................................................................................................. 295 
Table 0.6 - Model specification including an D-dimer x Lag time interaction effect (The post D-dimer 
model).................................................................................................................................................. 296 
Table 0.7 – First cycle of stepwise forward selection of time-dependent effects (The post D-dimer 
model) ................................................................................................................................................. 297 
Table 0.8 - The post D-dimer model specification following imputation of missing variable data. P=P-
value. ................................................................................................................................................... 298 
Table 0.9 - Monte Carlo error acceptability for analysis based on 50 imputed datasets ................... 300 
Table 0.10 - Summary statistics for discrimination and calibration of the pre D-dimer model ......... 315 
Table 0.11 - Final specification and estimates for the pre D-dimer model after fitted to all trial data, 
with a random effect on the baseline hazard ..................................................................................... 318 
Table 0.12 - Baseline (recurrence free) survival at particular time points to combine with patient 
specific predictor values for individual risk prediction (Pre D-dimer model) ..................................... 318 
Table 0.13 - Values of log D-dimer used in post D-dimer model to assess 10% change in D-dimer value
 ............................................................................................................................................................. 322 
Table 0.14 - Results for summary sensitivity for scenario 1 ............................................................... 355 
Table 0.15 - Results for summary specificity for scenario 1................................................................ 356 
Table 0.16 - Results for summary sensitivity for scenario 2 ............................................................... 357 
Table 0.17 - Results for summary specificity for scenario 2................................................................ 358 
Table 0.18 - Results for summary sensitivity for scenario 3 ............................................................... 359 
Table 0.19 - Results for summary specificity for scenario 3................................................................ 360 
Table 0.20 - Results for summary sensitivity for scenario 7 ............................................................... 361 
Table 0.21 - Results for summary specificity for scenario 7................................................................ 362 
Table 0.22 - Results for summary sensitivity for scenario 8 ............................................................... 363 
Table 0.23 - Results for summary specificity for scenario 8................................................................ 364 
Table 0.24 - Results for summary sensitivity for scenario 9 ............................................................... 365 
Table 0.25 - Results for summary specificity for scenario 9................................................................ 366 
Table 0.26 - Results for summary sensitivity for scenario 12 ............................................................. 367 
Table 0.27 - Results for summary specificity for scenario 12.............................................................. 368 
Table 0.28 - Results for summary sensitivity for scenario 15 ............................................................. 369 
Table 0.29 - Results for summary specificity for scenario 15.............................................................. 370 
Table 0.30 - Results for summary sensitivity - scenario 1 with 5 studies ........................................... 371 
Table 0.31 - Results for summary specificity - scenario 1 with 5 studies ............................................ 372 
Table 0.32 - Results for summary sensitivity - scenario 2 with 5 studies ........................................... 373 
Table 0.33 - Results for summary specificity - scenario 2 with 5 studies ............................................ 374 
Table 0.34 - Results for summary sensitivity - scenario 3 with 5 studies ........................................... 375 
Table 0.35 - Results for summary specificity - scenario 3 with 5 studies ............................................ 376 
Table 0.36 - Results for summary sensitivity - scenario 1 with 10 MIDC imputations ........................ 377 
Table 0.37 - Results for summary specificity - scenario 1 with 10 MIDC imputations ........................ 378 
Table 0.38 - Results for summary sensitivity - scenario 2 with 10 MIDC imputations ........................ 379 
Table 0.39 - Results for summary specificity - scenario 2 with 10 MIDC imputations ........................ 380 
Table 0.40 - Results for summary sensitivity - scenario 3 with 10 MIDC imputations ........................ 381 
Table 0.41 - Results for summary specificity - scenario 3 with 10 MIDC imputations ........................ 382 
 
LIST OF ABBREVIATIONS 
 
AIC  Akaike Information Criteria  
AUC  Area Under the (ROC) Curve 
BIC  Bayes Information Criteria  
CI  Confidence Interval 
EPP  Events Per Predictor 
FP  Flexible Parameteric (Model) 
IECV   Internal-External Cross-Validation  
IPD  Individual Participant Data 
LP  Linear Predictor 
MAR  Missing At Random 
MCAR  Missing Completely At Random 
MFP  Multivariable Fractional Polynomial 
MI   Multiple Imputation 
MICE  Multiple Imputation by Chained Equations 
MIDC  Multiple Imputation using Discrete Combinations 
ML  Maximum Likelihood 
MNAR  Missing Not At Random 
NI   No Imputation  
OAC  Oral Anticoagulants 
REML  Restricted Maximum Likelihood  
RFS  Recurrence-Free Survival 
ROC  Receiver Operating Characteristic (Curve) 
RVTE  Recurrent Venous Thromboembolism (Database) 
SI  Single Imputation  
VTE  Venous Thromboembolism 
1 
 
CHAPTER 1: INTRODUCTION 
 
1.1 Overview of the thesis 
In medicine, prognosis is defined as the prediction of future outcomes in patients with a 
certain baseline health condition (1). Prognosis is of ever increasing importance to clinicians, 
researchers and funders as more and more patients are living with primary conditions and 
many of these with additional comorbidities (2, 3). Prognosis is crucial to inform clinicians of 
the risk of a patient’s future health outcomes, which allows decisions to be made on 
appropriate treatment strategies. Similarly estimating a patient’s prognosis provides useful 
information for the patient on the likely future course of their illness (1). Knowledge of 
prognosis enables selection or stratification of patients for clinical trials, typically using 
prognostic models, which tailor predictions to individuals based on their own set of prognostic 
factors (4-6). Prognostic models and single factors are also important for adjustment for, and 
understanding of case-mix variation in patient outcomes across centres or studies (7).  
Prognosis research is therefore a crucial part of medical research, and the PROGRESS initiative 
suggests a framework of four key areas; overall prognosis (3), prognostic factor research (8), 
multivariable prognostic modelling (9), and stratified medicine research (10). The overall or 
average prognosis of a group of people describes the course of future outcomes in the context 
of current strategies for diagnosis and treatment of a given health condition (3). For example, 
the overall risk of recurrent venous thromboembolism (VTE) in patients with an unprovoked 
initial VTE is much greater than those with a provoked VTE over time (see Figure 1.1); there 
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may be differences in prognosis for individual patients, but on average unprovoked patients 
are at greater risk of recurrence. This motivates clinical research to address this risk, in 
developing better diagnostic strategies, different treatment regimens specific to unprovoked 
patients, or identifying those at highest risk for further care. 
Prognostic modelling and prognostic factor research are popular topics because of their many 
uses, and these areas form the main interest of this thesis (9, 11). Prognostic factors may be 
useful as predictors of treatment response, particularly where the factor is potentially 
modifiable, or may be used to decide on further testing or procedures (8). Prognostic factors 
also form the basis of prognostic models, to allow prediction of an individual’s risk of outcome 
given their values of the included factors (predictors) (9). 
 
Figure 1.1 - Overall prognosis for recurrent VTE following initial provoked and unprovoked VTE 
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The increasing popularity of prognostic factor and model research in medicine has been 
facilitated by the growing trend of data sharing, and availability of large datasets such as 
patient electronic health records (EHR) (12-14). Large datasets of individual participant data 
(IPD) are becoming more easily accessible providing a wealth of information often from 
multiple studies, centres, clinical settings and geographical locations. Availability of IPD from 
multiple studies provides a unique opportunity for both prognostic factor and model research. 
The effect of prognostic factors can be assessed and combined (‘meta-analysis’) across 
multiple studies, increasing sample size to detect true effects, and allowing for patient case-
mix variation to give better estimates of prognostic effect (15). Prognostic models can also be 
developed allowing for such variation by incorporating factors which explain the clustering of 
patients in studies or centres, and allowing for different implementation strategies in new 
populations (16-19).  
Given this clustering of patients within studies, centres and countries, traditional evidence 
synthesis methods have a natural application for both prognostic factor and model research, 
which is a major theme of this thesis. IPD meta-analysis techniques have further potential uses 
for model development and validation (12, 20, 21), while others have led the way in the use 
of evidence synthesis methods for prognosis research using multiple clusters (12, 20, 22-24).  
This research thesis focuses on the application and development of statistical methods for 
prognostic model and factor research. Specifically, this thesis uses evidence synthesis 
techniques in the development, validation, implementation and assessment of prognostic 
models and factors, with the aim of improving their performance, transportability and 
external validity.  
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In this introduction chapter, a framework for prognosis research is described and the key 
statistical concepts outlined, in regard to both single studies and meta-analysis of multiple 
studies. The rationale for the thesis is then given, and then the aims and outline of subsequent 
chapters is provided. 
1.2 Prognosis research structure 
Despite the importance of prognosis in medicine, historically prognosis research in the 
literature is of low quality and low impact (25). Over the last decade there has been a 
concerted effort to improve the quality, reporting and impact of prognosis research (1, 3, 25). 
The PROGnosis RESearch Strategy (PROGRESS) partnership, published a series of articles 
proposing a framework of four prognosis research themes (3, 8-10), one on each of the 
following areas; 
(1) Fundamental (overall) prognosis research – The study of the natural course of health 
conditions in the context of current care (3). 
(2) Prognostic factor research – The study of single factors and their association with patient 
outcomes (8).  
(3) Prognostic model research - The development, validation, and impact of statistical models 
which combine several factors in order to predict individuals risk of outcome (9). 
(4) Stratified medicine research - The use of prognostic information to help stratify treatment 
decisions for individuals (10). 
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These articles provide guidance on the undertaking of prognosis research in each of the above 
themes, and highlight particular challenges in the field and ways to improve the current 
standards of prognosis research. Further to these articles, special attention has been paid to 
the area of prognostic model research (1, 26-28). Prognosis is often a multifactorial problem 
and as such prognostic models naturally replicate the process many clinicians use to make 
predictions for their patients. Often single prognostic factors do not give accurate individual 
predictions for longer term outcomes, meaning prognostic models are required (8). Prognostic 
model research is also complicated, and there is no agreed strategy for development of a 
model, increasing the likelihood of poorly developed models (27).  
This thesis focuses primarily on the examination of single prognostic factors and the 
development/validation of prognostic models; the aim is to utilise and develop statistical 
methods for improving the development, validation and implementation of factors and 
models when data from multiple studies are available. The following sections discuss 
prognostic factor and model research in more detail. 
1.3 Prognostic factor research 
A prognostic factor is any measure that is associated with a future outcome in a group of 
patients with a given health condition (8). These factors may be biological, environmental or 
psychological, and can range from simple (e.g. sex, age or weight), to complex factors 
measured in individuals (e.g. biomarkers, physiological or imaging variables). Prognostic 
factors are referred to by many names in the medical literature including; predictors, risk 
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factors, prognostic variables, and prognostic markers. In this thesis the terms ‘prognostic 
factor’ and ‘predictor’ will be most often used.  
Prognostic factors have many potential uses in improving health outcomes including (8); 
• Classifying disease at diagnosis (e.g. presence of elevated blood pressure combined 
with significant proteinuria used to define pre-eclampsia (29, 30)),  
• Informing treatment strategies, 
• Forming the building blocks for prognostic models (e.g. use of patients D-dimer levels 
to predict recurrence risk in VTE patients (15)), 
• As potential predictors of treatment response, 
• Monitoring disease progression (e.g. the RECIST criteria used to define response to 
treatment in cancer patients, which uses patient scans and measurements of tumour 
size (31)), 
• As potential treatment effect modifiers (e.g. treatment response to tamoxifen is 
dependent on patients oestrogen receptor (ER) status (32) as shown in Figure 1.2) 
• And, as potential confounders to be adjusted for in analyses 
 




1.4 Prognostic model research 
Multivariable prediction models combine multiple individual predictors to either predict the 
risk of developing a future outcome (prognostic model), or the risk of an outcome being 
present or absent (diagnostic model) (33, 34). In this thesis the term ‘prediction model’ is used 
interchangeably with ‘prognostic model’, as the focus is always on future outcomes, but key 
differences are highlighted where necessary. As with prognostic factors, prediction models 
have many names in the literature including; prediction/risk score, prediction/risk tool, 
prediction index, prediction rule, or classification rule among others. Prediction models 
combine two or more individual predictors within a multivariable regression model, 
commonly a logistic or cox regression model, which are discussed in detail in the next section, 
following which further details on the phases of prediction model research are discussed. 
Examples of prognostic models include the QFracture algorithm to predict individuals 10-year 
probability of osteoporotic or hip fracture (35, 36), and the DASH score for predicting risk of 
recurrent VTE in unprovoked VTE patients after cessation of therapy (37). The DASH score 
combines scores for predictors including abnormal D-dimer levels (+2 score), age ≤ 50 years 
(+1 score), male sex (+1 score) and hormone use (-2 score), to calculate patient’s cumulative 
recurrence risk at one, two and five years from cessation of therapy, with estimated 95% 
confidence intervals (see Table 1.1).
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Table 1.1 – Predicted cumulative recurrence risks for groups of patients as defined by the DASH score (37). 
DASH score 
Cumulative recurrence (%, 95% Confidence interval) 
1 Year 2 Years 5 Years 
-2 2.4 (0.3–15.8) 5.2 (1.3–19.2) 5.2 (1.3–19.2) 
-1 1.9 (0.3–5.9) 1.9 (0.6–5.9) 5.7 (1.5–20.5) 
0 4.2 (2.3–7.7) 5.4 (3.1–9.3) 9.5 (3.8–22.3) 
1 5.1 (3.4–7.5) 8.7 (6.3–12.0) 15.9 (10.1–24.3) 
2 8.4 (6.2–11.5) 12.8 (9.9–16.4) 25.3 (17.6–35.7) 
3 14.6 (11.3–18.8) 20.5 (16.4–25.5) 40.9 (31.2–52.4) 
4 21.9 (13.6–34.1) 33.6 (23.3–46.8) 61.3 (44.3–78.5) 
 
Prediction models are a natural step towards the stratified medicine approach which is the 
final theme described by the PROGRESS partnership (10). They allow clinicians and patients to 
jointly make informed decisions on treatment strategies based on the patients’ prognosis (9). 
Importantly such models can be used to identify subgroups of patients with different levels of 
risk, in whom relative treatment effects may have greater absolute benefit or harm (4). 
Prediction models can also be used to increase power and reduce sample size requirements 
in clinical trials by prognostic targeting or predictor adjustment (5, 6), and in understanding 
differences in prognosis across centres or countries (7).  
1.5 Statistical methods for prognosis and prediction models 
The following introduces the key statistical methods for prognosis research, specifically those 
used in assessing the prognostic effect of single factors, and in developing clinical prediction 
models. In prognosis research the most common prediction models aim to predict either 
binary outcomes or time-to-event outcomes, for which typically either logistic or survival 
models are used, respectively.  
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1.5.1 Logistic regression 
Logistic regression models are used in prognosis to model the relationship between one or 
more predictors and a binary outcome (e.g. mortality), usually a short-term outcome for which 
all patients have complete follow-up (34). They are also commonly used as diagnostic models 
for example modelling disease presence or absence. As a generalised linear model the logistic 
regression model (see Equation 1.1) uses a logit link to associate a binary outcome,	 with a 
combination of predictors	 = (, 
, … ), and regression coefficients	 = (, 
, … ). 
The outcome relates to the probability of having the event,	 = ( = 1).  
() = log  1 −  =  +  =  
Equation 1.1 
The logit link function limits the back-transformed probability () from the model to lie 
between zero and one. The linear predictor (LP) is defined as the combination of the intercept 
term,	 and the set of predictors with their associated coefficients	. Where interest lies in 
the effect of a single predictor or prognostic factor the vector  may contain only one 
predictor, , or alternatively a set of other predictors as adjustment factors to ascertain the 
prognostic ability of the predictor beyond other potential confounders. Each coefficient within 
 relates to a log odds ratio, giving the change in log odds for a 1-unit increase in the 
associated  (conditional on any other factors in the model), typically estimated using 
maximum likelihood. This is sometimes known as the prognostic or predictive effect of a 
factor. The model can be easily extended to incorporate random effects, to allow for 
differences in predictor effects across clusters within the data for example. 
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Using the logistic model for prognosis 
For prognosis, predicted probabilities for any individual, i, can be obtained by back-
transforming the linear predictor from Equation 1.1 using the inverse function, also called the 
logistic function (38), as below;  
 = !"( ) = !#$( ) = exp	( )1 + exp	( ) = 11 + exp	(− ) 
Equation 1.2 
The top panel of Figure 1.3 shows the predicted values from Equation 1.1, which can be seen 
to lie outside of the range [0, 1] on the logit scale. In contrast the bottom panel in Figure 1.3 
shows the probability of an event as calculated by transforming Equation 1.1 using the logistic 
function given in Equation 1.2. The typical sigmoid shape of the logistic function is evident and 
ensures predictions lie between zero and one. The HERDOO2 model is an example of a 
published prognostic model developed in a logistic framework, for predicting risk of recurrent 




Figure 1.3 - Example of the probability of event from the logistic model (logit(p) = LP (as in Equation 1.1)) against the 
linear predictor (top panel) and the probability of an event transformed using the logistic function (p = 1/1+exp(-LP)) 




Figure 1.4 - Examples of published prediction models using logistic and Cox regression model structure (39, 40). 
1.5.2 Cox regression 
The Cox proportional hazards model is the most commonly used model in the literature for 
time-to-event outcomes (such as the Vienna prediction model (40), see Figure 1.4), allowing 
for patients with different lengths of follow-up and censoring (41). Right censoring is common 
in prognostic studies where patients may be lost to follow-up, or withdraw from the study, or 
Examples of published prediction models 
The following give real examples of logistic and Cox regression models developed for the 
prediction of risk of recurrent VTE post cessation of therapy, in patients with an initial 
unprovoked VTE. 
Logistic prediction model example 
The HERDOO2 model is a logistic regression model for which the LP was defined as 
follows, where the regression coefficients represent log odds ratios as in Equation 1.1; 
LP = (–3.9717 x intercept) + (1.2977 x BMI ≥ 30 kg/m2) + (0.6473 x post-thrombotic signs) 
+ (0.9155 x D-dimer ≥ 250 μg/L) + (0.8084 x age ≥ 65 years) 
Cox prediction model example 
The Vienna model is presented as a nomogram which is based on a Cox regression model, 
meaning that the regression coefficients in the LP below represent log hazard ratios, as in 
Equation 1.3. 
LP = (0.64 x Male) + (0.96 x PE) + (0.73 x Proximal DVT) + (0.24 x D-dimer (per doubling)) 
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where the study ends before the patient has an event. In such cases the patient is censored 
at the last time they were known to have not had the event. It models the hazard function 
over time, ℎ(; ) with  = (, 
, … ), representing the vector of included predictors (42). 
As for the logistic model, a single predictor can be investigated in isolation by including only 
one predictor in the vector	.  
The baseline hazard,	ℎ*() represents the hazard rate at time t, when all predictors equal zero. 
The Cox model makes no assumptions about the form of the baseline hazard, allowing various 
complex hazard shapes to be captured by the model. It does however, in its simplest form, 
make the assumption that hazard rates are proportional between patient subgroups over 
time; the proportional hazards assumption. The vector of coefficients  = (, 
, … ) are 
estimated on the log scale (see Equation 1.3) by maximising the partial likelihood, which is 
independent of	ℎ*(). 
ℎ() = ℎ*()exp	() ln(ℎ()) = ln(ℎ*()) +  
Equation 1.3 
Each  coefficient in the model relates to a log hazard ratio, giving the change in log hazard 
for a 1-unit increase in the associated  (conditional on any other factors in the model). The 
cumulative hazard function, ,() represents the total hazard accumulated up to time t, and 
can be directly calculated by summing the hazard function given in Equation 1.3 as follows; 




Using the Cox model for prognosis 
As previously discussed, for prognosis interest usually lies in prediction of absolute risks for 
individuals, which can be calculated by first transforming the cumulative hazard function to 
obtain the baseline survival function	1*(); 
1*() = exp	(−,*()) 
Equation 1.5 
And then using the baseline survival function to obtain a predicted survival probability, 1 () 
at time t for individual i by transforming Equation 1.3 as follows; 
1 () = 	 1*()234	(5) 
Equation 1.6 
1.5.3 Flexible parametric models 
Flexible parametric (FP) models go beyond the Cox model and extend standard parametric 
survival models, such as the Weibull or exponential model, by modelling the baseline hazard 
more accurately (43-45). Standard parametric models assume distributional shapes for the 
baseline hazard, but are restricted and often unable to capture realistic hazard functions 
which may rise and fall over time. For example the Weibull model assumes a monotonic shape, 
either rising over time or falling over time. Parameterisation of the baseline hazard is 
important for prognosis; firstly in order to obtain individualised absolute risk predictions over 
time and secondly, for out-of-sample prediction enabling external validation. The following 
sections briefly describe the framework for flexible parametric models which will be used in 
later chapters of the thesis, beginning with restricted cubic splines. 
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Restricted cubic splines 
FP models utilise restricted cubic splines to flexibly model the baseline hazard on the log-
cumulative hazard scale. By fitting cubic splines between cut points over time, known as knots, 
FP models can better capture fluctuations in the baseline hazard. Restricted cubic splines are 
used over cubic splines to force the function to be linear before the first knot and after the 
last knot, known as the boundary knots (defined as the minimum and maximum event times), 
so as to ensure a more biologically plausible function in the tails of the distribution where 
there is more likely to be sparse data (46). To fit a restricted cubic spline for variable  we 
create new variables, 6, in the linear predictor, known as basis functions. We define n interior 
knots, k1, …, kn, and the boundary knots, kmin and kmax, then the spline function can be written 
in terms of parameters 7 and the new variables z1, …, zn+1 as below; 
#!89() = 7* + 7*6 + ⋯+ 7;<6;< 
Equation 1.7 
The basis functions are calculated by; 
6 =  6 = ( − = )<> − ? ( − =@ ;)<> − (1 − ? )( − =@AB)<>  
Equation 1.8 
Where λi may be calculated using the following formula for i = 2, …, n+1; 




FP model specification 
FP models under the proportional hazards assumption are a generalisation of the Weibull 
model (46, 47). Royston and Parmar propose to extend the Weibull model as follows by first 
defining the Weibull log cumulative hazard; 
ln ,() = ln ? + 7 ln  = 7* + 7 ln  
Equation 1.10 
Showing that the hazard can be described in terms of a constant and a linear function of log 
time, and therefore we can easily make the baseline component of the equation more flexible 
to improve on the Weibull model (where the baseline can only be a monotonic function over 
time). We can generalise Equation 1.10 with restricted cubic splines as follows, 
ln,() = #!89(ln ) = 7* + 7 ln  + 7
6(ln ) + 7>6
(ln ) + ⋯ 
Equation 1.11 
Where we combine the constant and linear terms from Equation 1.10, with the basis functions 
from the restricted cubic spline as in Equation 1.8. There is a basis function for each knot in 
the model and a corresponding regression coefficient. It follows naturally that, Equation 1.11 
collapses to a Weibull model in the case with zero knots. Equation 1.11 can be further 
extended to incorporate a set of predictors in a linear predictor,	 so that, 
ln,() = ln,*() +  = #!89(ln ) +  
Equation 1.12 
Where  = ( …C) and  = ( …C) define vectors of predictors and their 
corresponding coefficients (log hazard ratios). Non-proportional hazards can also be assumed 
for the included predictors,  using restricted cubic splines, but this is not considered here. 
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The models are estimated using maximum likelihood, with suitable starting values for the 
coefficients, , derived from a Cox model with covariates  (44-46). 
Using FP models for prognosis 
In prognosis the emphasis is to obtain individual absolute risk predictions to inform treatment 
decisions. Individual predictions at time, t, can be obtained from an FP model just as in 
Equation 1.6, by first transforming Equation 1.12 above to obtain the baseline survival 
function and then using Equation 1.13 below to obtain survival probabilities,	1().   
1*() = exp	(− exp(ln,*())) 1() = 	1*()234	() 
Equation 1.13 
1.6 Phases of prognostic model research 
The following sections discuss the three established stages of prediction model research; (i) 
model development with internal validation, (ii) external validation, and (iii) impact evaluation 
(1, 9, 10, 26-28), and describes in detail the key statistical measures of model performance. 
1.6.1 Model development 
There are many statistical approaches and methods used for the development of prediction 
models and as such there is little agreement on the best strategy (27). There is however 
general consensus that good quality data and suitable sample size are required for all model 
development studies (48). In clinical research it is often the case that a more parsimonious 
model is preferred, owing to ease of implementation and face validity (26). The general aim is 
to build a model using a set of predefined predictors, which has good discrimination (able to 
distinguish between those at high and low risk of outcome), and calibration (agreement 
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between predicted and observed event rates) performance. Chapters two and three of this 
thesis focus on a review of published prediction models and a model development study, 
respectively. Below some important statistical considerations in model development are 
discussed, though many others exist (34, 38). 
Model structure and candidate predictors 
An appropriate regression framework should be selected based on the outcome for which 
predictions are required, for example dichotomous outcomes (such as presence or absence of 
disease) may be modelled using a logistic model, and time-to-event outcomes (such as time 
to death) could be modelled using either Cox or a (flexible) parametric survival model. 
Consideration must also be given to the specification of the intercept/ baseline hazard, 
especially when there are multiple centres or studies (clusters) within the development data; 
options include a fixed, proportional or random-effects baseline hazard which can be assumed 
across studies. This choice is also effected by the proposed implementation method for the 
model in practice. These issues will be revisited later in the thesis (in chapters 3 and 4), as they 
are unique issues arising from the use of clustered data for prediction modelling. 
A set of candidate predictors for potential inclusion in the model should be predefined and 
should include predictors for which there is previous evidence or biological plausibility (27, 
34). A systematic review of the literature is perhaps the best approach to identifying a set of 
candidate predictors, though there will often be more predictors than can sensibly be used in 
the model (27). In this case data reduction strategies are useful, to exclude candidate 
predictors which are highly correlated with each other for example (38). It is unwise to select 
candidates based on univariable selection methods, which can lead to either not identifying 
19 
 
important predictors or exclusion of predictors which are associated with the outcome after 
adjustment for confounders (other predictors) (38, 49). 
Functional form of continuous predictors 
It is very common in the literature for continuous predictors to be dichotomised at some 
arbitrary cut point, perhaps the median or, even worse, some data-driven ‘optimal’ cut-off 
(50-52). Continuous predictors should not be arbitrarily cut as this leads to a loss of statistical 
power to detect the true association between the predictor and outcome (50, 53). 
Categorisation also leads to a loss of prognostic information; splitting the predictor into 
categories assumes that those either side of the cut-off have very distinctly different 
prognosis, while those within a category are assumed to have similar prognosis, both strong 
assumptions (51). A better approach is to investigate whether the predictor has a linear or 
non-linear form, where the later could be modelled by some transformation (e.g. restricted 
cubic splines or fractional polynomials) of the original predictor (54, 55). Consideration should 
be taken with regard to the interpretation of more complex non-linear terms, as well as the 
models applicability and face validity. 
Data quality and missing data 
It is important that both predictors and outcomes have consistent definitions and 
measurement methods within the data used for development, that mimic those that will be 
available in practice to ensure the model’s applicability. Problems often arise when there are 
multiple clusters with differences in definitions or measurement methods, and when 
predictors or outcomes with significant measurement error are included. These issues may 
reduce the predictive performance of the model (27).  
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Missing data is highly prevalent in medical research, and many statistical methods have been 
developed to handle this under certain assumptions (56, 57). Multiple imputation is preferable 
to a complete case (CC) analysis; firstly because exclusion of patients with missing predictor 
information reduces power and secondly, because as patient data is rarely missing completely 
at random, a CC analysis can lead to bias in predictor effect estimates (58). Finally predictors 
with large amounts of missing data may not be useful in practice for example because 
measurement is costly and the predictor is not routinely collected. 
Selection of predictors for the final model 
There are various methods for selection of predictors for the final model, though currently no 
agreement on the best approach (27, 38, 59). One such method includes all candidate 
predictors in a full model, regardless of their significance; this method potentially avoids 
overfitting and selection bias (38). Other approaches use automatic stepwise procedures, in 
which predictors are selected for inclusion or exclusion from the model based on significance 
tests at a pre-specified significance level. Such methods are data-driven and as such are 
susceptible to overfitting and inclusion of predictors based on spurious effects (and omission 
of genuine predictors by chance). Backward elimination, which aims to reduce a full model, is 
preferred to forward selection which tests predictors for inclusion from the null model (27, 
60), because the former is based on effects that are fully adjusted for other factors. 
1.6.2 Internal validation 
The performance of a model measured in the development dataset is described as the 
apparent performance and is often optimistic (34). The use of selection procedures (e.g. to 
choose predictors or their functional form) in model development studies commonly results 
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in selection bias and overfitting, where predictor effects are likely overestimated leading to 
such optimism (38, 48). Overfitting is of greatest risk when the development dataset is small 
and where predictors have weak effects (27). Apparent performance is only likely to provide 
a valid estimate of model performance when the development dataset is extremely large (34). 
Conversely, without correction for overfitting in small datasets a developed model is highly 
likely to give poorer performance in new patients. Therefore, internal validation methods 
should be routinely included as part of any model development study, to quantify the 
optimism in model performance measures (see section 1.6.4). Some internal validation 
methods are now described below.  
Split-sample validation 
A common internal validation approach in the literature is to randomly dichotomise the 
dataset into ‘training’ and ‘test’ samples, for development and validation of the model, 
respectively. So called split-sample validation is not recommended as it often shows optimistic 
performance of the model, because the validation sample is very similar to the development 
sample as the data was only split at random (34). It has been shown that in small datasets the 
results of split-sample validation can vary depending on the split (48, 61, 62).  Split-sample 
validation also raises questions as to whether there is adequate sample size for model 
development; in smaller datasets it may be more efficient to use all data for development and 
then rather apply a validation method that utilises the whole data such as cross-validation or 
bootstrapping (described below). 
A potentially more useful variant is the non-random split-sample validation, where the dataset 
may be split by some clustering factor such geographical location, centre, study or time (28, 
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33, 63, 64). This may be considered as an intermediary to external validation, as the validation 
data may be distinctly different from the development data in some key characteristics (33). 
However similar problems as with split-sample validation may arise in small samples, and so 
this approach is best reserved for situations when the development data remains extremely 
large even after some clusters are removed. Temporal validation, using the same or similar 
patients at a different time point allows assessment of how model performance may change 
over time, for example changes in case-mix over time have been seen to cause severe 
calibration drift as in the original EUROSCORE model (65).  
Cross-validation 
Cross-validation improves on split-sample validation by using the whole dataset for both 
development and validation of the model. A common approach involves randomly splitting 
the dataset into 10 groups of equal size, though any number of groups may be used. The 
model is then developed using 9 of the splits, and validated in the 10th split. This process is 
repeated so that 10 models are developed and tested in 10 validation samples. The 
performance measures calculated in each validation sample are then averaged to give the 
overall performance of the model. This approach can be performed at the individual level, 
where the model is developed on all but one patient (used for validation), however this is 
often computationally intensive and does not yield greater accuracy (38). The cross-validation 
approach is potentially most appealing in the context of meta-analysis, where a study could 
be removed for validation, and then the model developed on the remainder, with this process 
repeated across all cycles of the omitted study (20, 66). This ‘internal-external cross-




Bootstrapping allows for use of the whole dataset through resampling with replacement from 
original dataset, meaning sample size can be maintained as opposed to splitting methods 
which reduce the development sample (38, 67). Bootstrap validation accounts for all 
uncertainty in the model development strategy, and allows estimation of the amount of 
optimism in the final model. When the degree of optimism is estimated it can be used to 
modify the developed model, uniformly shrinking predictor effects overestimated due to 
overfitting. Shrinkage of predictor effects in the final model can improve the potential 
performance in new patients (see section 1.6.4). Similar adjustment factors can be calculated 
for apparent performance statistics (e.g. C-statistic), giving better estimates of the models 
performance after accounting for optimism.  
The bootstrap procedure begins by developing a model in the original data and calculating its 
apparent performance in the original dataset. A bootstrap sample is then created by sampling 
‘n’ patients with replacement from the original data. The model development strategy is 
repeated in the new bootstrap sample; it is critical that all steps of the original process are 
repeated in the new sample, as this accounts for all uncertainty in the development strategy 
(33, 38, 68). The performance of the model in the original dataset is calculated and then 
subtracted from the apparent performance of the model in the bootstrap sample to give the 
estimated optimism in performance. A new bootstrap sample is generated and the optimism 
calculated many times, for example 1000 bootstrap samples may be taken. The optimism 
calculated from each bootstrap sample is then averaged and subtracted from the apparent 
performance of the original model to give the optimism-corrected performance estimate.  
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1.6.3 External validation 
It is well known that overfitting in development data often leads to poor performance of 
models in new patients outside of the development dataset (34, 38). Despite the use of 
internal validation to estimate potential optimism, evaluating the generalisability of the model 
requires external data (28). Even after shrinkage, the developed model could perform poorly 
in new populations due to poor methodology used in the development study (26, 28). 
However, a key reason for differences in model performance between development and 
validation samples is differences in case-mix, such as clinical setting (e.g. primary versus 
secondary care) or predictor-outcome distributions (e.g. adult versus child population) (26). 
Using a model in a new external population is essentially attempting to extrapolate the model, 
and as such reasonable performance may be seen where validation case-mix overlaps with 
the development cohort (26).  
As discussed above, some instances of non-random split-sample validation may be arguably 
considered as external validation, for example where the developed model is validated in 
patients from a different country. In this way external validation is possible as part of a 
development study (33). Alternatively external validation may be performed on an existing 
published model using new patients, and performed by independent researchers, at a 
different time (26, 33, 34, 64, 69). Ideally external validity of the model should be tested 
multiple times in different external populations to assess its performance given variations in 
case-mix (70). Where multiple external datasets are available performance statistics can be 
summarised across datasets using meta-analysis methods as described later (see section 
1.8.2) (19-21, 24, 71). 
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1.6.4 Model performance statistics 
Measuring model performance both internally and externally requires statistical measures of 
both discrimination and calibration. Various statistics have been proposed to measure both 
properties (72), and the below sections discuss some of the most commonly used statistics 
within this thesis, which focuses on time-to-event prognostic models. 
Discrimination 
The discrimination performance of a model refers to the models ability to separate between 
patients with and without the outcome of interest by assigning higher risk probabilities to 
those who will have the outcome. A models discriminative performance is highly dependent 
upon the case-mix variation in the dataset, with greater discrimination (separation) seen in 
datasets with wider variation (70, 73). Given this it is common for the discrimination of a 
model to vary across different validation samples, further motivating the use of meta-analysis 
methods to summarise heterogeneity in performance across studies, centres or locations (24). 
Some new statistical measures of discrimination have been proposed to identify and adjust 
for heterogeneity in performance, but these are not considered in this thesis (73, 74). 
Discrimination is commonly reported in terms of the C-statistic, sometimes referred to as the 
concordance index, is equivalent to the area under the receiver operating characteristics 
(ROC) curve for logistic regression models. The C-statistic is defined as the proportion of 
patient pairs (one with and one without the event), for which the model correctly assigns a 
higher predicted risk to the patient with the outcome (38). This calculation is complicated by 
censoring in time-to-event models, where Harrell’s C-statistic can instead be used, which 
excludes any pairs which cannot be ordered. It is not possible to order pairs where either; 
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both patients have been censored, or both patients have an event at the same time point, or 
where one patient survives beyond another patients censoring time (38, 67). A C-statistic of 
one indicates perfect discrimination, whereas a value of 0.5 represents no discriminative 
ability beyond chance. 
Royston’s D-statistic is another measure of prognostic separation specifically proposed for 
survival curves (75). The D-statistic is strongly related to the standard deviation of the linear 
predictor; it gives the log hazard ratio between two groups defined by dichotomising the linear 
predictor at the median (75). Royston’s R2D gives a measure of explained variation based on 
the D-statistic, to give an interpretation similar to R2 in linear regression models (75). 
Calibration 
Calibration measures the agreement between expected (model predictions) and observed 
event probabilities. Calibration performance should ideally be evaluated across the risk 
spectrum, and it is common to consider deciles of predicted risk (68, 76). It can be used to 
indicate how much the model under or over-predicts the absolute risk of outcome. Poor 
calibration may be observed in external validation datasets, and in this situation recalibration 
or updating methods may help to improve performance. The use of recalibration using meta-
analysis techniques is the focus of chapter 4 of this thesis (64, 69). Calibration performance is 
often neglected in validation studies and poorly reported in the literature (77).  
In this thesis calibration performance is measured using both the difference in, and ratio of, 
the expected (E) and observed (O) event probabilities, E-O and E/O, respectively. Observed 
event probabilities can be calculated by averaging the outcome variable for logistic models, 
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or the survival probabilities estimated by the Kaplan-Meier method for survival models. 
Expected probabilities are calculated as the average of the models predicted probabilities. In 
survival analysis expected and observed probabilities are usually calculated at specific time-
points (34). Perfect calibration is represented by a value of one for the E/O statistic, or zero 
for the E-O statistic.  
Ratio or difference in E and O? 
The E-O statistic is an appealing measure as it is easily interpretable as the absolute difference 
between the observed and predicted event probabilities (34), and can be visualised simply for 
survival models in a calibration plot as the difference between the Kaplan-Meier and model 
prediction curve over time. The ratio of E/O is less easily interpreted, as two cases with the 
same absolute difference in calibration may result in two very different E/O statistics 
depending on the size of the probabilities. For example, take an example where E=0.95 and 
O=0.9, the absolute difference is E-O=0.05 meaning the model predicts event probabilities 5% 
higher than observed for the population as a whole, and the ratio is E/O=1.05. Now take a 
second example with E=0.1 and O=0.05; here, E-O=0.05 again showing the model predicts 
event probabilities 5% higher than observed for the population as a whole, however the ratio 
E/O=2. The latter is considerably different than the previous 1.05 value, even though the 
absolute difference in risk is the same.  
Other commonly used measures of calibration include the calibration slope and calibration-
in-the-large (CITL), which are more frequently referred to in the case of logistic prediction 
models. In logistic regression the CITL is defined as the difference between the numbers of 
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predicted and observed events. It can be calculated either directly, or by fitting a logistic model 
with the LP fixed as an offset predictor (i.e.	 = 1), giving  as the CITL; 
() =  + () 
Equation 1.14 
The CITL for the logistic model is similar to the E-O statistic discussed above for survival 
models, but gives an estimate of calibration across the whole risk spectrum, unlike in the case 
of survival models where E-O must be calculated at specific time points. 
The calibration slope for logistic regression relates to the slope of a calibration plot in which 
expected risk probabilities are plotted against observed risk probabilities (see Figure 1.5), 
across groups of patients with similar predicted risks (typically presented in deciles) (34). The 
calibration slope can be calculated using a logistic model as in Equation 1.14, where the LP is 
fitted (not as an offset) and the corresponding regression coefficient represents the 
calibration slope. Figure 1.5 illustrates four calibration plots with different calibration slopes, 
which relate to situations in which; (i) there is perfect calibration (i.e. E=O), (ii) there is some 
systematic miscalibration, in this case over prediction, (iii) there is large variation in predicted 
risks, potentially due to overfitting during model development, and finally (iv) there is large 
miscalibration, potentially seen when validating a model in a new population with very 




Figure 1.5 - Examples of calibration plots for logistic prediction models (71). Where the dashed line represents perfect 
calibration of E=O, and a=CITL and b=calibration slope. 
1.6.5 Impact studies 
The implicit aim of prediction models is to provide accurate predictions of patient outcome 
probabilities, to supplement decision making for clinicians and to ultimately improve patient 
healthcare and outcomes (1, 78). Well-developed models, which have shown promise through 
external validation and are easily applied in practice, should be assessed for their impact on 
patient outcomes, clinician decision-making and cost-effectiveness (26). Studies evaluating 
such outcomes are referred to as ‘impact studies’.  
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Impact studies aim to measure the effect of using a model versus not using a model (usual 
care), and therefore are suited to a randomised controlled trial design (79). The impact of 
using a prediction model on patient outcomes and cost-effectiveness often requires long-term 
follow-up and is highly dependent on the uptake of the model by clinicians (26). It may 
therefore be more practical to conduct an initial study on behavioural change in clinicians, to 
assess the models uptake, with these studies requiring no patient follow-up. Randomisation 
by centres using a cluster design is preferred to avoid biases introduced by the clinicians within 
centres (26). 
Impact studies may show a greater effect when the model is used to guide decision making by 
suggesting treatment strategies for patients falling within certain risk categories, as opposed 
to studies in which the absolute risk probability for the individual is provided alone and 
decision making is more subjective for the clinician (79). Similarly studies evaluating the 
impact of risk predictions provided automatically based on computerised systems may show 
greater performance (80). There are relatively few impact studies published in relation to the 
number of model development and validation studies published (9), but one good example is 
the STarTBack trial (81). The STarTBack trial randomised 1537 patients with back pain to either 
non-stratified usual care, or stratified care pathways based on patients predicted prognosis 
using the STarTBack tool (low, medium, high risk) (81). The trial found significant 
improvements in disability and quality of life measures in the stratified care group, as well as 
cost benefits (81). Chapters 5 and 6 of this thesis begin to move toward model implementation 
and impact, looking at meta-analysis methods for summarising and identifying the best 
thresholds for use of a model from published literature.  
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1.7 The TRIPOD statement 
The TRIPOD (Transparent reporting of a multivariable prediction model for individual 
prognosis or diagnosis) statement is a 22 item checklist, aiming to improve the quality of 
reporting and methods used for primary prediction model studies (33, 68). The checklist 
applies to all model development, validation and updating studies, and to all clinical settings. 
TRIPOD aims to better inform researchers in aspects of primary model studies including the 
design and analysis of such studies, and the interpretation of models and their generalisability. 
In terms of methodology, the accompanying explanation and elaboration paper provides 
detailed guidance on issues in development and validation including; handling of missing data, 
modelling of continuous predictors, selection of predictors for inclusion in the model, types of 
validation studies, model performance measures, and updating strategies (68). 
The TRIPOD guidelines were developed to address the history of shortcomings in terms of 
both reporting and methodology in the prediction model literature (77, 82-84). TRIPOD will 
hopefully lead to future improvements in the reporting and methodology of prediction model 
studies, through uptake of the guidelines by the research community and the support of 
academic journals. While such improvements will likely take a substantial amount time, there 
has been some evidence to suggest that similar guidelines have improved the reporting quality 
in the literature. For example for the CONSORT statement for reporting of randomised trials 
(85), and for the STARD statement for reporting of diagnostic test accuracy studies (86, 87).  
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1.8 Systematic reviews and meta-analysis of prognosis and 
prediction studies 
1.8.1 Systematic reviews  
There is an abundance of published research investigating potential prognostic factors and 
prediction models, making systematic review and evidence synthesis highly desirable to 
inform clinical decision making and establish evidence-based research in prognosis. 
Traditionally systematic reviews summarise the available evidence on a particular treatment, 
though there is increasing interest in synthesis of prognostic factor effects or prediction model 
performance (8, 9, 71). Much research has been conducted on the methods for reviews of 
prognostic factors and prediction models including topics such as; search filters (88-90), study 
design (8, 9), data extraction (91), critical appraisal of published evidence (92-94), and 
synthesis of model performance (71). In this thesis, chapter 2 focuses on a systematic review 
of published prediction models, and utilises a preliminary version of the upcoming PROBAST 
tool for assessing risk of bias in primary prediction model studies (92, 95).  
Systematic reviews of prediction models have previously shown the poor methodological and 
reporting quality of primary development and validation studies (77, 82-84), as well as the 
overflow of development studies and lack of respective validations (9, 82). The PRISMA 
(preferred reporting items for systematic reviews and meta-analyses), and PRISMA-IPD 
statements provide guidance on important reporting issues, which should be taken into 
account in any review and synthesis of prognostic factor or model studies (96, 97). Also the 
TRIPOD (Transparent reporting of a multivariable prediction model for individual prognosis or 
diagnosis) statement aims to improve the quality of reporting and methods used for primary 
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prediction model studies, which should improve the quality of prognosis research in the future 
(33, 68).  
This thesis aims to use meta-analytic methods for prognostic factor and prediction model 
research, with the aim of improving identification of important predictors, as well as 
prediction model performance, transportability and external validity. In the next sections the 
statistical methods for evidence synthesis are described for both aggregate data and IPD 
meta-analyses, as will be used in this thesis. 
1.8.2 Traditional meta-analysis 
Traditionally meta-analyses summarise the evidence on a single treatment effect obtained 
from study publications, typically as measured in a randomised controlled trial (RCT). 
However, it has become increasingly pertinent to summarise the association between 
potential prognostic factors and patient outcomes, due to the large number of often small 
studies, reporting conflicting results, in order to inform clinical practice. The increased interest 
in stratified medicine has also increased the use of meta-analysis to investigate potential 
effect-modifiers, or interactions, where treatment may have greater benefit or harm in 
particular subgroups of patients; for example it has been shown that Tamoxifen is only 
beneficial in estrogen receptor (ER) positive patients (32). Finally, meta-analysis is increasingly 
being used to summarise the external performance of prediction models, which is the focus 
in this thesis and the basis of the below model descriptions (19-21, 24, 71, 98). 
Given multiple validation studies reporting estimates of model performance statistics (e.g. 
Harrell’s C-statistic), a formal meta-analysis may be performed in order to summarise and 
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compare performance across studies (19, 20). Either a fixed-effect or random-effects meta-
analysis may be used; a fixed-effect model assumes model performance is the same in each 
study, which is highly unlikely. Therefore, it is more appropriate to use a random-effects model 
as this allows for heterogeneity in performance, for example due to case-mix variation as 
discussed previously (see section 1.6.3) (70, 73).  
Fixed and random-effects meta-analysis models 
The statistical notation for fixed-effect and random-effects meta-analysis models are now 
given. Let D  be the estimate of a particular performance statistic of interest where  = 1		E 
validation studies, and let 1F 
	be the associated variance of	G . A fixed-effect meta-analysis 
assumes that the true model performance is the same in all studies and that D  are estimates 
of this common performance H as given by (99); 
D ~JKH, 1F 
L 
Equation 1.15 
Maximum likelihood (ML) estimation using the inverse variance method is the most common 
approach to estimate the pooled effect, where a weighted average is calculated as (100);  
HD = ∑ D N O P∑ N O P  
Equation 1.16 
Where; 






QRS(HD) = 1∑ N O P  
Equation 1.18 
Conversely, a random-effects meta-analysis allows for between-study variation in the 
performance statistic, assuming that the different studies are estimating different but related 
underlying performance statistics as given in Equation 1.19 below (99); 
D ~JKH , 1F 
L H ~J(H, T
) 
Equation 1.19 
This model assumes that D  follows a normal distribution around the ith study’s true 
performance, θi, and that θi itself is normally distributed around an average performance, θ 
and a between-study variance	T
. The between-study variance quantifies the heterogeneity 
across studies, and there has been much debate over how best to estimate	T
 (101-104).  
Previous studies have shown that using restricted maximum likelihood (REML) estimation may 
better account for the uncertainty in the estimated T
 as ML is known to underestimate the 
between-study variance (105-110). Equation 1.19 reduces to Equation 1.15 when between-
study variance is zero. The inverse variance method can be used to calculate the pooled effect 
estimate as in the fixed effects model, but now with weights calculated with the estimated 
between-study variance included; 




It should be noted that the random-effects model assumes between-study normality of true 
effects, which may not always hold for different model performance statistics. Current 
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research has suggested some transformations for discrimination and calibration performance 
statistics to approximate normality, but further research is still needed (24, 71, 111). 
Usually of most interest will be the estimated HD and its 95% confidence interval, which is 
commonly derived by	HD ± 1.96	1Z(HD), where 1Z(HD) is the standard error of	HD. Other 
methods have been suggested to account for the uncertainty in the estimated between-study 
variance	T
, with current research favouring the Hartung-Knapp-Sidik-Jonkman (HKSJ) 
method for calculating 95% confidence intervals (102, 104). Also of interest may be an 
approximate prediction interval, such as a 95% prediction interval (see Equation 1.21). A t 
distribution is used in the calculation of the prediction interval, rather than a normal 
distribution, to allow for the additional uncertainty in T






The prediction interval infers the potential model performance in a new population similar to 
those included in the meta-analysis (112, 113). A narrower prediction interval implies more 
consistent performance in new external populations, and is thus desirable if the model is to 
be generalizable outside of a few local settings. This equation is only an approximation (114), 
and perhaps the ideal, more natural framework for predictive inferences is a Bayesian 
framework, though this is outside the scope of the thesis. 
Issues with traditional meta-analysis 
The use of traditional aggregate data meta-analysis in the prognosis field is hindered by 
widespread poor reporting and publication bias. Sources of heterogeneity are therefore rife 
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in meta-analyses of prognostic factors, interaction effects and model performance. Primary 
studies may use different statistical analysis methods, adjust for different sets of predictors 
and report different effect measures such as odds or hazard ratios, which may be adjusted or 
unadjusted effect estimates. There is often poor quality of primary studies, with many small 
studies, with no protocol, and no clear aims. Differences in treatments used, disease stage, 
methods of measurement and cut-offs used for factors or models, all leads to large 
heterogeneity in the meta-analysis diluting the evidence base and conclusions. However many 
of these issues can be addressed if IPD are available and an IPD meta-analysis performed. 
1.8.3 Individual participant data (IPD) meta-analysis 
Advantages over aggregate data meta-analysis 
IPD meta-analysis uses the raw patient level data to calculate and synthesise the effect of 
interest from each study. Many of the issues discussed above seen in traditional meta-analysis 
such as poor reporting and publication bias can be addressed using an IPD meta-analysis (115-
117). Having IPD allows re-analysis of the data using consistent choices for analysis in each 
study such as; choice of adjustment predictors, choice of cut-offs for continuous predictors, 
handling of missing data, length of follow-up, examination of non-linear trends, and 
assessment of modelling assumptions. It is also possible to check the results of the original 
study publications by calculating the aggregate data directly within each study. Where model 
performance is of interest any unreported statistics (such as calibration slopes, E/O, or C-
statistics), can be calculated manually where IPD is available. Importantly having IPD allows 
greater investigation of the causes of between-study heterogeneity, and potential effect-
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modifiers (interactions) as discussed earlier (see section 1.8.2) by avoiding ecological bias 
(118).  
Statistical approaches to an IPD meta-analysis 
IPD meta-analyses can be performed using two different approaches; a two-stage or one-
stage IPD meta-analysis (119, 120). The two-stage method first analyses each study separately 
to obtain the aggregate data needed for the second stage, in which a standard fixed-effect or 
random-effects meta-analysis model is used as described above. The one-stage method 
instead analyses all the IPD from all studies in one model allowing for the clustering of patients 
within studies (16). Usually results are similar for the two methods, though there are a number 
of reasons why a two-stage and one-stage analysis may yield different results (120, 121). 
Issues with IPD meta-analysis 
Despite the many benefits of using IPD meta-analysis over aggregate data meta-analysis, the 
IPD approach still has many challenges. There are many logistical challenges facing an IPD 
meta-analysis study; in particular, it is often time-consuming and costly in terms of obtaining, 
cleaning and analysing the data. Despite extensive efforts to obtain IPD from all identified 
study authors, IPD may still be unavailable for some studies leading to an availability bias in 
the analyses (122). Further, issues of publication bias are just as relevant in an IPD analysis as 
for a traditional aggregate data meta-analysis.  
As with traditional meta-analysis many issues remain for IPD analyses due to primary study 
deficiencies. Even with the raw patient level data some differences between studies cannot 
be addressed; for example, differences in outcome definitions, methods of measurement, 
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treatment strategies, or available predictors within each study. Continuous predictors may 
have been categorised by the study authors, making reconstruction of the continuous 
predictor impossible. Where predictors have not be measured in particular studies results in 
systematic missingness, in recent years a number of studies have developed methods to 
handle systematically missing predictors using multivariate meta-analysis and imputation, 
though this is not considered in this thesis (123-130). 
1.9 Current challenges facing prediction model research 
This chapter has discussed key aspects of the design and methods used in prognosis research, 
and prediction modelling studies in particular. This thesis aims to make a contribution toward 
improved methodology in prognosis research. Therefore, in this section the thesis topics are 
motivated by summarising the existing challenges facing the field, with particular attention 
given to prognostic model research as this forms the main focus of the majority of subsequent 
chapters in the thesis. 
In recent years an ever increasing number of prediction models have been published, with 
many published models developed to answer the same research questions (9, 77, 82, 84, 131-
133). For example a recent review by Damen et al. found 363 prediction model development 
studies all predicting cardiovascular disease (CVD) risk in the general population (82), while 
Perel et al. found 102 competing models predicting outcomes in patients with traumatic brain 
injury (TBI) (84). Evidence also suggests that many of these primary development and also 
validation studies are of poor methodological and reporting quality (77, 133-136). As 
discussed earlier, this has led to the creation of the TRIPOD statement which aims to improve 
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the reporting of primary studies for prediction model development, validation and updating 
in the future (33, 68). 
Despite the increasing number of development studies there has not be a corresponding 
increase in validation and impact studies evaluating existing models (9). Where external 
validation studies have been conducted there is evidence of poor quality and in particular 
there has been an emphasis on model discrimination, with calibration performance of the 
model often not reported (77). Calibration is a key feature of model performance as discussed 
above (see section 1.6.4), with model miscalibration leading to invalid individualised risks, and 
subsequently to poor or even harmful clinical decision making (65, 76).  
Development of new models based on poor performance of existing models at external 
validation, or worse without any external validation of existing models, is counterintuitive to 
evidence based medicine and simply research waste (64, 69). Therefore, rather than aiming 
for new models, new research should aim to validate existing prediction models and compare 
competing models head-to-head in new external datasets to identify the best performing 
model for future impact studies (137-140). Another approach to reduce future research waste 
is to tailor models to new external populations, through recalibration or updating methods 
(34, 64, 69, 141-145). Recalibration methods are discussed in detail in chapter 4 of this thesis, 
and involve adjusting an existing model to the characteristics of individuals in a new 
population (146). In this way recalibration and updating methods combine evidence from 
previous patients used to develop the existing model, with information on new patients (64).  
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However, once an existing model has been adjusted (even in the simplest manner), it can be 
considered a new model in need of external validation before use in new patients external to 
the update population (147). This implies that some cycle of constant model updating and 
immediate validation is needed, and points toward the use of a more dynamic prediction 
approach. Future prognosis research may look to develop the existing methodology for 
dynamic prediction, so that models learn from each new patient (or measurement) they are 
applied to in a similar way to how a doctor learns, making ever more informed decisions with 
experience. Current methods include the joint modelling of longitudinal measurements (e.g. 
biomarker levels over time) to inform prognosis of a time-to-event outcome (e.g. myocardial 
infarction) (148, 149). 
Given the advent of ‘big data’ and IPD meta-analyses of large datasets, methods for externally 
validating, comparing, recalibrating and updating prediction models should become easier in 
the future (21, 82). These datasets will often contain clustering of patients by centre, study or 
country, which naturally lend such data to meta-analytic analyses, but with much greater 
opportunity (and statistical power) to investigate heterogeneity (21). Between-study 
heterogeneity in model performance can be interrogated further in terms of patient case-mix, 
and particularly heterogeneity in predictor effects between-studies. 
Finally in the interests of reducing research waste and with the wealth of competing models 
available, future research may look to improve methods for synthesis of the models 
themselves. Previous research has proposed the aggregation of prediction models, forming a 
kind of ‘meta-model’, as an amalgamation of the available models regression coefficients (23). 
Current research suggests model performance is improved by model aggregation in small 
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external datasets, while model development may be preferable in larger datasets with 
significant between-study heterogeneity, though it should be noted that updating methods 
were not considered in these studies (23, 150). 
1.10 Aims and outline of the thesis 
Given the increasing number of prognosis studies, and the availability of big datasets and IPD 
from multiple studies, it is clear that meta-analysis methods will play a critical role in the 
development and evaluation of prognostic factors and, in particular, prognostic models in the 
coming years. This represents an exciting opportunity, which forms the focus of this thesis. 
The broad aim of the thesis is to apply and develop methods for evidence synthesis of 
prognosis research, in particular to improve individualised predictions from prognostic models 
developed and/or validated using meta-analysis techniques. The key aims are: 
• To review the methodology and reporting of prognostic models in a specific clinical 
setting, to illustrate the importance of a systematic review and meta-analysis of 
prognostic models, and the difficulties of applying meta-analysis without IPD; 
• To use IPD from multiple studies to develop and validate a new prognostic model in a 
clinically relevant setting; 
• To develop and illustrate evidence synthesis methods that externally validate the 
performance of an existing prognostic model using IPD from multiple studies; 
• To extend such methods to identify how to best recalibrate and update an existing 
model when its external validation performance is otherwise heterogeneous; 
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• To develop and examine, through simulation, a novel method for improving meta-
analysis of prognostic studies when studies do not provide IPD but do provide the 
predictive accuracy of a continuous factor at different thresholds.  
The thesis therefore includes a mixture of clinical application and methodology development, 
and the chapters are briefly outlined below. 
Chapter 2 aims to systematically review all available evidence on prognostic models for 
predicting the risk of a recurrent VTE. The review discusses many aspects of prognostic model 
development and validation through a critique of the existing literature in the clinical area. 
The identified models differ in many key areas including; selection of predictors, handling of 
missing data, patient selection, statistical analysis and model validation. Risk of bias 
assessments suggest models require further validation. Recommendations for further 
research are provided, and the review motivates the work in chapter 3. 
Chapter 3 builds on the previous chapter which reviewed the available evidence and identified 
a number of existing models with many methodological issues. The aim is to develop a new 
prognostic model using IPD from seven studies, using meta-analysis techniques to account for 
the clustered nature of the data. In particular an internal-external cross-validation (IECV) 
approach is used to maximise the use of the data for development and validation of the model. 
Model development aims to overcome the methodological issues identified in the previous 
chapter, and uses the IECV framework to examine the model’s calibration and discrimination 
performance across multiple settings. The work arising from Chapters 2 and 3 has been 
published in Health Technology Assessment and BMJ Open (95, 98). 
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Chapter 4 aims to investigate how model recalibration methods help to improve model 
performance when IPD from multiple validation studies are available. Four options are 
examined to recalibrate an existing flexible parametric survival model in breast cancer across 
multiple centres and countries by: (i) shifting the baseline hazard by a constant, (ii) re-
estimation of the shape of the baseline hazard, (iii) adjustment of the linear predictor as a 
whole (calibration slope), and (iv) adjustment of individual predictor effects. IPD meta-analysis 
is used to examine calibration and discrimination performance across studies for each of the 
strategies, to ascertain if and how they improve performance and reduce heterogeneity. 
Recommendations are given for those using IPD meta-analysis for external validation on the 
use of an existing model in new populations. This work has been presented at the 37th 
International Society of Clinical Biostatistics Conference (ISCB), and the Royal Statistics Society 
2016 International Conference, and is being drafted for submission to Statistics in Medicine. 
Chapter 5 tackles the situation when IPD are not available, and aims to develop a new method 
to deal with missing (partially reported) threshold information in test accuracy meta-analysis, 
where a single prognostic factor (predictive test) is used to inform the prognosis of an 
outcome for an individual patient. For continuous tests, primary studies usually report 
predictive test accuracy results at multiple thresholds, but the set of thresholds used often 
differs. Without IPD, this creates missing data when performing a meta-analysis at each 
threshold. A standard meta-analysis (NI: No Imputation) ignores such missing data. A Single 
Imputation (SI) approach has been proposed to recover missing threshold results using a 
simple piecewise linear interpolation. In this chapter a new method is proposed that performs 
Multiple Imputation of the missing threshold results using Discrete Combinations (MIDC), to 
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address short-comings of the SI method. Stata software code is developed for others to use, 
and an example is given that shows how the MIDC method may give very different results to 
the NI method. 
Chapter 6 covers an extensive simulation study which aims to evaluate the statistical 
properties of the new MIDC method developed in chapter 5. The study is designed to evaluate 
the performance of new MIDC method in comparison to the previously proposed SI method 
and when missing data is ignored (NI). Several scenarios are considered, including varying the 
amount of missing data, the missingness mechanism and the assumed spacing of reported 
thresholds. The findings indicate that the MIDC method gives best performance in general, 
unless extreme unequal spacing is apparent. The work arising from Chapters 5 and 6 has been 
submitted for publication in Research Synthesis Methods. 
Finally, chapter 7 concludes with a summary of the key findings and recommendations from 




CHAPTER 2: A SYSTEMATIC REVIEW OF PROGNOSTIC 
MODELS FOR RECURRENT VENOUS THROMBOEMBOLISM 
(VTE) POST TREATMENT OF FIRST UNPROVOKED VTE 
 
2.1 Introduction 
In this chapter, the new research for this thesis begins by identifying and examining the quality 
of prognostic models in the important clinical area of venous thromboembolism (VTE), which 
is the third most common cardiovascular disease after heart attack and stroke. VTE is a chronic 
condition with estimated incidence at 1 per 1000 person years (151-153), and often presents 
as deep vein thrombosis (DVT), with some patients suffering an embolism in the lungs known 
as a pulmonary embolism (PE). An initial VTE developed in the presence of a known provoking 
factor may be termed “provoked”, while those developed in the absence of clinical risk factors 
may be termed “unprovoked” (153, 154). There are several known pre-disposing risk factors 
including surgery, trauma, hormone intake, pregnancy and prolonged immobility (153, 155). 
Such provoking factors can be considered as acquired risk factors because they are transient; 
that is, while they increase the risk of an initial VTE, they are temporary and when they are 
removed the patient is at a low risk of recurrence, for example post-surgery (153-155). 
The aim of therapy for VTE is twofold: initially to prevent extension of the acute thrombosis, 
and secondarily to prevent both recurrence and long term sequelae such as post-thrombotic 
syndrome and pulmonary hypertension. Current treatment comprises initial management 
with heparin, usually low-molecular weight heparin for a minimum of five days, overlapping 
with oral anticoagulant therapy (usually warfarin in the UK) until the International Normalised 
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Ratio (INR) is above two. It is usual to treat an initial VTE for a minimum of three months 
however the optimum duration of therapy beyond this is unclear (156, 157). Treatment with 
Novel Oral Anticoagulants (NOAC) is a new alternative treatment to heparin and warfarin. 
Due to the transient nature of provoking factors, patients with a first unprovoked VTE are at 
much higher risk of recurrent VTE (approaching 30% at five years after cessation of therapy) 
as the cause is unknown (153, 155). Prevention of recurrent VTE poses a difficult clinical 
decision problem; a balance must be struck between the risks of recurrent thrombosis if 
anticoagulant treatment is stopped versus the risks of bleeding associated with continued 
anticoagulation therapy (153, 156).  
Therefore it is important to identify individuals with a high risk of VTE recurrence compared 
to the risk of major bleeding on anticoagulation, in order to inform treatment strategies. 
However, the population of patients with unprovoked VTE is highly heterogeneous and risk of 
VTE recurrence varies considerably across individuals (37, 39, 40). Therefore there is much 
interest in developing prognostic models for VTE recurrence. As described in Chapter 1, a 
prognostic model is a statistical equation that predicts an individual’s outcome risk based on 
a weighted combination of multiple predictors (e.g. age, sex, biomarkers) (9). A key stage of 
prediction model research is model development. This uses a dataset to identify important 
predictors and then develops the model equation; it usually also examines the model's 
apparent performance in this same data, possibly using resampling techniques to adjust for 
optimism (internal validation). The next stage is external validation, which uses data external 
to the model development data and its source, and examines whether the model predictions 
are accurate in independent data from the same or another (related) setting. External 
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validation is crucial as model performance is usually over-optimistic when considered only in 
the development dataset (9, 33, 34). Validation typically focuses on a model’s predictive 
performance as measured by discrimination (i.e. the model’s ability to separate those with 
and without the outcome) and calibration (i.e. the agreement between the model’s predicted 
risk and the observed outcome risk) as described in chapter 1.  
2.1.1 Aims of this chapter 
A reliable prognostic model is needed for the unprovoked VTE population, in order to inform 
clinical and patient decision making with regard to treatment strategies (11), in particular 
whether or not to extend treatment beyond the initial period (e.g. 3 months) with oral 
anticoagulants (OAC) to prevent recurrent VTE.  However, there are multiple published studies 
describing the development and validation of prognostic models for VTE recurrence.  
Therefore, in this chapter the aim is to perform a systematic review to identify and summarise 
studies developing or validating a prognostic model for individual VTE recurrence risk 
following cessation of therapy for a first unprovoked VTE. Through the identification of 
existing studies the review will help to determine whether reliable prognostic models exist 
and, if not, what further research is needed within the field. In particular, the review appraises 
the quality of evidence for and against each existing model, to help clinicians and other 
practitioners to better understand their strengths and weaknesses (11), allowing more 
informed decisions to be made on which (if any) models to use in practice. A protocol for the 
review was registered with PROSPERO (CRD42013003494) and published in Systematic 
Reviews (158), and the findings of the review were published in BMJ Open in 2016 (95).  
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This chapter now begins by describing the methods of the review, followed by detailing the 
results and conclusions. It should be noted that a team of clinical and methodology experts 
were involved in the review on a supervisory level. However, all components of the review 
were primarily conducted by the PhD candidate (Joie Ensor), including the searches, selection 
of relevant studies, data extraction, qualitative and quantitative summaries, and 
recommendations.  
2.2 Methods 
The objectives of the review were to: 
• Identify relevant articles that described either development or validation of a 
prediction model predicting the risk of recurrent VTE or adverse outcome following 
cessation of therapy for a first unprovoked VTE 
• Summarise the quality (risk of bias) of identified studies 
• Qualitatively summarise the content of the models identified and their predictive 
performance 
• If considered appropriate, use meta-analysis to quantitatively summarise (pool) 
predictive performance across studies 
2.2.1 Search strategy to identify relevant studies 
The following bibliographic databases were searched: Cochrane Library (Wiley) (including the 
Cochrane Database of Systematic Reviews, DARE, HTA Databases and CENTRAL Register of 
Controlled Trials), MEDLINE (Ovid) 1950- July 2014, MEDLINE In - Process & Other Non-
Indexed Citations (Ovid) to date and EMBASE (Ovid) 1980- July 2014. Searches used index 
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terms and text words that encompassed the patient group supplemented by terms relating to 
recurrence or adverse outcome and prognostic factors; an example of the search strategy as 
used for MEDLINE is presented below; 
Database: MEDLINE (Ovid) 1946 to July Week 3, 2014 
Search strategy: 
1. exp Venous Thromboembolism/ 
2. Pulmonary Embolism/ 
3. exp Venous Thrombosis/ 
4. (vte or dvt or pe).ti,ab. 
5. deep vein thrombosis.ti,ab. 
6. pulmonary embolism.ti,ab. 
7. venous thrombo$.ti,ab. 
8. or/1-7 
9. (recurrence or recurr$ or re-occur$).ti,ab. 
10. Recurrence/ 
11. exp Death/ 
12. (death$ or mortality).ti,ab. 
13. Mortality/ 
14. clot$.ti,ab. 
15. Hypertension, Pulmonary/ 
16. pulmonary hypertension.ti,ab. 
17. post thrombotic syndrome.ti,ab. 
18. PTS.ti,ab. 
19. or/9-18 
20. “Predictive Value of Tests”/ 
21. predict$.ti,ab. 




26. exp Anticoagulants/ 
27. (anti-coagul$ or anticoagul$ or warfarin or ace nocoumarol 
or coumadin or coumarin or phenprocoumon or sintrom  or 
sinthrome or jantoven or marevan or waran or nicoum alone or 
dicoumarol or dicumarol).ti,ab. 
28. (phenindione or dabigatran or ximelagatran or a pixaban or 
rivaroxaban or edoxaban or azd0837 or ly517717 or y m150 or 
betrixaban or idraparinux).ti, ab. 
29. or/26-28 




Publicly available trials registers were also searched, such as ClinicalTrials.gov, UK Clinical 
Research Network Study Portfolio Database (UKCRN), WHO International Clinical Trials 
Registry Platform and the metaRegister of Controlled Trials (mRCT). Reference lists of all 
included papers were checked and subject experts were contacted. No restrictions on 
publication language were applied. 
In addition, abstracts from the Conference Proceedings Citation Index (CPCI) were searched 
in order to capture studies that were not yet fully published. 
2.2.2 Inclusion criteria 
Study Design: Studies of any design (e.g. cohorts, RCTs) or systematic reviews that developed, 
compared or validated a prognostic model (or clinical prediction rule based on a model) 
utilising multiple (at least two) predictors to predict the risk of recurrent VTE or adverse 
outcome (mortality or bleeding) following cessation of therapy for a first unprovoked VTE. The 
decision to focus on multivariable models was a consensus amongst the wider study team, 
who deemed VTE recurrence as a multi-faceted problem, and thus unlikely to be explained by 
just a single predictor. 
Patient group: Relevant patients were those aged ≥ 18 years with a first unprovoked VTE 
where the patient had received at least three months treatment with an OAC therapy. Studies 
with mixed populations (including those outside of remit) were included provided that 
appropriate data for the defined group of relevant patients was extractable.  
Setting: Studies in any setting were included. 
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Potential prognostic models: Studies were included if they reported a prognostic model 
utilising multiple predictors to predict the risk of recurrent VTE or adverse outcome following 
cessation of therapy for a first unprovoked VTE, in the defined patient group of interest. A 
prognostic model was defined as a combination of at least two predictors within a statistical 
model (e.g. a multivariable regression model), used to predict an individual’s risk of outcome 
(e.g. VTE recurrence). 
2.2.3 Study selection 
Study selection followed a two-step process. Titles and (where available) abstracts were 
initially screened by two reviewers (Joie Ensor and David Fitzmaurice) independently, using 
predefined screening criteria. These were broadly based on whether studies, 1) included 
patients with a first unprovoked VTE, who received a minimum of three months OAC therapy, 
and 2) developed or examined prognostic models in relation to individual prediction of VTE 
recurrence or other adverse outcomes (mortality or bleeding).  
Full texts of any potentially relevant articles were then obtained and two reviewers 
independently applied the full inclusion criteria (see APPENDIX A: Chapter 2 Appendices). Any 
discrepancies between reviewers were resolved by discussion or by referral to a third 
reviewer. Portions of non-English language studies were translated where necessary to 
facilitate study selection and subsequent data extraction. The study selection process was 
documented using the PRISMA flow diagram. Any relevant systematic reviews identified were 
screened to identify any further primary studies. Reference management software (Endnote) 
was used to record reviewer decisions, including reasons for exclusion. 
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2.2.4 Data extraction 
In those articles deemed relevant, data extraction was then conducted independently by two 
reviewers (Joie Ensor and Kym Snell) using an in-depth piloted data extraction form. 
Disagreements were resolved through discussion or referral to a third reviewer.  
Data extraction included the following elements: 
• Study characteristics (e.g. sample size, country, year) 
• Study design characteristics (e.g. design, length of follow-up) 
• Patient characteristics (e.g. summaries of age, sex, family history, treatment details in 
the sample) 
• Candidate predictors considered and their definitions (e.g. any thresholds used for 
continuous predictors, methods of measurement, timing of measurement post 
cessation of therapy) 
• Outcome measures (e.g. recurrence of VTE, mortality, bleeding) 
• Statistical methods employed and how predictors included in the analysis were 
handled (e.g. continuous vs. dichotomised). 
• Prognostic model details, including: the final model equation and included 
predictors; how the model was developed and how it can be used to obtain an 
individual’s risk probability; and any internal and external validation performance 
statistics for model performance (including discrimination and calibration) together 
with their confidence intervals. 
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2.2.5 Assessment of study quality (risk of bias) 
The quality (risk of bias) of any studies developing or evaluating a prognostic model was 
assessed by piloting an early version of PROBAST (Prediction study Risk Of Bias Assessment 
Tool), a tool for assessing risk of bias and applicability of prognostic model studies, that was 
nearing completion and ready for piloting when this review was undertaken (92). PROBAST 
defines risk of bias as “any flaw or shortcoming in the design, conduct or analysis of a primary 
study that is likely to distort the predictive performance of a model.” In particular, bias that 
would lead the reported calibration and discrimination of a model to be systematically wrong 
(beyond the play of chance). 
Particular elements were considered in the following domains: 
• Patient selection, such as 
o  what study design was used (e.g. prospective),  
o  if appropriate inclusions and exclusions were used, and  
o  whether patients had similar disease presentation, or if this was accounted 
for in analyses 
• Outcomes, such as whether 
o the outcome definition was pre-specified,  
o  included predictors were excluded from the outcome definition,  
o  the same definition and assessment was used for predictors and outcomes in 
all patients, and  
o  the outcome was determined blind to predictor information 
• Predictors, such as whether 
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o the same predictor definitions were used for all patients,  
o  predictors were measured blinded to outcome data,  
o  all predictor information was available at the time the model was intended 
for use, and  
o  non-linear associations for continuous predictors were considered and, if 
undertaken, predictor categorisation was not data-driven 
•  Sample size, such as   
o whether there was a pre-specified sample size consideration for model 
development accounting for numbers of events and multiple comparisons in 
selection of predictors,  
o  whether all enrolled patients were included in analyses, and  
o  how much data was available for external validation 
• Missing data, including whether 
o there was adequate reporting on completeness of data, and  
o  multiple imputation was considered 
• Statistical analysis, such as 
o  handling of continuous predictors,  
o  selection of possible predictors irrespective of univariable analyses,  
o  whether weights assigned to predictors in the final model’s statistical 
equation related to the same regression coefficients as from the fitted model 
in the development data 
•  Internal and external model validation  
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o  Whether model validations in terms of predictive performance were 
reported and how these were obtained; in particular, whether calibration and 
discrimination statistics were presented, and, during internal validation, 
whether over-fitting and optimism was evaluated and accounted for (e.g. 
using bootstrapping or shrinkage techniques)  
 
2.2.6 Summarising identified evidence 
For each unique model identified, the evidence available was summarised using the extracted 
data. In particular, each model was narratively summarised in terms of; the model 
development and validation methodology, the included predictors and how they were coded, 
the specification of the model and how it could be used, whether the model was validated 
internally and externally (and if so how), and the reported performance of the model in terms 
of calibration and discrimination. The PROBAST evaluation was used to determine the risk of 
bias of the model (that is, whether the model is likely to work as intended for the VTE 
population of interest), with model’s classed as low, moderate, or high risk of bias.  
The consistency of development methods used and main findings were examined to identify 
whether studies at higher risk of bias produced different results and conclusions to those 
considered to be at low risk of bias. 
If multiple studies were found that validated the same prognostic model, it was planned to 
meta-analyse estimates of calibration (e.g. Expected/Observed events) and discriminatory 
(e.g. C statistic) performance using a random-effects meta-analysis (113, 159), to summarise 
58 
 
the model's average performance across different settings and its potential performance in a 
future setting. 
2.2.7 Relevant articles identified outside of search dates 
Before publication of the review in BMJ Open, a further search was performed beyond the 
initial literature search period, in case further studies had been published. Two relevant 
studies were identified; these were published in February 2015 (160) and September 2015 
respectively (161); both of these will be discussed in detail later as evidence found outside the 
systematic review searches (see section 2.3.4).  
2.3 Results 
2.3.1 Quantity of research available 
Searching of bibliographic databases resulted in 13,516 records identified after automatic 
removal of 1,879 duplicates. A further 2,747 duplicate records were manually removed, 
leaving 10,769 records to be screened for inclusion. Screening of titles and abstracts identified 
10,485 records irrelevant to the review question. Full text articles were sought for eligibility 
assessment, three articles were unobtainable from the British library (162-164) and a further 
three articles were unable to be translated into English (165-167) out of 19 non-English 
language articles (i.e. 16 were translated). Of the 278 full text articles assessed for inclusion, 
258 articles were excluded with; 
• 91 articles excluded as discussion or review articles that did not develop or update a 
prognostic model,  
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• 150 articles were excluded based on issues related to the model (e.g. not for 
individual prediction, emphasis on the effect of a single predictor etc.),  
• 3 articles were excluded based on the study population, and  




Figure 2.1 - PRISMA flow diagram showing the quantity of research available. 
61 
 
Twenty articles therefore met the inclusion criteria after screening, comprising seven on-going 
studies (168-174), eight conference abstracts (175-182), one project record referring to the 
project this work forms part of (98, 183), and four full text peer-reviewed articles (37, 39, 40, 
184).  
The authors of the 15 conference abstracts and on-going studies were contacted to seek 
additional information. Based on author responses 13 of the 15 abstracts/on-going studies 
were associated with the four full text articles already identified. The authors of the remaining 
two articles (which were both abstracts) did not respond to further enquiry and so no further 
publications could be found to supplement the available abstracts (168, 176). One, a study by 
Raskob et al. (176) is based on data from the EINSTEIN extension study (185), and aimed to 
identify a subgroup of patients at high and low risk of recurrent VTE. Further information 
regarding the study was unavailable from the included abstract, therefore it was unclear 
whether a prognostic model was developed and if individual recurrence risk could be 
predicted from such a model. The second abstract relates to the ongoing VISTA study (168), 
discussed later in the article.  
The remainder of this chapter focuses on summarising and critiquing in detail three of the full 
text articles included in the review (and their 13 associated abstracts). The fourth full text 
article was an update to one of the earlier models and is given special attention later (see 
section 2.3.3). First, a brief introduction to the full text articles and the models developed is 
given. Throughout this chapter these articles will be referred to using the name of the 
corresponding model developed (i.e. HERDOO2, Vienna, and DASH). 
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HERDOO2 model (39) 
Rodger et al. used conditional logistic regression to develop a prognostic model for use as a 
clinical decision rule (see Figure 2.2). This suggested that a female patient with less than two 
predictors (post-thrombotic signs (either leg hyperpigmentation, edema or redness), D-dimer 
level ≥ 250 µg/L, BMI ≥ 30 kg/m2 or age ≥ 65 years) could potentially safely discontinue OAC 
therapy after five to seven months of initial OAC therapy for an unprovoked VTE. A low risk (< 
3% annual recurrence risk) group of males could not be identified in the study and therefore 
Rodger et al. recommended that all male patients continue OAC therapy (39). 
Vienna prediction model (40, 184) 
Eichinger et al. used a Cox proportional hazards model to develop a prognostic model 
including sex, site of index event and D-dimer as predictors (see Figure 2.2). A nomogram 
based on the prognostic model was derived to allow easy implementation of the model and 
can be used to calculate patient’s cumulative recurrence rate at 12 and 60 months from 
cessation of therapy, with estimated 95% confidence intervals (40). Another full text article 
included in the review describes an update to the proposed Vienna model (see section 2.3.3), 
by recalculating the model at 3, 9 and 15 months after cessation of therapy using new 
measurements of D-dimer levels at these time points. Eichinger et al. used a dynamic 
prediction approach in the updated model and adapted a Fine-Gray model to allow for the 
competing risk between recurrence and death (in some of those who restart therapy) (184). 
DASH score (37) 
Tosetto et al. used a Cox proportional hazards model to develop a prognostic model including 
predictors for abnormal D-dimer levels (+2 score), age ≤ 50 years (+1 score), male sex (+1 
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score) and hormone use (-2 score) (see Figure 2.2). This proposed score can be used to 
calculate patient’s cumulative recurrence risk at one, two and five years from cessation of 
therapy, with estimated 95% confidence intervals. Tosetto et al. suggest that a combined 
DASH score ≤ 1 would indicate an annual recurrence risk < 5% and therefore indicate that a 
patient could potentially stop OAC therapy, conversely a DASH score > 1 would indicate annual 
recurrence risk > 5% and thus suggest patients should potentially continue OAC therapy (37).  
 
Linear predictors of models included in the review 
A linear predictor (LP) describes the combination of the included predictors and their 
estimated regression coefficients as described in chapter 1. The following describes the 
linear predictors for each of the included models. 
HERDOO2 
The HERDOO2 model is a logistic regression model for which the LP was defined as 
follows, where the regression coefficients represent log odds ratios; 
LP = –3.9717 + (1.2977 x BMI ≥ 30 kg/m2) + (0.6473 x post-thrombotic signs) + (0.9155 x 
D-dimer ≥ 250 μg/L) + (0.8084 x age ≥ 65 years) 
Vienna  
The Vienna model is presented as a nomogram which is based on a Cox regression model, 
meaning that the regression coefficients in the LP below represent log hazard ratios. 
LP = (0.64 x Male) + (0.96 x PE) + (0.73 x Proximal DVT) + (0.24 x D-dimer (per doubling)) 
DASH 
The DASH model is a score system based on the optimism corrected coefficients of a Cox 
regression model, with the following linear predictor; 
LP = (0.96 x D-dimer (abnormal)) + (0.43 x age ≤ 50 years) + (0.58 x Male) + (-1.05 x 
Hormone use in women (at time of initial VTE)) 
The scores used in the final rule were calculated by doubling the above regression 
coefficients and then rounding to the nearest integer. 
Figure 2.2 - Linear predictors of prognostic models included within the review 
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2.3.2 Quality assessment and critical appraisal 
Population characteristics 
The population characteristics of the three study populations were broadly similar across 
predictors measured in all studies (see Table 2.1). The median age of patients in the DASH 
population was somewhat higher than that of the HERDOO2 and Vienna study populations, 
and the Vienna study included longer follow-up compared to the other studies, both of which 
could affect estimates of predictor effects in the models.  
Patient selection & outcomes 
All of the three articles developed models based on data collected using a prospective design 
(see Table 2.2), which is ideal for prognostic modelling as predictor information can be 
collected blind to patient outcome. Across all three articles, recurrent VTE (at various 
predicted time points) was the primary outcome (see Table 2.2), and was objectively 
confirmed and independently adjudicated. Detection bias was limited in all three articles by 
pre-specification of outcome definitions, with the same definition and assessment used for all 
patients (within each study), meaning systematic differences in the determination of 
outcomes were avoided.  
The inclusion/exclusion criteria used in the three articles is summarised in Table 2.3, and 
common criteria included the exclusion of patients with high-risk thrombophiliac conditions, 




Table 2.1 - Summary patient characteristics of included model studies 
 Model HERDOO2 Vienna DASH 
Measurement statistics 
used 
Mean (SD) or Freq (%) 
Median (25th, 75th 
percentiles) or Freq (%) 
Median or % 
Patient characteristic n Recurrence n 
No 
recurrence 
n All n Recurrence n 
No 
recurrence 
Age (years) 91 53.6 (14.8) 555 52.3 (17.9) 929 54 (43, 63) 239 63 1579 61 
Male proportion 91 63 (69.2) 555 269 (48.5) 929 562 (60) 239 69.40% 1579 48.60% 
Site (Distal DVT) proportion 91 NA 555 NA 929 164 (17.7) 239 NA 1579 NA 
Site (Proximal DVT) 
proportion 
91 NA 555 NA 929 327 (35.2) 239 NA 1579 NA 
Site (PE) proportion 91 NA 555 NA 929 438 (47.1) 239 NA 1579 NA 
BMI (kg/m2) 91 30.3 (7.6) 555 28.9 (7.1) 909 27.1 (24.4, 30.1) ^ 27.2 ^ 27.2 
D-dimer (µg/L)ᶲ 91 383 (738) 555 294 (314) 832 355 (236, 558) 239 67.7%* 1579 42%* 
Factor V Leiden proportion 91 19 (20.9) 554 81 (14.6) 916 224 (24.4) 239 NA 1579 NA 
Duration of OAC (months) 91 5 to 7 555 5 to 7 929 6.6 (6.1, 8.0) 239 6.7 1579 6.8 
Duration of follow up 
(months) 
18 (1, 47)# 43.3 (14.7, 78.5) 22.4 
* DASH reported the percentage with abnormal D-dimer, defined as ≥ 500ng/mL 
^ BMI data available for 802 subjects, no reporting of number of subjects by event status 
# Follow-up for HER DOO 2 presented as mean (range) 
ᶲ D-dimer measured in ng/mL within the DASH article 
NA – The information was not provided for these fields. In particular, both the HERDOO2 and DASH studies did not include patients with distal DVT index events a priori. And the DASH 
study did not provide figures for the proportion of patients with Factor V Leiden, but the percentages of patients with thrombophilia were 23.4% and 20.9% for recurrence and non-
recurrence respectively.  
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Table 2.2 - Study characteristics 
 
Table 2.3 - Study inclusion/exclusion criteria 
Model HERDOO2 Vienna DASH 
Inclusion 
criteria 
First unprovoked VTE 
Received OAC 5-7 months 
No recurrent VTE on 
treatment 
First unprovoked VTE 
Age ≥ 18 
Received OAC ≥ 3 months 
First unprovoked VTE 
Including thrombophilic 
blood abnormalities 
where there were no 
other VTE risks 
Exclusion 
criteria 
Age < 18 
Deficiency in 
antithrombin, protein C or 
S 
Presence of lupus 
anticoagulant 
Already discontinued OAC 
Geographically 
inaccessible to follow-up 
Not proximal DVT or PE 
index event 
Deficiency in 
antithrombin, protein C or 
S 
Presence of lupus 
anticoagulant 








Model HERDOO2 Vienna DASH 
Year of 
publication 





Austria, Canada, Italy, 
Switzerland, UK, USA 
Study setting 
12 tertiary care centres, 
patients enrolled 
between October 2001 
and March 2006 
Recruited from 4 
thrombosis centres in 
Vienna between July 
1992 and August 2008 
Patient-level meta-
analysis of previously 
published studies (11) 
Study design 




Individual patient data 








12  12, 60  12, 24, 60  
Total sample 
size  
646 929 1818 
Events 91 176 239 
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All articles only included patients with a first unprovoked VTE, but definitions of unprovoked 
varied somewhat (see Table 2.4). The HERDOO2 and DASH models both included patients with 
hormone intake at time of index event, while the HERDOO2 model also included pregnancy 
associated VTE at index event within its definition of unprovoked VTE. The DASH model study 
justifies including hormone intake as unprovoked because some evidence suggests hormone 
therapy is a weak predictor for VTE recurrence (37, 186). However, evidence suggests that 
these risk factors are acquired (154), and inclusion of patients outside the unprovoked 
population might therefore lead to biased conclusions about predictor effects.  
Table 2.4 - Unprovoked VTE definition across studies 
Model HERDOO2 Vienna DASH 
Not provoked by: 
Trauma X X X 
Surgery X  X  X 
Cancer X X X 
Pregnancy - X X 
Immobility X - X 
Hormone intake - X - 
 
Predictors 
The three studies investigated a wide variety of candidate predictors, including clinical and 
laboratory predictors. There was some overlap between models (see Table 2.5), with D-dimer, 
age and sex being the most commonly included predictors. The Vienna model avoided the 
categorisation of continuous candidate predictors, while the DASH model investigated patient 
age in pre-specified quartiles, to allow for non-linear associations between age and recurrence 
risk. The HERDOO2 model in contrast performed chi-squared testing to identify the optimal 
threshold to dichotomise every continuous predictor under consideration.  
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Data-driven analyses are known to incite reporting biases, where optimal thresholds are 
reported without any clinical meaning (187). Dichotomisation of continuous predictors is also 
methodologically poor, as it seeks to separate patients risk into two categories, treating all 
those above the threshold as having the same constant risk (and similarly for those below the 
threshold), which is unrealistic in practice (187). 
All models also allowed for site of index event in some way. Both the HERDOO2 and DASH 
models excluded patients with distal DVT index events from their studies (37, 39), which is 
important risk stratification in itself (i.e. both models are not applicable to patients with distal 
DVT events). Only the Vienna model included such patients and adjusted for site of index event 
as a predictor in the model (see Table 2.5). The Vienna models predicted risks reflect the low 
risk of recurrence associated with distal DVT index events, and provides an estimate of risk 
(where the other models do not) which may be a helpful tool in consultation with patients and 
confirm treatment decisions (11).  
Table 2.5 – Predictors included in final model  
Model HERDOO2  Vienna DASH 
Predictors included:  
D-dimer X X X 
Age X - X 
Sex - X X 
BMI X - - 
Post thrombotic signs X - - 
Site of index event - X - 





The HERDOO2 model was markedly underpowered. The study collected information on 69 
predictors and considered at least 36 of these; however, there were only 91 recurrent events 
(see Table 2.2), meaning around 2.5 events per predictor (EPP) assuming all patients had 
complete data for candidate predictors. Previous evidence has suggested that an EPP < 10 can 
lead to bias in estimates of predictor effects and their standard errors, as well as the coverage 
of confidence intervals, with EPP=2 showing severe biases (188, 189). This may then cause 
over-fitted models (i.e. models that include inappropriate predictors or predictor effects that 
are too large) and subsequently misleading predictions. The Vienna and DASH models 
investigated 15 and 14 candidate predictors respectively, with 176 and 239 total events 
respectively (see Table 2.2). Following the same rule of thumb (EPP < 10) (188, 189), and 
assuming complete predictor availability for all patients (i.e. no missing data), the Vienna (just) 
and DASH models therefore had sufficient numbers of events to assess the predictors of 
interest with appropriate statistical power (see Figure 2.3). Recent evidence has questioned 
the EPP rule described above, highlighting deficiencies in the original studies and suggesting 
that there is no one-size fits all rule when it comes to sample size requirements for prediction 




Figure 2.3 - Events per predictor (EPP) for included studies, based on total sample size and number of predictors. NB: 
lines represent number of events required to maintain EPP=x for given number of predictors. 
 
Missing data 
All of the three included studies suffered from some degree of missing predictor information, 
and used a complete case analysis to overcome this issue. The presence of missing predictor 
data would further reduce the apparent EPP discussed above (see Figure 2.3). Each study also 
used a selection procedure meaning more predictors were considered, resulting in a higher 
proportion of missing predictor data. For example the Vienna prediction model considered 
peak thrombin as a predictor, for which 300 out of 929 patients had missing predictor 
information (40). Similarly, the DASH model considered predictors including BMI, for which 
71 
 
only 802 out of 1818 patients had complete predictor information (37). This means that the 
predictor selection process included a massively reduced sample size compared to the data 
used toward the final model, which may have increased the chance of spurious predictor-
outcome relationships (see Figure 2.4).  
 
 
Figure 2.4 - Final model sample size compared to total & selection sample size. Final model sample size=total sample 
minus patients with missing information in any predictor included in the final model; Predictor selection sample 
size=total sample size minus patients with missing predictor information in any predictor considered for inclusion in the 
model using a selection procedure. 
 
No methods to assess the impact of this missing predictor information were used, and in the 
Vienna and DASH models the number of missing recurrent events was not reported, so no 
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assessment of the impact on statistical power (nor EPP) could be made accurately. A complete 
case analysis in the presence of missing data may not represent the entire population, and 
reduces sample size giving lower power and making predictor effects only pertinent to a 
specific subgroup of the population with no missing data. Multiple imputation (MI) can be 
used as a sensitivity analysis to assess the impact of missing data on the performance of the 
model. MI using chained equations imputes missing predictor information from a posterior 
distribution based on the observed data (57); it increases sample size, power, and may 
improve the generalisability of the model. However, this was not used in the development of 
any of the articles.  
Statistical analysis 
A Cox proportional hazards model was used to develop both the Vienna and DASH models, 
which appropriately accounts for censoring of patients in the analysis of time-to-event 
outcomes such as recurrence (41). The HERDOO2 model used a conditional logistic model for 
analyses, which does not account for the censoring of patients over time and the variable 
lengths of individual follow-up (34).  
All studies recruited patients from different centres or countries (see Table 2.2), however only 
one (DASH model) stratified by source in their analyses. Stratification accounts for 
heterogeneity in the baseline recurrence risk in different patient groups. Ignoring the 
clustering of patients within centres or countries could lead to poor model calibration (where 
model predictions do not closely fit observed recurrence rates) and/or biased predictor effects 
(16, 17, 20), and thus could diminish performance in a new setting. The DASH model did not 
propose how to implement the model in practice; where models are stratified there a several 
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options for implementation and so it is important to be clear which one is to be used in 
practice (19, 20, 34) (e.g. use a single intercept related to one of the centres).  
The HERDOO2 model excluded predictors from multivariable analysis where univariable 
analysis yielded p-values ≥ 0.2; this predictor selection strategy was therefore completely data 
driven, which could lead to potential bias in results, with predictor effects that may be 
important in combination being excluded. The DASH model also excluded some predictors 
from multivariable analysis on the basis of univariable results. Univariable analyses are not 
recommended for decisions about inclusion of predictors in a multivariable model (49). 
Both the Vienna and DASH models used bootstrapping and shrinkage methods to adjust 
predictor coefficients for optimism (see chapter 1), but the HERDOO2 development did not 
account for optimism in predictor estimates, despite the extremely low EPP. The use of 
optimism correction methods reduces over-fitting by reducing the magnitude of predictor 
effects, to help ensure the model performance is more accurate in a new patient population 
(33, 38).  
The specification and application of the proposed models was described in various ways across 
the studies. Both the Vienna and DASH models were presented well, with an indication of how 
the predictors are combined to calculate a patient’s recurrence risk at a specific time point. 
Both provided cumulative recurrence risk at specific time points after cessation of therapy 
including an estimate of the uncertainty surrounding these estimates (95% confidence 
intervals). This information could be used to direct the decision making process, informing 
clinicians and patients of the individual’s level of risk, and therefore allowing individualised 
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treatment strategies. However, neither reported any estimate or parameterisation of the 
baseline hazard or survival function, which would be required for full external validation of 
the model in a new setting (144, 145, 147).  
Conversely the HERDOO2 model derived a clinical decision rule splitting patients into those 
with less than two predictors (from their model), and those with greater than two predictors, 
suggesting that one group should continue OAC therapy, while the other could safely stop. 
The HERDOO2 model does not allow fully individualised risk estimates at specific time points; 
it only indicates that fewer than two predictors would indicate a < 3% annual risk of 
recurrence. This therefore does not allow clinicians or patients to make decisions based upon 
their preference of recurrence risk threshold, limiting the applicability of the decision rule if a 
value other than 3% was of interest. 
Model validation 
Model performance was evaluated using internal validation in all the studies, but none 
reported an external validation (37, 39, 40). Internal validation was reported in terms of both 
calibration and discrimination with both the Vienna and DASH models presenting both 
(though not for the simplified Vienna nomogram, which constitutes the final model). The 
HERDOO2 model presented neither calibration nor discrimination statistics. The performance 
statistics reported are given in Table 2.6. Apparent C-statistics (which represent the 
discriminatory performance within the development data without adjustment for optimism) 
are between 0.65 and 0.72 for the different models, indicating moderate discrimination 
ability; however apparent performance is likely to be optimistic (34). The Vienna model also 
presented a bootstrap adjusted C-statistic (which accounts for optimism) of 0.646 for 
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predictions at five years post cessation of therapy, indicating a small reduction after 
accounting for optimism. The Vienna and DASH models also provided a bootstrap optimism-
adjusted calibration slope (or uniform shrinkage factor), which showed moderate calibration 
performance of 0.88 for the Vienna model, and strong performance of 0.97 for the DASH 
model (with 1 indicating perfect calibration). Both the Vienna and DASH models used their 
shrinkage factor to adjust the predictor effect values in their final model, to adjust for the 
optimism. 
External validation is the true indication of model performance in the wider population, as a 
model validated within its development dataset will give optimistic performance statistics (9, 
28, 147). External validation studies are currently being undertaken to validate both the 
HERDOO2 model (169-171) and the Vienna model (168), which will provide a more robust 
indication as to the overall performance (in terms of calibration and discrimination) of these 
models in new patient populations where they are intended for use. The REVERSE II study is a 
randomised trial aiming to compare the impact (on patient outcomes) of using the HERDOO2 
model to decide on cessation of OAC therapy, compared to standard practice (169, 171). The 
VISTA study is a randomised trial comparing the use of the Vienna model to decide on 












HERDOO2    
Model for use (Score) - - - 
Development model (Beta 
terms) 
- - - 
Vienna     
Model for use (Nomogram) - - - 
Development model (Beta 
terms) 
0.88 0.651 60 month = 0.646 
DASH    
Model for use (Score) - 0.71 - 
Development model (Beta 
terms) 
0.974 0.72 - 
* Bootstrap calibration slope 
^ C-statistic based on development data 
# C-statistic based on bootstrap internal validation 
 
2.3.3 Update to the Vienna prediction model 
The authors of the Vienna model also recently developed an update to the original Vienna 
model, with the aim of predicting recurrence risk at later time points using updated D-dimer 
measurements (184). New D-dimer measurements were taken at 3, 9 and 15 months post 
cessation of therapy, with analyses showing a slight decrease in hazard ratios for the effect of 
log D-dimer over time (though the 95% confidence intervals remained similar) (184). Three 
new nomograms were developed for use in practice to predict recurrence risk at 12 and 60 
months from time of new D-dimer measurement. A web based calculator was also developed 
by the authors allowing prediction of recurrence risk at any integer month after baseline (3 
weeks) and up to 15 months post cessation of therapy.  
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The updated model was adjusted for optimism using leave-one-out resampling (cross-
validation) to calculate shrinkage factors for 3, 9 and 15 months of 0.79, 0.81 and 0.7, 
indicating moderate calibration of the model but reduced performance compared to the 
original Vienna model (optimism-adjusted calibration slope = 0.88). Discriminatory 
performance for 5 year predictions at each new time point showed a small reduction in 
performance compared to the original model (optimism adjusted AUC values were, 0.61, 0.61 
and 0.58, for 3, 9 and 15 months, compared to AUC=0.646 for the original model) (40, 184). 
The updated Vienna model expands the earlier model by allowing dynamic prediction of 
recurrence risk over time, but while the earlier Vienna model has recently been externally 
validated (160), this model has not been externally validated to date, and shows inferior 
internal validation performance statistics compared to the original model. 
2.3.4 Relevant articles identified outside of review search dates 
Subsequent to the completion of the initial review searches (1950 – July 2014), two additional 
highly relevant studies were identified (160, 161). The first was an external validation of the 
Vienna prediction model using IPD from five studies, which aimed to assess the performance 
of the Vienna model in terms of both discrimination and calibration in a new population (15, 
160). 
The study reported that the derivation and validation populations were homogeneous after 
removal of patients with provoked VTE and those with missing predictor information (160). 
Discrimination was calculated using the C-statistic for comparison to the original Vienna 
model, with a C-statistic in the validation cohort of 0.626 compared to 0.646 (the optimism 
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adjusted discrimination – see Table 2.6) for the derivation data, indicating a reduction in the 
discriminatory performance of the model in a new setting.  
The true calibration of the model in the validation data could not be assessed without the 
baseline hazard function (76, 144, 145, 147). As the original Vienna model was developed 
using a Cox model which does not parameterise the baseline hazard function, this meant that 
assumptions about the shape of the baseline hazard function had to be made (144, 145, 147, 
160). The authors recalibrated the Vienna model assuming a Weibull distribution; however, 
this is akin to a new model development or updating of the model because the baseline hazard 
is refitted in the new data. Therefore this new model (including new baseline hazard) would 
itself require further external validation (144, 145, 147). As the authors could not use the Cox 
model directly to predict survival probabilities (due to the lack of baseline hazard function), 
they could only assess calibration using risk groups defined by the prognostic index alone, to 
make predictions for groups of patients within the validation data (76, 147). Comparison of 
observed and expected survival probabilities in five risk groups showed a general trend for the 
Vienna model to under predict the risk of VTE recurrence at 12 months post-cessation of 
therapy (160). It should be noted that the study did not validate the simplified Vienna 
nomogram proposed for use in practice (147, 160). 
The second study identified after the initial review period was an external validation of the 
updated Vienna model (see section 2.3.3) in a prospective multicentre cohort study (161). The 
study aimed to validate the updated model in elderly patients over 65 years old, and assessed 
the models performance in terms of discrimination and the proportion of recurrent events 
between high and low risk patients defined by the model. The study found no difference 
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between the proportion of recurrences in the low vs. high risk groups (where recurrence risk 
<6.2% 12 month was defined as low risk). Discriminative performance was poor at both 12 
and 24 months, with C-statistics of 0.39 (95% CI 0.25, 0.52) and 0.43 (95% CI 0.31, 0.54) 
respectively.  
The study suffered from a very low number of events, 17 and 26 by 12 and 24 months 
respectively. Therefore the conclusions of the study should be interpreted with caution, as it 
is known that small validation samples tend to show poor calibration and discrimination 
performance, with current recommendations indicating that validation sample sizes should 
be a minimum of 100 events and preferably ≥ 200 events (76, 191). Also there were several 
distinct differences between the derivation patient population for the updated Vienna model 
and the validation sample used by Tritschler et al. which naturally led to heterogeneity in 
model performance. In particular the validation study used a much older population (median 
(IQR) age 74 (69, 79.8) versus 54 (43, 63) in the derivation population). This also led to 
differences in D-dimer levels, with the elderly patients in the validation study having much 
higher D-dimer levels (median (IQR) D-dimer 1022 (607, 1755) versus 355 (236, 558) in the 
derivation population). Further to this, women in the validation study appeared to have much 
greater risk of recurrence than men, which is discordant with current evidence suggesting that 
men are between 1.5 to 2 times more likely to suffer a recurrence (37, 39, 40, 192, 193). These 
differences in baseline characteristics may mean that the predictor effects in the updated 
Vienna model were miscalibrated when applied in this new population, leading to the poor 
performance seen in the validation study. However, performance of the Vienna model in 
populations similar to the originally intended population may show adequate performance 
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and so further validation is needed in external populations with more similar case-mix to 
assess the models generalisability (28).  
2.3.5 Quality assessment and risk of bias summary of HERDOO2, Vienna and 
DASH models 
Quality assessment based on the early version of the PROBAST tool showed that there was 
evidence throughout the included studies of a moderate to high risk of bias (see Table 2.7), 
predominately because of a lack of external validation (see Table 2.6 and Table 2.7). The 
HERDOO2 model development suffered high risk of bias, due to some markedly poor 
methodological choices, including the choice of analysis model, substantially underpowered 
analyses, data-driven categorisation of predictors, lack of adjustment for optimism, and poor 
presentation of the model for use (see Table 2.7). In contrast, the Vienna prediction model 
and DASH score were considered generally methodologically sound in terms of their 
development. Both had statistical power to investigate their candidate predictors, accounted 
for optimism in their selection procedures, and the Vienna study assessed continuous 
predictors without categorisation and loss of information (though the DASH study did 
categorise continuous predictors). Both studies presented their proposed models more clearly 
than the HERDOO2 model; indicating the recurrence rate associated with predictor values and 
the uncertainty around those estimates. However, predictions were only provided for 
particular, discretised values of risk; for example both models provide predictions for only a 
small selection of time points (Vienna model for 12 and 60 months post therapy, DASH score 
for 1, 2 and 5 years from cessation of therapy), and only provide 95% confidence intervals for 
a small selection of predicted annual recurrence rates.  
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Despite being of generally good methodological quality for development, both Vienna and 
DASH were classed at moderate risk of bias due to a lack of sufficient external validation (see 
Table 2.7). The DASH score has received no external validation, and any such future validation 
should account for the method of implementation, which was not proposed by the authors. 
The Vienna model has now been externally validated (as discussed above), but issues remain 
because: (i) validation performance was shown to be lower than expected and uncertainty 
was high (160); (ii) a new Weibull baseline hazard component was added to the model, which 
itself requires additional validation (144, 145, 147); (iii) the nomogram version of the model, 
which is intended for use in practice, was not validated (147); and (iv) validation of the 
updated dynamic Vienna prediction model in a new population also indicated poor 
performance. Thus, until further external validation is undertaken and the results of on-going 




Table 2.7 - Quality considerations for included studies 
Model HERDOO2 Vienna DASH 
Use of a selection procedure? Yes Yes Yes 
Adjustment for optimism in selection procedure? No Yes Yes 
Events per predictor > 10? No Yes Yes 
Appropriate type of model? No Yes Yes 
Modelled continuous predictors as linear/non-
linear? 
No Yes No 
Considered multiple imputation to handle missing 
data? 
No No No 
Adjustment for optimism in internal validation? Yes Yes Yes 
Reported discrimination? No Yes* Yes 
Reported calibration? No Yes* Yes* 
Were final model predictor weightings related to 
regression coefficients? 
Yes Yes Yes 
Internal validation? No Yes* Yes 
External validation? No Yes* No 
Overall risk of bias classification? High Moderate Moderate 










* Not for the nomogram/score used in practice 
 
2.4 Discussion 
This systematic review of prognostic models for VTE recurrence risk, identified four full text 
articles developing three independent prognostic models (37, 39, 40, 184). A critique of the 
included studies described and identified the strengths and weaknesses of the studies with a 
particular focus on methods of patient selection, outcome reporting, predictor selection, 
sample size, model development and validation. 
Firstly, a key finding was the different definitions of unprovoked VTE across the included 
studies (see Table 2.4). The Vienna model study excluded patients with index events provoked 
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by use of female hormones, such as the oral contraceptive pill or hormone replacement 
therapy (HRT), while the HERDOO2 and DASH studies defined index events related to hormone 
use as unprovoked. Risk factors consistently defined as provoking across the studies included; 
surgery, trauma, immobility and pregnancy (see Table 2.4). The use of varying definitions to 
describe the unprovoked population creates confusion as to which population the proposed 
models are applicable to. Further research in developing prognostic models to predict 
recurrence risk in an unprovoked population should aim to use a standard, consistent 
definition for the population, excluding patients with acquired/removable risk factors (154), 
to ensure that model predictions are reliable for intended patients. Given the definition of 
unprovoked VTE used in the DASH and HERDOO2 studies, the proposed models may not be 
applicable within an unprovoked population (153, 154). 
Across the included studies various predictors were included within the proposed final 
models, with sex, site of index event and D-dimer level (post therapy) being included 
consistently within all three models, indicating strong evidence of an association with 
recurrence risk (see Table 2.5). As such any future model development should consider 
including these predictors, as they appear prognostic for recurrence risk, and thus evaluate 
new predictors in addition to these. Indeed the discrimination performance shown in current 
models was moderate at best and therefore any new model would ideally include additional 
predictors to improve the discriminatory performance statistically, though a parsimonious 
model may better facilitate implementation in practice (11, 27). While it has been discussed 
that the effect of D-dimer as a predictor may be dependent on the method/assay used, 
previous research has investigated the link between variability in D-dimer assays and 
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recurrent VTE, and found that varying assays do not alter the prognostic value of D-dimer in  
predicting recurrence (15).  
After evaluation of the models' development and validation criteria, all models were labelled 
with at least a moderate risk of bias (see Table 2.7). This was mainly due to a lack of robust 
external validation, which is essential as prognostic model performance is known to be 
optimistic when evaluated on the same data used to develop the model (9). The HERDOO2 
model development was classed at high risk of bias, as - alongside no external validation - it 
had methodological concerns, including the choice of analysis model, substantially 
underpowered analyses, data-driven categorisation of predictors, lack of adjustment for 
optimism, and the presentation of the model for use (39). The Vienna model and DASH score 
were methodologically sound, as they had adequate statistical power to investigate their 
candidate predictors, accounted for optimism in their selection procedures, the Vienna model 
assessed continuous predictors without categorisation and loss of information, and both 
presented their proposed models clearly (37, 40). However, until further external validation is 
performed, the true performance in new populations cannot be ascertained.  
The new external validation study for the Vienna model adds important information on the 
applicability of the model in practice. The study shows that the ability of the model to identify 
those at high and low risk of recurrence is weaker in a new population outside of the 
derivation dataset (160). However, it is important for the Vienna model to undergo further 
validation, because the validation study related to the fitted model (i.e. the prognostic index 
from the fitted Cox model), and not the nomogram (which potentially used a simplified set of 
regression coefficients) which was recommended for use. The updated dynamic Vienna 
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prediction model has now also been externally validated in an elderly population, which 
showed poor discriminatory performance, but suffered from small validation sample sizes and 
large variations in case-mix from the original models intended population (161). Therefore, it 
may be a concern that the current randomised trial to evaluate the impact of using the Vienna 
model in clinical practice is premature (168); that is, reliable external validation performance 
should ideally be established first, before examining impact (26, 64, 79).  
This is the first systematic review identifying prognostic models for VTE recurrence risk in the 
unprovoked population, and as such it is a strength of the study that a robust systematic 
methodology was used, which yielded a large amount of potential research, making it unlikely 
that any relevant study was not included. An important limitation of this review is that the 
conclusions and quality classifications for the prognostic models discussed in this article are 
based on the reporting standards of the original articles. Further, it was not possible to 
perform a quantitative analysis of the identified articles due to a lack of homogeneity in many 
areas, including the included predictors, model structure and study populations (23, 71).  
In conclusion, currently available models to predict risk of recurrent VTE in an unprovoked 
population have several limitations. In particular, sufficient external validation has not yet 
been performed for two of the available models and this review indicates that further 
validation studies are required before the models are implemented in practice. Even then the 
impact of the models on clinical decision-making and, crucially, patient outcomes should be 
evaluated through a randomised trial, ideally, or health economic modelling exercise (9, 26, 
64, 79, 98). Any new models should try to build on the existing work, ensure external validation 
in multiple populations, transparency in reporting of model development as outlined in the 
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TRIPOD statement (33, 68), and finally improved statistical analyses to ensure model 
predictions are more robust. 
The next chapter in this thesis aims to develop and externally validate a new prognostic model 
in this field, as part of a project commissioned by the HTA. Given the findings of this review, 
chapter 3 will aim to build on the previous evidence in terms of both their strengths and 
weaknesses. The new model development will consider the previous evidence for and against 
important predictor effects, and the most common definitions for unprovoked VTE diagnosis. 
In particular chapter 3 will aim to address the shortcomings of previous models in terms of 
the reporting and application of the model, ensuring that future research can use the full 





CHAPTER 3: DEVELOPMENT OF A PROGNOSTIC MODEL 
USING META-ANALYSIS METHODS: PREDICTING RISK OF 




As highlighted in chapter 2, prevention of recurrent VTE is a challenging clinical decision 
problem, which must balance the risks of recurrent thrombosis if OAC therapy is stopped 
versus the risks of bleeding associated with continuing treatment. This has been highlighted 
in recommendations from the 9th ACCP antithrombotic guidelines (156), which particularly 
highlighted this issue of balancing the risks of recurrence and bleeding in unprovoked 
population. The guidelines suggested that those suffering an initial unprovoked DVT should 
be treated with different lengths of anticoagulation therapy dependent upon their bleeding 
risk (156). Those at low to moderate risk of bleeding are suggested to have extended 
treatment over three months of therapy, while those at high risk are recommended to have a 
further three months of therapy beyond this (156).  
Previously the emphasis from a clinical perspective has been to identify those patients at 
sufficiently high risk of recurrence to justify continuing therapy. More recently the emphasis 
has shifted to identifying those patients at sufficiently low risk of recurrence to justify 
cessation of therapy. This reflects an appreciation of the importance of risk of recurrence, with 
recurrent events being fatal in approximately 5% to 9% of patients (40).  
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The current UK guidelines from the British Committee for Standards in Haematology (BCSH) 
(157) state that all patients with a proximal DVT or PE should be treated for at least 3 months, 
in line with ACCP guidance. In terms of extending treatment beyond three months it is stated 
that therapy should be continued if the risk from recurrence on stopping treatment is greater 
than the risk from anticoagulant-related bleeding. However, these opposing risks are not 
easily predicted in an individual. In a patient with an average risk of warfarin-related bleeding 
the annual risk of recurrent VTE that would favour continued anticoagulant therapy has been 
estimated to be between 3% and 9% (157). 
In terms of identifying those patients who may require longer duration of therapy the BCSH 
guidelines identify that patients with unprovoked venous thrombosis have an annual risk of 
recurrence of more than 9% in the first year after stopping treatment (157). As this risk 
exceeds the risk of warfarin-related bleeding, the BCSH recommend that patients with a first 
unprovoked or recurrent episode of proximal DVT or PE should be considered for long term 
anticoagulation (157). The issue is not straightforward, however, as whilst the cohort risk for 
patients with a history of unprovoked venous thrombosis may be greater than 9% as 
suggested by the BCSH, individual patients risk of recurrence is highly heterogeneous.  
The BCSH guidelines illustrate this through identification of a lower annual risk in patients with 
a normal D-dimer result after completion of initial warfarin therapy compared to those with 
an elevated D-dimer (3·5% vs. 9%) (157). D-dimer is a breakdown product of fibrin, the 
principal constituent of a venous clot, and has been mainly used within the context of 
diagnosis of VTE. Within the diagnostic context a normal d-dimer result, defined usually by the 
laboratory, effectively rules out an acute VTE when used in combination with a clinical risk 
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score (194). Risk of recurrence has also been related to the presence of post-thrombotic 
syndrome and male sex (193, 195, 196). 
As most recurrences are easily preventable using anticoagulant therapy, it is of great 
importance that patient characteristics associated with risk of recurrence are identified, so 
that patient therapy can be stratified. Stratification of patients with unprovoked VTE according 
to their recurrence risk might be achieved on the basis of clinical predictors such as gender, 
comorbidities, or weight; or by measuring laboratory markers of thrombophilia such as factor 
V Leiden, the prothrombin 20210A mutation, natural coagulation inhibitor deficiencies, 
elevated coagulation factors, and antiphospholipid antibodies (39, 40, 170, 193). More 
recently efforts have been made to utilise global coagulation markers, including D-dimer, as 
prognostic tools (39, 40). 
Prognostic models are useful tools in the area of VTE recurrence because the population is 
highly heterogeneous and therefore it is useful to have a mechanism to predict individuals’ 
risk rather than arbitrarily categorise patients when deciding upon treatment strategies (39, 
40). As discussed in chapter 1 a prognostic model combines multiple predictors to predict the 
risk of a patient with particular characteristics having an event within a specified time. 
Individual risk predictions can help to inform clinical and patient decision making with regard 
to treatment strategies, in this scenario whether or not to extend treatment with oral 
anticoagulants (OAC) to prevent recurrent VTE. 
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3.1.2 Aims of this chapter 
The systematic review in Chapter 2 highlighted several applicability and methodological issues 
in existing models (95). There was a lack of consistent and appropriate definitions for a first 
unprovoked VTE, for example with some studies not considering hormone intake to be a 
provoking risk factor (37, 39). Several methodological issues were also identified including: 
mishandling of continuous predictors in analyses, underpowered analyses and poor 
presentation of final models for use in practice. Some of the existing models identified by the 
systematic review had not been externally validated (to date), and though internal validation 
had often been performed, external validation is needed to indicate true performance of a 
model in practice.  
The research in this chapter will build on the findings of the systematic review, with the aim 
to develop and externally validate a new prognostic model for the prediction of individual 
recurrence risk following cessation of therapy for a first unprovoked VTE. Individual 
participant data (IPD) will be utilised from multiple cohort studies in order to develop a new 
prognostic model based on multiple predictors, and simultaneously to externally validate the 
developed model. The aim is to provide a final, validated prognostic model which allows 
individualised recurrence risk prediction, which could be used to inform patient care as part 
of an evidence based approach. 
3.2 Methods 
The research that follows was conducted by the PhD candidate, Joie Ensor. The work was 
directed by statistical and clinical supervisors, and input was received throughout the project 
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from a wider collaborating group.  The aims and methods for data collection, patient inclusion, 
model development and model validation are now described. 
3.2.1 Identifying, obtaining & cleaning IPD 
IPD from multiple cohort studies was identified for the project through external collaborators 
in Canada, who had already produced such a database (which will be referred to as the 
‘Recurrent VTE’ (RVTE) database throughout this chapter). Agreement on the sharing of this 
IPD was made with the database holder, clearly stating the intended use of the data for this 
project and agreeing appropriate recognition for those that originally collected the data to be 
used.  
The RVTE database contained seven trials investigating an association between D-dimer, 
measured after anticoagulation was stopped, and VTE recurrence. It included a total of 1634 
patients with a first unprovoked VTE; the median follow-up time post-treatment is 22 months 
and there are 230 recurrent events post-treatment. The database had key two benefits: (i) the 
availability of D-dimer values, which clinical members of the project team thought may add 
considerable predictive value, and (ii) the seven trials in the database allowed internal-
external cross-validation (20, 66), a novel way to develop a model whilst also examining its 
performance in external data, within the framework of an IPD meta-analysis. 
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3.2.2 Population at baseline and outcome of interest 
What defined a relevant population? 
For the purposes of this research, and based on the advice of clinical collaborators, an initial 
VTE was defined as unprovoked where there was no history in the previous three months of 
any of the following risk factors; 
• Major surgery, 
• Lower limb trauma, 
• Use of combined oral contraceptive pill or hormone replacement therapy (HRT), 
• Pregnancy, 
• Significant immobility, or 
• Active cancer 
Unprovoked patients were therefore selected from the RVTE database by excluding those 
patients with a history of any of the above provoking risk factors within the last three months. 
Baseline characteristics of the RVTE database 
The population characteristics of the seven trials in the RVTE database at baseline were 
summarised using means and standard deviations for continuous variables, and using counts 
and percentages for categorical variables.  
Baseline patient characteristics were summarised firstly for the whole database and secondly 
by individual trial. A summary of the number of recurrent events, total patients, as well as the 
median and longest follow-up for each of the seven trials was also presented to describe the 
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recurrent events within the RVTE database. The percentage of missing data within the whole 
database was also presented by each candidate predictor. 
Outcome of interest 
The outcome of interest was the recurrence of a VTE following cessation of therapy for a first 
unprovoked VTE. 
3.2.3 Available candidate predictors 
Seven candidate predictors were available within the RVTE database and all were considered 
for inclusion in the prognostic model; these were:  
• Age (Years),  
• BMI (kg/m2),  
• Gender (Female/ Male),  
• Site of index event (Distal DVT/ Proximal DVT/ PE),  
• Treatment duration before cessation of therapy (Months),  
• D-dimer level post cessation of therapy (ng/mL), and  
• Lag time between cessation of therapy and measurement of D-dimer (Days) 
All candidate predictors were continuous except for gender and site of index event which were 
categorical, with gender being dichotomous (Male/Female) and site of index event having 
three categories: proximal deep vein thrombosis (DVT), distal DVT, and pulmonary embolism 
(PE). Patient age and BMI were measured at cessation of therapy (15). Ultimately, BMI was 
not considered, for reasons described below. 
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3.2.4 Issue of different start-points and the need for two models 
Most predictors were available at the cessation of therapy. However, D-dimer was measured 
after some lag time from cessation of therapy, to allow for the effects of therapy on D-dimer 
to diminish. The average lag time was around 37 days post therapy within the RVTE database, 
while the standard lag time is around 30 days post therapy (197). To address this, the project 
team agreed that two models should be developed: a pre D-dimer model (start-point at 
cessation of therapy) and a post D-dimer model (start-point at the time of D-dimer 
measurement) (see Figure 3.1). 
 
Figure 3.1 – Timeline of patient therapy and start points for pre and post D-dimer use 
 
Post D-dimer model: start-point when D-dimer measured 
The primary analysis aimed to utilise D-dimer post cessation of therapy to potentially improve 
the predictive performance of the prognostic model, as the predictive ability of D-dimer is well 
documented (15, 40, 198-204). Such a model could be used to inform a decision on extended 
duration of therapy in patients who have already stopped therapy for a given lag time. All 
seven candidate predictors could be selected for inclusion in the model. 
 
 Duration of OAC Lag time 
Start of OAC 
therapy for index 
event 
Start point for use 
of pre D-dimer 
model 
Start point for use 
of post D-dimer 
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Pre D-dimer model: start-point at cessation of therapy 
A secondary analysis was to develop a prognostic model which could be used to predict 
individual’s risk of recurrent VTE at the time of cessation of therapy. As such, candidate 
predictors for potential inclusion were only age, gender, BMI, site of index event and 
treatment duration. Such a model could be used to obtain individual recurrence risk 
predictions at the exact time when cessation of therapy is being considered. These predictions 
could then inform decisions on whether to continue or stop therapy (alongside other 
information including the risk of bleeding and patient preference). 
3.2.5 Univariable (unadjusted) summary of candidate predictors 
The univariable (unadjusted) association between each predictor and recurrence was 
assessed using a Cox proportional hazards model (41), assuming right censoring as described 
in chapter 1. A simple linear trend was assumed for continuous predictors during univariable 
analysis, though more complex trends were investigated during predictor selection for the 
multivariable model (see section 3.2.6). This assessed the impact of each predictor individually 
in relation to recurrence. A summary table of the univariable association with recurrence for 
each candidate predictor was presented, including the estimated hazard ratio with 95% 
confidence intervals and the corresponding p-value. 
3.2.6 Development of prognostic model 
Model structure 
As the outcome of interest was time-to-event (time to recurrence), prognostic models were 
developed using a flexible parametric (FP) survival model, fitted using the methods of Royston 
and Parmar (43, 47). As described in chapter 1, FP models allow firstly, a risk score to be 
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calculated for an individual patient, which is the combination of parameter estimates (log 
hazard ratio estimates) from the model combined with the individual patient’s predictor 
values; and secondly, the probability of recurrence by particular time points to be estimated 
for an individual patient, by utilising the risk score alongside the estimated baseline survival 
in the population. 
The FP models were fitted using maximum likelihood estimation via the stpm2 (205) command 
in Stata 12.1, with extension to random effects (frailty modelling) as required (206). Model 
assumptions (e.g. proportional hazards) and model fit were suitably checked throughout (see 
APPENDIX B: Chapter 3 Appendices). 
Modelling baseline hazard 
A key part of model development in the Royston Parmar framework is to estimate the baseline 
hazard. Firstly the spline complexity for the baseline hazard which best fit the available data 
was investigated visually and through model fit statistics, considering possible degrees of 
freedom (d.f.) ranging from 1d.f. to 5d.f.  
Comparisons were made between models with different d.f. using the Akaike information 
criteria (AIC) and Bayes information criteria (BIC) statistics, with smaller values preferred. The 
AIC and BIC provide a measure of how well the model fits the data, whilst penalising models 
with greater complexity (207). The AIC and BIC are somewhat subjective in isolation and 
therefore should be compared as a difference relative to the lowest value. As a guideline when 
comparing models a difference of two or less (in AIC or BIC) would provide strong evidence of 
an appropriate model fit, differences between four and seven weaker evidence, and 
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differences greater than ten essentially no evidence of a strong model fit (207). For example 
when comparing a model with additional predictors to a model without, a difference of less 
than two in the AIC or BIC would suggest that the additional predictor is not required to 
improve the model fit. 
Accounting for clustering by trial-specific baseline hazards 
Recall that the RVTE database contained seven trials, and so accounting for clustering of 
patients within trials is potentially important. During model development a comparison of the 
baseline hazards across the trials was carried out. If the shape and magnitude of the baseline 
hazard was similar between trials a simplistic model would consider using a common baseline 
hazard for all seven trials. This could be achieved by stacking all seven trial datasets into one 
large dataset and ignoring the clustering of patients within trials, thereby calculating a single 
baseline hazard. However, ignoring the clustering of patients within trials is known to create 
bias in the predictor-outcome associations (16). Therefore, if the baseline hazard between 
trials did not appear similar, clustering of patients within trials was accounted for by allowing 
for any between-trial heterogeneity in the baseline hazard across trials (16). This was achieved 
using FP models with a random-effect on the baseline hazard, thereby producing a weighted 
mean baseline hazard and an estimate of between-study variability around this mean. This 
approach thus allows a separate baseline hazard for each trial and estimates the distribution 
of these (proportional) baselines across trials (20). The average baseline hazard was taken as 
the baseline hazard to be used in the final model, though it was recognised that large 
between-study variability in the baseline may affect calibration of the model in some 
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populations. This would be investigated using internal-external cross-validation (see section 
3.2.7), and motivates statistical methodology development in Chapter 4. 
Predictor selection & specification 
In order to identify a suitable set of predictors to be included in the prognostic model, the 
multivariable fractional polynomial algorithm (MFP) described by Sauerbrei and Royston (54, 
59) was used. The MFP algorithm selects predictors and their transformations as appropriate 
using a backward selection process; a nominal alpha of 0.15 was chosen to warrant exclusion 
from the model so as to be more inclusive. Furthermore, patient age was considered to be of 
clinical and prognostic importance a priori, and thus forced to remain in the model, regardless 
of its significance. The MFP algorithm allows continuous variables to be modelled 
appropriately using fractional polynomials for non-linear trends (59), as opposed to being 
categorized, which has been discussed throughout the literature as suboptimal, for example 
leading to a loss of power (33, 51, 52, 68, 187). 
Also considered for inclusion was a potential interaction effect between the candidate 
predictors, patient age and D-dimer level, based on clinical judgement which suggested that 
because D-dimer levels increase with age a compound effect may therefore be plausible (208, 
209). Potential time-dependent predictor effects (non-proportional hazards) were also 
evaluated for the final models (see APPENDIX B: Chapter 3 Appendices). 
Handling missing data and exclusion of BMI 
Complete case data was used in the development of all models. As a sensitivity analysis, and 
under the assumption of a missing at random (MAR) mechanism, multiple imputation by 
99 
 
chained equations (MICE) was used to impute missing values of patient level data for the 
predictors included in the final model (210) (57) (56). Model coefficients were compared to 
those of the complete case as a sensitivity analysis. To make MAR more plausible all available 
predictors were included within the imputation model, as well as the outcome (observed 
recurrences) and the baseline hazard as suggested by White et al. (57). To give an indication 
as to whether missing data was indeed MAR, summary statistics for population characteristics 
were compared between complete cases and those with missing information. The 
reproducibility of the imputation results was examined using the Monte Carlo (MC) error as 
discussed by White et al. (57). 
As a rough guide, the number of imputed datasets should equal the largest proportion of 
incomplete data observed within individual trial populations (57); in this analysis 48% was the 
largest proportion of incomplete data (see APPENDIX B1: Summary characteristics of the RVTE 
database), resulting in 50 imputed datasets being used. In the RVTE database the patient BMI 
predictor had substantial missingness, and was not recorded for any patient in three of the 
seven trials. Therefore given the need to recognise the clustering of patients within the same 
trial, it was not deemed sensible to impute these missing values using the data available from 
the other trials in which BMI was recorded (211). In particular, when undertaking this project, 
methods for imputation of such systematically missing predictors was not well developed, 
although subsequently methods are emerging (123, 124, 127-130). Therefore in the primary 
analyses for both models (Pre and Post D-Dimer models), utilising all seven trials data, it was 
decided to exclude BMI as a candidate predictor due to the amount of missing data (see 
section 3.3.1).  
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Sample size considerations 
When undertaking this work, there was no general consensus about sample size required for 
prognostic model development. Previous research suggests a general rule of thumb of at least 
ten events for each candidate predictor considered in a prognostic model (189). For the 
primary model, there were seven candidate predictor effects (age, gender, site of VTE, D-
dimer post-treatment, lag time and treatment duration) for consideration, but some of these 
were continuous predictors, which could have potentially required non-linear modelling (e.g. 
fractional polynomials) that would increase the number of predictor effects to be estimated 
(e.g. if age + age2 is included, then ‘age’ relates to two predictors). 
The RVTE database included seven trials in total, with 1634 patients with follow-up 
information post-treatment, and 230 of these had a recurrence; there was good follow-up 
(median 22 months) and nearly all patients had complete data on all seven candidate 
predictors. During the internal-external cross-validation procedure (see section 3.2.7 for 
description) one study is excluded for model development in each cycle, which meant that 
between 1196 and 1543 patients, and between 161 and 221 recurrences, were available for 
the development phase of the prognostic models. Thus, there were at least 23 (= 161 events 
divided by 7 candidate predictors) events for each of the seven candidate predictors, which is 
considerably greater than the minimum ten per predictor rule, and gave adequate scope for 
modelling of non-linear trends and clinically plausible interactions as necessary. The events 
per predictor was lower for the Post D-dimer model (due to missing predictor information), 
with at least 18 events per predictor in the IECV procedure. Therefore the available sample 
size for the development of the prognostic model was deemed suitable.  
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Assumption checks & sensitivity analyses 
Continuous predictors were assumed to be normally distributed and this assumption was 
checked using graphical methods. After inspection of the distribution of candidate predictors 
a natural log transformation was applied as necessary to achieve approximate normality (prior 
to the use of the MFP algorithm). Influence of individual data points was assessed by plotting 
leverage residuals against fitted data. The proportional hazards assumption for each predictor 
was tested using scaled Schoenfeld residuals plotted against the variable of interest. Plots of 
Martingale residuals against continuous predictors were used to assess their functional form. 
Deviance residuals were used to identify outliers. When running the final model sensitivity 
analyses were performed by excluding any outlying values and checking the robustness 
(accuracy) of the model to these. 
3.2.7 Internal-External Cross-Validation (IECV) 
IECV framework 
The model development strategy outlined in Section 3.2.6 was implemented within the 
framework laid out by Debray et al. (20) for developing, implementing and evaluating clinical 
prediction models using an IPD meta-analysis (IPD from multiple studies). This approach 
adapts the Internal-External Cross-Validation (IECV) procedure first described by Royston et 
al. (66) whereby N-1 trials are iteratively selected from the N total trials in the IPD meta-
analysis, and the prognostic model is developed within this subset of trials, leaving the 
remaining trial for external validation of the model (see Figure 3.2). Thus N different models 
are derived (one for each cycle) and each is subsequently externally validated in the other 
omitted trial. In this manner, it is possible to investigate (across all permutations of the 
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excluded trial) whether model performance remains consistent when applied in another trial’s 
population that is not included during model development (external validation). It is important 
to ensure adequate sample size for model development within each cycle of the IECV, 
therefore for this study the largest trial (Eichinger et al.) was always included in the model 
development set of studies. 
 
 
Figure 3.2 - Schematic of Internal-External Cross-Validation (IECV) approach 
 
Validation performance statistics 
For each cycle of the IECV approach, an FP model was developed and estimated according to 
Section 3.2.6, thereby producing a model with an average baseline hazard and risk score 
equation for the included predictors. The performance of this model was then assessed in the 
excluded validation trial based on both its discrimination and calibration (72).  
Exclude a trial
Develop model
Validate model using excluded trial
Repeat steps 1-3 for a different omitted trial, until all trials have been omitted








The discriminatory ability of the developed model (to distinguish between those who will and 
those who will not have a recurrence) was examined in the external dataset using Harrell's C 
statistic (212, 213) with bootstrapping (1000 resamples) used to obtain 95% confidence 
intervals. Larger C statistics indicate a greater degree of separation in a prognostic models risk 
score, with a C statistic of 1 showing perfect discrimination and a value of 0.5 showing no 
discrimination beyond chance. 
Calibration of the developed model was assessed by comparing observed (O) and predicted 
(E) probabilities of recurrence over time, both visually and statistically. To do this, in the 
external dataset each individual’s predicted probability (from the developed model) of 
recurrence was calculated over time, and the population-average of these predicted survival 
curves was then plotted against the Kaplan-Meier curve of observed event risk over time in 
the population. Excellent calibration would be revealed by the Kaplan-Meier and predicted 
survival curves matching closely. To quantify differences in the curves for each group at a 
particular time-point, the observed recurrence-free probability (from the Kaplan-Meier curve) 
and the predicted recurrence-free probability were calculated, and then their difference (E-O) 
calculated with 95% confidence intervals. A difference of zero would indicate perfect 
calibration. 
Meta-analysis to summarise performance 
Development and validation was repeated across all cycles of the IECV, each time excluding a 
different trial from model development for external validation (see Figure 3.2). Therefore 
across all cycles, n of each validation statistic was obtained (n discrimination statistics, and n 
calibration statistics at each time-point, etc.). For each statistic, a random-effects meta-
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analysis was undertaken to summarise the performance across all cycles of the IECV (see 
chapter 1 for a description of random-effects meta-analysis). This analysis weights by the 
inverse of the variance of each omitted study's estimated statistic plus the estimated 
between-study heterogeneity in the true statistic value. The model was estimated using the 
method of moments (DerSimonian and Laird), giving an estimate of the average statistic, the 
between-study heterogeneity in the statistic, and an approximate 95% prediction interval for 
the statistic in an external validation population (112, 113). Good prognostic models would 
have excellent average estimates for each calibration and discrimination statistic, and ideally 
have little or no heterogeneity in the statistic across different external validation populations.  
Production of final model after completion of IECV 
If the meta-analysis showed that the performance of the model produced by the IECV 
approach was consistently good across all cycles (e.g. with calibration close to perfect at all 
time-points), then a final model was developed using all the trial data combined, with clear 
guidance for how to use the model to make individual predictions of recurrence risk over time. 
However, where model performance was not consistently good across each cycle, trials in 
which the model performed badly in external validation were identified and investigated for 
any unusual features. Potential differences in case-mix across the trials may lead to poor 
validation such as different methods of predictor measurement or different treatment 
strategies (21). Where trials with poor validation were identified a model based on a set of 
IPD excluding these trials was considered. Similarly, if particular time-points performed poorly 




Finally, where a suitable model was identified, performance of simpler versions were also 
examined, to check whether adequate model performance could be achieved with fewer 
included predictors, so as to ensure the simplest and most easily applicable, yet accurate 
model for clinical practice was derived (34).  
3.2.8 Comparison to existing prognostic models 
It was planned to examine the performance of any existing prognostic models or decision rules 
identified by the systematic review (see Chapter 2) in the RVTE database, if the necessary 
predictors within these models were available in the database. In particular, head-to-head 
comparisons of any such models would add important information on which models 
performed best and could be used for further evaluation for example in impact studies. 
However such comparison was not possible; firstly because the majority of models identified 
by the review contained predictors not recorded in the RVTE database, and secondly because 
the holders of the RVTE database did not permit validation of the Vienna model, as there was 
an ongoing study to validate this model in the database (160).  
3.3 Results 
3.3.1 Exploratory analysis of RVTE database 
Exploratory analysis identified some extreme values of patient age and BMI predictors (patient 
ages of zero, and BMI values lower than 10) which were removed from the dataset as 
erroneous data. D-dimer levels, lag time and treatment duration were all found to have a 
strong positively skewed empirical distribution, and a log transformation was therefore 
applied in order to approximate normality (see APPENDIX B1: Summary characteristics of the 
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RVTE database and APPENDIX B2: Exploratory analysis figures). Patients with treatment 
durations above 1000 days were removed as this was considered erroneous data based on 
clinical expertise. These exclusions due to extreme values of predictors led to eight patients 
being excluded; age equal to zero (no. excluded=1), BMI less than ten (no. excluded=3) and 
treatment durations greater than 1000 days (no. excluded=4). 
As previously mentioned there was a large amount of missing data across the trials for patient 
BMI, with around 57% of BMI data missing over the whole database, with systematic missing 
in three trials leading to exclusion of BMI as a candidate predictor. Across the trials there was 
also some missing data on D-dimer levels and lag time, with 15% and 11.4% missing 
respectively. No missing data was present for age, gender, treatment duration or site of index 
event variables. 
3.3.2 Pre D-dimer model 
The Pre D-dimer model development identified only two important predictors; patient gender 
and site of index event. Model validation through the IECV approach showed very poor 
performance of the model in terms of discrimination. Random-effects meta-analysis of C-
statistics from each cycle of the IECV, gave a pooled C-statistic of 0.56 (95% CI: 0.51, 0.6). A 
95% prediction interval accounting for heterogeneity between trials suggested that the C-
statistic for the model used in a new setting could vary anywhere between 0.49 and 0.62, 
which represents a potentially broad range of performance from discrimination no better than 
chance to a higher but still rather weak level. The poor performance is potentially to be 
expected given that the model only includes two predictors, which may not adequately 
describe variation in the population.  
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Given the very poor discriminatory performance of the Pre D-dimer model, it was decided that 
it would not be clinically useful and so the focus of the remainder of this chapter is on the 
development and validation of the Post D-dimer model. A summary of the validation 
performance and presentation of the final Pre D-dimer model is provided in the appendices 
(APPENDIX B5: Pre D-dimer model validation performance and APPENDIX B6: Final pre D-
dimer model), with further details published elsewhere (98). 
3.3.3 Post D-dimer model: Development and validation 
The results of the development and validation of the Post D-Dimer model for prediction of the 
risk of VTE recurrence are now described below. Candidate predictors available for the post 
D-dimer model were age, gender, site of index, treatment duration, D-dimer, and lag time (the 
number of days from cessation of therapy to measurement of D-dimer) (see section 3.2.4). 
This involved six of the seven trials within the RVTE database; the Baglin trial could not be 
included because lag time was not recorded.  For the IECV approach, due to its large size, the 
Eichinger trial was always included in the model development set of studies. This ensured a 
large sample size for model development in each cycle of the IECV. Thus, in summary, there 
were six studies and seven candidate predictors, with five cycles of the IECV approach 
conducted.  
Complete case data 
The complete case data for the development of the post D-dimer was somewhat different to 
the original RVTE database described above (see APPENDIX B1: Summary characteristics of 
the RVTE database). Eight patients with unrealistic values were excluded based on the 
exploratory analysis conducted previously (see section 3.3.1).  There was substantial missing 
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data for both D-dimer and lag time predictors; 243 patients were excluded from the analysis 
based on missing D-dimer levels, while a further 183 patients were excluded based on missing 
lag time data (despite having recorded D-dimer levels). The whole of the Baglin (198) trial had 
to be excluded from the complete case analysis due to missing (unspecified) lag time data. 
These exclusions led to a reduction in overall sample size to 1200 patients, and a reduction in 
the number of included events down to 161 recurrent events (see Table 3.1). 
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Table 3.1 - Summary of baseline characteristics and candidate predictors for the complete-case data used for development of the post D-dimer model 
Trial Palareti 03  Palareti 06  Poli  Tait  Eichinger  Baglin  Shrivastava  All 
Recurrences/Total 31/280 23/268 12/81 17/99 69/387 - 9/85 161/1200 
Follow-up (months)                 
Median 20.8 20.2 19 21.9 28.5 - 26.2 21.6 
Longest 31.4 37.2 49 41.6 114.8 - 51.2 114.8 
Candidate factors                 
Age* (Years) 70.1 (12.3) 65.5 (13.52) 64.5 (14.2) 60.9 (13.8) 54.1 (15) - 54.9 (12.8) 61.7 (15.2) 
BMI* (kg/m2) - - - 29.1 (6.2) 27.9 (4.8) - 32.3 (7.2) 28.8 (5.7) 
Treatment duration* 
(Months) 

















Lag time# (Days) 28 (24, 33) 31 (29, 35) 30 (30, 30) 26 (22, 35) 21 (16, 27) - 48 (30, 227) 29 (22, 33) 
Gender^                 
Female 128 (45.7) 99 (36.9) 28 (34.6) 36 (36.4) 146 (37.7) - 22 (25.9) 459 (38.25) 
Male 152 (54.3) 169 (63.1) 53 (65.4) 63 (63.6) 241 (62.3) - 63 (74.1) 741 (61.75) 
Site of index event^                 
Distal DVT 12 (4.3) 0 (0) 0 (0) 0 (0) 88 (22.7) - 10 (11.8) 110 (9.2) 
Proximal DVT 217 (77.5) 165 (61.6) 57 (70.4) 59 (59.6) 147 (38) - 57 (67) 702 (58.5) 
PE 51 (18.2) 103 (38.4) 24 (29.6) 40 (40.4) 152 (39.3) - 18 (21.2) 388 (32.3) 
Unspecified DVT 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) - 0 (0) 0 (0) 




Initial univariable analyses were performed by fitting each candidate predictor against 
recurrence individually using a Cox proportional hazards model, so as to assess the association 
between each predictor and recurrence (ignoring clustering of patients within trials). 
Summaries of the univariable association between each predictor and recurrence including 
the hazard ratio and a 95% confidence interval are presented below (see Table 3.2). These 
unadjusted results do not consider each predictor's prognostic association after adjustment 
for other predictors, which is more important for the prognostic model, but provide an initial 
summary. 
Univariable analyses of the predictors considered in the post D-dimer scenario (see Table 3.2) 
show that unadjusted hazard ratios for patient age and treatment duration are close to 1, with 
hazard ratios of 1.003 (95% CI: 0.99, 1.01) and 1.199 (95% CI: 0.93, 1.52) respectively. As these 
are continuous predictors, the hazard ratios compared the change in rate of VTE recurrence 
for each 1-unit change in the predictor, and so hazard ratios close to 1 may actually have a 
large impact when multiplied by a large predictor value. However, confidence intervals for 
both predictors included 1, with large p-values, providing no statistical evidence that the 
unadjusted recurrence rate was affected by age or duration of treatment. Conversely, the 
effect of male gender appears to be significantly different from 1 with a hazard ratio of 1.56 
(95% CI: 1.12, 2.21) indicating that the unadjusted recurrence rate is around 60% higher for 
men compared to women. Compared with distal DVT, both proximal DVT and PE have a 
greater than 5 fold increase in recurrence rate, with hazard ratios of 5.5 (95% CI: 2.02, 15.01) 
and 5.69 (95% CI: 2.06, 15.74) respectively. While gender and site of index event appear to 
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have significant prognostic value independently, multivariable analysis should be used to 
assess whether they retain prognostic value when adjusted for other predictors. 
The effect of a patients D-dimer levels appeared to indicate an increase in recurrence rate of 
around 70% for every 1-unit increase in log D-dimer levels, with a hazard ratio of 1.716 (95% 
CI: 1.43, 2.06). Conversely the lag time between cessation of therapy and measurement of 
patient’s D-dimer levels appeared to decrease recurrence rate by around 20% for every 1-unit 
increase in log lag time.  
Table 3.2 - Univariable Cox regression analysis of the candidate predictors for the post D-dimer model  
Candidate factors Hazard ratio Lower 95% CI Upper 95% CI P-value 
Age 1.003 0.993 1.014 0.513 
Treatment duration 
(months) 1.199 0.926 1.552 0.169 
Gender         
Male 1.564 1.108 2.207 0.011 
Site of index event         
Proximal DVT 5.498 2.015 15.007 0.001 
PE 5.693 2.060 15.736 0.001 
D-dimer (Log) 1.716 1.428 2.061 < 0.001 
Lag time in days (Log) 0.824 0.627 1.083 0.166 
 
Development of multivariable prognostic model 
Baseline spline complexity 
In order to consider the complexity (number of knots) required for the baseline spline function 
a series of preliminary models were fit with varying numbers of knots for the spline function. 
Comparisons were then made between the models using the AIC and BIC statistics, with 
smaller values preferred. While simply concerned with the complexity of the model there is 
no need for variable selection and so a full model is fit, assuming linearity for continuous 
predictors (46).  
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Table 3.3 shows the AIC and BIC values for proportional hazards models with between 1 and 
5 degrees of freedom (d.f.) for each of the five models fitted (five cycles of the IECV), where 
the model is built using a derivation dataset based on five trials excluding the trial named in 
the column header. For simplicity at this stage, the clustering of patients within trials was 
ignored, and so the set of five trials used in each cycle of the IECV approach was analysed as 
one large dataset. 
Given that lower values of the information criteria represent a better fit, it can be seen that in 
general across the five derivation datasets a model with 3d.f. minimizes the BIC. The lowest 
values of AIC vary between 3d.f. to 5d.f. across the derivation datasets, but the unit value of 
the AIC actually varied very little. The BIC often selects simpler models because increasing 
numbers of parameters carry greater penalties on the BIC (207), as such increasing the 
number of d.f. increases the internal knots used and so inflates the number of parameters 
giving higher BIC values.  
The BIC criteria was consistently minimised by a model with 3d.f. except in one instance where 
the minimum value was very close (difference less than one) to the BIC for a 3d.f. model. The 
AIC was variable, with the minimum AIC most often occurring for models with 4d.f. however 
the unit value of the AIC was very close (difference no greater than three) to that for 3d.f. 
models. Given that 3d.f. minimised the BIC consistently and the minimal AIC values were close 
to 3d.f. models, as well as considering visually the shapes seen in the baseline hazards for each 
trial (see Figure 3.3), a complexity of 3d.f. was deemed appropriate for the post D-dimer 
model. This relates to a baseline spline function with four knots. 
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Table 3.3 - Comparison of degrees of freedom for baseline spline complexity across derivation datasets for the post D-
dimer scenario 















1 974.0 1026.6 1141.8 1110.5 1173.2 
2 969.2 1020.0 1134.6 1106.6 1165.0 
3 964.7 1012.6 1128.9 1097.3 1154.4 
4 963.2 1012.2 1127.6 1094.0 1153.7 
5 962.8 1014.5 1129.4 1095.7 1155.5 
BIC 
1 999.8 1053.0 1168.8 1137.2 1200.5 
2 997.9 1049.3 1164.6 1136.3 1195.2 
3 996.2 1044.8 1161.9 1130.0 1187.7 
4 997.6 1047.3 1163.6 1129.6 1190.0 
5 1000.0 1052.5 1168.5 1134.3 1194.8 
 
 
Figure 3.3 - Comparison of baseline spline complexity with differing numbers of internal knots (Example shown for 





Baseline hazard within trials 
Investigation of the baseline hazard function using a null model (with no predictors) was also 
undertaken within each trial in the RVTE database, to ascertain whether the shape and 
magnitude of the baseline hazard in each trial was noticeably different. Examination of the 
baseline hazard functions within each trial (see Figure 3.4 and Figure 3.5) showed the shape 
of the baseline hazard across trials was similar, with a peak in hazard just under 1 year from 
cessation of therapy, and a fall in hazard thereafter. There was also a rise in the baseline 
hazard seen in the Poli (214) trial after two years from cessation of therapy, which was not 
seen in the other trials; however this was considered to be potentially due to the small number 
of individuals in this trial, as illustrated in Figure 3.5 by the large confidence interval 
surrounding the tail of the hazard function. While the shape of the baseline hazard across 
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Given the shape of the baseline hazard appeared similar across trials, but there was variation 
in the magnitude, it was considered appropriate to develop the post D-dimer model by 
assuming proportional baseline hazards across trials and placing a random-effect on the 
baseline hazard. This therefore allowed estimation of an average baseline hazard across trials 
and allowed for variability in each trial's own baseline hazard away from this average. 
Selection of predictors & model estimates during IECV cycles 
Candidate predictors were entered into the multivariable fractional polynomial (MFP) 
algorithm of Sauerbrei and Royston (54, 59) (see section 3.2.6).  
As previously discussed, given its large number of patients relative to the other trials, the 
Eichinger (203) trial was forced to remain in the development dataset throughout all cycles of 
the IECV approach; therefore no model was built without the Eichinger trial population, and 
subsequently no external validation was performed in the Eichinger trial. The trial was 
included in all models developed because it was the largest population available and therefore 
would have a large impact on any final model produced. Thus, although there were six trials 
available, there were only five cycles of the IECV approach for the post D-dimer model. 
The results of predictor selection and parameter estimates at each cycle of the IECV approach 
are shown in Table 3.4. Treatment duration was not significant during predictor selection and 
so was excluded from the developed models in all cycles. Age was forced to be included, and 
the effect of age was estimated in the opposite direction to that estimated in univariable 
analysis.  All other predictor coefficients were estimated to be similar in magnitude to those 
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seen during univariable analysis for the post D-dimer model, although 95% confidence 
intervals were altered due to adjustment. 
Table 3.4 - Model regression coefficients and selected predictors for each IECV cycle for the post D-dimer model (Hazard 
ratios (Lower 95% CI, Upper 95% CI)) 
Candidate 
predictors* 







Cycle 3: Poli 
excluded 
















































































* Treatment duration was not selected for inclusion in any cycle of the IECV 
NB: An empty cell indicates the predictor was not selected for inclusion in the model 
 
Model validation in the IECV cycles 
The final step of the IECV approach (see section 3.2.7) is to assess, in each cycle, the developed 
model's performance within the external validation trial. As the validation trial was excluded 
from model development the performance of the model within this dataset can be deemed 
as external validation. Model performance is now assessed in terms of both discrimination 
and calibration as described previously (see section 3.2.7).  
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Across all cycles, there were 92 events in the external validation data. Although the number 
of events in each cycle was considerably less, the results were pooled across cycles, and thus 
the total effective sample size was 92. Previously research has recommended a minimum of 
100 events and 100 non-events to achieve sufficient power for external validation studies (76, 
191, 215), and so overall the total events was akin to this, although not within each cycle. 
Model performance statistics for the post D-dimer model developed in each cycle of the IECV 
approach are presented in Table 3.5, and show C-statistics ranging from 0.65 in the Poli (214) 
trial to 0.80 in the Shrivastava trial (216). Discrimination overall, across all validation trials, 
showed a pooled C-statistic from a random-effects meta-analysis (see Figure 3.6) of 0.69 (95% 
CI: 0.63, 0.75), which reveals moderately good discrimination on average. A random-effects 
meta-analysis was performed as there were expected to be different discriminatory effects 
within each validation trial, as opposed to one true C-statistic in all trials as assumed under a 
fixed-effect meta-analysis (21). Importantly the approximate 95% prediction interval for the 
C-statistic in a new population was 0.59 to 0.79, which suggests potentially large variability in 
discrimination performance across settings. 
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Table 3.5 - Summary statistics for discrimination and calibration of the post D-dimer model in each cycle of the IECV 
approach  







































































Figure 3.6 - Random-effects meta-analysis of discrimination performance as measured by the C-statistics obtained, for 
each cycle of the IECV approach for the post D-dimer model 
Calibration for the post D-dimer model (see Table 3.5) was consistently strong across all cycles 
of the IECV up to 2 years post cessation of therapy. The E-O statistics were close to zero for 
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time-points up to about 2 years, but larger discrepancies were apparent thereafter, for 
example in the Palareti 2006 (204) and Poli (214) trials. The close relationship between the 
model’s predicted recurrence-free survival probabilities (Expected, E) and the true observed 
recurrence-free survival probabilities (Observed, O) up to 2 years can be seen for each trial in 
Figure 3.7. There was no strong evidence of systematic miscalibration in all trials (i.e. any 
miscalibration could be in both directions, above or below the observed Kaplan-Meier curve). 
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Figure 3.8 - Random-effects meta-analysis of calibration performance (at 1 year post therapy) within validation trials 
across IECV cycles (The post D-dimer model) 
 
Figure 3.9 - Random-effects meta-analysis of calibration performance (at 2 years post therapy) within validation trials 




A random-effects meta-analysis of the calibration statistics at one year post cessation of 
therapy (see Figure 3.8) gave a pooled value of -0.02 (95% CI: -0.05 to 0.01), indicating close 
agreement on average in the validation trials. There was heterogeneity in calibration 
performance (I-squared = 61.7%), and the 95% prediction interval for the calibration at one-
year in a new population is -0.12 to 0.08. The interval is wide partly due to the observed 
heterogeneity, but also partly reflecting the uncertainty in the between-study heterogeneity 
estimate (due to there being only five validation trials). Similar results can be seen for a 
random-effects meta-analysis of calibration statistics at two years post cessation of therapy 
(see Figure 3.9) showing consistent agreement on average in the validation trials at two years. 
Note that meta-analysis was performed on the E-O scale, rather than E/O scale, to aid 
interpretation of any miscalibration on the absolute scale (see chapter 1 for a discussion on 
the interpretation of these statistics). 
3.3.4 Final model: Post D-dimer model 
The IECV approach identified that the post D-dimer model had a moderately good 
discrimination shown by an average C-statistic of 0.69 (similar to other published risk 
prediction models (24)) and good calibration on average across trials, especially up to 2 years, 
and given this it was deemed appropriate to produce a final D-dimer model based on all the 
trials combined (see section 3.2.7).  
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Thus model development proceeded with all six trials included. The specification and 
parameter estimates of this final post D-dimer model are now described, alongside sensitivity 
analysis evaluating some aspects of model fit.  
Specification and parameter estimates 
The final post D-dimer model was developed using the whole trial dataset, with potential 
candidate predictors including patient age, gender, treatment duration, site of index event, D-
dimer and lag time as discussed previously (see section 3.2.4). A random-effect was placed on 
the baseline hazard to allow for between-trial heterogeneity. The MFP algorithm was used to 
perform predictor selection, as described previously (see section 3.2.6), with patient age, 
gender, site of index event, D-dimer and lag time (note the natural logarithm of D-dimer and 
lag time were used due to skewness as before) being selected for inclusion in the final post D-
dimer model. Estimated hazard ratios remained similar to those seen through cycles of the 
IECV as expected (see Table 3.6). D-dimer was associated with a two-fold increase in 
recurrence rate for every one unit increase in log ng/mL. Log lag time was associated with a 
25% reduction in recurrence rate, which is likely to reflect that healthier patients live longer, 
therefore the more time that passes before measuring D-dimer, the more likely patients 
remaining in the trial are healthier and therefore have a lower recurrence rate (see Table 3.6). 
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Table 3.6 - Specification and estimates of the final post D-dimer model fitted to all trial data 
Predictor Beta coefficient (95% CI) Hazard ratio (95% CI) P-value 
Age -0.0105 (-0.022, 0.0011) 0.99 (0.98, 1.001) 0.075 
Gender      
Male 0.55 (0.19, 0.89) 1.72 (1.22, 2.44) 0.002 
Site of index 
event 
 
    
Proximal DVT 1.74 (0.67, 2.79) 5.67 (1.96, 16.43) 0.001 
PE 1.76 (0.68, 2.83) 5.79 (1.98, 16.94) 0.001 
D-dimer (log) 0.7 (0.51, 0.89) 2.01 (1.66, 2.45) <0.001 
Lag time (log) -0.29 (-0.58, 0.002) 0.75 (0.56, 1.002) 0.051 
 
The estimated average baseline survival, S0(t) from this model is shown below in Figure 3.12 
and allows practitioners to estimate the average baseline survival for a specific time point, 
which can be used to predict recurrence free survival probability using Equation 3.1. Section 
3.3.5, below, details how to use the estimated baseline S0(t) in combination with the 
estimated predictor effects to make predictions over time for new individuals. 
The apparent calibration of the model in the entire dataset was excellent, as expected due to 
the final model being developed on the same set of data (see Figure 3.10).  
A plot of the recurrence probabilities over time in centiles of the distribution of the prognostic 
index was used (see Figure 3.11), to give an idea of what may happen to individuals at the 
fringes of the risk spectrum (46). It is clear from Figure 3.11 that while the 50th centile 
corresponds roughly to the predicted curve seen in Figure 3.10, there is a marked increase in 
the probability of recurrence for those in the 90th centile of the prognostic index. This 
separation reflects the good discrimination observed during the IECV approach, where the 




IECV showed very slight miscalibration on average; for example, at 1-year the summary E-O 
was -0.02, and at 2 years was -0.03. To address this, some form of shrinkage was considered. 
However, the research team noted that there was heterogeneity in the direction of 
miscalibration across studies, and therefore choosing a particular shrinkage factor was 
problematic. Therefore, and given the miscalibration was only very small on average, no 
shrinkage was undertaken. However, this issue motivates subsequent methodology research 
in Chapter 4. 
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Figure 3.11 - Probability of recurrence across the risk spectrum (The post D-dimer model) 
Model checking 
During development of the post D-dimer model, a number of assumptions were made and 
only complete data were used. The robustness of the final model to these assumptions and 
other issues was investigated as appropriate and laid out in section 3.2.6. Checks for the 
proportional hazards assumption, outliers, leverage and the functional form of continuous 
predictors showed no issues for the post D-dimer model (see APPENDIX B4: Model checking 
results: Post D-dimer model). 
Sensitivity analysis 
To check the robustness of the complete data model to missing data, a multiple imputation 
approach was used as described in section 3.2.6. Results gave similar conclusions about the 
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results: Post D-dimer model). As the complete data model was already validated during the 
IECV approach, and it performed well in terms of calibration and discrimination, the Post D-
dimer model as derived using complete data was retained as the final model.  
Further to this the inclusion of possible interaction effects and time-dependent effects in the 
model was considered as discussed in section 3.2.6. Given the selected nominal alpha level for 
these analyses no additional predictors were included in the model (see APPENDIX B3: 
Sensitivity analysis results: Post D-dimer model). 
Summary 
Based on the external validation within each IECV cycle, on average across populations the 
performance of the post D-dimer model is expected to be between moderate and good in 
terms of discrimination and have good calibration up to at least 2 years post cessation of 
therapy. Thus including D-dimer and lag time appears beneficial for improved prediction of 
recurrence risk following cessation of therapy for a first unprovoked VTE. Performance may 
be improved by the inclusion of further predictors not available in the RVTE database, but 
given the reasonable pooled discrimination and pooled calibration identified across the IECV 
external validations, the model appears robust and potentially useful for informing clinical 
decisions, at least on average. Further research may look to reduce potential heterogeneity of 
model calibration performance across populations, especially in regard to later time-points. 
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3.3.5 Using the post D-dimer model to make predictions for new individuals: 
a detailed illustration of the model in practice 
The final post D-dimer model has the potential to stratify the largely heterogeneous 
population of unprovoked patients, allowing for better decision making on duration of 
treatment for these high risk patients. This section now explains the practical application of 
the final post D-dimer model. 
In order to predict an individual’s risk of recurrence the beta coefficients must be combined 
with the baseline risk corresponding to the time that prediction is required for (see chapter 
1). The equation to combine these parameters is given below (see Equation 3.1), along with 
the beta values from the post D-dimer model (see Equation 3.2). In Equation 3.1, S0(t) 
represents the average baseline (recurrence free survival) risk at time t, and ] represents 
the risk score for a patient as shown in Equation 3.2. 
Equation 3.1 – Post D-dimer model equation to predict probability of recurrence free survival at time t 
1() = 1*()^B_(]) 
Equation 3.2 - Risk score equation for the post D-dimer model 
] = (−0.0105	 × c9) + (0.545	 × e98/9S:gR!9) + (1.735	 × 19: SjR!	klm)+ (1.756	 × 19: Z) + (0.701 × lnk-/j9S) + (−0.291 × ln R	j9) 
Equation 3.1 allows the prediction of a recurrence free survival probability at a particular time 
point after cessation of therapy, meaning that the probability of recurrence by a specific time 
point, R(t), can also be predicted and is equal to: 
Equation 3.3 - Post D-dimer model equation to predict probability of recurrence by time t 
p() = 1 − 1() 
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The average baseline risk at time t, S0(t), can be estimated for any time t (post cessation of 
therapy) by reading off its value from the predicted curve presented in Figure 3.12, and 
provided for specific time points (six months, one, two and three years) within Table 3.7.  
Table 3.7 - Baseline (recurrence free) survival at particular time points to combine with patient specific predictor values 
for individual risk prediction (Post D-dimer model) 
Model predictor 
Time from cessation of therapy 
6 months 1 year 2 years 3 years 
S0(t) 0.9996 0.9993 0.9988 0.9983 
 
 
Figure 3.12 - Average baseline (recurrence free) survival function for the post D-dimer model 
 
Example application of the model 
As an example of the potential application of the post D-dimer model, three example patients 
were created using varying predictor information to illustrate patients at different risk of 
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time), the 25th, 50th and 75th percentile of the predictors distribution was used for patients A, 
B and C respectively, to reflect the RVTE database (see Table 3.1). All three patients were 
selected as male, and the site of index event was selected as distal DVT, proximal DVT and PE 
for patients A, B and C respectively. An example of the risk score created using these patient 
characteristics is presented for patient A in Equation 3.4. Both recurrence free survival 
probability and probability of recurrence were predicted at over time post cessation of 
therapy for patients A, B and C respectively (see Figure 3.13). 
Equation 3.4 - Risk score equation for Patient A using the post D-dimer model 
] = (−0.0105	 × c9	(= 51)) + (0.545	 × e98/9S:gR!9	(= 1))+ (1.735	 × 19: SjR!	klm	(= 0)) + (1.756	 × 19: Z	(= 0))+ (0.701 × ()	k	/j9S	(= 5.55)) + (−0.291 × ()	R	j9(= 3.14)) 
 
Table 3.8 - Model parameters for three example patients and recurrence free survival/recurrence risk predictions using 
post D-dimer model 
Model predictor Patient A Patient B Patient C 
Age (years) 51 64 74 
Gender       
Male 1 1 1 
Female 0 0 0 
Site of index       
Distal DVT 1 0 0 
Proximal DVT 0 1 0 
PE 0 0 1 
D-dimer (ng/mL) 275 417.5 747 
Log (D-dimer) 5.55 6.03 6.62 
Lag time (days) 22 29 33 
Log (Lag time) 3.14 3.4 3.53 
 
The post D-dimer model predictions are presented in Figure 3.13 and Figure 3.14, with 
recurrence free survival probability and probability of recurrence calculated using Equation 
3.1 and Equation 3.3, respectively. Predicted recurrence free survival probability can be seen 
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to decrease over time for all three example patients (see Figure 3.13). The predicted S0(t) is 
markedly different between patient A and the other two patients, this is likely due to lower 
values of continuous predictors such as D-dimer, and also the low risk site of index event 
(Distal DVT) contributing little within the post D-dimer model (see Equation 3.1) to patient A’s 
risk of recurrence. Smaller differences were observed between patient B and C, reflecting the 
similar effect seen for proximal DVT and PE index events (see section 3.3.4). 
The predicted probabilities of recurrence free survival can be seen in Figure 3.13 at the 
intersection of the vertical gridlines with the predicted curves. For example the vertical 
gridline corresponding to one year from cessation of therapy, intersects with the predicted 
curve for patient A at the predicted probability of recurrence free survival (0.985) from 
Equation 3.1 using patient A’s risk score (see Figure 3.13). 
Similarly the predicted probability of recurrence over time from cessation of therapy can be 
predicted using the post D-dimer model (see Equation 3.3). The probability of recurrence is 
opposite to the probability of recurrence free survival, increasing over time from cessation of 
therapy (see Figure 3.14). The same trends seen in Figure 3.13 between patients A, B and C 




Figure 3.13 - Predicted recurrence free survival for three example patients using the post D-dimer model 
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As the systematic review in Chapter 2 identified that existing prognostic models were 
inconsistent in their definition of an unprovoked VTE, and were at a moderate to high risk of 
bias due to a lack of external validation, it was important to address this in new research. This 
project therefore used the IPD meta-analysis database supplied by the Recurrent VTE 
collaborative group (RVTE) to develop and externally validate two new models: a pre D-dimer 
model and a post D-dimer model. Ideally external validation of the existing models identified 
by the review would also have been undertaken, but the lack of permission and unavailable 
predictors in the database prevented this. This work has been published (98), and now the key 
findings, recommendations and limitations are summarised. 
Development and validation of a new prognostic model 
The RVTE database contained seven trials (198, 203, 204, 214, 216-218), and therefore 
allowed the novel framework of Debray et al (20) to be utilised for model development and 
external validation. This approach adapts the Internal-External Cross-Validation (IECV) 
procedure first described by Royston et al (66), whereby N-1 trials are iteratively selected from 
the N total trials in the IPD meta-analysis, and the prognostic model is developed within this 
subset of trials, leaving the remaining trial for validation of the model. In this manner, it was 
possible to investigate (across all permutations of the excluded trial) whether model 
performance remained consistent when applied in another trial’s population that was not 
included during model development. In other words, external validation was possible on 
multiple occasions. Although a complete-case analysis was primarily performed, a sensitivity 
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analysis using multiple imputation under a missing at random assumption led to the same set 
of predictors being included, and gave similar parameter estimates in the models. 
In all models, the Royston-Parmar approach was used to flexibly model the baseline hazard 
using restricted cubic splines. The baseline hazard is essential for individualised predictions 
from a survival model, and the use of splines allowed the shape to be modelled flexibly, 
without forcing a particular parametric form. This is likely to improve the performance and 
generalisability of the developed prognostic model, especially as the shape of the baseline 
hazard was observed to be very similar across the set of trials in the RVTE database.  
The development of the pre D-dimer model was considered as, in contrast to the post D-dimer 
model, it allows individual risk predictions at the exact time therapy might cease. However, it 
contained only two predictors: gender and site of index event. Upon external validation (in 
the IECV approach using the RVTE database) the model had poor discrimination with an 
average C-statistic of 0.58 across the trials. Although calibration appeared good on average, 
there was heterogeneity in calibration performance across trials, and in some it was rather 
poor. The pre D-dimer model is therefore clearly inadequate, which is not surprising given only 
two predictors were identified as important. Further research is needed to extend the set of 
included predictors. In particular, it may be that D-dimer measured without a lag-time is also 
an important predictor, and therefore datasets need to be collected to examine whether this 
adds prognostic value in terms of calibration and discrimination. At the time of this work there 
were currently three studies known to be on-going in UK (Exact), Holland (VISTA) and Canada 




The development of the post D-dimer model allowed the inclusion of D-dimer measured at a 
particular lag-time, along with age, gender, site of index. This model had substantially 
improved discrimination performance compared to the pre D-dimer model. C statistics ranged 
from 0.64 to 0.81 in the IECV cycles, with the average C-statistic of 0.69; other published 
clinical prediction models have similar discriminatory ability (24). Calibration of the model 
appeared excellent on average across the external validation trials, especially up to 2 years, 
although there remained heterogeneity. Ideally, further external validation studies would be 
helpful to examine this heterogeneity further, as it was estimated with large uncertainty in 
the IECV approach (due to only 5 external validation trials). Furthermore, the patients included 
in the RVTE database were enrolled in clinical trials, and thus may not be representative of all 
populations of interest.  
Heterogeneity of performance across studies 
Examining heterogeneity of prognostic model performance across studies and populations is 
a novel idea: most prognostic models are just considered in one external validation study, or 
just report the average performance across multiple clusters (e.g. practices, studies) (17).  
Ideally there would be no heterogeneity, but this is a very high standard to attain, and this 
issue is rarely evaluated for other well-used prediction models (21), and was never considered 
for the DASH, Vienna or HERDOO2 models for VTE recurrence. The IECV showed that 
calibration of the post D-dimer model was excellent up to about two years, on average across 
the trials. This means that across applicable populations, it is expected the final post D-dimer 
model would perform well on average up to two years. Heterogeneity in calibration 
performance at the individual population-level would be reduced if a population-specific 
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baseline hazard were used, rather than our average baseline hazard (or equivalently a 
population-specific S0(t) rather than our average So(t) currently in the model) (19, 20). 
Identifying population-specific baseline survival functions would facilitate conditional 
predictions, where interest lies in predictions at the specific level, and this may also improve 
performance of the model (17). Heterogeneity might also be reduced by including additional 
predictors. These areas could be the subject of further work.  
One particular area for potential heterogeneity is in the use of various D-dimer assays across 
the studies in the RVTE database. There is inherent variability in the different D-dimer assays 
used, particularly in the recommended cut-offs used to decide on a normal or abnormal D-
dimer result. In the RVTE database there were five D-dimer assays used, with each study using 
one assay exclusively (see Table 3.9). This is a potential limitation of the post D-dimer model 
in that the model was built on data using these five assays to measure patient D-dimer, and 
therefore predictions from the model in practice may only be valid in cases where one of these 
assays was used.  
























* Enzyme-linked immunosorbent assay;  
^ Latex immunoassay 
 
However, it may also be considered a strength to have used data based on multiple assays, as 
this enhances the generalisability of the model, making applicable to a wider population. 
Previous research has investigated the link between variability in D-dimer assays and 
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recurrent VTE, and found that various assays do not differ in ability to predict recurrence (15). 
It is also not possible to differentiate the study-level assay effect from other study-level 
covariates, such as location of study or year of study. It is therefore difficult to discern if any 
assay effect is genuine, as it may be confounded by other study-level covariates. Further, if 
one included assay in the model, then external validation of the model in the excluded trials 
would not be possible as most trials used a unique assay. The discrimination of the post D-
dimer model was shown to be reasonably consistent, with moderate to good discrimination 
regardless of the D-dimer assay used in the validation study. Similarly, the calibration 
performance up to 2 years appears very good in all trials, with generally very small 
miscalibration on average. Therefore, by developing a model using all assays, the hazard ratio 
obtained for D-dimer appears to provide reasonably robust predictions in external validation 
on average, regardless of the assay available. Finally, a small sensitivity analysis was conducted 
to crudely assess the impact of differences in the continuous scale of D-dimer assays on the 
predicted risk of recurrent VTE from the post D-dimer model, with results showing very little 
change in the predictions, certainly not enough to alter a clinical decision on choice of therapy 
(see 0). 
An interesting area for discussion is the observed effect of D-dimer and lag time in the final 
post D-dimer model. The effect of a patients D-dimer level appears to indicate an increase in 
recurrence rate of around 70% for every 1 unit increase in log D-dimer level, with a hazard 
ratio of 1.716 (95% CI: 1.43, 2.06). Conversely the lag time between cessation of therapy and 
measurement of patient’s D-dimer appears to decrease recurrence rate by around 20% for 
every 1-unit increase in log lag time. This effect appears to be counterintuitive as it may be 
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expected that recurrence rate would increase the longer it takes to measure patients D-dimer 
and identify those with high D-dimer at greater risk of recurrence. However the observed 
effect of lag time may be acting as a proxy for time from cessation of therapy itself, in that the 
more time which elapses from cessation of therapy the greater chance that patients at higher 
risk of recurrence will have already had a recurrence, leaving a more selected population of 
healthier patients.  
Clinical usefulness 
Given the good discrimination and the excellent average calibration performance 
demonstrated through external validation, the Post D-dimer model would appear suitable for 
informing patient counselling and clinical decision making at a particular lag-time post 
cessation of therapy. Section 3.3.5 detailed how to apply the model in practice, to obtain 
individual risk predictions for new patients.  
In terms of usefulness in clinical practice, it should be noted that the post D-dimer model has 
important limitations. Because anticoagulation significantly lowers D-dimer, measurement of 
D-dimer in the dataset was always performed after some lag time (or wash-out period), to 
allow the effects of therapy to subside. Therefore the post D-dimer model is only applicable 
at a set lag time post cessation of therapy, meaning it can be used only after a delay in making 
the decision on a patient’s therapy. While this is current practice, with D-dimer recommended 
to be measured around 30 days after cessation of therapy, there has been some evidence 
toward the predictive ability of D-dimer on therapy (219) and there are several on-going 
studies investigating the predictive ability of D-dimer on-therapy. Evidence from the RVTE 
database suggests that approximately 58.7% of recurrent events occurred within the 30 day 
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lag time before D-dimer measurement (for the pre D-dimer model dataset). Thus, as 
mentioned above, more clinically useful models might be derived by extending the pre D-
dimer model with other predictors measured without any lag time. 
It should be discussed that many may consider an initial distal DVT as a low risk group of 
patients, in whom many would not favour prolonged OAC therapy, and that some would chose 
not to include such a low risk group within the model development (for example the DASH 
model did not consider such patients). However, this tendency to cease therapy in patients 
with initial distal DVT, has in this case been captured within the post D-dimer model through 
the inclusion of such patients. This means that predictions from the model indicate that in the 
majority of cases these patients have low predicted risk of recurrence. Subsequently in 
practice post D-dimer model predictions would lead to the same decision not to prolong OAC 
therapy. 
Limitations 
It is important to note that patients who died without any recurrence were censored in the 
analysis performed in this chapter and therefore predictions from the Post D-dimer relate to 
a hypothetical world where patients cannot die before a recurrence occurs. The proportion of 
deaths before a recurrence is likely to be very small (especially up to 2-3 years follow-up where 
the model calibrates well), and therefore the model predictions would not change importantly 
if a competing risks model had been used. Further research may look to investigate the 
performance of a Post D-dimer model developed in a competing risks framework as seen in 
the updated Vienna model (184). 
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A potential limitation of the study is the exclusion of BMI as a candidate predictor due to 
systematic missingness in three of the included studies. While it was the intention of the study 
to consider BMI as a potential predictor, it was considered inappropriate to impute across 
studies. Selection of the BMI predictor within the model was also not assumed certain, 
because while there is evidence to suggest that BMI is an important predictor for a first VTE 
event, there is conflicting evidence for the effect of BMI on VTE recurrence. The systematic 
review undertaken in chapter 2, identified three models which assessed the impact of 
predictors in combination on VTE recurrence, and could therefore be considered the strongest 
evidence to date of which predictors affect recurrence risk. Of these three, the Vienna model 
found BMI to be a weak predictor (1.19 HR per 5kg/m2 change in BMI), and to be non-
significant when optimism was adjusted for (40). The DASH model found BMI to be non-
significant at univariate analysis, as did the HERDOO2 model (37, 39). The HERDOO2 then went 
on to split their analysis by gender and only then found BMI to be important in women alone 
(p-value = 0.02) (39). Heit et al. and Eichinger et al. also provide conflicting evidence suggesting 
that BMI is a weak risk factor in the order of a HR of around 1.2, with 95% CI’s covering values 
close to 1 (220, 221). This evidence suggests that BMI may not be a strong consistent predictor 
of VTE recurrence risk when adjusted for other important predictors including site of index 
event. However, further research is warranted. 
Further limitations concern the use of new oral anticoagulants (NOAC’s). The studies included 
in the RVTE database used primarily warfarin to treat patients first VTE, none of the studies 
used any of the NOAC’s. In this regard the model is built on and therefore applicable to 
patients treated with warfarin. This was a limitation of the available study data, because no 
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studies used NOAC’s, the effect of these drugs could not be accounted for in the modelling 
process. 
It must also be noted that while external validation was possible using the IECV approach, it 
would also be beneficial to undertake external validation in non-trial datasets, and therefore 
the post D-dimer model could also be considered at moderate risk of bias (see quality 
assessment defined within chapter 2), until such external validation is undertaken. 
There are also potentially broader uses of the post D-dimer model, as prognostic models are 
useful at many stages of the translational pathway toward improved patient outcomes (9).  
For example, it might be used to improve the design and analysis of randomised trials in 
patients with a first unprovoked VTE, as a stratification factor in the randomisation process 
(to ensure treatment groups are balanced in the predicted risk of recurrence) or as an 
adjustment factor to increase statistical power (5, 6). Inclusion criteria for trials may also be 
restricted to individuals with a high risk of recurrence based on the model. It could also be 
used to adjust for case mix variation (confounding) in health services research and 
observational studies. 
Recurrent VTE collaborative database 
A slight tension in using the RVTE database was that parts of it had already been used to 
develop the DASH score and Vienna model (37, 40). However, the new research conducted 
within this chapter can be seen to enhance current research which uses the RVTE database, 
and research in this field in general, by: 
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(i) Using the novel IECV approach to externally validate the model multiple times, unlike 
existing scores which rarely have external validation (see Chapter 2); 
(ii) The identification of additional predictors not previously picked up (e.g. age, lag time); 
(iii) Directly modelling the baseline hazard, which allows predictions over all follow-up times 
up to five years or more (rather than at just a few time-points as in previous models); 
(iv) Not requiring simplification of the model to make predictions, as the provided equation 
can be used to predict recurrence using the values at hand (i.e. no need for a simplified score) 
and the baseline survival; 
(v) Identifying the distribution of population characteristics for use in subsequent health 
economics modelling and impact studies. 
Further, the DASH score developed by Tosetto et al. using the RVTE database is fundamentally 
different to proposed post D-dimer model developed within this chapter. The DASH score is 
only applicable in a distinctly different population of patients, one which uses a different 
definition of an unprovoked first VTE (37). Indeed the DASH score includes predictors for 
hormone intake, where any patients provoked by hormone intake were excluded from the 
post D-dimer model development as per the pre-defined definition of unprovoked VTE (see 
section 3.2.2). As such the DASH score could not be compared to the post D-dimer model, as 
they include different predictors, and are applicable in different populations, despite both 
being developed within the RVTE database. 
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Further research recommendations 
The systematic review (see chapter 2) and model development within this chapter provide a 
new prognostic tool to aid clinical decision making for patients who sustain a first unprovoked 
VTE. The clinical paradigm shifted whilst this project was being undertaken with a view now 
to identify those patients at sufficiently low risk of recurrence that they can safely stop oral 
anticoagulation therapy after a relatively short period of time (usually 3-6 months). Currently 
available models are not routinely used within UK practice and have not been included within 
NICE guidelines. The post D-dimer model may therefore have an important role in the future. 
However, a number of further research recommendations arise from this work, which are now 
outlined. 
Develop and externally validate a prognostic model that can be used at the point of 
considering cessation of therapy. This should build on the pre D-dimer model, and thus 
include gender and site of index event. Evaluation of the prognostic ability of D-dimer levels 
measured at the exact time of cessation of therapy is needed (i.e. measured at a lag time of 
0). 
Further external validation of the post D-dimer model, especially in non-trial populations. 
Trial populations available within the RVTE database may be a select group of individuals, and 
thus the post D-dimer model requires validation in other populations, for example from cohort 
studies or large databases. Such datasets may not currently be available that contain D-dimer 
values, and so further observational studies are needed that enrol new patients, measure their 
predictors following cessation of therapy (including D-dimer measurements and lag time), and 
recording of VTE outcomes.   
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Further research to examine if between-study heterogeneity in the calibration performance 
of post D-dimer model can be reduced. Though the post D-dimer model performed 
excellently on average across all trial populations, there was between-trial heterogeneity in 
the calibration. Further research should seek to reduce this heterogeneity, by potentially 
updating the model with additional predictors (requiring further external validation of course) 
and/or by identifying revised S0(t) functions for populations that differ importantly from the 
average So(t) currently used in the model (i.e. perform model recalibration). 
Further research to develop and validate a prognostic model for bleeding on therapy. There 
is an immediate need to develop a prognostic model to predict individuals’ risk of bleeding 
whilst on therapy. This would allow the balance between risk of recurrence and risk bleeding 
to be accounted for in the decision of treatment strategy, and also an effective economic 
evaluation to be undertaken.   
Direction for subsequent chapters of the thesis 
The first chapters of this thesis have focused on the development and evaluation of models 
for VTE recurrence. However, a number of methodological challenges have arisen, which will 
now become the focus for the remainder of the thesis. In chapter 4, the issue of how to reduce 
heterogeneity in a model’s calibration performance across multiple studies will be considered 
in detail. In particular, whether recalibration and model updating techniques can be applied 
to reduce heterogeneity, and thus improve consistency in performance across different 
populations and settings (21). Unfortunately, due to externally imposed restrictions in using 
the RVTE database beyond the work presented above, a different clinical setting and IPD meta-
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analysis dataset will be used in Chapter 4 to explore the methodology. However, it is hoped 
that in the future, the holders of the RVTE database will themselves look to examine the issue 
of heterogeneity using the novel approaches developed. In chapters 5 and 6, the issue of 
missing predictor values will be revisited, and methodology work undertaken to improve risk 
predictions in that situation.
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CHAPTER 4: INDIVIDUAL PARTICIPANT DATA META-
ANALYSIS FOR EXTERNAL VALIDATION AND 




The previous chapter developed and validated a prognostic model for VTE recurrence. This 
built on a systematic review which identified a number of existing models which unfortunately 
could not be validated in the data at hand. The new model performed well on average across 
omitted studies in the internal-external cross-validation (IECV) approach. However, there was 
heterogeneity in the model’s calibration and discrimination performance across studies, 
especially at later time-points. This suggests that, ideally, approaches to improve the model’s 
performance in particular populations and settings may be important, to reduce or ideally 
remove this heterogeneity (19, 20, 64, 69, 142-145).  
Model recalibration is perhaps the simplest approach to improve model performance in new 
(external) populations or settings, with model updating further adjusting the existing model 
(usually the regression coefficients) (34, 64, 69). Methodology in this area is well developed 
for both binary and time-to-event outcomes (34, 142-145). Royston and Altman also describe 
potential methods for external validation of an existing Cox model given different levels of 
reported model statistics, but do not discuss recalibration or updating of an existing model 
(147). Approaches to model recalibration and updating for time-to-event models have been 
described by van Houwelingen et al., and are based on parametric models as these allow 
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estimation (and thus recalibration) of the baseline hazard, an essential part of a survival model 
(144, 145). 
The focus in this chapter is how external validation and model improvement (updating) can 
be examined when Individual Participant Data (IPD) are available from multiple studies. Where 
multiple studies are available for external validation, model performance may be assessed on 
multiple occasions and summarised using evidence synthesis methods. This allows potential 
comparison of different recalibration methods across a set of validation studies of differing 
case-mix. Previous work has proposed the use of IPD meta-analysis to compare model 
implementation strategies focusing on logistic regression models, and multivariate meta-
analysis (19, 20, 24). In this chapter, the focus is on external validation of a flexible parametric 
survival model, and how IPD meta-analysis can help examine model performance, and 
evaluate the best recalibration strategies in different settings to reduce heterogeneity. FP 
models improve on standard survival models such as the Cox model, by using splines to 
parameterise the baseline hazard, enabling external validation and adjustment of the baseline 
hazard which is of key interest in this chapter. 
The remainder of the chapter is structured as follows. Section 4.2 introduces a motivating 
example and individual participant dataset. Section 4.3 briefly describes the methods and 
advantages of FP modelling using the Royston-Parmar approach (44, 45), revisits the methods 
for synthesis of model performance statistics from multiple validation studies, and discusses 
in detail methods for model recalibration. Section 4.4 presents the results of the recalibration 
methods using a motivating example in breast cancer, and Section 4.5 concludes with some 
discussion. Note that, due to restrictions imposed by the owners of the RVTE database utilised 
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in Chapter 3, it was not permissible to use the VTE IPD meta-analysis any further in this thesis. 
Hence, the motivating example in this chapter will utilise a new IPD meta-analysis database in 
breast cancer, kindly provided by Dr Maxime Look (Rotterdam). 
4.2 Motivating example 
4.2.1 Breast cancer dataset 
The IPD meta-analysis dataset used in this chapter contained 5978 breast cancer patients, 
with follow-up ranging from 1 to 120 months (for more information on the original study see 
(222)). It was formed by pooling datasets from eight centres (hereafter referred to as ‘studies’ 
for simplicity) across six countries, with Rotterdam having the largest patient numbers (see 
Table 4.1). The focus here is on using the IPD to identify a prognostic model that reliably 
predicts an individual’s probability of recurrence-free survival over time, defined as the time 
to recurrence or death from any cause. Though there is also methodological interest in how 
to develop a prognostic model utilising more than one study (20, 66), this chapter only 
consider how to perform external validation and model updating using the IPD multiple 
studies, for a previously proposed prognostic model. 
To this end, for illustrative purposes and to ensure most studies were available for external 
validation, we selected just one study (Rotterdam) as a derivation dataset in which to build 
the prognostic model. The remaining seven studies were thus immediately available for 
external validation. In the Rotterdam study there were 2627 patients with 1224 events and a 
median follow-up of 64 months (max 120 months). Previous research has suggested that 
adequate sample size for model development should have at least 10-20 events per predictor 
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(EPP), making the Rotterdam study suitable for investigation of up to 60 predictor effects (188, 
189, 223, 224). A recent study has questioned the validity of the EPP rules previously 
proposed, and highlighted that sample size requirements for model development likely vary 
based on a number of factors and are therefore case-specific, though further research is 
needed in this area (190).  
In the validation studies, the number of events ranged from 80 to 211 per study, with a total 
of 1019 events across all validation studies. Study characteristics are summarised in Table 4.1. 
In terms of validation, recent evidence suggests that at least 100-200 events and non-events 
are required for external validation (76, 191, 215), meaning that the breast cancer data is likely 
sufficient for validation within each study, perhaps apart from the Nijmegen study which has 
a relatively small sample size of 80. 
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Table 4.1 - Summary statistics for Look et al. dataset. NB: RFS – Recurrence free survival; * Median; # Number and percentage. 
Model phase Development Validation 
Study Rotterdam Sweden Lille Nijmegen St Cloud Switzerland Denmark1 Denmark2 
Total sample size 2627 621 552 293 499 620 444 322 
RFS (Events) 1224 137 150 80 168 150 211 123 
% Events 47% 22% 27% 27% 34% 24% 48% 38% 
Follow up (Months)* 63.64 106.84 60.71 52.90 97.84 42.71 48.34 55.36 
Min 1.18 3.04 1.08 1.28 4.01 1.71 1.02 1.02 
Max 120.00 120.00 120.00 120.00 120.00 83.45 120.00 100.17 
Age (Years)         
Mean 56.46 58.47 57.00 56.68 58.82 57.94 53.86 56.21 
SD 13.28 11.64 11.19 13.01 12.56 11.31 10.85 10.73 
Lymph nodes#                 
0 1371 (52.19) 226 (36.39) 381 (69.02) 153 (52.22) 233 (46.69) 357 (57.58) 299 (67.34) 152 (47.2) 
1 to 3 684 (26.04) 243 (39.13) 96 (17.39) 89 (30.38) 177 (35.47) 165 (26.61) 95 (21.4) 89 (27.64) 
4 to 10 422 (16.06) 125 (20.13) 57 (10.33) 33 (11.26) 72 (14.43) 56 (9.03) 46 (10.36) 57 (17.7) 
> 10 150 (5.71) 27 (4.35) 18 (3.26) 18 (6.14) 17 (3.41) 42 (6.77) 4 (0.9) 24 (7.45) 
Menopausal status#                 
pre 1076 (40.96) 191 (30.76) 193 (34.96) 103 (35.15) 146 (29.26) 206 (33.23) 220 (49.55) 104 (32.3) 
post 1551 (59.04) 430 (69.24) 359 (65.04) 190 (64.85) 353 (70.74) 414 (66.77) 224 (50.45) 218 (67.7) 
Tumour size#                 
≤ 20mm 1177 (44.8) 217 (34.94) 302 (54.71) 102 (34.81) 211 (42.28) 298 (48.06) 179 (40.32) 96 (29.81) 
>20-50 mm 1296 (49.33) 396 (63.77) 242 (43.84) 165 (56.31) 271 (54.31) 306 (49.35) 232 (52.25) 192 (59.63) 
>50 mm 154 (5.86) 8 (1.29) 8 (1.45) 26 (8.87) 17 (3.41) 16 (2.58) 33 (7.43) 34 (10.56) 
Adjuvant treatment#                 
no 1998 (76.06) 142 (22.87) 278 (50.36) 172 (58.7) 177 (35.47) 125 (20.16) 310 (69.82) 132 (40.99) 
yes 629 (23.94) 479 (77.13) 274 (49.64) 121 (41.3) 322 (64.53) 495 (79.84) 134 (30.18) 190 (59.01) 
152 
 
4.3 Methods for examining performance of an FP model using IPD 
meta-analysis 
4.3.1 Flexible parametric models 
Chapter 1 introduced the framework for flexible parametric survival models for developing 
prediction models (43-46). This current chapter assumes a prediction model has already been 
developed in this framework, and is of the form,   
ln,() = ln,*() +  = #!89(ln ) +  
Equation 4.1 
where the baseline hazard is modelled using splines as discussed in chapter 1 and of the form; 
#!89(ln ) = 7* + 7 ln  + 7
6(ln ) + 7>6
(ln ) + ⋯ 
Equation 4.2 
In Equation 4.1,  = ( …C) and  = ( …C) define vectors of predictors and their 
corresponding coefficients. 
Advantages of FP models 
Flexible parametric (FP) models extend standard parametric survival models, such as the 
Weibull or exponential model, by modelling the baseline hazard more accurately (43-45). 
There are several benefits to using FP models over other more traditional parametric or semi-
parametric models for this chapter. In particular, semi-parametric models such as the Cox 
model do not estimate the baseline hazard, providing only relative effects not absolute risks. 
Being able to parameterise and estimate the baseline hazard is essential for prognostic model 
research; firstly in order to obtain individualised absolute risk predictions over time and 
secondly, for out-of-sample prediction enabling external validation. Also, other parametric 
153 
 
models such as the Weibull model cannot capture complex baseline hazard shapes which rise 
and fall over time. Even parametric models which can encompass turning points in the hazard 
function (e.g. generalised gamma) will often not be able to fit well to complex functions (46).  
Figure 4.1 shows the baseline hazard function as estimated in the Rotterdam study of breast 
cancer dataset, using varying numbers of degrees of freedom to estimate the baseline spline 
function. It is clear from the plot that the baseline hazard peaks around 1.5 years from surgery, 
and then falls steadily up to the end of follow-up time. The dotted line shows the special case 
of 1 degree of freedom, where the FP model collapses to the Weibull model (see chapter 1). 
It is clear that the Weibull model cannot capture the peak and then drop in hazard seen in the 
Rotterdam study. The two solid curves for 2df and 3df best represent the baseline hazard 
shape; the best fit can be identified by comparison of AIC and BIC values (as in chapter 3). 
Finally, the generalised gamma distribution is also plotted and again does not capture the true 
shape of the baseline hazard here, despite being able to handle turning points in the hazard 
function (see Figure 4.1). Later, we discuss that flexible modelling of the baseline hazard is 
also important when re-calibrating a model to a new population (see section 4.3.4).  
The focus of this chapter is on how to validate an existing FP model using IPD from multiple 
studies. The following sections re-introduce important performance measures, and explain 






Figure 4.1 - Baseline hazard function in the Rotterdam study estimated using various numbers of knots for the baseline 
spline in an FP model. The baseline hazard estimated using a generalised gamma distribution is also included. 
 
4.3.2 Performance statistics 
The predictive performance of a prognostic model is often described in terms of calibration 
and discrimination (33), both of which can be measured using various statistics (72). This 
chapter focuses on expected (E) and observed (O) survival probabilities, allowing calculation 
of both the ratio (E/O) and difference (E-O) in these quantities at specific time points, as well 
as calibration plots to summarise calibration performance (147). The discrimination 
performance of the model was measured using Harrell’s C-statistic (212), and Royston’s R2D 
and D-statistic (see chapter 1) (75).  
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Calibration plots are a common method of assessing calibration, in which observed events 
(typically using a Kaplan-Meier curve), and expected events (as predicted by the prognostic 
model) are plotted over time, to provide a visual assessment of their agreement.  
The E-O statistic can be considered as the difference between the Kaplan-Meier survival 
estimate and the developed models’ predicted survival probability at a specific time point in 
the validation study (34, 98). If the E-O statistic is >0 or <0 there is indication of either over or 
under fitting, respectively. That is, predictions are systematically too narrow or too extreme. 
Perfect agreement between the observed and predicted event rate would give an E-O statistic 
of zero. For the ratio of expected and observed rates as commonly used in logistic regression 
models, a value of one defines perfect calibration. However there are some limitations to the 
E/O statistic in terms of interpretation as highlighted in chapter 1. 
Harrell’s C-statistic gives the proportion of pairs of patients for whom the model predictions 
and observed outcomes are similar (212). That is for any two patients randomly selected, one 
with the outcome and one without, the model predicts a higher survival probability for the 
patient without the outcome. Royston’s D-statistic is a measure of separation in survival 
curves related to the standard deviation of the linear predictor; it gives the log hazard ratio 
between two groups defined by dichotomising the linear predictor at the median (75). 
Royston’s R2D gives a measure of explained variation based on the D-statistic, to give an 
interpretation similar to R2 in linear regression models (75). 
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4.3.3 External validation in multiple studies with meta-analysis of 
performance 
Given IPD from multiple studies, the predictive performance of an existing model can be 
externally validated multiple times. This leads to multiple estimates for each validation 
statistic of interest (e.g. Harrell’s C-statistic), and so naturally lends itself to a formal meta-
analysis in order to summarise and compare performance across studies (19, 20).  
Let Yi be the estimate of a particular performance statistic of interest where i represents the 
validation study and let 1 
	be the associated variance of Yi, then a random-effects meta-
analysis could be used as given in Equation 1.19; 
 ~J(H , 1 
) H ~J(H, T
) 
Equation 4.3 
This model assumes that Yi follows a normal distribution around the ith study’s true 
performance,	H  and that H  is also normally distributed around an average performance, θ 
and a between-study variance	T
. Pooling of different model performance measures may not 
naturally meet these normality assumptions, and therefore such measures require rescaling 
to approximate normality before synthesis. Recent studies have suggested appropriate 
transformations for some common performance statistics as listed in Table 4.2 (24, 71, 111).  
Table 4.2 - Transformation of model performance statistics required to approximate between-study normality 









Usually of most interest will be the estimated θ and its 95% confidence interval, which is 
derived by	H ± 1.96	1Z(H ), where 1Z(H ) is the standard error of	H . Also of interest may be 
an approximate prediction interval, such as a 95% prediction interval (see Equation 1.21). A t 
distribution is used in the calculation of the prediction interval, rather than a normal 
distribution, to allow for the additional uncertainty in T
 (112, 113). 
H ± *.*
[q	T
 + 1Z(H )
 
Equation 4.4 
This infers the potential model performance in a new population similar to those included in 
the meta-analysis (112, 113). A narrower prediction interval implies more consistent 
performance in new external populations, and is thus desirable if the model is to be 
generalizable outside of a few local settings. Stata code to perform the meta-analysis methods 
described above is provide in the appendix (see APPENDIX C2: Stata code), for Stata 14 (225). 
4.3.4 Recalibration strategies in a single validation study 
If model performance is not good upon external validation, then recalibration strategies may 
be considered to improve performance. Here four possible methods are proposed (see Table 
4.3) for recalibrating a prognostic model (developed using the FP approach) within a single 
validation study. The four recalibration methods were chosen to progressively increase the 
extent to which the model is adjusted, and closely link to previously selected methods for a 
binary outcome example (226). Stata code is provided in the appendix (see APPENDIX C2: Stata 
code), for each of the methods. 
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Table 4.3 - Recalibration methods to be investigated 
Method Recalibration technique 
1 Re-estimate intercept within H0(t) 
2 Re-estimate entire H0(t) 
3 
Method 1 + Scale linear predictor 
(i.e. ) by a scaling factor 
4 
Method 1 + Re-estimate 
particular predictor coefficients 
 
Recalibration options 
Recalibration Method 1: keep the same predictor effects and baseline hazard shape, but 
change the magnitude of the baseline hazard  
For this approach, the developed model is applied to the validation study but the constant 
term, 7* in Equation 4.2 is re-estimated within the validation data, to give	7*r^s in Equation 
4.5. Other terms in the model are not altered. This is the simplest form of recalibration, 
allowing the baseline hazard in the developed model to be shifted by a constant factor to 
better represent the validation population’s baseline hazard. This kind of recalibration is 
useful when the baseline hazard rate differs substantially between derivation and validation 
samples (64). In logistic regression the constant term can be related to prevalence of disease 
and so can be easily altered in new patient populations (20, 146). In survival data it represents 
a part of the baseline hazard function and so could be interpreted as a constant shift increasing 
or decreasing the hazard at any particular time.  
ln,() = #!89(ln ) = 7*r^s + 7 ln  + 7
6(ln ) + 7>6
(ln ) + ⋯ 
Equation 4.5 
Recalibration Method 2: keep the same predictor effects but change the entire baseline 
hazard (shape and magnitude).  
This approach extends method 1 to allow adjustment for any differences between the 
derivation and validation populations in terms of the overall magnitude (method 1), and 
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additionally the shape of the baseline hazard. So for example the validation population may 
have a much earlier and sharper peak in their baseline hazard and a long flattened tail, and so 
recalibration of the FP model to capture this shape may potentially improve the performance 
of the model in external populations. To implement this method, whilst keeping predictor 
effects fixed at their original values, the baseline hazard shape and magnitude are completely 
re-estimated in the validation sample giving a new baseline hazard term as below; 
ln,() = ln,*()r^s +  = #!89(ln )r^s +  
Equation 4.6 
Recalibration Method 3: keep the same baseline hazard shape, change the magnitude of 
the baseline hazard and adjust the linear predictor as a whole by a constant (t). 
In this approach, method 1 is extended to additionally adjust the linear predictor by a constant 
scalar term, u which is estimated in the validation data, so that Equation 4.1 is adjusted as 
follows, 
ln,() = ln,*() + u() 
Equation 4.7 
As such method 3 allows for a scaling of the predictor effects as a whole, by some constant 
scalar. For example, if predictor effects are systematically too large, then u	will be < 1 and 
predictor effects will be shrunk. This may occur when a model was over-fitted during model 
development.  
Recalibration Method 4:  keep the baseline hazard shape and the linear predictor fixed, but 
re-estimate the effect of particular predictors   
Poor performance in a validation study may relate specifically to one or a few predictor effects 
for example, a single predictor, 	 corresponding to a particular variable X1. Method 4 builds 
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on method 1 by additionally re-estimating  in the validation data to give		r^s, keeping 
other all other terms fixed giving; 
ln ,() = ln,*() +  = #!89(ln ) +  + r^sv 
Equation 4.8 
Where  now excludes	v. Method 4 could be extended to allow additional predictor 
effects to be re-estimated within the validation data. Further all recalibration methods could 
be combined, though this would be equivalent to developing an entirely new model without 
using information from the original model. 
4.3.5 IPD meta-analysis to compare recalibration strategies 
The recalibration methods described above can be subsequently evaluated using IPD meta-
analysis to identify the best recalibration strategy to be recommended for implementing the 
model in general (19). In assessing strategies for model recalibration the aim is to achieve 
good model performance on average as indicated by the pooled performance statistic	HD , as 
well as small between-study heterogeneity	T̂ 
 (see Equation 1.19). Importantly the 95% 
prediction interval can also be used to assess the generalisability of the model in new 
populations similar to those included in the meta-analysis (112, 113).  
For method 4, to identify a problematic predictor effect across studies (for adjustment) 
requires the examination of its heterogeneity. The original model could be refitted in each 
validation study and the parameter estimates for each predictor pooled in a random-effects 
meta-analysis using Equation 1.19. By synthesising the predictor coefficient from each 
validation study a pooled predictor effect across studies can be obtained, and importantly an 
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estimate of between-study heterogeneity, T
	as in Equation 1.19. If T
	is large, or similarly if 
the prediction interval for a predictor effect is wide, then this may signal that calibration would 
be improved if the predictor effect was re-estimated. 
4.4 Results: Application to the Breast Cancer Example 
4.4.1 Visual comparison of the baseline hazard rate in each study 
It is helpful to first plot the baseline hazard rate in each study, and compare it to that from the 
development study. Figure 4.2 presents the baseline hazard function (when all predictors are 
fixed at zero) in the validation studies, and shows substantial differences in terms of both the 
shape and magnitude compared to the baseline hazard in the Rotterdam study used for model 
development. Differences in the magnitude of the baseline hazard represent differences in 
the rate of events, while differences in the shape of baseline hazard indicate they are non-
proportional. These differences may be expected here as the studies in the IPD dataset are 
from different countries, which are likely to have different patient case-mix, for example some 
countries may have better breast cancer screening programmes or differing treatment 
strategies. Figure 4.2 shows that the baseline hazard rate is highest in the Rotterdam study, 
and is much smaller and flatter in the other studies. Given these differences calibration 
performance at external validation is expected to be poor, especially if differences are not 




Figure 4.2 - Baseline hazard functions in all 8 studies in the IPD dataset. 
4.4.2 Overview of the model development 
Using the Rotterdam dataset a prognostic model was developed using a flexible parametric 
proportional hazards (PH) framework (as described in detail in chapter 1). The included set of 
predictors was pre-defined, to reduce the potential for optimism in model performance due 
to predictor selection methods (38). The predictors were: age (in years), tumour size (≤ 20mm, 
>20-50 mm, >50 mm), number of lymph nodes (0, 1-3, >3-10, >10), menopausal status, and 
adjuvant treatment (yes or no). Although ideally tumour size and lymph nodes would have 
been included as continuous, unfortunately their data were provided as categorical. The effect 
of age was assumed to be linear for simplicity. Given this set-up, including five predictors and 
some categorical predictors, there were eight predictor effects to be estimated, and thus 153 
events for each. Given this large sample size, and because this is merely an illustrative 
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example, we did not consider it necessary to investigate overfitting (over-optimism) in our 
developed model; thus, there was no adjustment of estimated predictor effects (i.e. no 
shrinkage). There was no missing data for the included predictors. 
The final model was of the form, 
1() = 	 1*()234	(wx) 
where; 
 = c9 + 
m.j.S	169(> 20 − 50jj)+
m.j.S	169(> 50jj) + zJ.		{jℎ	J/9#(1 − 3)+[J.		{jℎ	J/9#(4 − 10) + |J.		{jℎ	J/9#(> 10)+}g98R.#R!	#R.#(#)+~c/.QR8	S9Rj98({9#)
 
Equation 4.9 
and S(t) represents the survival probability at time ‘t’, S0(t) represents the baseline survival 
probability at time ‘t’, and the  	represent the regression coefficients of the included 
predictors. Table 4.4 shows the beta coefficients (log hazard ratios) for the predictors in the 
developed model.  There was strong statistical evidence that all the included predictors were 
associated with the hazard rate, with increasing tumour size and number of nodes leading to 
increased hazard rates, and those with adjuvant treatment and post-menopausal women also 
having increased hazard rates. Age appeared to slightly decrease hazard rates per one year 
increase in age (HR 0.981, 95% CI 0.973, 0.989). This is consistent with previous analysis of this 
dataset and with current research, as it is known that young breast cancer patients have a 
higher mortality rate (222, 227).  
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Table 4.4 - Predictor effect estimates for the developed model 
Predictor Beta HR Lower 95% CI Upper 95% CI P-value 
Age -0.019 0.981 0.973 0.989 < 0.0001 
Tumour size      
≤ 20mm 0     
>20-50 mm 0.472 1.602 1.399 1.835 < 0.0001 
>50 mm 0.833 2.299 1.825 2.897 < 0.0001 
Lymph nodes      
0 0     
1-3 0.647 1.909 1.602 2.275 < 0.0001 
>3-10 1.260 3.525 2.965 4.191 < 0.0001 
>10 1.682 5.376 4.289 6.739 < 0.0001 
Menopausal status      
Pre 0     
Post 0.236 1.267 1.036 1.548 0.021 
Adjuvant treatment      
No 0     
Yes -0.454 0.635 0.540 0.747 < 0.0001 
 
The estimated baseline survival function, S0(t) is shown in Figure 4.3, which shows a gradual 
decline in survival probability over increasing years from surgery. The curve can be perfectly 
described by Equation 4.10 below, which is a combination of time and log time variables.  
1*() = exp	(− exp(ln,*())) ln,*() = 		−1.031 − 1.294( − 4.265) + 0.349 (ln  − 6.186) + 2.531(v − 3.737)+ .044(v × lnv − 4.927)	 
Equation 4.10 
Where; 




Figure 4.3 - Baseline survival function for developed model (solid line) and predicted survival probability for example 
individual described in equation 4.11 (dashed line). 
Such presentation of baseline survival is rarely reported in practice but is important as it allows 
researchers to compute the baseline survival at any chosen time point; this can then be 
combined with predictor effects as in Equation 4.9, to calculate the survival probability for any 
individual (147). For a new individual, to obtain the probability of recurrence-free survival by 
time ‘t’, one simply needs to input their predictor values and combine with the S0(t) value for 
the time of interest. So, for a 55 year old patient with a 30mm tumour and 5 lymph nodes, 
who is post-menopausal and has an adjuvant treatment, then their 1 year survival probability 







1(1) = 	0.905234	(*.z|) = 0.852 
Equation 4.11 
The survival function for this example patient is presented in full in Figure 4.3 alongside the 
baseline survival curve. 
Model performance measured in the same data as used for derivation of a model is known as 
apparent performance, and is potentially optimistic, with performance in new patients and 
settings often substantially lower (see chapter 1) (34). The apparent discrimination 
performance of the developed model is given in Table 4.5 (with bootstrap derived 95% 
confidence intervals); it shows promising discrimination in terms of Harrell’s C-statistic (C-
statistic=0.68), and Royston and Sauerbrei’s D statistic (log hazard ratio = 1.108, hazard 
ratio=3.03) (75, 212).  The R2D is only 23%, showing that there is a large amount of variation in 
the outcome which is not explained by the model (see section 4.3.2). Calibration performance 
is by definition perfect in the derivation dataset (see chapter 1), and can be assessed visually 
across risk groups of the linear predictor (LP) as in Figure 4.4 (34, 76, 144, 145, 147). 
Table 4.5 - Apparent discrimination performance of the developed model 
 
Estimate 95% LCI 95% UCI 
C-statistic 0.683 0.671 0.696 
D statistic 1.108 0.986 1.222 





Figure 4.4 - Calibration plot showing apparent performance of the developed model in the Rotterdam derivation data. 
Dashed lines = KM curve. Solid lines = model predictions. 
Ideally the developed model would be used in other patient populations outside of the 
Rotterdam dataset where applicable, and as such this model requires external validation, 
which is the focus of the remainder of this chapter.   
4.4.3 IPD meta-analysis of external validation performance of original model 
The following results present the performance of the developed model in the validation 
studies (see Table 4.1), using the meta-analysis methods described above with appropriate 
transformation of performance statistics as required (see Table 4.2). Table 4.6 and Table 4.7 
give the summary results from a random effects meta-analysis of the developed model’s 




Discrimination performance of the model across the validation studies was moderate, with C-
statistics ranging from 0.61 to 0.73 (see Table 4.6). Prediction intervals (PI) from random 
effects meta-analysis indicate a wide range of possible performance in any new patient 
populations, showing potentially excellent, but also potentially inadequate discrimination of 
the model in new patients; for example the 95% PI for the C-statistic ranges from 0.56 to 0.76 
(see Table 4.6). 
Table 4.6 - Discrimination performance of the developed model when applied to the validation studies. CI – Confidence 
interval, PI – Prediction interval 
Study C-statistic R2D D-statistic 
Weak performance value 0.5 0 0 
Sweden 0.73 (0.68, 0.77) 0.34 (0.23, 0.44) 1.46 (1.12, 1.81) 
Lille 0.64 (0.59, 0.69) 0.13 (0.05, 0.23) 0.79 (0.48, 1.11) 
Nijmegen 0.66 (0.59, 0.72) 0.18 (0.06, 0.30) 0.94 (0.53, 1.35) 
St Cloud 0.65 (0.60, 0.70) 0.15 (0.07, 0.24) 0.86 (0.58, 1.16) 
Switzerland 0.72 (0.67, 0.76) 0.30 (0.21, 0.40) 1.36 (1.06, 1.66) 
Denmark 1 0.61 (0.57, 0.65) 0.11 (0.04, 0.19) 0.71 (0.42, 1.00) 
Denmark 2 0.67 (0.62, 0.71) 0.21 (0.12, 0.32) 1.06 (0.75, 1.40) 
Meta-analysis (scale) Logit Logit Normal 
Pooled (95% CI) 0.67 (0.63, 0.70) 0.20 (0.14, 0.28) 1.02 (0.80, 1.24) 
95% PI (0.56, 0.76) (0.06, 0.49) (0.34, 1.70) T
 0.03 0.22 0.06 
I2 (%) 67.75 67.2 68.28 
 
In terms of calibration of the model, Figure 4.5 shows very weak performance of the model in 
all validation studies, with systematic under prediction of survival probabilities, except in the 
Denmark studies where the model over predicts survival. This is indicative of heterogeneity in 
the calibration performance of the model, as seen in Table 4.7, heterogeneity is increasing 




Figure 4.5 - Calibration plot showing performance of the developed model in the seven validation studies. Dashed lines = 




Table 4.7 - Calibration performance (E-O & E/O) statistics for the developed model fitted in the validation studies and meta-analysis results (Null value = 0 & 1 respectively). 
Study E-O 6 months E-O 1 year E-O 2 year E-O 3 year E-O 4 year E-O 5 year E-O 6 year 
Sweden -0.01 (-0.02, -0.01) -0.05 (-0.07, -0.04) -0.12 (-0.14, -0.11) -0.17 (-0.19, -0.15) -0.2 (-0.22, -0.17) -0.21 (-0.24, -0.18) -0.22 (-0.25, -0.19) 
Lille -0.01 (-0.02, 0) -0.03 (-0.04, -0.02) -0.05 (-0.07, -0.02) -0.06 (-0.09, -0.02) -0.06 (-0.09, -0.02) -0.04 (-0.08, 0) -0.05 (-0.09, -0.01) 
Nijmegen -0.02 (-0.02, -0.01) -0.06 (-0.07, -0.04) -0.08 (-0.11, -0.04) -0.09 (-0.13, -0.05) -0.12 (-0.16, -0.07) -0.11 (-0.16, -0.05) -0.08 (-0.15, -0.01) 
St Cloud -0.01 (-0.02, 0) -0.03 (-0.05, -0.02) -0.08 (-0.1, -0.05) -0.1 (-0.13, -0.07) -0.11 (-0.14, -0.07) -0.12 (-0.15, -0.09) -0.13 (-0.16, -0.09) 
Switzerland 0.01 (0, 0.02) -0.01 (-0.03, 0.01) -0.04 (-0.06, -0.01) -0.04 (-0.07, -0.01) -0.03 (-0.07, 0.01) -0.02 (-0.07, 0.02) -0.01 (-0.06, 0.05) 
Denmark 1 0.02 (0, 0.04) 0.03 (0.01, 0.06) 0.06 (0.02, 0.1) 0.06 (0.02, 0.11) 0.09 (0.05, 0.14) 0.08 (0.04, 0.13) 0.11 (0.06, 0.16) 
Denmark 2 0 (-0.01, 0.02) 0.02 (-0.01, 0.06) 0 (-0.04, 0.05) 0.02 (-0.03, 0.07) 0 (-0.05, 0.05) 0.01 (-0.04, 0.06) -0.02 (-0.08, 0.03) 
Meta-analysis (Normal scale) 
Pooled  0 (-0.01, 0) -0.02 (-0.04, 0) -0.04 (-0.09, 0) -0.06 (-0.11, 0) -0.06 (-0.13, 0.01) -0.06 (-0.14, 0.02) -0.06 (-0.14, 0.03) 
PI (-0.03, 0.02) (-0.09, 0.05) (-0.20, 0.11) (-0.26, 0.15) (-0.31, 0.19) (-0.34, 0.22) (-0.37, 0.25) 
Tau2 0 0 0 0.01 0.01 0.01 0.01 
I2 (%) 72.58 89.88 93.79 95.22 95.93 96.12 96.16 
Study E/O 6 months E/O 1 year E/O 2 year E/O 3 year E/O 4 year E/O 5 year E/O 6 year 
Sweden 0.99 (0.98, 0.99) 0.94 (0.93, 0.95) 0.87 (0.85, 0.89) 0.81 (0.79, 0.83) 0.78 (0.75, 0.8) 0.75 (0.73, 0.78) 0.73 (0.71, 0.76) 
Lille 0.99 (0.98, 1) 0.97 (0.95, 0.98) 0.95 (0.92, 0.98) 0.93 (0.9, 0.97) 0.93 (0.89, 0.97) 0.94 (0.9, 1) 0.93 (0.88, 0.99) 
Nijmegen 0.98 (0.98, 0.99) 0.94 (0.93, 0.96) 0.91 (0.88, 0.95) 0.88 (0.84, 0.93) 0.85 (0.8, 0.9) 0.85 (0.79, 0.92) 0.88 (0.8, 0.98) 
St Cloud 0.99 (0.98, 1) 0.97 (0.95, 0.98) 0.92 (0.89, 0.94) 0.89 (0.86, 0.92) 0.87 (0.84, 0.9) 0.84 (0.81, 0.88) 0.83 (0.79, 0.88) 
Switzerland 1.01 (1, 1.02) 0.99 (0.97, 1.01) 0.96 (0.93, 0.99) 0.95 (0.92, 0.99) 0.96 (0.92, 1.01) 0.97 (0.91, 1.03) 0.99 (0.92, 1.09) 
Denmark 1 1.02 (1, 1.04) 1.04 (1.01, 1.07) 1.08 (1.03, 1.14) 1.09 (1.03, 1.17) 1.15 (1.07, 1.25) 1.14 (1.06, 1.24) 1.21 (1.1, 1.34) 
Denmark 2 1 (0.99, 1.03) 1.03 (0.99, 1.07) 1 (0.95, 1.06) 1.03 (0.96, 1.11) 1 (0.93, 1.08) 1.01 (0.93, 1.11) 0.96 (0.88, 1.05) 
Meta-analysis (Log scale) 
Pooled  1 (0.99, 1) 0.98 (0.96, 1) 0.95 (0.91, 1) 0.93 (0.87, 1) 0.92 (0.84, 1.01) 0.92 (0.83, 1.02) 0.92 (0.82, 1.04) 
PI (0.97, 1.02) (0.91, 1.05) (0.80, 1.13) (0.73, 1.20) (0.67, 1.28) (0.63, 1.35) (0.60, 1.41) 
Tau2 0 0 0 0.01 0.01 0.02 0.02 
I2 (%) 72.21 89.7 93.81 95.14 95.89 95.94 95.82 
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4.4.4 IPD meta-analysis of external validation performance after 
recalibration 
The previous section showed that the breast cancer model had large variability in performance 
across the seven studies used for external validation. Although average performance was 
good, it would be better to reduce the inconsistency (heterogeneity) in performance and 
ensure it works well in all settings. The aim of this section is to consider recalibration of the 
developed model to potentially improve the consistency in calibration performance of the 
model, and identify the best recalibration strategy using meta-analysis methods. 
Recall that recalibration methods evaluated are: re-estimating the magnitude of the baseline 
hazard (method 1), additionally re-estimating the shape of the baseline hazard (method 2), or 
additionally estimating a scalar to adjust the linear predictor as a whole in addition to method 
1 (method 3). The final method re-estimates the magnitude of the baseline hazard (method 
1) and additionally re-estimates the regression coefficient of a single predictor (method 4). 
Random-effects meta-analysis was used to identify the most heterogeneous predictor effect 
for re-estimation using method 4. First the developed model was fitted in each validation 
study separately and all regression coefficients were stored. Next a random-effects meta-
analysis was performed on each predictor in turn to quantify the heterogeneity in the 
predictor effect across the validation studies using Equation 1.19. This process identified the 
tumour size predictor as having the most heterogeneous predictor effect, with a between-
study variance of T̂
 = 0.242 and E




Figure 4.6 - Random-effects meta-analysis of tumour size regression coefficient [ln(HR)] from each validation study. 
 
Impact of recalibration methods on discrimination performance 
Table 4.8 shows the performance of the model after using each of the recalibration methods, 
and additionally repeats the previous summary results relating to the original performance of 
the developed model for comparison. It is clear that the discrimination performance of the 
model was unaffected by recalibration methods 1 to 3, as expected given that these did not 
substantially alter the relative ranking of the linear predictor (69). Discrimination is strongly 
influenced by the case-mix of the population in which the model is applied; however only 
method 4 makes any adjustment to the effect of individual predictors, and even then only to 
one predictor (Tumour size). Harrell’s C-statistic varied only by 0.01 in the lower confidence 
and prediction limit, but did not alter in terms of the pooled performance even after 
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recalibration with method 4 (see Table 4.8 and Figure 0.51). The D and R2D statistics fluctuated 
across the methods again by only 0.01, showing no influence of the recalibration methods on 
the discrimination performance of the model. Further, there was no change in the 





Table 4.8 - Comparison of random effects meta-analysis results for each recalibration method (including both discrimination and calibration performance). CI – Confidence interval, 













C-statistic           
Pooled effect (CI) 
0.67 (0.63, 
0.70) 0.67 (0.63, 0.70) 0.67 (0.63, 0.70) 0.67 (0.63, 0.70) 0.67 (0.64, 0.7) 
95% PI (0.56, 0.76) (0.56, 0.76) (0.56, 0.76) (0.56, 0.76) (0.56, 0.76) 
Tau2 0.03 0.03 0.03 0.03 0.03 
I2 (%) 67.75 67.75 67.75 67.75 66.92 
R2D           
Pooled effect (CI) 
0.20 (0.14, 
0.28) 0.19 (0.13, 0.27) 0.20 (0.14, 0.28) 0.19 (0.13, 0.27) 0.20 (0.14, 0.28) 
95% PI (0.06, 0.49) (0.05, 0.5) (0.06, 0.48) (0.05, 0.5) (0.06, 0.49) 
Tau2 0.22 0.27 0.22 0.27 0.22 
I2 (%) 67.2 70.99 67.2 70.99 68.35 
D-statistic           
Pooled effect (CI) 
1.02 (0.80, 
1.24) 1.01 (0.78, 1.23) 1.02 (0.81, 1.24) 1.01 (0.78, 1.23) 1.04 (0.83, 1.26) 
95% PI (0.34, 1.70) (0.29, 1.72) (0.34, 1.7) (0.29, 1.72) (0.36, 1.72) 
Tau2 0.06 0.07 0.06 0.07 0.06 
I2 (%) 68.28 71.67 68.28 71.67 69.48 
E-O (1 year)           
Pooled effect (CI) -0.02 (-0.04, 0) -0.01 (-0.02, 0) 0 (-0.01, 0) -0.01 (-0.02, 0) -0.01 (-0.02, 0) 
95% PI (-0.09, 0.05) (-0.03, 0.01) (-0.01, 0.01) (-0.03, 0.01) (-0.03, 0.01) 
Tau2 <0.0001 <0.0001 0 <0.0001 <0.0001 
I2 (%) 89.88 46.92 0 45.11 46.17 
E-O (3 year)           















95% PI (-0.26, 0.15) (-0.03, 0) (-0.02, 0.01) (-0.03, 0) (-0.03, 0) 
Tau2 0.01 0 0 0 0 
I2 (%) 95.22 0 0 0 0 
E-O (6 year)           
Pooled effect (CI) 
-0.06 (-0.14, 
0.03) 0 (-0.01, 0.02) 0 (-0.02, 0.01) 0 (-0.01, 0.02) 0 (-0.01, 0.02) 
95% PI (-0.37, 0.25) (-0.02, 0.02) (-0.02, 0.02) (-0.02, 0.03) (-0.02, 0.02) 
Tau2 0.01 0 0 0 0 
I2 (%) 96.16 0 0 0 0 
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Impact of recalibration methods on calibration performance 
Calibration performance was substantially improved through use of each recalibration 
method investigated, compared to the developed model without recalibration. Each 
recalibrated model’s predictions were extremely close to the observed Kaplan-Meier curve in 
each study. For example, Figure 4.7 shows the excellent calibration performance of method 1 
(shown by the solid lines), in contrast to the large miscalibration for predictions from the 
originally developed model (short dashed lines).  
Expected (E) minus observed (O) statistics represent the difference between these two curves, 
and results from random effects meta-analysis are presented in Table 4.8. An example forest 
plot for the E/O ratio statistic measured at 3 years post-surgery using all methods is given in 
Figure 4.8, and shows excellent improvement after recalibration. The improvement was also 
observed in the E-O statistic, which is more intuitive to interpret. For example the E-O statistic 
for the original model in the Sweden validation study is -0.17, which represents a serious 
under estimation of the risk. This is equivalent to a patients predicted probability of survival 
being 17% lower than the truth, which could be the difference between a patient being given 
a particular treatment or not. However after recalibration of the model using method 1, the 
magnitude of the baseline hazard is increased and the under prediction is reduced to just 2%. 
Furthermore after recalibration of the whole baseline hazard using method 2, the models’ 
predictions are perfect (E-O=0). 
The prediction intervals calculated from the random effects meta-analysis were much 
narrower after recalibration using methods 1 and 2. A narrower prediction interval indicates 
that the calibration performance is expected to be consistent across settings or populations 
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similar to those included in the meta-analysis (see Table 4.8). This reflects very little estimated 
heterogeneity in calibration performance, with the	T
 = 0.01 for E-O for the developed model 
reduced further to zero heterogeneity after use of recalibration methods; similarly the I2 
statistics was reduced from 95% to 0% at 3 years (see Table 4.8).  
 
Figure 4.7 - Calibration plot showing performance of the model after recalibration via method 1 compared to the 
developed model in the seven validation studies. Long dashed lines = KM curve. Solid lines = method 1 model 
predictions. Short dashed lines = developed model predictions. 
Which recalibration method is best? 
While all recalibration methods showed distinct improvement compared to the developed 
model, there was little difference in performance across the methods. For example the E-O at 
three years was -0.06 for the developed model and, -0.01, 0, -0.01 and -0.01 for methods 1 to 
4 respectively (see Table 4.8). The corresponding 95% prediction interval for the developed 
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model was -0.26 to 0.15, indicating potentially poor performance of the model in new settings. 
After recalibration using methods 1 to 4, the 95% prediction intervals were narrow ranging 
from -0.03 to 0.01, showing much greater consistency in calibration performance (see Table 
4.8). Given the limited improvements in calibration performance and consistency across 
validation studies, simple recalibration of the magnitude of the baseline hazard (method 1) 
appears to be most useful in this applied example. Other examples in different settings would 




Figure 4.8 - Random effects meta-analysis of calibration performance (E/O at 3 years post-surgery) of the model in all 





Evidence suggests that there is currently much waste in the literature where prognostic 
models are concerned, with many newly published models but relatively few validations of 
existing models (9, 82). Development of a new model solely due to poor external performance 
is perhaps counterintuitive to evidence based medicine, as it is throwing away useful 
information gleaned from previous patient populations (64, 69). It has been suggested that in 
this age of large datasets more could be done to perform external validations, and head to 
head comparisons of existing models, as well as recalibrating existing models to new patient 
populations (64, 82). Therefore recalibration offers a potential solution to poor performance 
of existing models in new patients; instead of developing a new model researchers can 
recalibrate or update existing models, using information from both previous and new patients 
(64, 69).  
This chapter examined the use of recalibration methods for improving the performance of an 
existing prediction model at external validation, when multiple validation studies are available 
and the developed model is based on Royston and Parmar’s flexible parametric approach. In 
the applied example, when making predictions using the existing model directly, 
discrimination performance was moderate, but calibration was poor with substantial over and 
under prediction of observed event rates as is common in new patient populations, due to 
changes in case-mix variation and baseline hazard rate (26, 28, 69, 79).  Therefore, various 
recalibration strategies were considered and evaluated using IPD meta-analysis. The findings 
showed that recalibration of the magnitude of the baseline hazard gave large improvements 
in the calibration performance of the model. The method is simple, as it only requires re-
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estimation of the intercept in the validation study. Similar improvements have been shown 
through recalibration of the intercept in logistic prediction model examples (69, 142, 146). The 
other methods investigated (recalibration of the baseline hazard shape, linear predictor, or 
individual predictors), showed little additional improvement beyond just adjustment of the 
intercept alone. Between-study heterogeneity in calibration performance was substantial for 
the original model, but reduced to almost zero after recalibration. Consequently, the 95% 
prediction intervals were much narrower after recalibration, which highlights that consistency 
in calibration performance is expected in new populations similar to those in the meta-
analysis. 
While calibration performance was almost perfect after recalibration of the intercept, 
discrimination performance was unaltered by such methods. It is well known that adjustment 
of the baseline risk or hazard does not materially alter the relative rankings of the linear 
predictor and as such does not impact on model discrimination (69). Only more invasive 
recalibration or updating methods altering the effect of the predictors in the model, may 
impact the discriminative performance. As such only method 4, which allowed recalibration 
of individual heterogeneous predictor effects, altered the discrimination performance of the 
model at validation in this case study (though not importantly).  
One limitation of recalibration methods is the level of information required about the existing 
model for recalibration to be possible. Here FP models were used because they naturally allow 
flexibility to investigate the recalibration of various parts of the model; however in practice 
many published prognostic models are Cox models. This hinders the use of even simple 
recalibration methods because it is very rare that an estimate of the baseline hazard (or 
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baseline survival) is published, and this is essential to individualised prediction and 
recalibration (46, 147). Despite this Royston and Altman have laid out detailed methods for 
external validation of a Cox model elsewhere (147). For example, even if authors have only 
presented 1*() at a few specific time points, it is possible to make predictions and gain some 
assessment of calibration performance (though this is rarely reported) (147). In terms of 
recalibration difficulties remain, though a combination of methods 1 to 3 may be possible 
provided the linear predictor is adequately reported, though this level of recalibration is 
essentially a new model development (147).  
In the motivating example, IPD was available from seven validation studies, which is perhaps 
a rare situation. IPD from multiple studies is difficult to obtain, clean and analyse, and the 
difficulties associated with IPD in general have been widely discussed (ref). However, the 
availability of IPD is increasing, and similar opportunities arise with big datasets from e-health 
databases (21). Given large datasets, one could instead simply develop a new model, including 
study-specific intercepts and, if necessary, study-specific predictor effects to allow for 
between-study heterogeneity. Previous evidence in logistic prediction models suggests that 
where the development dataset is relatively large in comparison to the validation dataset, that 
recalibration of the original model is preferable to new model development (143). While this 
was not assessed here, further research may look to weigh the benefits of new model 
development versus recalibration of an existing model. However, it is worth noting that such 
an approach would neglect the originally developed model, which in the example was itself 
based on a large dataset. Therefore, it seems sensible to start from the original model, using 
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recalibration methods as necessary, and then, perhaps as a last resort, develop an entirely 
new model if recalibration fails.  
Further practicalities relate to the use of the model in practice. In this case study recalibration 
of the intercept provided the best model performance, but this means that for every new 
population a new intercept must be calculated. This leads to a kind of stratified model, which 
may be difficult to use in practice if the intended population was different from those used for 
validation. In that situation one may be forced to use a pooled intercept (e.g. from a random 
effects meta-analysis of the study-specific intercepts) (206). However such an approach may 
substantially weaken performance compared to when study-specific intercepts are available.  
Importantly any recalibration, in any form could strictly be viewed as a new model, which itself 
requires external validation in new data, in potentially different patient populations, new 
settings, different geographical locations or at different times (28, 33, 68, 147). This could 
mean a never ending cycle of recalibration followed by external validation, with then further 
recalibration, and so on. Further research of this issue is needed. Ideally this process of 
external validation and potential recalibration should be performed in the future for the VTE 
model which was developed in chapter 3. 
Previous work has proposed the use of a closed testing procedure to identify the best 
recalibration method to improve performance while avoiding overfitting for logistic prediction 
models (226); such an approach could also be evaluated for time-to-event models in further 
work. Wynants et al. recently investigated the performance of prediction models in clustered 
data, and recommend the use of conditional model predictions as they perform well at both 
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the population and centre level in terms of both calibration and discrimination (17). This 
implies that models using study-specific intercepts may give greatest performance (where 
interest lies in good study-level performance), as was observed in this case study and previous 
research (19, 20).  
Finally, it is important to note that the conclusions of this work are based on one case study, 
in one particular cancer, and therefore that results may vary for other examples. To this end, 
future research could look to extend this work to a simulation study investigating the effect 
of recalibration methods on external model performance in varying settings.  
The next chapter continues to focus on meta-analysis for summarising prognostic 
performance, but now considers a single predictor and the issue of using aggregate data 




• Where model performance is weak or heterogeneous at external validation, 
recalibration methods may substantially improve performance 
• A variety of recalibration methods are possible, ranging from changing the 
intercept to modifying the shape of the baseline hazard and magnitude of 
predictor effects 
• In the case study presented, all recalibration methods showed improvement in 
the calibration performance of an FP model, but discrimination performance 
was unaffected in the case study 
• Simple recalibration of the intercept alone showed dramatic improvement in 
the calibration performance of an FP model, and was the method identified as 
best for this particular case study 
• Between-study heterogeneity in model performance was removed after model 
recalibration using all methods, leading to narrow prediction intervals that 
indicate consistency in calibration performance was achieved 
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CHAPTER 5: DEVELOPMENT OF A MULTIPLE IMPUTATION 
METHOD FOR HANDLING MISSING THRESHOLD RESULTS 
IN TEST ACCURACY META-ANALYSIS 
 
5.1 Introduction 
Previous chapters in this thesis have focused on multivariable prediction models, which 
contain two or more predictors (prognostic factors) to inform individualised risk prediction. In 
situations where the outcome to be predicted is short-term (e.g. hypocalcaemia within 48 
hours of a thyroidectomy), a single predictor may be sufficient for robust prediction. In 
particular, if a predictor is associated with something in the body that means the outcome will 
inevitably become apparent in the near future. Such predictors are sometimes referred to as 
prognostic tests, and have much similarity to diagnostic tests. Essentially, the test result for 
each patient is labelled as either positive or negative, with those that test positive considered 
at high risk of the outcome. The aim is for a prognostic test to have both high sensitivity 
(probability of being test positive for those that will develop the outcome) and high specificity 
(probability of being test negative for those that will not develop the outcome). Having fore-
knowledge of the likely outcome is important to manage individuals in terms of their care and 
treatment. For example, for the thyroidectomy patients, a negative test result may allow them 
to leave the hospital earlier, and thus save beds, whereas those who test positive may be 
monitored closely or given treatment to manage their calcium levels. 
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Primary studies that evaluate the accuracy of a continuous test often report sensitivity and 
specificity values at multiple thresholds which define test positive and test negative patients. 
However, the choice of threshold(s) used often varies across different primary studies. 
Therefore, systematic reviews aiming to summarise a continuous test’s accuracy across 
multiple studies are usually limited by heterogeneity in the reported thresholds across studies. 
This inconsistent presentation of results for multiple thresholds creates a problem for 
researchers aiming to meta-analyse test accuracy results across multiple studies, for example 
to establish the best threshold for using the test in practice. Each threshold may have a 
different number of studies available, and there can be an abundance of information for some 
thresholds but a scarcity for others. In such cases it is common to meta-analyse the results for 
each threshold separately, utilising the subset of two by two tables of test accuracy results 
available for each. Due to the lack of an established and validated alternative method, The 
Cochrane Handbook for Diagnostic Test Accuracy Reviews (Chapter 10) suggests “Estimating 
summary sensitivity and specificity of the test for a common threshold, or at each of several 
different common thresholds” and notes that “Each study can contribute to one or more 
analyses depending on what thresholds it reports. Studies which do not report at any of the 
selected thresholds are excluded” (228). However, this approach excludes studies from a 
meta-analysis if they do not report the threshold of interest, even if they did report results for 
other (often similar) threshold values. A further concern is selective reporting of threshold 
results in primary studies, where thresholds are more likely to be reported when they give 
large sensitivity and specificity results (229). This potentially leads to over-optimistic meta-




In this chapter a novel statistical method is proposed to deal with missing (partially reported) 
threshold information in test accuracy meta-analysis, where a single test (predictor) is used to 
inform the prognosis of an outcome (or condition) for an individual patient. Although the focus 
of this thesis is on prognosis (future outcomes), the issues and proposed method apply equally 
to diagnostic tests. Therefore, examples will be given for both prognostic tests (for predicting 
short-term outcomes) and diagnostic tests (for predicting presence of an existing disease). 
Before introducing the method, it is important to highlight existing methods and approaches 
for dealing with multiple thresholds in test accuracy meta-analysis. Firstly, the multiple 
thresholds issue could be avoided if individual participant data (IPD) were available, as the 
continuous test could then be analysed at a consistent threshold in all studies and therefore 
selective reporting could be avoided. However, in this chapter the focus is on meta-analysis 
of reported results, that is, where IPD are not available. In this situation, several methods have 
already been proposed to synthesise results from multiple thresholds simultaneously, but 
most require a complete set of threshold results (230-232), or require an approximate within-
study normality assumption on logit-sensitivity and logit-specificity estimates (with known 
within-study variances), rather than modelling the two by two data directly (233, 234). Hamza 
et al. (231) proposed a multivariate random-effect meta-analysis approach which models the 
within-study relationship between threshold value and test accuracy. An alternative survival 
model framework for meta-analysing multiple thresholds was later proposed by Putter et al. 
(232), to counter convergence problems with the Hamza method. However, both these 
methods require all studies to report all thresholds of interest, and therefore have limited 
applicability as most applications will encounter missing thresholds in some studies. Dukic and 
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Gatsonis (230) proposed a method for multiple and missing thresholds, but it only allows a 
summary ROC (SROC) curve to be derived and does not give summary estimates at each 
individual threshold of interest. Steinhauser et al. recently proposed a novel method assuming 
either a normal or logistic distribution for the underlying test or biomarker, and used a linear 
mixed model to allow estimation of an SROC curve and any desired threshold value (e.g. 
Youden’s index) (235). However, the method requires an assumption of the distribution of the 
test, which might not be known and may only be estimable if IPD are available.  
Riley et al. also proposed a single imputation (SI) method to impute a two by two table for any 
missing threshold in a study that is bounded between two other available thresholds (236). A 
meta-analysis can then be done at each threshold, with studies with imputed two by two 
tables synthesised with studies with known two by two tables. This was proposed as an 
exploratory method (sensitivity analysis) to examine the potential impact of the missing 
threshold results on meta-analysis conclusions. The use of imputed results provides more 
information at each threshold allowing meta-analysis results to be produced with more 
precision and, in the situation of selectively reported thresholds, potentially less bias. An 
empirical evaluation was previously undertaken to assess the performance of the SI approach, 
which showed promising results though no simulations were conducted to compare results to 
a known truth (236). Further, a concern is that the SI approach provides conservative standard 
errors for estimates of sensitivity and specificity, as it only includes a single imputed value, 
which ignores the uncertainty associated with it. In particular, the distance between a missing 
threshold and its nearest neighbour is ignored; in other words, the smaller the distance 
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between two known thresholds, the more certain we should be about the imputed results for 
intermediate thresholds, but this is ignored in the SI approach. 
Given these shortcomings, in this chapter a multiple imputation method based on discrete 
combinations of missing values (MIDC approach) is proposed, to address the potential 
disadvantages of the SI approach. The proposed method imputes missing two by two tables 
between two known threshold results similar to the SI approach, but repeats this process on 
multiple occasions, each time using a randomly selected two by two table from the set of all 
possible discrete combinations of possible missing values. On each occasion, the imputed 
results are added to the meta-analysis and summary results are estimated using standard 
methods for each threshold. These multiple sets of summary estimates are then combined 
using Rubin’s rules (56), as in standard multiple imputation applications (56, 57), to give overall 
summary estimates of sensitivity and specificity for each threshold. In this way the MIDC 
approach allows for the uncertainty in imputed threshold results and the distance between 
missing and known results. 
The remainder of the chapter is structured as follows. Section 5.2 describes the methods of 
the SI and MIDC approaches in detail. Stata code is developed and provided in the Appendix, 
which allows users to quickly apply the SI and MIDC methods to real applications, and thus is 
potentially useful for Cochrane and researchers conducting test accuracy meta-analyses. 
Section 5.3 illustrates the approaches using two real examples, and highlight the benefits of 
the MI and SI approaches over the standard approach of not allowing for missing threshold 
results. Finally, section 5.4 concludes with some discussion. 
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This work has been submitted for publication in Research Synthesis Methods, and part of the 
Stata software developed was included within a publication in Systematic Reviews (236). The 
work has also been presented at the statistical conferences including; the Methods for 
evaluating medical tests and biomarkers symposium (MEMTAB), Birmingham, UK, in July 2016 
(237), and the 37th International Society of Clinical Biostatistics Conference (ISCB), 
Birmingham, UK, in August 2016. 
5.2 Methods for single and multiple imputation of missing 
thresholds 
In this section the SI method proposed by Riley et al. is introduced, and then the proposed 
new MIDC method is outlined in detail, with explanation of accompanying Stata code. 
5.2.1 Single Imputation (SI) of missing threshold results 
The SI method follows a simple piece-wise linear approach within each study separately, 
imputing a single value for any missing threshold results that are bounded between two 
known thresholds in logit receiver operating characteristic (ROC) space (236). It assumes a unit 
increase in threshold value corresponds to a constant increase (or decrease) in logit-specificity 
and logit-sensitivity; such a linear relationship is often assumed in meta-analyses that model 
the relationship across multiple thresholds (231, 234, 235), especially when the number of 
available thresholds is too small to examine non-linearity.  
Considering missing sensitivity results as an example, the following formula is used to impute 
the missing logit-sensitivity threshold result ({0 ) for threshold t in study i; 
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Equation 5.1 
 
where { (0") is the observed logit-sensitivity estimate for the nearest reported threshold 
below t, and { (0<) is the observed logit-sensitivity estimate for the nearest reported 
threshold above t. Weightings, N 0 are given to each of the observed estimates, depending on 
how close their respective threshold values are to that of the missing threshold.  If the missing 
threshold value is exactly in the middle of the two bounding thresholds, then the imputed { 0 
is simply the average of { (0") and	{ (0<). Each pair of imputed logit-sensitivity and logit-
specificity estimates is then converted back to a two by two table, utilising the known true 
number of those diseased and non-diseased in the study. It should be noted that the 
converted two by two table numbers can be non-integer values, and that as such they often 
need to be rounded to produce a whole number, as otherwise statistical software (usually) 
will not recognise the data as binomial; to be conservative when using the SI method two by 
two table numbers are rounded down to the nearest integer. 
Meta-analysis is performed for each threshold separately, with any studies giving imputed two 
by two tables, synthesised along with studies providing an observed two by two table. A 
standard meta-analysis model is used at each threshold separately, such as the bivariate 
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Here, Di and NDi give the number of diseased and non-diseased in study i, 0 gives the 
summary (average) logit-sensitivity and 0
 gives the summary logit-specificity at threshold t, 
.0  and .0 
 give the random-effects for logit-sensitivity and logit-specificity, T0 and T0
 give 
the between study standard deviations in the true logit-sensitivity and logit-specificity across 
studies for threshold t , and the off-diagonals in ∑0 represent the between-study covariance 
between the true logit-sensitivity and logit-specificity for threshold t . Equation 5.2 collapses 
to a univariate meta-analysis for each of sensitivity and specificity separately when the 
between study correlation ρ12 is zero. Indeed, as this correlation is typically due to differences 
across studies in the threshold value (239), when analysing each threshold separately a 
correlation of zero is quite plausible. 
Riley et al. (236) suggested the SI approach as a simple exploratory method, to allow meta-
analysis results after imputation to be compared with those from a standard analysis that 
analyses each threshold separately with no imputation (NI) (i.e. Equation 5.2 applied to each 
threshold separately, and thus studies with missing results for a particular threshold are 
excluded for that threshold’s meta-analysis).  
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5.2.2 Multiple imputation of missing threshold results based on discrete 
combinations (MIDC) 
The new MIDC method is now introduced, and a schematic of the approach is provided in 
Figure 5.2. It follows four key steps, as now described. 
Step 1: Identification and random selection of discrete combinations for imputing values 
for missing thresholds in each study separately 
For each missing threshold bounded between two known thresholds, the MIDC method 
recognises that the missing sensitivity and specificity must lie within a rectangle formed 
between the two nearest known threshold results (see Figure 5.1). Further, the missing 
number of true positives (TPs), false negatives (FNs), true negatives (TNs) and false positives 
(FPs) at the missing threshold must be whole numbers of patients within this quadrilateral 
between those known for the neighbouring thresholds.  
Table 5.1 shows an illustrative example of a study reporting test accuracy results for a 
continuous test where there are 39 true diseased and 146 true non-diseased patients. Assume 
that the thresholds of interest for meta-analysis are 1, 2, 3, 4 and 5, but that this particular 
study only reports two by two tables for thresholds 1 and 5. Therefore, there are three missing 
thresholds (r=3) to be imputed by the MIDC method, and it is clear that the missing TP must 
be ≤ 35 and ≥ 30, the missing FN must be ≤ 9 and ≥ 4, the missing TN must be ≤ 104 and ≥ 95, 
and finally the missing FP must be ≤ 51 and ≥ 42.   Therefore, there are six potential values 
(n=6) for the TP in the missing thresholds (i.e. 35, 34, 33, 32, 31, 30), and ten potential values 
for the TN in the missing thresholds (i.e. 104, 103 … 96, 95). It follows naturally that imputing 
TP also defines FN (or vice-versa) given the total diseased, and imputing TN also defines FP (or 
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vice-versa), and therefore we only need to consider imputing two cells in the missing two by 
two table; for example, TP and TN. 
 
Figure 5.1 - Illustrative ROC curve with missing threshold results bounded within the rectangle 
 
Table 5.1 – Example data for a single study reporting a continuous test measured at a partial set of multiple thresholds of 
interest for meta-analysis 
Threshold  Missing TP FN TN FP 
1 No 35 4 95 51 
2 Yes ? ? ? ? 
3 Yes ? ? ? ? 
4 Yes ? ? ? ? 




First focus on imputing TP (and thus FN) for the three missing thresholds. There are 56 possible 
discrete combinations (of three values) for the TP to be imputed for the three missing 
thresholds, taking into account that the missing TP is bounded between 35 and 30 and that as 
threshold value increases the number of TPs must be equal to or less than the number of TPs 
at the previous threshold (see Table 5.2 for illustration). The MIDC method randomly selects 
one of these possible combinations, from the list of all combinations, assuming that all 
possible combinations are equally likely (see Figure 5.1). In the same manner, a value for the 
missing TN (and FP) can be imputed for the same missing thresholds. 
Table 5.2 – First and last five of the 56 possible combinations of the imputed TP values for thresholds 2, 3 and 4 in Table 
5.1 




Threshold 2 Threshold 3 Threshold 4 
1 35 35 35 
2 35 35 34 
3 35 35 33 
4 35 35 32 
5 35 35 31 
…. …. …. …. 
52 32 30 30 
53 31 31 31 
54 31 31 30 
55 31 30 30 
56 30 30 30 
 
The above describes a single imputation using the MIDC method in a single study for a 
particular set of missing thresholds. In each study separately, this approach can be used to 
impute TP, FN, TN and FP for all missing but bounded thresholds. Note that, as in the SI 
method, in a particular study there is no imputation for those thresholds that are not bounded 
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(i.e. those missing thresholds that fall above the largest reported threshold or below the 
smallest reported threshold). 
Step 2: Meta-analysis of imputed and observed two by two tables 
In step 2 a meta-analysis is now applied to each threshold separately, including the imputed 
and observed two by two tables available from the studies. For example, Equation 5.2 can be 
applied to produce summary logit-sensitivity and logit-specificity estimates, and between-
study heterogeneity estimates. 
Step 3: Generate multiply imputed datasets and multiple meta-analysis results 
Steps 1 and 2 are then repeated ‘M’ times, leading to ‘M’ meta-analysis results (one for each 
cycle). As the imputation procedure generates new imputations in each cycle, the subsequent 
meta-analysis results may also be different for each cycle. 
Step 4: Combine across the multiple meta-analysis results using Rubin’s rules 
The meta-analysis estimates obtained from each of the ‘M’ cycles are then combined using 
Rubin’s rules, as commonly applied in traditional multiple imputation methods and detailed 
in full elsewhere (56). Briefly, Rubin’s rules produce an overall meta-analysis estimate by 
averaging the `M’ summary estimates, and calculates an appropriate standard error by 
accounting for both within and between-imputation variance of the estimates (56, 57). This 
provides final meta-analysis estimates for each parameter of interest and its associated 




5.2.3 Potential advantages of the MIDC method over the SI method 
By repeated random sampling from the set of all possible combinations of the missing two by 
two tables, the MIDC approach has three potential advantages over the SI method. Firstly, by 
considering multiply imputed datasets, it accounts for the uncertainty of the imputed two by 
two tables. Secondly, as it imputes the two by two tables directly, this ensures that all imputed 
values are whole numbers, which is not necessarily the case with the SI method. Thirdly, the 
method allows for the distance between known and missing threshold results, such that it is 
more likely that a missing threshold close to the known threshold will take a TP (or TN) value 
similar to the observed TP (or TN) value for the closest known threshold. This is illustrated for 
Multiple Imputation using Discrete Combinations (MIDC) approach schematic 
STEP 1: In each study separately; 
• Identify all missing thresholds of interest that are bounded by two thresholds for 
which two by two tables are available 
• For each set of missing thresholds contained within a bound, derive the set of all 
discrete combinations for the missing two by two tables 
• Randomly select a discrete combination from the set of all combinations, thereby 
imputing a single two by two table for all missing but bounded thresholds 
STEP 2: For each threshold separately, apply a meta-analysis (e.g. model (2)) to combine the 
imputed and observed two by two tables from all available studies, to produce one set of 
meta-analysis results for each threshold 
STEP 3: Repeat steps 1 and 2 a total of M times, to obtain M sets of meta-analysis estimates 
for each threshold 
STEP 4: Use Rubin’s rules to combine the M meta-analysis results for each threshold 
separately, to produce a final estimate and standard error for each parameter in the meta-
analysis model. 
Figure 5.2 - Schematic of the multiple imputation using discrete combinations (MIDC) method 
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the current example in Table 3, where the probability of threshold 2 taking each of the six 
possible numbers of TPs is given; it is clear that it is most likely that a TP of 35 will be imputed 
for threshold 2, which is the observed TP value in the closest neighbouring threshold 1. This is 
simply because there are more combinations that include a TP of 35 than any other value. 
Table 5.3 – Probability of each TP value being imputed for missing threshold 2, which is bounded between 35 from 
threshold 1 and 30 from threshold 5  
Possible TP value Probability of TP value being imputed for threshold 2 
35 0.375 (=21/56) 
34 0.268 (=15/56) 
33 0.179 (=10/56) 
32 0.107 (=6/56) 
31 0.054 (=3/56) 
30 0.018 (=1/56) 
 
5.3 Software to implement the methods 
Software was developed (by the PhD candidate, Joie Ensor) to implement the MIDC and SI 
methods within Stata. The complete code for the MIDC approach is presented in the appendix 
(see APPENDIX D: Chapter 5 Appendices), and as part of a submitted article to Research 
Synthesis Methods. The software to implement the SI approach has been published as part of 
the publication proposing the SI method (236). The program for the MIDC approach follows 
the schematic laid out in Figure 5.2. In particular, each possible discrete combination has a 
unique combination number, which follows the pattern shown in Table 5.2. For each 
imputation the discrete combination number is chosen randomly from a uniform distribution 
ranging from 1 to the total number of possible combinations. The corresponding combination 
is then identified, by exploiting the relationship between the unique combination number and 
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cumulative sums of squares, which can be used to calculate the value at each missing 
threshold separately. 
5.3.1 MIDC Stata module 
The following sections briefly describe the user written Stata module midc , which applies the 
MIDC method as described above (see section 5.2.2).  
Command line syntax 
midc, studyvar(varname) thresholdvar(varname) imput ations(int) 
sensitivity(string) specificity(string) covariance( string) 
Where the data are arranged with one line per threshold for each study, where thresholds are 
identified by a variable named in thresholdvar() , and studies are identified by a variable 
named in studyvar() .  
Options 
studyvar(varname) specifies the name of a variable identifying data relating to each 
study (Note this may be in any format including numeric, string or factor variables). 
thresholdvar(varname) specifies the name of a variable identifying data relating to 
each threshold (Note this may be in any format including numeric, string or factor variables). 
imputations(int) specifies the number of imputation datasets to be generated, meta-
analysed, and combined using Rubin’s rules. 
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sensitivity(string)  either specifies the name of a variable containing the sensitivity 
if this data is available, or specifies the name of a new variable to contain the computed 
sensitivity. 
specificity(string)  either specifies the name of a variable containing the specificity 
if this data is available, or specifies the name of a new variable to contain the computed 
specificity. 
covariance(string)  variance-covariance structure of the random effects, where 
options include;  
• independent  one variance parameter per random effect, all covariances zero 
• exchangeable  equal variances for random effects, and one common pairwise 
covariance 
• identity  equal variances for random effects, all covariances zero 
• unstructured  all variances-covariances distinctly estimated 
Data format 
For each threshold value within each study, data for midc  must consist of true positive (tp), 
false positive (fp), true negative (tn) and false negative (fn) values which form the traditional 
2x2 table format commonly seen in diagnostic test accuracy studies. The program can accept 
datasets with or without missing rows of threshold information; midc  prepares a dataset for 
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imputation by creating the missing threshold rows using the user input study and threshold 
identifying variables. The following shows a printout of the first five rows of a typical example 
dataset accepted by the midc  command. 
list study threshold tp fp fn tn in 1/5, noo clean 
 
    study   thresh~d    tp    fp    fn     tn   
    Apgar          0    19     4   292   2107   
    Apgar          1   112    83   199   2028   
    Apgar          2   167   157   144   1954   
    Apgar          3   189   218   122   1893   
    Apgar          4   213   311    98   1800 
 
Model estimation 
For the MIDC method any number of imputation datasets can be specified within the 
command line (imputations  option), though it should be noted that computation time will 
increase with increasing numbers of imputation datasets. Equation 5.2 is then used to 
synthesise the available results for each threshold separately, allowing for estimation of the 
between-study correlation using the previously described options (covariance  option). It 
should be noted that fixing the between-study correlation to zero (independent  option) 
avoids common computation issues associated with this parameter (240, 241). The model is 
fitted via maximum likelihood estimation using Gauss-Hermite quadrature with quadrature 
points equal to the number of studies in the meta-analysis (up to a maximum of 5 quadrature 
points). Following meta-analysis, Rubin’s rules are applied to combine the meta-analysis 
results from each imputation dataset, giving one meta-analysis result for each threshold. All 
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95% confidence intervals are derived on the logit scale using the summary estimates 
combined from all imputation datasets using Rubin’s rules, and then back-transformed. 
Example Stata output 
The following shows an example of the command line and output for the midc  program as 
used in the first applied example described later. 
midc, st(studyname) th(thresholdid) sens(sens) spec (spec) 
cov(independent) imp(5)  
Note: Number of imputation datasets = 5 
Note: Bivariate random-effects model fitted with co variance 
structure = independent 
Imputing dataset 1 
................................................... ... 
Total thresholds imputed = 54 
Imputing dataset 2 
................................................... ... 
Total thresholds imputed = 54 
(Output omitted) 
Imputing dataset 5 
................................................... ... 
Total thresholds imputed = 54 
 
Program took 6.061 seconds, for each imputed datase t 





5.4 Applied examples 
In order to illustrate the use of the imputation methods in practice applied examples are now 
presented, one for a diagnostic test and one for a prognostic test. 
5.4.1 Protein/Creatinine ratio (PCR) for the detection of significant 
proteinuria in patients with suspected pre-eclampsia 
The first example is based on a systematic review and meta-analysis investigating the 
performance of Protein/Creatinine ratio (PCR) as a diagnostic test for the detection of 
significant proteinuria in patients with suspected pre-eclampsia (30). This review is an ideal 
situation in which to apply the imputation methodology proposed, as it found 13 studies which 
reported various possible thresholds for PCR, with each study reporting on a different set of 
thresholds. This made the original meta-analysis problematic, due to small numbers of studies 
reporting on any one threshold. In total there were 23 thresholds considered across all 13 
studies, with five studies reporting only one threshold, and the largest meta-analysis possible 
containing only seven studies. The studies and two by two tables for each threshold are 
presented in Table 5.4 (236). 
204 
 
Table 5.4 - PCR data at each threshold for the 13 studies identified in Morris et al. 
 
First Author Threshold ID Threshold value TP FP FN TN Total  High proteinuria Normal proteinuria 
Al Ragip 1 0.13 35 51 4 95 185 39 146 
 6 0.18 33 42 6 104    
 7 0.19 33 39 6 107    
 8 0.2 31 38 8 108    
 22 0.49 29 23 10 123    
Durnwald 3 0.15 156 35 12 17 220 168 52 
 8 0.2 152 27 16 25    
 15 0.3 136 23 32 29    
 19 0.39 123 14 45 38    
 20 0.4 120 12 48 40    
 23 0.5 106 9 62 43    
Dwyer 3 0.15 54 28 2 32 116 56 60 
 5 0.17 51 25 5 35    
 7 0.19 50 18 6 42    
 12 0.24 41 8 15 52    
 14 0.28 37 3 19 57    
 19 0.39 31 0 25 60    
Leonas 15 0.3 277 7 5 638 927 282 645 
Ramos 23 0.5 25 1 1 20 47 26 21 
Robert 15 0.3 27 4 2 38 71 29 42 
Rodriguez 2 0.14 69 34 0 35 138 69 69 
 3 0.15 68 34 1 35    
 4 0.16 68 26 1 43    
 5 0.17 65 25 4 44    
 6 0.18 62 24 7 45    
 7 0.19 62 21 7 48    
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First Author Threshold ID 
Threshold 
value 





 8 0.2 60 19 9 50    
 9 0.21 60 17 9 52    
Saudan 8 0.2 14 27 0 59 100 14 86 
 13 0.25 13 14 1 72    
 15 0.3 13 7 1 79    
 18 0.35 12 4 2 82    
 20 0.4 11 3 3 83    
 21 0.45 10 0 4 86    
Schubert 3 0.15 9 3 0 3 15 9 6 
 4 0.16 9 2 0 4    
Shahbazian 8 0.2 35 2 3 41 81 38 43 
Taherian 2 0.14 67 7 6 20 100 73 27 
 3 0.15 67 3 6 24    
 4 0.16 65 1 8 26    
 5 0.17 64 1 9 26    
 6 0.18 63 0 10 27    
 8 0.2 59 0 14 27    
Wheeler 9 0.21 59 13 9 45 126 68 58 
Yamasmit 7 0.19 29 6 0 7 42 29 13 
 9 0.21 29 5 0 8    
 10 0.22 29 4 0 9    
 11 0.23 28 3 1 10    
 12 0.24 28 2 1 11    
 13 0.25 28 1 1 12    
 14 0.28 27 1 2 12    
 16 0.31 26 1 3 12    
 17 0.32 25 1 4 12    
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The NI method was applied to each threshold using Equation 5.2 with maximum likelihood 
estimation. This reflects what happens with current meta-analyses of test accuracy studies: 
each threshold is analysed separately with no imputation, and thus only uses studies which 
report the results for that threshold. The results are shown in Table 5.5 and Table 5.6, for 
sensitivity and specificity respectively. 
The MIDC and SI methods were also applied using Equation 5.2 with parameter estimation via 
maximum likelihood, but with between-study correlation set to zero to avoid the common 
computation issues associated with this parameter (15, 16). For the MIDC method five 
imputation datasets were performed before Rubin’s rules was applied (giving one meta-
analysis results dataset), five was selected to reduce computation time. The imputation 
methods summarise not only the published evidence available for each threshold but also 
utilise imputed data for the missing, unpublished evidence (for bounded thresholds). As such 
the methods can be used to assess if the conclusions of the original meta-analysis are robust 
(e.g. to potential selective threshold reporting bias) for each threshold. The following presents 




Table 5.5 - PCR example sensitivity results for all methods, including the summary sensitivity, its standard error and the number of studies reporting the threshold 



















1 1 0.897 0.528 1 0.897 0.528 1 0.897 0.528 
2 2 0.982 1.684 3 0.957 0.759 3 0.956 0.784 
3 5 0.944 0.316 6 0.939 0.206 6 0.938 0.243 
4 3 0.960 0.808 6 0.925 0.214 6 0.933 0.276 
5 3 0.909 0.247 5 0.911 0.175 5 0.910 0.174 
6 3 0.873 0.223 5 0.894 0.161 5 0.894 0.162 
7 4 0.902 0.242 6 0.889 0.160 6 0.895 0.175 
8 6 0.875 0.188 8 0.886 0.206 8 0.884 0.218 
9 3 0.892 0.250 7 0.880 0.146 7 0.881 0.178 
10 1 0.983 1.451 5 0.901 0.562 5 0.891 0.523 
11 1 0.966 1.018 5 0.868 0.335 5 0.855 0.304 
12 2 0.877 0.844 5 0.844 0.295 5 0.849 0.344 
13 2 0.953 0.724 5 0.838 0.336 5 0.836 0.339 
14 2 0.818 0.701 5 0.816 0.296 5 0.813 0.296 
15 4 0.938 0.583 7 0.887 0.451 7 0.889 0.459 
16 1 0.897 0.610 5 0.782 0.287 5 0.782 0.281 
17 1 0.862 0.539 5 0.761 0.261 5 0.759 0.239 
18 1 0.857 0.764 4 0.715 0.214 4 0.725 0.217 
19 2 0.662 0.281 4 0.695 0.201 4 0.704 0.222 
20 2 0.720 0.165 3 0.724 0.150 3 0.727 0.151 
21 1 0.700 0.583 3 0.697 0.146 3 0.705 0.148 
22 1 0.744 0.367 2 0.675 0.149 2 0.667 0.147 
23 2 0.844 0.996 2 0.844 0.996 2 0.844 0.996 
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Table 5.6 - PCR example specificity results for all methods, including the summary specificity, its standard error and the number of studies reporting the threshold 




















1 1 0.651 0.174 1 0.651 0.174 1 0.651 0.174 
2 2 0.604 0.363 3 0.624 0.208 3 0.631 0.224 
3 5 0.562 0.407 6 0.583 0.332 6 0.586 0.336 
4 3 0.803 0.719 6 0.660 0.420 6 0.664 0.416 
5 3 0.765 0.678 5 0.677 0.448 5 0.678 0.441 
6 3 0.856 1.043 5 0.728 0.583 5 0.730 0.554 
7 4 0.708 0.130 6 0.720 0.437 6 0.722 0.424 
8 6 0.818 0.569 8 0.775 0.405 8 0.777 0.398 
9 3 0.750 0.195 7 0.710 0.170 7 0.709 0.166 
10 1 0.679 0.594 5 0.712 0.231 5 0.717 0.239 
11 1 0.769 0.658 5 0.744 0.277 5 0.744 0.239 
12 2 0.863 0.340 5 0.768 0.296 5 0.770 0.286 
13 2 0.848 0.280 5 0.811 0.397 5 0.821 0.406 
14 2 0.945 0.514 5 0.849 0.474 5 0.845 0.453 
15 4 0.917 0.786 7 0.914 0.515 7 0.914 0.520 
16 1 0.923 1.041 5 0.890 0.579 5 0.874 0.509 
17 1 0.923 1.041 5 0.897 0.568 5 0.892 0.556 
18 1 0.953 0.512 4 0.903 0.643 4 0.917 0.771 
19 2 0.976 2.598 4 0.935 0.875 4 0.932 0.852 
20 2 0.903 0.766 3 0.877 0.491 3 0.878 0.490 
21 1 0.994 1.427 3 0.943 1.265 3 0.943 1.263 
22 1 0.842 0.227 2 0.833 0.191 2 0.832 0.190 
23 2 0.863 0.340 2 0.863 0.340 2 0.863 0.340 
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Figure 5.3 shows a dramatic change in summary sensitivity and specificity (in ROC space) when 
using the MIDC method compared to the original NI approach. For example for threshold 13, 
the summary sensitivity was 0.953 and 0.836 for the NI and MIDC methods, respectively, with 
associated standard errors of 0.724 and 0.339. After imputation it is clear that there is 
generally a shift in summary estimates, both downward and to the right in ROC space. This 
indicates a decrease in sensitivity (downward shift) and specificity (shift right), as may be 
expected in the presence of publication bias or selective reporting, where weaker performing 
threshold results may not be reported. Therefore, the application of the MIDC method reveals 
that the original conclusions from the NI method are not robust, with summary sensitivity and 
specificity estimates lower than estimated when ignoring missing data.  
There are comparatively small differences between the MIDC and SI methods, with both 
indicating that summary estimates shift in the same direction. The MIDC method shifts the 
summary estimates by a slightly greater magnitude compared to the SI method, and this 
difference is likely caused by the MIDC method additionally accounting for the uncertainty in 
imputed threshold results and/or providing two by two tables that do not require rounding, 
unlike the SI approach. Taking threshold 13 as an example again, the summary sensitivity for 





Figure 5.3 - Summary estimates of sensitivity and specificity in ROC space for all methods. NB: Arrows represent change 
from NI summary estimates 
 
Figure 5.4 presents the standard errors of sensitivity and specificity at each threshold, showing 
the shift in standard error from the NI to MIDC method. Using the imputation approaches 54 
additional threshold results were gained for meta-analysis, which reduced the standard errors 
of the summary sensitivity and specificity at many thresholds (by as much as 70% in some 
cases, see Table 5.5 and Table 5.6), also leading to substantially narrower confidence intervals. 
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The SI approach performed similarly to the MIDC method, with substantially smaller standard 
errors that the NI approach (see Figure 5.4). 
Thus, in summary, the use of more evidence through imputation via either the SI or MIDC 
methods had a substantial impact on the summary results for the PCR tests at each threshold. 
Test accuracy results are not as promising for the PCR test after imputation, which was missed 
when using the NI approach. Further, in this particular example, there appears to be very little 
difference between the MIDC and SI approaches. 
 




5.4.2 Apgar score to assess the health of newborn children 
The second example is based on a systematic review and meta-analysis investigating the 
performance of the Apgar score as a prognostic test for neonatal mortality in pre-term (<37 
weeks gestation) babies with a low birth weight (<2.5kg) (242). The Apgar score is essentially 
a prognostic model, as it is formed by a combination of prognostic factors used to measure a 
newborn baby’s health (243); it takes values from 0 to 10 and is usually measured at one, five 
and ten minutes after birth (244). Babies with low values have a worse prognosis. The review 
identified 11 studies which examined the prognostic ability of the Apgar score in terms of its 
sensitivity and specificity after using a threshold to dichotomise the score into high and low 
risk groups. However, the studies used various possible thresholds for dichotomising the 
Apgar score. In total across the 11 studies there were five studies reporting only one threshold, 
and the largest number of studies for a particular threshold was nine. The studies and two by 
two tables for each threshold are presented in Table 5.7. 





TP FP FN TN Total  TD TND 
Apgar 0 19 4 292 2107 2422 311 2111 
  1 112 83 199 2028 2422 311 2111 
  2 167 157 144 1954 2422 311 2111 
  3 189 218 122 1893 2422 311 2111 
  4 213 311 98 1800 2422 311 2111 
  5 237 439 74 1672 2422 311 2111 
  6 253 606 58 1505 2422 311 2111 
  7 266 859 45 1252 2422 311 2111 
  8 290 1365 21 746 2422 311 2111 
  9 307 1906 4 205 2422 311 2111 
Beeby 3 49 135 39 400 623 88 535 
Behnke 3 113 144 48 443 748 161 587 
  6 148 326 13 261 748 161 587 







TP FP FN TN Total  TD TND 
  6 128 427 23 1039 1617 151 1466 
Heller 3 97 1267 91 31106 32561 188 32373 
  6 147 4916 41 27457 32561 188 32373 
Ikonen 3 35 25 65 443 568 100 468 
  6 55 70 45 398 568 100 468 
Issel 3 20 45 52 585 702 72 630 
  7 52 169 20 461 702 72 630 
Kato 4 6 75 0 147 228 6 222 
Luthy 3 26 47 9 164 246 35 211 
Serenius 3 28 30 45 108 211 73 138 
Tejani 6 47 142 6 197 392 53 339 
 
The NI, SI and MIDC methods were applied as before for the PCR example, where the meta-
analysis model given in Equation 5.2 was estimated using maximum likelihood for each 
threshold of interest, with between-study correlation again set to zero to avoid computational 
issues (15, 16). For the MIDC method five imputation datasets were selected as for the PCR 
example, with Rubin’s rules used to combine the five imputed datasets into one final meta-
analysis results dataset. The results are shown in Table 5.8, for sensitivity and specificity 
respectively. 
Results showed that imputation was only possible in a few instances in the central thresholds; 
in particular, many studies reported on thresholds 3 and 6, but not 4 and 5. In total 11 
additional thresholds were imputed using the SI and MIDC methods. Figure 5.5 shows a shift 
in the summary sensitivity and specificity (in ROC space) when using the MIDC method 
compared to the original NI approach, for thresholds 4, 5 and 6 where imputation was 
possible. For example, for threshold 5, the summary sensitivity was 0.762, 0.707 and 0.685 for 
the NI, SI and MIDC methods, respectively, with associated standard errors of 0.133, 0.292 
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and 0.282. After imputation there is generally a shift in summary estimates, downward and to 
the left in ROC space, similar to what was seen in the PCR example. This indicates a decrease 
in sensitivity (downward shift) and an increase in specificity (shift left). Applying the SI and 
MIDC methods therefore reveals that the original conclusions from the NI method for 
thresholds 4 to 6 are not robust, with summary sensitivity and specificity estimates differing 
from those estimated when ignoring missing data.  
It is of particular interest that in this example the standard errors increase in comparison to 
the NI approach, where imputation is possible. This is likely due to the large between-study 
heterogeneity which is better estimated with the increased data available after imputation 
(see Table 5.8). For example take threshold 5 again, for the NI method only 1 study reported 
sensitivity for threshold 5, meaning heterogeneity could not be estimated and only this studies 
estimates could be used for the summary sensitivity. Whereas for the SI and MIDC methods 
at threshold 5 the estimated heterogeneity was 0.69 and 0.66 respectively, which represents 
very large between-study variability in comparison to the summary estimate of sensitivity 
itself.  
Thus, as seen in the PCR example, the use of the SI or MIDC methods made a substantial 
difference to the summary results for the Apgar score at some thresholds, suggesting that the 
methods are important to use in practice. It was also observed again that there was little 
difference between the SI and MIDC methods, in terms of summary estimates, standard errors 
and between-study heterogeneity estimates. This example also illustrates the potential 




Table 5.8 - Summary results for the Apgar example, for summary sensitivity and specificity using NI, SI and MIDC methods. 























0 1 0.061 0.237  1 0.061 0.237  1 0.061 0.237  
1 1 0.360 0.118  1 0.360 0.118  1 0.360 0.118  
2 1 0.537 0.114  1 0.537 0.114  1 0.537 0.114  
3 9 0.535 0.213 0.60 9 0.535 0.213 0.60 9 0.535 0.213 0.60 
4 2 0.691 0.122 0.00 7 0.645 0.297 0.72 7 0.646 0.198 0.70 
5 1 0.762 0.133  6 0.707 0.292 0.69 6 0.685 0.282 0.66 
6 6 0.819 0.291 0.67 7 0.796 0.284 0.71 7 0.788 0.316 0.80 
7 2 0.807 0.292 0.34 2 0.807 0.292 0.34 2 0.807 0.292 0.34 
8 1 0.932 0.226  1 0.932 0.226  1 0.932 0.226  
























0 1 0.998 0.500  1 0.998 0.500  1 0.998 0.500  
1 1 0.961 0.112  1 0.961 0.112  1 0.961 0.112  
2 1 0.926 0.083  1 0.926 0.083  1 0.926 0.083  
3 9 0.879 0.256 0.76 9 0.879 0.256 0.76 9 0.879 0.256 0.76 
4 2 0.774 0.382 0.53 7 0.852 0.284 0.74 7 0.879 0.181 0.71 
5 1 0.792 0.054  6 0.817 0.272 0.66 6 0.806 0.270 0.65 
6 6 0.710 0.287 0.70 7 0.724 0.254 0.67 7 0.722 0.261 0.69 
7 2 0.664 0.222 0.31 2 0.664 0.222 0.31 2 0.664 0.222 0.31 
8 1 0.353 0.046  1 0.353 0.046  1 0.353 0.046  




Figure 5.5 - Summary estimates of sensitivity and specificity in ROC space for all methods, for the Apgar example. NB: 
Arrows represent change from NI summary estimates 
5.5 Discussion 
To inform clinical decision making, meta-analysis results on the accuracy of a test should be 
accompanied with clear guidance on the threshold to use for defining test positive and test 
negative patients. However, often test accuracy meta-analyses suffer from having small 
and/or discrepant numbers of studies for each threshold of interest. In this chapter a new 
method was proposed to deal with this problem, based on multiple imputation from the set 
of all available discrete combinations of missing two by two tables. The results of the applied 
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PCR example showed a shift in the summary sensitivity and specificity estimates using both 
imputation methods, indicating that ignoring the missing threshold information (NI method) 
may have led to biased summary results. The example also highlighted a large improvement 
in precision, with standard errors substantially smaller for both imputation methods due to 
the addition of 54 threshold results for meta-analysis.  
Theoretically, the MIDC method was developed to improve on the current SI method by 
allowing for uncertainty associated with the imputed threshold results, and also uncertainty 
associated with the distance between the missing threshold and the nearest known threshold 
results. However, in the two examples, there was very little difference between the SI and 
MIDC results. The MIDC method is more complex as it imputes missing threshold results 
multiple times and combines these results to give one summary performance at each 
threshold; this inevitably increases computation time, but only slightly (in the applied example 
the SI and MIDC methods took 9.55 and 30.3 seconds to run, with MIDC performing five 
imputations). While this work focuses on the application to tests reporting continuous results 
future research could extend these methods for use with tests reporting ordinal results. The 
Software to implement the MIDC procedure in Stata is presented in the appendix. 
There has been debate concerning the order in which meta-analysis and Rubin’s rules should 
be performed. The MIDC approach performs meta-analysis on the imputed dataset and then 




One limitation of the imputation methods is that neither the MIDC or SI approaches constrain 
the ordering of threshold results, meaning that in real world examples the imputed results 
may lead to imperfect SROC curves (as seen in the PCR example Figure 5.3) (234). The methods 
of Hamza et al. and Riley et al. constrain the threshold results to be ordered, however these 
methods are limited by requiring either complete data or a normality assumption on the logit 
estimates within-studies (231, 234).  Further work may look to address this problem.  
The multiple imputation approach for the MIDC method used discrete combinations, but an 
alternative approach may be to assume some distribution for the true underlying diagnostic 
test distribution, which would allow potential imputations to be drawn from some posterior 
distribution as in standard multiple imputation approaches; however this would require the 
distribution of the test be known, and this will often be unlikely and impractical for those 
researchers (often non-statisticians) who are undertaking such meta-analyses. Steinhauser et 
al. propose a method based on distributional assumptions for the underlying test distribution 
(235). In their examples either a normal or logistic distribution is assumed for the diagnostic 
test, though in practice more complex distributions may better fit particular examples. Indeed 
the distributions of diseased and non-diseased patients within individual studies may differ, 
meaning multiple distributional assumptions are needed. In practice the true underlying test 
distribution is difficult to ascertain without IPD, though in some cases such distributions may 
be available in published literature.  
Finally, there are now numerous published methods to address the synthesis of multiple and 
missing thresholds in test accuracy meta-analysis (230-236, 238, 239), and so it is pertinent 
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that future work should aim to investigate a head-to-head comparison of the available 
methods through simulation (245). 
5.5.1 Motivation for subsequent chapter 
Given that the MIDC and SI approaches appeared to give similar results in terms of both 
summary estimates of sensitivity and specificity, as well as their associated standard errors, 
the next chapter will examine whether these findings generalise using simulations. A 
simulation study enables the performance of the new MIDC method to be compared against 
the SI and NI methods in relation to a known truth. This is not possible in a single example 
(such as the PCR example above), as the true summary estimates are unknown and so no 
assessment of the methods statistical properties is possible. In contrast, the simulation study 
in the next chapters allows the statistical properties of the methods to be compared, relative 
to known true values of sensitivity and specificity, to identify situations in which the 
imputation methods perform better or worse than the NI approach. In particular, methods 
are compared in terms of properties including; the bias and precision of summary estimates, 
the coverage of estimated 95% confidence intervals, and the bias and precision of between-
study heterogeneity estimates. 
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CHAPTER 6: A SIMULATION STUDY TO EVALUATE THE 
PERFORMANCE OF IMPUTATION METHODS FOR MISSING 
THRESHOLD RESULTS IN TEST ACCURACY META-ANALYSIS 
 
6.1 Introduction 
Where multiple primary studies report on the performance of a continuous test, it is important 
to synthesise all the evidence at multiple thresholds to inform how best to use the test in 
clinical practice. In the previous chapter, it was highlighted that a common problem in a test 
accuracy meta-analysis is missing threshold data, due to reporting of different thresholds 
across the primary studies. To address this, a new Multiple Imputation by Discrete 
Combinations (MIDC) method was proposed. The MIDC method imputes a two by two table 
for any missing threshold in a study that is bounded between two other available thresholds, 
and repeats this multiple times to account for uncertainty. The MIDC method theoretically 
improves on the previously proposed single imputation (SI) method of Riley et al. in a number 
of ways (see Chapter 5) (236). In particular, it accounts for the uncertainty of imputations, and 
always imputes whole numbers.   
In chapter 5 the MIDC and SI methods were applied to two real examples, which illustrated 
how they could be used in practice to investigate the robustness of results from a standard 
meta-analysis approach of only analysing observed data with no imputation (NI) (228). In the 
PCR example there was evidence of a large improvement in the precision of the summary 
estimates of sensitivity and specificity when using either the SI or MIDC imputation methods, 
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as expected given the increase in available data after imputation. In terms of summary 
estimates there was a shift in their values compared to the NI method, potentially indicating 
that there was bias in the original results using the NI method. The second example 
additionally indicated that the imputation methods could be beneficial in improving 
estimation of between-study heterogeneity. Thus there were promising signs of benefit for 
both imputation methods over the NI method. However, the applied examples also indicated 
that the SI and MIDC methods may be similar, as they produced very similar summary 
sensitivity and specificity results and associated standard errors.   
These are only two possible examples, and so it is now important to investigate whether the 
observed performance of the methods generalises to other situations. The methods may 
perform better or worse under different scenarios, and so a simulation study is warranted to 
evaluate the MIDC, SI and NI approaches across a range of settings and under different data 
generating mechanisms (245). An empirical evaluation of the SI method has been published 
elsewhere, but no simulations comparing to a known truth were conducted (236). 
In this chapter a simulation study is therefore designed and implemented to evaluate the 
performance of the MIDC and SI approaches, in comparison with each other and the standard 
NI approach. Several scenarios are considered including varying the proportion of missing 
information, the missingness mechanism, the relationship between threshold value and test 
accuracy, and levels of heterogeneity between studies. The work has been submitted to the 
journal Research Synthesis Methods, and is currently under review. 
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The outline of the chapter is as follows. Section 6.2 describes the simulation study design and 
methods in detail. Section 6.3 presents the results for all the simulation study scenarios, and 
Section 6.4 concludes with some discussion and recommendations. 
6.2 Simulation study methods 
A simulation study is now described to compare performance of the MIDC and SI methods 
with each other, and also with the standard approach of ignoring missing thresholds which is 
referred to throughout as ‘NI’ (no imputation). The simulation procedure was undertaken for 
each of a range of different scenarios. This followed a step-by-step process, as now explained 
in detail. 
As described in chapter 5, the Stata code to perform the SI and MIDC methods as well as the 
simulation study, was developed by the PhD candidate (Joie Ensor) and Stata 14 code is 
provided in appendix for the MIDC method (see APPENDIX D: Chapter 5 Appendices) (225). 
6.2.1 Step 1: Define the scenario 
Table 6.1 shows the 15 different scenarios considered, covering different values for the 
amount of heterogeneity, the amount of missing data, the missingness mechanism, and the 
assumed threshold spacing. A simulation was carried out for each of the 15 scenarios. All 
simulations assumed there were 10 studies available for the meta-analysis, which is typical of 





Table 6.1 - Simulation scenarios including base case and sensitivity scenarios 







1 10 10% 0 50 MCAR Equal 
2 10 10% 0.25 50 MCAR Equal 
3 10 10% 0.5 50 MCAR Equal 
Greater chance of missingness 
4 10 10% 0 70 MCAR Equal 
5 10 10% 0.25 70 MCAR Equal 
6 10 10% 0.5 70 MCAR Equal 
Missing not at random 
7 10 10% 0 50 MNAR Equal 
8 10 10% 0.25 50 MNAR Equal 
9 10 10% 0.5 50 MNAR Equal 
Unequal threshold spacing  
10 10 10% 0 50 MCAR Unequal 
11 10 10% 0.25 50 MCAR Unequal 
12 10 10% 0.5 50 MCAR Unequal 
Extreme unequal threshold spacing  
13 10 10% 0 50 MCAR Extreme Unequal 
14 10 10% 0.25 50 MCAR Extreme Unequal 
15 10 10% 0.5 50 MCAR Extreme Unequal 
* Assumed threshold spacing; ^MCAR = Missing Completely At Random, MNAR = Missing Not At Random 
 
6.2.2 Step 2: Generate the number of participants per study 
For each meta-analysis dataset of 10 studies, the number of patients per study were randomly 
selected to be between 30 and 200 using a uniform(30,200) distribution; so as to replicate a 
small to moderate sample size within studies. 
6.2.3 Step 3: Generate the true disease status for each patient in each study 
Prevalence of disease for all scenarios was set to 10% (see Table 6.1), with disease status in 
each meta-analytic dataset being sampled from a Bernoulli(0.1) distribution, to reflect a 
typical disease prevalence of 10%. Later, as an extension to the work, a prevalence of 50% was 
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also investigated and this is briefly discussed in section 6.3.6 (with results shown in APPENDIX 
E5: Extensions). 
6.2.4 Step 4: Generate the true sensitivity and specificity values for each 
threshold in each study 
The true sensitivity and specificity results at each threshold for each study were calculated 
using two linear models with either logit-sensitivity or logit-specificity as responses, and 
threshold value as an independent predictor (see Equation 6.1). This approach naturally 
induces a linear relationship between threshold value and logit sensitivity/specificity. For the 
assumed linear relationship, the coefficients for the constant and threshold predictor were 
calculated based on those from a previous test accuracy meta-analysis (243), as follows, 
mS.9	!-#98#Q{	8	#./{		R	ℎS9#ℎ!/()= 	 	+ 	(−0.2719091 × ℎS9#ℎ!/()) 
mS.9	!-#9$${	8	#./{		R	ℎS9#ℎ!/()= 	
 	+ 	(0.2851818 × ℎS9#ℎ!/()) 
 = 	J(3.304182, T
) 





Where T2 defines the amount of between-study heterogeneity in the true logit-sensitivity and 
logit-specificity, which was set to either be zero, 0.25 (moderate) or 0.5 (high) depending on 
the scenarios chosen (see Table 6.1). The mean summary ROC curve that these equations 
(Equation 6.1) represent is shown in Figure 6.1 and the assumed linear relationship is 
illustrated in Figure 6.2 for logit-sensitivity over a range of threshold values. 
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For each study, the true intercepts (1	and	2) were drawn randomly from the two normal 
distributions in Equation 6.1. This then produced two final equations in each study, which 
could be used to derive the true logit values at each threshold (	  	1		m), from which the 
true sensitivity (sensti) and true specificity (specti) could be obtained by back-transforming 
from the logit scale. 
 
Figure 6.1 - Mean summary ROC curve used for the simulations based on Equation 6.1, illustrating the different threshold 





Figure 6.2 - Illustration of the linearity assumption between logit-sensitivity and threshold as defined by Equation 6.1, 
with threshold spacing defined by the scenarios in Table 6.1 
 
Scenarios 1 to 9 assumed equal threshold spacing, but in scenarios 10 to 15 unequal threshold 
spacing was assumed (see Figure 6.1 and Figure 6.2), with scenarios 13 to 15 investigating a 
more extreme unequal threshold spacing. 
The eleven thresholds were fixed for all scenarios to be consistent, and this was based on the 
real example used to inform the parameters in Equation 6.1 (243).  The numerical values of 
the continuous test corresponding to the 11 thresholds were held constant across all studies 
within each scenario. The chosen threshold values were integer values from 1 to 11 for 
simulation scenarios 1-9; for scenarios 10-12 a transformation of these threshold values was 




mℎS9#ℎ!/	QR!.9	S	#$98RS#	10-12 = (mℎS9#ℎ!/	QR!.9	S	#$98RS#	1-9).[5  
Equation 6.2 
 
Scenarios 13-15 were introduced as an extreme scenario to examine the effect of missing 
thresholds in the centre of the ROC curve. For these scenarios extremely unequal spacing of 
thresholds was considered as a combination of “bunching” of similar thresholds (at either end 
of the continuous measurement scale) and of “large gaps” between thresholds in the centre 
of the continuous scale (see distribution of squares in Figure 6.1 and Figure 6.2). In real 
applications, bunching of thresholds may be observed, for example, in meta-analyses when a 
set of studies have used a very similar threshold, but with differences in the last digit or 
decimal place. Large gaps may occur, for example, between thresholds chosen to optimise a 
test for rule out purposes (where a low threshold would be evaluated) or rule in purposes 
(where a high threshold would be evaluated). Threshold values were hand selected to create 
this effect for scenarios 13-15, with thresholds at 0.15, 0.6, 1.15, 2.37, 2.95, 8.37, 8.76, 9.15, 
9.6, 10.15 and 10.76 (see Figure 6.2). It should be noted that scenarios 13-15 examine the 
effect of missing thresholds in the centre of the ROC curve, though a similar issue could occur 
elsewhere on the ROC curve. 
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6.2.5 Step 5: Generate the observed number of TP, TN, FP and FN at each 
threshold 
For each study separately, an observed two by two table was then generated for each 
threshold. To create this the multinomial distribution was expressed as a series of conditional 
binomial distributions (231). Firstly, to calculate the number of TPs above threshold 1 (the 
lowest threshold, t =1), TP1i was randomly sampled from a binomial distribution with Di=the 
total number of diseased in study ‘i’, and sens1i=estimated sensitivity for threshold 1 in study 
‘i’.  
m 		~	8jR!(k , #98# ) 
Equation 6.3 
And thus, 
J  k − m  
Equation 6.4 
 
For subsequent thresholds, the TPti were derived using a conditional binomial distribution. For 
example, the number of TPs were generated above threshold 2 out of the subset of patients 
who were positive above threshold 1, by calculating the observed m 		minus a random 
sample from a m
 	~	8jR! m 	, ^; 	^;¡  distribution. In this way, each successive TPti 
accounted for the previous TP(t-1)i value. 
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TNti and FPti for the non-diseased population were generated in a similar manner for each 
threshold. 
6.2.6 Step 6: Create missing results for some thresholds 
Step 5 produced complete data (i.e. a two by two table) for each threshold in each study. To 
create missing data, some of the two by two tables in each study were removed using either 
a missing completely at random (MCAR) or, for scenarios 7 to 9, a missing not at random 
(MNAR) mechanism (57, 246).  For the missing completely at random scenarios, each two by 
two table was given a percentage probability of being missing according to the percentage 
missing data dictated by the scenarios setting (see Table 6.1). For the missing not at random 
scenarios, two by two tables could only be missing where the observed Youden’s index was < 
0.7 (where Youden’s index = sensitivity + specificity – 1, and therefore provides an overall 
measure of test performance) (247). This reflects a situation where test performance is worse 
than expected at this threshold, and so it is vulnerable to publication bias and non-reporting 
in the study publication (248-250). Such thresholds were given a 50% chance of being missing 
in scenarios 7 to 9. Other thresholds where Youden’s index was at least 0.7 were always 
assumed to be available.  
6.2.7 Step 7: Apply meta-analysis to each simulated dataset using NI, SI or 
MIDC methods 
Steps 1 to 6 were applied to obtain 1000 meta-analysis datasets in each scenario. For each 
dataset, the NI, SI and MIDC methods were applied separately to produce 1000 meta-analysis 
results for each type of approach. For the MIDC method five imputation datasets were 
performed before Rubin’s rules was applied (giving one set of meta-analysis results per 
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dataset) (56); five imputations was chosen to reduce the computation time of the overall 
simulation study. A bivariate random-effects meta-analysis model (see Equation 5.2) as 
presented in chapter 5 was used to synthesise the available results for each threshold 
separately (238, 239), but with the between-study correlation set to zero to avoid the common 
computation issues associated with this parameter (240, 241). The model was fitted via 
maximum likelihood estimation using Gauss-Hermite quadrature (251), with quadrature 
points equal to the number of studies in the meta-analysis. However, where more than five 
studies remained after missingness was generated, the number of quadrature points was 
restricted to be no greater than five, as additional points over this limit had little impact on 
summary estimates but increased computation time. Convergence issues with the bivariate 
model meant that some simulation runs were discarded; only runs which converged for all 
three methods were retained, so as to maintain a fair comparison. 
The performance of the three methods in each scenario was summarised and compared in 
terms of the bias in the mean of the summary (logit) sensitivity and (logit) specificity estimates; 
the mean of the standard errors of the summary results; the mean bias in the estimate of	T, 
and the percentage coverage of the 95% confidence intervals for the summary sensitivity and 
specificity. The 95% confidence intervals for the summary sensitivity and specificity at each 
threshold were derived on the logit scale using the summary logit estimate +/- 1.96 




6.3.1 Base case settings (Scenarios 1 to 3) 
The three base-case settings of scenarios 1 to 3 each involved a 10% prevalence, 50% of 
thresholds missing completely at random, and equal threshold spacing, but varied according 
to the magnitude of between-study heterogeneity (see Table 0.14, Table 0.15, Table 0.16, 
Table 0.17, Table 0.18 and Table 0.19). For each scenario, mean summary estimates from the 
1000 simulations from each of the NI, SI and MIDC approaches were plotted at each threshold 
in ROC space and compared with the true ROC curve (see Figure 6.3). When the heterogeneity 
was zero or moderate, there was very little bias at all thresholds, for either the NI method or 
the imputation methods. However, there was slight bias when the heterogeneity was large 
for all methods (Scenario 3), with summary sensitivity and specificity underestimated across 
the thresholds. The bias was slightly worst for the SI method, and the MIDC and NI methods 




Figure 6.3 – ROC curves compared to true estimates (base case scenarios 1-3) 
 
Coverage of 95% confidence intervals was similar across the methods when there was no 
between-study heterogeneity in scenario 1 (coverage ranged from 92% to 96%), with the NI 
method performing at least as well as the SI and MIDC methods (see Figure 6.4). At moderate 
heterogeneity (scenario 2), the two imputation approaches had improved coverage over the 
NI approach (i.e. closer to 95%) at most thresholds for specificity, while SI and MIDC 
performed similarly (see Figure 6.4). For example, at a threshold value of 4 the coverage for 
specificity was 89.2%, 92.3% and 93.8% for the NI, SI and MIDC approaches, respectively. The 
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improvement in coverage by using the MIDC or SI approaches rather than NI was even more 
pronounced at a high level of between study heterogeneity (see Figure 6.4), with MIDC 
performing best. For example, in scenario 3 with a threshold value of 4 the coverage for 
specificity was 83.7%, 88.6% and 90.1% for NI, SI and MIDC approaches respectively. 
The improvement in coverage by using the imputation methods is most likely due to the 
estimate of between-study heterogeneity being substantially improved by including more 
studies at each threshold after imputation (see Figure 6.5). Maximum likelihood estimates of 
variances are known to be downwardly biased in small samples, and thus increasing the 
sample size via imputation ensures an improvement. Though downward bias in T̂ remains for 
both MIDC and SI, it is far smaller than the bias for NI, and the MIDC method consistently 
provides the least biased T̂ values across the thresholds (see Figure 6.5).  
Despite the larger estimates of between-study variance (T̂) after imputation, the incorporation 
of additional results via imputation substantially improves the precision of summary estimates 
in the MIDC and SI approaches compared to NI (see Figure 6.6). The gain in precision is largest 
in the central thresholds, where there is greater opportunity for imputation (i.e. higher chance 
of a missing threshold falling between two known bounding thresholds); indeed for these 
thresholds the imputation approaches were usually able to recover data on all ten studies in 
the meta-analysis (see APPENDIX E1: Base case scenarios). Mean standard errors were almost 
identical for the SI and MIDC approaches, but with the MIDC method providing slightly inflated 








Figure 6.5 – Mean estimate of ¢ for summary sensitivity for scenario 2 and 3. Dashed line indicates the true simulated ¢ 





Figure 6.6 – Mean Standard errors (base case scenarios 2-3) 
 
6.3.2 Greater chance of missingness (Scenarios 4 to 6) 
In scenarios 4 to 6 the percentage of thresholds missing completely at random was increased 
to 70%. In terms of bias, the findings were similar to those in scenarios 1 to 3, with the 
summary ROC curves showing very small bias for all the methods when the between study 
heterogeneity was large. Coverage and precision was again substantially improved by using 




percentage of missing data. For example, at a threshold value of 5 in scenario 6 the coverage 
was 78.9%, 88.6% and 88.7% for the NI, SI and MIDC methods, respectively. The two 
imputation methods were similar in terms of mean standard errors, which were reduced by 
up to 43% compared to the NI method.  
6.3.3 Missing not at random (Scenarios 7 to 9) 
Under the MNAR assumption in scenarios 7 to 9, a threshold was always present when the 
observed Youden’s index was > 0.7, but otherwise had a 50% chance of being missing akin to 
selective reporting bias (see Table 0.20, Table 0.21, Table 0.22, Table 0.23, Table 0.24 and 
Table 0.25). Figure 6.7 shows the summary ROC curves for each method from scenario 9 (high 
heterogeneity), and for the NI method it reveals an upward bias (overestimation) of summary 
sensitivity and specificity at each threshold when not accounting for the missing threshold 
data. There was also a similar upward bias for the NI method in scenarios 7 and 8, where there 
was lower heterogeneity. In contrast, the SI and MIDC methods reduce this bias through 
imputation, and produce mean ROC curves that are close to the true summary ROC curve in 
each of scenarios 7 to 9.  
Coverage of 95% confidence intervals was again consistently better when using the 
imputation approaches than the NI approach. Differences between the SI and MIDC methods 
were generally small, though slightly better for the MIDC method when heterogeneity was 
large (see Figure 6.8 for results of scenario 9). Precision was also greatly increased when using 











Figure 6.8 - Coverage of 95% confidence intervals for MNAR scenario 9. Dashed line indicates ideal 95% coverage. 
 
6.3.4 Unequal threshold spacing (Scenarios 10 to 12) 
All previous scenarios involved equal spacing of logit sensitivity and logit specificity across the 
range of thresholds. Scenarios 10 to 12 assess how the imputation methods perform given 
unequal threshold spacing along the ROC curve, as was depicted previously in Figure 6.2. 
Figure 6.9 presents the mean of the summary ROC curves from the simulation results for 
scenario 12 (high heterogeneity). All methods showed some downward bias in summary 
sensitivity and specificity estimates, but the SI method performed worst (see Table 0.26 and 
Table 0.27). The imputation methods again improved performance over the NI in terms of 
smaller standard errors and less biased estimates of	T̂, with the MIDC generally performing 




Figure 6.9 - Mean summary ROC curves all methods. Unequal threshold spacing scenario 12 
 




6.3.5 Extreme unequal threshold spacing (Scenarios 13 to 15) 
The impact of unequal threshold spacing was explicitly examined under more extreme, 
unequal spacing situations (scenarios 13 to 15). These represented scenarios where 
thresholds were reported at either end of the ROC curve, but not reported in the central part 
of the ROC. This scenario may occur where studies are considering tests for rule in or rule out 
purposes as discussed in section 6.2.4. The concept was shown graphically in Figure 6.2. 
Figure 6.11 presents the mean of the summary ROC curves for the simulations results of 
scenario 15 (high heterogeneity). Interestingly, the NI method showed little bias in sensitivity 
and specificity at the available thresholds; however, the two imputation methods performed 
poorly in terms of the central thresholds (see Table 0.28 and Table 0.29).   
The coverage of 95% confidence intervals appeared better when using either the SI or MIDC 
imputation approaches in the outer reported thresholds (see Figure 6.12). However, the 
coverage of the imputation methods dropped substantially in the central thresholds. For 
example, in scenario 15 at a threshold value of 5 (a central threshold) the coverage for 
sensitivity was 96.4%, 63% and 73.8% for the NI, SI and MIDC respectively, while at a threshold 
value of 8 (an outer threshold) the coverage was 90.6%, 92.8% and 93.8% respectively. 
Precision of the summary results was again improved using SI or MIDC compared to NI, but 






Figure 6.11 - Mean summary ROC curves all methods. Unequal threshold spacing scenario 15 
 






Prevalence of 50%   
All simulations were repeated with a prevalence of 50%, rather than 10%. In particular, for 
scenarios 1 to 9 the NI approach generally performed worst, whilst the MIDC method 
performed generally best in terms of lower standard errors, coverage closest to 95%, and 
reduction in bias of T̂ estimates and, in scenarios 7 to 9, summary estimates. For example, 
Figure 6.13 shows the coverage results for scenario 9 with a prevalence of 50%, for which the 
MIDC is generally closest to the 95% level for all thresholds for which there is missing data. 
Only in extreme scenarios 13 to 15 was the NI method preferable, for example in terms of 
coverage at central thresholds as seen under the 10% prevalence results.  
It was observed that under the assumption of a 50% prevalence of disease, the coverage of 
95% confidence intervals for summary sensitivity and specificity were similar (regardless of 
the method used), unlike at 10% prevalence, where the coverage of 95% confidence intervals 
for summary sensitivity was higher than those for summary specificity (see Figure 6.13).  At 
10% prevalence the estimates of specificity will have far greater precision than sensitivity, due 




Figure 6.13 - Coverage of 95% confidence intervals for MNAR scenario 9. Comparing simulations results at 10% 
prevalence (top figures) and 50% prevalence (bottom figures). Dashed line indicates ideal 95% coverage. 
 
Alternative number of studies 
Simulations were also conducted with a smaller number of studies; five studies was chosen to 
represent a smaller meta-analysis dataset as is commonly seen in the literature. Conclusions 
remained broadly similar, though the methods struggled with convergence issues, likely due 
to the use of the bivariate random-effects model as discussed earlier. Convergence was good 
under a no heterogeneity setting (scenario 1), but very poor at moderate and high 
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heterogeneity leaving only 59/1000 runs for analysis. It is important to note that this is not 
the number of SI and MI runs which converged, but rather failures to converge for the NI 
method which meant the corresponding SI and MI results were removed to allow fair 
comparison. The NI failures are likely due to very small numbers of studies, around 2 studies 
per meta-analysis as the base case scenarios created 50% missing threshold results; even 
where the SI and MI could impute the missing thresholds there would be very little data for 
estimating the model. Results of this extension are presented in APPENDIX E5: Extensions, for 
the base case scenarios. 
Increased number of imputation datasets 
Finally, as an extension the number of imputation datasets used in the MIDC method was 
increased from five imputation datasets to ten to investigate the effect of additional 
imputations on the summary estimates. Conclusions remained the same with ten imputation 
datasets, indicating that small numbers of imputations may be sufficient at least in the base 
case settings. Results of this extension are presented in APPENDIX E5: Extensions, for the base 
case scenarios. 
6.3.7 Summary of simulation findings 
In general, across scenarios 1 to 9 where the equal spacing assumption was made, the 
simulations suggest that both the SI and MIDC methods perform better than the current 
standard NI method (228), in terms of coverage and precision of summary sensitivity and 
specificity estimates, either when thresholds are missing completely at random or selectively 
reported according to Youden’s index (247). This held for prevalence’s of either 10% or 50%. 
Improvements are due to the extra information arising from the imputed data, which also 
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leads to improved estimation of the between-study variances. Further, when there is selective 
reporting due to Youden’s index (247), the findings suggest that the SI or MIDC methods can 
even reduce bias in the summary ROC curve, as well as improving coverage and precision. 
There is generally very little difference in the SI and MIDC methods, but the latter was 
noticeably better in terms of estimating the between-study variances and generally gave 
better coverage, due to slightly larger standard errors of summary estimates. However, when 
moderate unequal threshold spacing was assumed (Scenarios 10 to 12) the NI and MIDC 
methods performed better than the SI in terms of bias, with MIDC giving better estimation of 
standard errors and between-study variances as before.  
A concern, however, for both the imputation methods is that their performance deteriorated 
under extreme unequal spacing (scenarios 13 to 15), and the NI method performed far better 
in this situation, for example in terms of coverage and bias. 
6.4 Discussion 
The results from the simulation study, across a wide-range of scenarios, suggests that the 
previously proposed SI method and the new MIDC method help regain otherwise lost 
information, and generally improve performance of meta-analysis results compared to the NI 
method, unless there is extreme unequal spacing of thresholds. The SI and MIDC methods 
dramatically increase precision of summary estimates of sensitivity and specificity at each 
threshold, as more data are added via imputation, which usually leads to a distinct 
improvement in coverage of 95% confidence intervals compared to the standard NI method. 
This is especially evident when heterogeneity is large, as the SI and MIDC methods improve 
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estimates of between-study variance. Further, when thresholds are selectively missing due to 
a poor Youden’s index, the findings suggest that the SI or MIDC methods generally reduce bias 
in the summary ROC curve compared to the NI method. In the situation of moderate unequal 
threshold spacing the MIDC and NI methods perform better in terms of bias and coverage; 
and therefore the threshold spacing assumption is important to the correct performance of 
the SI method. There is very little difference in most scenarios between the SI and MIDC 
methods; however, in a few scenarios there was improved estimation of between-study 
variances with the MIDC method and increased standard errors allowing for uncertainty in the 
imputation, sometimes leading to slightly better coverage. Therefore, the simulation suggests 
that generally the MIDC approach should be preferred to the SI method. Results were found 
to be consistent at lower (10%) and higher (50%) levels of prevalence. 
Limitations of the simulation study 
Model convergence is known to be an issue with the bivariate model used in the simulation 
study and there were some problems with convergence observed. However this was not 
substantial enough to effect the conclusions of the main simulation study. The largest number 
of simulations failing to converge occurred in the high heterogeneity scenario with 70% 
missing threshold data, where difficulties with convergence may be expected due to sparse 
data. Even in this scenario the number of failed convergences only reached around 500, 
leaving 500 simulations for analysis.  
Another limitation of this simulation study was the focus on using 10 studies in most 
simulations. This was chosen firstly because of the increased computation time required to 
conduct the simulations for larger numbers of studies, and because it is typical of many meta-
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analyses in the test accuracy field. However, the extension to investigate a smaller meta-
analysis datasets of five studies showed similar findings, but suffered with convergence issues 
due to the small number of studies further reduced through missingness. Due to the large 
computation time of the simulations, only five MIDC datasets were used throughout the 
simulation study. As with common multiple imputation methods, the number of MIDC 
datasets (or imputations) can be increased to reduce uncertainty further. However, in reality 
sensitivity analyses could be conducted in individual cases to decide on an appropriate 
number of MIDC datasets to reduce uncertainty as required. One possible recommendation 
could be to ensure M is set to be 100*p, where p is the proportion of missing studies for the 
threshold with the most missing data that can be imputed, to be consistent with guidance 
elsewhere (57, 58). An extension of the simulation study investigated the use of ten 
imputation datasets for the base case scenarios, and results showed no difference indicating 
that a small number of imputations may be sufficient when using the MIDC method. 
Limitations of the MIDC method and further work 
The simulation study identified some limitations of the imputation methods. In situations of 
extreme unequal spacing, the MIDC and SI methods perform less well, and so judgement is 
needed as to whether this is likely to be the case in particular examples. Therefore a key issue 
is how we detect extreme unequal spacing, and how we draw conclusions from the imputation 
methods in these cases; further research is needed to investigate these questions. One cause 
of this problem (illustrated in the extreme unequal spacing scenarios) is “bunching”, where 
we have a set of thresholds across studies of which some are very close together (for example 
say that we had thresholds of a biomarker at 10, 20, 20.1, 20.15, 20.2, 20.25, 20.3, 30 40, 50). 
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Where bunching occurs, two possible solutions could be i) to group thresholds that are very 
close together, or ii) to select a subset of thresholds for analysis, so that the thresholds are 
roughly equally spaced. The effects of different subsets of thresholds could then be 
investigated in sensitivity analyses.   
Also, the imputation methods utilise a linearity assumption in the change in logit-sensitivity 
and logit-specificity as the threshold value increases by one-unit. Steinhauser et al. assume a 
distributional shape for both the diseased and non-diseased population, but assessing the true 
distribution of the test would require IPD across the range of the test, which will often not be 
reported (235). Further work may aim to assess how suitable the linearity assumption is, and 
to what extent deviation from this distribution matters. 
As discussed in chapter 5, there is now a clear need for a large simulation study to compare 
head-to-head the available methods for handling multiple and partially reported thresholds in 
diagnostic and prognostic test accuracy meta-analyses (230-232, 234-236). Such a study could 
help to identify which methods perform well under certain situations and guide use of the 
methods in practice to improve the reporting test accuracy meta-analyses. 
Conclusion 
In conclusion, the simulation study extends the work of the previous chapter and supports a 
recommendation for the use of the MIDC method in practice when threshold spacing is not 
extreme. If the spacing of results across threshold values is not clear, then the MIDC method 
could still be used as a sensitivity analysis. For example, researchers who retain the NI 
approach as their primary analysis method could subsequently use the MIDC method to 
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investigate the potential impact of missing threshold information on the summary sensitivity 
and specificity of the test, assuming the underlying spacing is not extreme. This could be 
particularly important in flagging that summary test accuracy may be weaker than originally 
thought from the NI results, perhaps due to publication bias related issues. Similarly, if 
applicable, other methods for dealing with multiple thresholds might be considered (230-232, 
234). Indeed, further research is urgently needed to compare the MIDC approach with all the 




CHAPTER 7: DISCUSSION 
 
7.1 Overview of the thesis 
Prognosis research forms a crucial part of medical research, informing clinical judgement 
through prediction of risk of future health outcomes given some baseline condition (3). The 
work in this thesis has focussed on prognosis research to identify and evaluate single 
prognostic factors and, in particular, multivariable prediction models to predict individuals’ 
risk of outcome given specific patient characteristics (9). Prediction model research includes 
several important steps which are needed to ensure a model is useful in practice, including 
development, validation and impact assessment (1, 3, 8-10, 26-28). Evidence showing poor 
quality in the reporting and methodology used in the prediction model literature has led to 
various studies calling for improvements and providing guidelines for future research (33, 68, 
77). The increasing availability of large datasets including clustering of patients, in studies, 
centres, regions or countries, provides a great opportunity for the future of prediction model 
research (252). By utilising multiple studies and the clustered nature of large datasets the work 
showed how more robust inferences can be made for prognostic factors and prediction 
models; in particular, models can be developed, validated and updated in various settings and 
patient populations immediately (21), whilst investigating heterogeneity between populations 
of patients and the effect of such heterogeneity on the model and its performance (19, 21, 24, 
71). 
The overall aims for the thesis were the application and development of novel statistical 
methods for prognosis research, using evidence from multiple studies. Chapters 2 to 4 
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focussed on prediction models, and the reporting, development, validation and updating of 
such models, particularly where data is available from multiple studies. Chapters 5 and 6 
focussed on issues with the synthesis of prognostic (or diagnostic) predictors reported at 
different thresholds in primary studies, and developed a novel statistical method to handle 
such issues. The following provides a short summary of the chapters of this thesis. 
7.1.1 Summary of the chapters 
The thesis contained a mix of clinical application and methodological development. A 
systematic review was undertaken in chapter 2, of studies developing or validating prediction 
models for individual recurrence risk in patients with a first unprovoked VTE. The aim was to 
determine if reliable prediction models exist and if not what further research is needed in the 
field. The review identified a number of existing models with various shortcomings, leading to 
several recommendations for further research, including the need for external validation 
across multiple settings. Given the findings of the review in chapter 2, a new prognostic model 
for VTE recurrence risk was developed in chapter 3. The model development aimed to address 
issues highlighted through chapter 2 in a number of ways including; the use of previously 
identified predictors, robust statistical modelling, a novel internal-external validation 
procedure, and appropriate presentation of the final model for future research. Chapter 3 also 
raised awareness of heterogeneity in predictive performance across settings, and the need to 
address this formally in further research. Therefore, Chapter 4 aimed to assess the use of 
recalibration methods to improve the external performance of existing models, in this way 
previous research can be combined with newly collected information, reducing research 
waste. A novel IPD meta-analysis approach was used to compare the performance of 
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recalibration strategies across multiple studies in an applied example; results showed 
substantial improvements in calibration performance of the existing model in new patient 
populations via a simple recalibration of the model’s intercept term. 
Chapters 5 and 6 focused on meta-analysis methods for synthesising continuous predictor 
effects where primary studies report on various different thresholds. Chapter 5 proposed a 
novel method to impute missing threshold information between two known threshold values 
within primary studies. The method improved on previous work in a number of ways, in 
particular by allowing multiple (rather than single) imputation, and was shown to indicate 
potential bias in summary meta-analysis estimates in an applied example. Chapter 6 further 
assessed the new method proposed in chapter 5 through an extensive simulation study. 
Various settings were simulated by varying the proportion of missing information, the number 
of studies in the meta-analysis, the disease prevalence and the assumptions of the method. 
The new method was compared head-to-head against a previous approach and the current 
standard analysis method, with results suggesting the new method gives benefits over current 
approaches in most settings, apart from under extreme situations.  
7.2 Publications arising from this thesis 
The work in this thesis has led to a number of publications, of which the PhD candidate (Joie 
Ensor) is either the first author or a co-author. A first-author protocol and final review 
manuscript have been published in Systematic Reviews and BMJ Open respectively (95, 158), 
based on the systematic review of prognostic models for recurrent VTE risk conducted in 
chapter 2. Further, the work conducted in chapter 2 combined with the development of a new 
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prognostic model in chapter 3 has been published in full in Health Technology Assessment 
(98), with the PhD candidate as the first author. Another manuscript describing the 
development of the methods proposed in chapter 5, and assessed through simulation in 
chapter 6, is currently under review at Research Synthesis Methods, again with the PhD 
candidate as the first author. The Stata code for the single imputation approach was part of a 
paper published in Systematic Reviews (236), and the multiple imputation code will be 
submitted to the Stata Journal. Finally, the work described in chapter 4 for the recalibration 
of flexible parametric survival models, will be drafted for publication and submitted in the 
near future, with Statistics in Medicine the target journal. 
Additional publications which the PhD candidate has contributed to from knowledge gained 
through this thesis include; a recent guide to systematic review and meta-analysis of 
prediction model performance (71), and an earlier article on the methodological challenges 
facing systematic reviews of prognosis studies (253), using knowledge from chapter 2. A 
number of publications based on the use of meta-analysis methods for the development and 
validation of prediction models in clustered datasets (19, 21), based on knowledge from 
chapters 3 and 4. Also the candidate has contributed to publications based on meta-analysis 
methods for multiple and missing thresholds in diagnostic test accuracy meta-analysis based 
on knowledge gained through the work included in chapters 5 and 6 (234, 236). Finally, the 
PhD candidate has also contributed to other work in the general area of individual participant 




7.3 Contribution to applied and methodological research 
This thesis has contributed to both applied and methodological research as outlined in the 
following by chapter and summarised in Figure 7.1. 
Chapter 2 
The systematic review conducted in chapter 2 identified published prediction models for 
recurrence risk in patients with a first unprovoked VTE. As the first systematic review of 
prediction models for VTE recurrence risk, this work adds importantly to the clinical area by 
identifying all available models and summarising their strengths and weaknesses to help 
practitioners decide on which if any models to use in practice (95). Risk of bias was assessed 
using the PROBAST tool to judge the quality of the developed models (92). The review 
identified a set of predictors that were found to be important within all models, and there is 
therefore strong evidence that these predictors are associated with risk of recurrent VTE after 
adjustment. The published evidence also suggested that there are differences in the working 
definition of an unprovoked VTE population. The lack of a standardised definition for the 
population limits the applicability of the identified prediction models. Finally the review 
identified several methodological and reporting issues in the development and validation of 
prediction models; such as the handling of missing data, and data-driven categorisation of 
predictors. This adds further evidence of the shortcomings in prognosis and prediction model 
research, and lends more weight to the need for initiatives such as the TRIPOD statement, to 




Chapter 3 built on the review undertaken in chapter 2, to develop a new prognostic model for 
the prediction of VTE recurrence risk in patients with initial unprovoked VTE. While external 
validation and head-to-head comparison of the existing models was not possible in the 
available dataset, the new model could aim to improve on previous models in some aspects. 
Notably the use of a flexible parametric framework transfers a number of benefits to the new 
model (44, 45). Flexible parametric (FP) models flexibly capture the shape of the baseline 
hazard and fully parameterise it, enabling out-of-sample prediction of absolute risks (46). A 
fully parameterised model enables prediction in new patients, external validation and 
updating of the model. Previous models were developed using a Cox model, which does not 
parameterise the baseline hazard (41, 42). Given this the published models can only be used 
to predict at specific time points for which absolute risks have been provided, and only for 
groups of patients defined by certain predictor values (37, 40, 161). Assessment of model 
calibration is particularly difficult where absolute risks cannot be predicted for individuals, 
with calibration assessment of a Cox model only possible in risk groups defined by the linear 
predictor (144, 147). In contrast Chapter 3 provides an equation for the baseline survival as 
well as the linear predictor for the new model, allowing individual prediction at any time point 
as recommended by the TRIPOD guidelines (33), and thus preparing the new model for future 
research. 
Chapter 3 also highlighted the use of IPD meta-analysis methods for the development and 
validation of prediction models using data from multiple studies. The internal-external cross-
validation (IECV) approach proposed by Royston et al. and extended by Debray et al. allows 
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use of all the data for both development and validation (20, 66). The Post D-dimer model in 
chapter 3 was developed using the IECV method, by developing the model on N-1 studies, 
validating the model in the Nth study, and repeating this process N times each time excluding 
a different study population for validation. This meant that N external validations were 
possible, providing N sets of performance statistics which could be synthesised using a 
traditional random-effects meta-analysis. Meta-analysis allows examination of the 
heterogeneity in the models external performance across studies, and also the potential 
performance in a new setting, using a 95% prediction interval (19, 21, 24). 
Chapter 4 
The work in chapter 4 focusses on reducing heterogeneity of the performance of an existing 
prediction model by updating it in new settings. Results of the case study in breast cancer used 
in chapter 4, indicated that recalibration and updating methods could substantially improve 
the calibration performance of an existing FP model in external populations. Previous work 
has introduced methods for recalibration and updating of survival models in particular case 
studies, using a Weibull parametric model (144, 145). Chapter 4 contributes to the 
methodological literature firstly by illustrating the use of recalibration methods using FP 
models, which offer benefit over and above the Weibull model which can only capture 
monotonic baseline hazard shapes (as discussed in chapter 1). Secondly the new work used 
IPD random-effects meta-analysis techniques to compare recalibration methods across 
multiple validation studies, which in the case study indicated that a simple recalibration of the 




Chapters 5 and 6 
As IPD is not always available, Chapter 5 described the development of new methodology for 
test accuracy meta-analyses suffering from differing numbers of studies providing information 
on each threshold of interest. The new Multiple Imputation with Discrete Combinations 
(MIDC) method aimed to improve on a previously proposed Single Imputation (SI) method, 
which imputes missing threshold information between bounding known threshold 
information. The MIDC method developed in chapter 5 is more theoretically sound than the 
previous SI method, as it accounts for uncertainty in the imputed threshold data, and in the 
distance between known and missing threshold values. The MIDC method imputes missing 
threshold data multiple times and combines these using Rubin’s rules to give the overall 
summary performance at each threshold. Software code for the method was developed using 
Stata, and when applied to two examples this showed evidence of potential bias in summary 
estimates of sensitivity and specificity.   
Chapter 6 evaluated the statistical properties of the MIDC method compared to the SI method 
and the standard analysis approach in which No Imputation (NI) is performed. Simulation 
results showed substantial gains in the precision of summary performance at each threshold 
using the MIDC and SI methods, and improved estimation of between-study heterogeneity 
estimates likely due to increased threshold data gained by imputation. Bias in the summary 
performance at each threshold was reduced using the imputation methods, particularly when 
threshold data were selective reported due to publication bias. The MIDC method improved 
on the SI method by allowing for the uncertainty in imputations leading to slightly inflated 
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standard errors. Simulations also indicated that the imputation methods performed poorly 
under an extreme unequal threshold spacing assumption. 
The new MIDC method developed in chapters 5 and 6 provides a fast and useful method to 
assess the potential impact of missing threshold information in diagnostic test accuracy meta-
analysis, particularly in the presence of publication bias. Importantly a Stata program to 
implement the new MIDC method was developed in chapter 5 enabling researchers to use the 





Key research contributions of the thesis 
• Summarised and appraised available prediction models for recurrent VTE risk in 
unprovoked patients 
o Identified a lack of a standardised definition of unprovoked VTE 
o Identified a set of potential important predictors associated with VTE 
recurrence risk after adjustment for confounding 
o Identified several methodological and reporting issues in the existing 
prediction models 
• Developed a new prediction model for VTE recurrence risk in the unprovoked 
population 
o Used flexible parametric modelling framework allowing individual absolute 
risk prediction in new patients over time 
o Used a novel internal-external cross-validation procedure to maximise the 
available data for both development and validation of the model 
o Assessed model performance across different patient case-mix, and found 
moderate heterogeneity in performance across validation populations 
o Reported the full model including baseline survival, for use in future 
research 
• Illustrated the use of model recalibration and updating methods to improve the 
external performance of an existing prediction model 
o Used data from multiple studies and random-effects meta-analysis 
methods to externally validate an existing FP model 
o Used four recalibration methods to improve model performance including; 
re-estimation of the magnitude or shape of the baseline hazard, or re-
estimation of the predictor effects, either as a whole or individually 
o Results showed that recalibration methods substantially improved 
calibration performance of the existing model in new patients 
• Developed and evaluated a new method for imputing missing threshold 
information in diagnostic test accuracy meta-analysis 
o Developed new Multiple Imputation by Discrete Combinations (MIDC) 
method, which theoretically improves on current methods 
o Developed Stata code to implement the new method 
o Applied to two real examples, and showed that original results (without 
imputation) may be considerably different to those from MIDC 
• Conducted extensive simulation study to evaluate performance of the new method 
o Investigated various scenarios including, varying the amount of missing 
threshold information, the prevalence of disease, and the missingness 
assumption 
o The new method was compared head-to-head with existing methods 
o Results indicated that the new method is a useful technique to assess the 
potential impact of missing threshold data in meta-analysis, particularly in 
the presence of publication bias 
o Simulations indicated that under the assumption of extreme unequal 
threshold spacing the imputation methods performed poorly 
Figure 7.1 - Key research contributions of the thesis 
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7.4 Further research 
While the work in this thesis has made some important contributions to current clinical 
research and methodological knowledge as described above, there are various areas for 
further research arising from the work presented in this thesis, which are now highlighted 
below.  
Chapter 2 
The systematic review in chapter 2 highlighted several areas in which future research could 
be improved (95). Primarily there is an immediate need for a standardised definition of what 
constitutes an unprovoked first VTE. Without a standard definition of the population of 
interest, prediction models cannot be developed on the same population in which they are 
intended for use. Where a model is applied to patients not meeting the same definition as 
that used in the model development cohort, model performance is likely to be different, with 
potential miscalibration of predictions (9, 28, 33, 68, 76).  
Secondly any future model development studies should aim to utilise predictors that were 
found to be consistently important after adjustment across all identified models. This set of 
predictors should also be collected routinely in clinical studies assessing VTE patients, as they 
have strong evidence of an association with recurrence risk, and future cohorts in which these 
factors have been collected could be potentially used as model validation datasets. 
The review assessed the quality of identified prediction models and found several limitations, 
primarily the need for further external validation of the models. Therefore further research is 
needed to validate the existing models in new patient populations to assess their 
264 
 
generalisability (21, 28, 63, 69, 256). It is also important that new research compares the 
existing models performance in terms of discrimination and calibration, in the same patients, 
to assess which models are most useful (257). Finally, future research beyond head-to-head 
comparison and validation studies, should look to assess the impact of the available models 
on patient and cost-effectiveness outcomes (26, 64, 69, 79).  
Chapter 3 
There are several areas for further research arising from the new model development 
conducted in chapter 3, in particular the new Post D-dimer model requires further external 
validation. While the model was developed using a novel IECV approach, this technique could 
be seen as somewhere between internal and external validation (33, 34, 68, 256). As such 
truly external validation in new patients is needed before the model is assessed for it impact 
on patient and cost outcomes (26, 28, 64, 69). Particularly chapter 3 used IPD from seven 
randomised controlled trial datasets, and therefore future validation studies should aim to 
assess the models performance in non-trial populations. Further research could also look to 
assess whether model updating methods could reduce the between-study heterogeneity in 
model performance observed during the IECV procedure in chapter 3.  
Chapter 3 also attempted to develop a model for use at the time of cessation of therapy, 
allowing treatment decisions to be made without putting patients at risk of recurrence 
through withdrawal of treatment. The Pre D-dimer model showed very poor discriminative 
performance during validation, making it clinically useless. However, future research may look 
to improve the performance of this model by incorporating additional important predictors, 
as prediction at cessation of therapy is of most use clinically. D-dimer appears to have 
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important prognostic value (15, 198, 199), as identified in the Post D-dimer model in chapter 
3, therefore future research should investigate the predictive value of D-dimer measured on 
therapy. 
Finally, it is important that future research aims to develop a prediction model for an 
individual’s bleeding risk in this population. Treatment decisions for unprovoked VTE patients 
must weigh the balance between off-therapy VTE recurrence risk and on-therapy bleeding 
risks (156, 258). There is no existing model to predict bleeding risks in this population making 
it difficult to assess this balance in practice. 
Chapter 4 
Chapter 4 found that recalibration and updating methods were potentially useful to improve 
model calibration in new patients, which indicates further the potential power of such 
methods in the fight against research waste in the prognosis and prediction field. The use of 
recalibration methods could substantially reduce the trend of increasing numbers of new 
models in the literature where useful models already exist (82, 84, 133). Future work could 
attempt to evaluate recalibration methods in a range of other case studies, to identify the 
most appropriate recalibration methods to use in general in practice. Vergouwe et al. recently 
proposed a closed testing procedure to select recalibration methods for a logistic prediction 
model (226), a similar procedure could be evaluated for survival models in the future. 
Similarly it is important that future research identifies if and when there is greater benefit in 
developing a new model, compared to recalibrating an existing model. It may be that where 
large datasets are available for external validation, new model development could have 
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greater power than the existing models. However this would mean ignoring the previous 
evidence captured in the existing model, recalibration methods combine information from 
previous patient cohorts with that from new patients meaning no information is wasted (64, 
69). A previous example in a logistic setting indicated that recalibration is preferred if 
validation samples are small compared to the original model development sample (143). 
Chapters 5 and 6 
As with any new methodological development the newly proposed MIDC method requires 
further research to address limitations, and identify alternative approaches that may be 
possible. The simulations undertaken in chapter 6 tested the MIDC and SI methods under an 
assumption of extreme unequal threshold spacing and indicated that in this scenario the 
methods perform poorly. Therefore it is important for further research to investigate firstly 
how situations of extreme unequal spacing can be detected, and secondly how the results of 
the imputation methods can be interpreted in such settings.  
Both imputation methods provide estimates at particular thresholds of interest, however 
neither method constrains the ordering of thresholds, which can lead to imperfect SROC 
curves in practice. Previous studies have addressed this issue by constraining threshold values 
to be ordered but also have limitations (231, 234). 
The MIDC method assumes a linear relationship between threshold and logit-
sensitivity/specificity, and the suitability of this assumption and effect of departures from it 
could be assessed in further research. Importantly other research has assumed a distributional 
shape for the underlying continuous measurements in both the diseased and non-diseased 
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populations (235). However it is likely that in practice the true underlying distribution of the 
test could not be assessed without IPD over the range of the test, which is unlikely to be 
reported. 
Finally, there are now a number of methods available for handling multiple and missing 
threshold data in test accuracy meta-analysis (230-236, 238, 239), and it is therefore 
important that future research aims to compare these methods head-to-head on the same 
data and in various settings in an extensive simulation study.  
7.5 Limitations of IPD meta-analysis 
The majority of this thesis used individual participant data (IPD) from multiple studies. IPD 
provides the raw patient level information from the original studies, as opposed to aggregate 
data which is summarised patient data, such as mean age or proportion of males in the study. 
IPD meta-analysis methods were used in this thesis for the development, validation and 
updating of prognostic models. IPD meta-analyses offer many opportunities for prognosis 
research, however it is also important to highlight their limitations (259-261). 
Firstly, the quality of an IPD meta-analysis is only as good as the quality of the primary studies 
included (260). As such, when primary studies are of poor quality an IPD meta-analysis is not 
necessarily more reliable than an aggregate data meta-analysis of the same set of studies. 
Furthermore, there is no guarantee that studies willing to share their data are the studies of 
highest quality, and perhaps the only way to guarantee quality is to set up a prospective IPD 
meta-analysis (262-265). Therefore, IPD meta-analyses should ideally include some form of 
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quality assessment to highlight differences across studies (that do and do not provide IPD) and 
consider the potential impact of quality on conclusions.  
Secondly, akin to the quality of evidence from primary studies is the potential for availability 
bias in IPD meta-analyses. Availability bias describes the potential bias caused when the 
provision of studies IPD is somehow dependent on the study’s results (122, 260). For example, 
smaller studies with non-significant results may be less likely to be published and therefore 
harder to identify for inclusion (259). Even where these studies are identified, authors may no 
longer have the IPD, or be unwilling to collaborate. In this way it is common for IPD meta-
analyses to obtain IPD from less studies than there are published summary results (266); 
where this is the case methods to combine IPD and aggregate information may be utilised 
(267, 268). 
Thirdly, it is important to consider before undertaking any IPD meta-analysis, the substantial 
investment of time and costs involved (122, 260, 266). For example the time taken to contact 
primary study authors, to obtain and clean the IPD from all studies, and to prepare the data 
for meta-analysis ensuring consistency across studies.  
Many other limitations exist, such as the between-study heterogeneity in follow-up lengths, 
methods of measurement, outcome definitions, and factors recorded (269). Some of these 
were prevalent in the IPD meta-analysis of Chapter 4, and warrant further research. 
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7.6 Opportunities with Big data 
The increasing availability and use of ‘big’ datasets from IPD meta-analyses, multicentre 
collaborations, and patient Electronic Health Records (EHR) data provides a unique 
opportunity to improve prediction model research (21). This thesis has focused on the use of 
IPD from multiple studies in prediction model research, but the methods used here could be 
applied to other big datasets in which patients are clustered by centre, hospital, region, 
country or some other clustering factor. Of the phases of prediction model research outlined 
in chapter 1 (3, 8-10), one area in particular that could potentially gain the most from 
availability of big data is external validation (21). It has been discussed that there are ever 
increasing numbers of new model development studies being published without a 
corresponding increase in external validation studies (9). This leads to research waste, with 
many models available to predict the same outcomes (82, 84, 133), and little to indicate which 
models if any to use in practice (78).  
One reason for a lack of corresponding external validation studies is the availability of data, 
with development studies often including only one cohort making it most efficient to retain 
all patient data for development of the model (62). But with big datasets this is no longer an 
issue, as such datasets can be split into development and validation samples without reducing 
the power to detect genuine predictor-outcome associations. And with clustered data it is 
possible to assess the developed models generalisability in external patient data using non-
random splitting by cluster (e.g. by centre and country as in chapter 4) (33). In large clustered 
datasets model performance can be tested in multiple different external populations, allowing 
assessment of variation in performance due to differences in patient case-mix (70). Such 
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variation in performance across validation populations can be examined using meta-analysis 
methods as shown in this thesis and elsewhere, enabling investigation of the causes of 
heterogeneity in model performance (19-21). Further, this interrogation of heterogeneity in 
model performance can help to identify where, and how performance can be improved in 
particular clusters using recalibration methods as shown in chapter 4 of this thesis.  
Big datasets therefore offer a great opportunity to enhance the reliability of prediction 
models, increase uptake of such models into practice and reduce research waste by getting 
the most out of existing research and all available patient data (21). However, similar to that 
raised above for IPD meta-analysis, EHR data may come with many methodological challenges 
to be addressed (12, 252, 269, 270). In particular the quality of EHR data is often poor in 
comparison to primary research studies because it is routinely collected data input by general 
practitioners (GPs) and not originally intended for research (271). This leads to several issues 
including; non-standard definition of patient outcomes and diagnoses, unrecorded predictors, 
incomplete follow-up and missing patient level data. Data may be systematically missing, 
where all information for a predictor is not recorded in a particular cluster of the data, and in 
this case novel methods are needed to impute such data to enable validation in the cluster 
(123-130).  
There are also substantial time and monetary costs involved in obtaining and checking large 
datasets of EHR or IPD from multiple studies (21). One of the benefits of big data highlighted 
above was the ability to split such datasets into development and validation samples, but this 
also requires care. Where few clusters are available as in IPD meta-analyses, novel methods 
such as the IECV approach used in this thesis could be employed to maximise the use of the 
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data for development and validation (20, 66). In large EHR datasets there may be many 
clusters meaning a large number could be reserved for validation, ensuring testing is possible 
in populations of differing patient case-mix (21). Where model development is of interest care 
must be taken with large EHR datasets containing millions of patient records, as spurious 
predictor-outcome associations are likely to be falsely identified as important. Predictor-
outcome associations could be investigated across clusters to identify potentially 
heterogeneous predictor effects for exclusion, which could reduce heterogeneity in the 
performance of the final model (20). 
7.7 Conclusions 
Prognosis research aims to understand, explain and predict future outcome risk for individuals 
with a particular disease or health condition, in order to inform and improve patient care 
through better decision making and stratified medicine. The prognosis field is historically 
plagued by poor reporting and methodology, leading to a concerted effort in recent years to 
provide guidance on best practice in prognosis research, which should lead to future 
improvements (1, 3, 8-10, 25-28, 33, 68, 93). This thesis has contributed toward these 
improvements in terms of both applied and methodological work, by encouraging and 
facilitating the use of meta-analysis methods to summarise predictive performance, especially 
when large, combined datasets are available (21, 252). It is hoped that the use of such 
evidence synthesis methods (19, 20, 24), alongside robust statistical models for absolute risk 
prediction (27, 44, 45), will help improve the development, validation and updating of 





APPENDIX A: Chapter 2 Appendices 
Full text inclusion criteria 
CRITERIA Yes C/T No Prognostic model 
Reviews & 
Discussions       Does the study do more than just discuss a model 
Population       Are patients at least 18 years old 
      
Could the population or a defined subpopulation 
be considered as unprovoked (if not why not) 
      
Can we identify results specifically for the 
unprovoked population 
      
Did patients receive at least 3 months treatment 
with either a vitamin K antagonist or an oral 
anticoagulant 
Outcome 
      
Does the model predict least one of: 
recurrence/mortality/bleeding/QoL 
Models 
      
Does the model aim to do more than assess a 
single factor adjusted for other things 
      
Is the model used to predict risk of one of the 
above outcomes 
DECISION 
Exclude with reason 
  
Does the study 
include an economic 
evaluation of a 
model?   
Comments   
IF INCLUDED: Yes C/T No Factors 
If the study is 
included, what is 
their definition of 
unprovoked? 
      Major surgery 
      Lower limb trauma 
      
Use of oral contraceptive pill or hormone 
replacement therapy 
      Pregnancy 
      Significant immobility 
      Cancer 
      
Thrombophillia (e.g. antiphosphlipid syndrome, 
factor V leiden etc.) 
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Unprovoked = no history (within 3 months) of major surgery; lower limb trauma e.g. 
fracture, cast; use of the combined oral contraceptive pill or hormone replacement therapy ; 
pregnancy; significant immobility e.g. confined to bed for 3 days; cancer 





APPENDIX B: Chapter 3 Appendices 
APPENDIX B1: Summary characteristics of the RVTE database 
Within this section a description and summary of the individuals and candidate predictors in 
the RVTE database is presented. 
Description of data 
Summary statistics for the baseline patient characteristics and available predictors in the 
RVTE database are described in Table 0.1, and show that across the whole database there 
were 230 recurrent events out of 1634 patients with a first unprovoked VTE. There were 
some trials with very small numbers of recurrences, for example Tait (218) and Shrivastava 
(216), with 17 and 9 recurrent events respectively. Other trials were larger, with the 
Eichinger trial having the largest number of events and patients, with 69 recurrent events 
out of 391 patients. The exclusion of hormone related index VTE events, inline with the 
definition of unprovoked VTE within the study (see section 3.2.2), showed that there were 14 
hormone related recurrent events excluded. 
The median follow-up across all seven trials was 22 months, with the longest follow-up being 
almost 10 years in the Eichinger (203) trial, giving sufficient follow-up time to yield 
meaningful conclusions from the prognostic model. 
Summary statistics for each of the candidate predictors are also presented in Table 0.1, with 
continuous predictors described as means and standard deviations, and categorical 
predictors described as counts and percentages. Across the seven trials, patient age 
appeared to be similar with an overall average age of 61 years for the whole population. 
Treatment duration appeared generally similar across trials, with an average across trials of 
around 12 months, and the greatest average treatment duration seen in the Palareti 2006 
(204) trial of 21 months. D-dimer levels appeared to have large variability, with large 
interquartile ranges, and three trials (Poli (214), Eichinger (203) and Shrivastava (216)) 
having noticeably lower D-dimer levels. There may be significant outliers causing the large 
variation seen in D-dimer levels recorded in each trial, and this was investigated in the 
exploratory analysis (see section 0). The mean BMI across the seven trials was around 28 
kg/m2, however there were a large proportion of missing data across the trials for BMI. 
There was also missing data from one trial for lag time, but overall across the trials there was 
an average lag time of around 38 days, with the greatest mean lag time being 143 days in 
the Shrivastava (216) trial. The percentage of males and females were consistent across the 
trials (see Table 0.1), as were the proportions of index site, except for distal DVT where the 
Eichinger (203) trial had a noticeably greater proportion of patients with a first distal DVT, 
possibly explained by differences in the inclusion and exclusion criteria used in the original 
studies which collected the data (see Table 0.2).
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Table 0.1 - Summary of baseline characteristics and candidate predictors 






Poli  Tait  Eichinger  Baglin  Shrivastava  Total 
Recurrences/Total 31/280 38/438 26/156 17/100 69/391 40/178 9/91 230/1634 
Follow-up (months)                 
Median 20.8 20 24 22.2 28.6 37.6 26 22.1 
Longest 31.4 37.2 96 41.6 119.2 70.9 51.2 119.2 









(13.8) 54.1 (15) 
64.6 
(16.6) 55.4 (12.6) 
62.1 
(15.2) 
BMI* (kg/m2) - - - 28.9 (6.5) 28 (4.8) 26.9 (6.6) 32.3 (7.2) 28.5 (6) 
Treatment duration* 

























Lag time# (Days) 28 (24, 33) 31 (29, 35) 30 (30, 30) 
26 (22, 





Gender^                 
Female 128 (45.7) 179 (40.9) 55 (35.3) 37 (37) 147 (37.6) 65 (36.5) 24 (26.4) 635 (38.9) 
Male 152 (54.3) 259 (59.1) 101 (64.7) 63 (63) 244 (62.4) 113 (63.5) 67 (73.6) 999 (61.1) 
Site of index event^                 
Proximal DVT 217 (77.5) 274 (62.6) 96 (61.5) 60 (60) 148 (37.9) 107 (60.1) 60 (65.9) 962 (58.9) 
Distal DVT 12 (4.3) 0 (0) 0 (0) 0 (0) 88 (22.5) 0 (0) 12 (13.2) 112 (6.9) 
PE 51 (18.2) 164 (37.4) 60 (38.5) 40 (40) 155 (39.6) 71 (39.9) 19 (20.9) 560 (34.3) 





Table 0.2 - Inclusion and exclusion criteria of trials within the RVTE database (15) 
Trial Inclusion criteria Exclusion criteria 
Palareti 03 First VTE Lupus Anticoagulant 
Palareti 06 First unprovoked VTE 
Recent pregnancy or puerperium, leg fracture, immobilisation for > 3 days, surgery, APS, active 
cancer, antithrombin deficiency, serious liver or renal disease, other indication or contraindication 
for anticoagulation, limited life expectancy, geographic inaccessibility 
Poli First unprovoked VTE  APS, Active cancer 
Tait 
Acute VTE (last 5 
weeks) 
Life expectancy < 3 months, anticipated duration of OAC > 1 year, unavailable for follow-up 
Eichinger First unprovoked VTE 
Surgery, pregnancy, or trauma in previous 3 months, Cancer, APS, Natural coagulation inhibitor 
deficiency, long-term anticoagulation 
Baglin First VTE 
Postoperative or pregnancy associated VTE, APS, Cancer, thrombosis within 6 weeks of surgery, 
other indication for prolonged anticoagulation 
Shrivastava First unprovoked VTE 






A summary of the percentage of missing data across the trials, and as a whole, is presented 
by candidate predictors in Table 0.3. As mentioned previously there was a large amount of 
missing data across the trials for the candidate factor BMI, with around 57% of BMI data 
missing over the whole database. This mostly consisted of three trials (Palareti 2003 (217), 
Palareti 2006 (204) and Poli (214)) where patient BMI data was not originally recorded, but 
there was also a significant amount of missing BMI data in the Baglin (198) trial (27% 
missing). Across the trials there was also some missing data on D-dimer values and lag time, 
with 15% and 11.4% missing respectively. There was a large percentage of missing D-dimer 
values in the Palareti 2006 (204) (38%) and Poli (214) (48%) trials. Lag time data was not 
available by individual patient within the Baglin (198) trial, though D-dimer was reported to 
have been measured between one to two months after cessation of therapy (198). No 
missing data was present for age, gender, treatment duration or site of index event 
variables. 
Table 0.3 - Percentage of missing data for candidate predictors 







Poli  Tait  Eichinger  Baglin  Shrivastava  All 
Age 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
BMI 100.0 100.0 100.0 0.0 1.8 27.0 0.0 56.9 
Treatment 
duration 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
D-dimer 0.0 38.4 48.1 0.0 0.0 0.0 2.2 15.0 
Lag time 0.0 38.4 48.1 0.0 1.0 100.0 5.5 11.4 
Gender 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Site of index 
event 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 
Other candidate predictors were known in all studies for at least some patients. As there was 
a degree of missing data in these candidate predictors (D-dimer, lag time, treatment 
duration) a sensitivity analysis imputing any missing information was considered. Therefore, 
as mentioned in the Methods section above (see section 3.2.6); prognostic models were 
developed based firstly on a complete case scenario, and secondly on a scenario using 
multiple imputation techniques to impute missing patient data.  
Distribution of candidate predictors, correlation and outliers 
An exploratory analysis was performed on each of the candidate predictors firstly 
considering their empirical distributions and assessing these for normality using histograms 
and normal probability plots (see 0), with transformations considered as appropriate where 
there were departures from normality. Possible outliers were inspected, with erroneous 
patient values leading to removal of patient data, and outliers deemed to be extreme (but 
plausible) considered for sensitivity analysis to assess their effect on the final model. 
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Associations between the candidate predictors were investigated using scatter plots (see 0) 
and correlation statistics (see Table 0.4) for continuous factors, and box plots (see 0) to 
assess the relationship between categorical and continuous factors. 
The candidate predictors of patient age and BMI were found to be approximately normally 
distributed, with some extreme values identified (patient ages of zero, and BMI values lower 
than 10) which were removed from the dataset as erroneous data. D-dimer score, lag time 
and treatment duration were all found to have a strong positively skewed empirical 
distribution, and a log transformation was therefore considered in order to approximate 
normality (for histograms and normal plots of transformed factors see 0). Patients with 
treatment durations above 1000 days were removed as this was considered erroneous data 
based on clinical expertise.  
Continuous candidate predictors were examined visually using scatter plots (see Figure 0.17) 
and empirically using correlation coefficients (see Table 0.4). It is clear from Table 0.4 that 
there were low to moderate correlation between the continuous predictors, and visual 
inspection of the scatter plots confirmed these findings. The strongest correlation was 
between age and log D-dimer, which was 0.5 (see Table 0.4). Investigation of relationships 
between continuous factors and categorical factors for gender and site of index event was 
undertaken using box plots (see Figure 0.18 to Figure 0.29). Across the five continuous 
predictors considered for inclusion there appeared to be no distinct differences between 
males and females, or between proximal DVT, distal DVT and PE based on visual examination 
of the box plots. There were several outliers observed in the box plots, particularly for 
treatment duration and lag time, but also in the other candidate factors. When establishing 
the final prognostic models a sensitivity analysis was performed by excluding any outlying 
values for any predictor and checking the robustness of the model to these extreme values. 
Table 0.4 - Correlation coefficients between continuous candidate predictors 








Age 1.00     
BMI -0.03 1.00    
Log D-dimer 0.50 0.02 1.00   
Log lag time 0.02 0.14 0.08 1.00  
Log treatment 
duration 





APPENDIX B2: Exploratory analysis figures 
 
Figure 0.1 - Box plot of patient age (years) 
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Figure 0.3 - Histogram & normal plot for patient age squared (years-squared) 
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Figure 0.5 - Histogram & normal plot for patient BMI 
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Figure 0.7 - Box plot for patient D-dimer score (ng/mL) 
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Figure 0.9 - Histogram & normal plot for patient Log D-dimer score (ng/mL) [Outlier - D-dimer=20] 
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Figure 0.11 - Histogram & normal plot for patient lag time (days) 
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Figure 0.13 - Box plot for patients treatment duration (months) 
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Figure 0.16 - Histogram & normal plot for patients Log treatment duration (months) [treatment durations > 1000 months 
removed] 
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Figure 0.18 - Box plots for patient age (years) by gender 
 









































Figure 0.20 - Box plots of patients BMI by gender 
 
 
































Figure 0.22 - Box plots of patients Log D-dimer score (ng/mL) by gender 
 
 




































Figure 0.24 - Box plots of patient Log lag time (days) by gender 
 
 

































Figure 0.26 - Box plots of patient Log treatment duration (months) by gender 
 
 

















































Figure 0.28 - Box plots of patient age x log D-dimer interaction by gender 
 


































































APPENDIX B3: Sensitivity analysis results: Post D-dimer model 
Interaction effects 
Interaction effects quantify a differential effect of a predictor in a specific subgroup of the 
population. An interaction effect can be either an increased risk or decreased risk beyond 
that associated with a single characteristic. For example within the pre D-dimer model, both 
gender (being male) and site of index event (having a first PE) are associated with significant 
increases in recurrence rate; thus an interaction between gender and site of index event 
would imply that patients who are both male and have a PE are at increased risk beyond that 
associated with being male or having a PE alone. 
As genuine interaction effects are rare and hard to identify, and because data dredging to 
identify interactions may find spurious results, the clinical team were asked for their 
guidance regarding which interaction terms are most important to examine.  The clinical 
team suggested investigating an interaction of D-dimer and age, as it was felt plausible that 
the predictive effect of D-dimer value (a measure of general coagulability) may change as 
age increases.  
To test for an interaction between age and D-dimer, the final Post D-dimer model was re-
fitted including a term for the multiplication of age and D-dimer score. The interaction effect 
was shown to be insignificant at the 5% level, with a 95% confidence interval ranging from 
0.98 to 1.01, and a P-value of 0.3 (see Table 0.5). Thus no interaction term was included in 
the final model. 
Table 0.5 - Model specification including an Age x D-dimer interaction effect (The post D-dimer model) 
Predictor 
Beta coefficient (95% 
CI) Hazard ratio (95% CI) P-value 
Age 0.026 (-0.048, 0.101) 1.03 (0.95, 1.11) 0.49 
Gender    
Male 0.539 (0.185, 0.894) 1.71 (1.2, 2.44) 0.003 
Site of index event    
Proximal DVT 1.633 (0.623, 2.643) 5.12 (1.86, 14.05) 0.002 
PE 1.671 (0.651, 2.691) 5.32 (1.92, 14.74) 0.001 
D-dimer (Log) 1.045 (0.309, 1.781) 2.84 (1.36, 5.94) 0.01 
Lag time in days (Log) -0.371 (-0.675, -0.067) 0.69 (0.51, 0.93) 0.02 
Age x D-dimer interaction term -0.006 (-0.018, 0.006) 0.99 (0.98, 1.01) 0.298 
 
Further to this, an interaction effect between D-dimer levels and lag time was examined as 
the two predictors are inextricably linked; it is plausible that the prognostic importance of D-
dimer levels varies over lag time (the time taken between cessation of therapy and the 
measurement of D-dimer levels). As previously, the final Post D-dimer model was re-fitted 
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including a term for the multiplication of D-dimer level and lag time. The interaction effect 
was shown to be insignificant at the 5% level, with a 95% confidence interval for the hazard 
ratio ranging from 0.79 to 1.57, and a P-value of 0.552 (see Table 0.6). Thus no interaction 
term for D-dimer and lag time was included in the final model. 
Table 0.6 - Model specification including an D-dimer x Lag time interaction effect (The post D-dimer model) 
Predictor Beta coefficient (95% CI) Hazard ratio (95% CI) P-value 
Age -0.012 (-0.024, -0.001) 0.988 (0.976, 0.999) 0.037 
Gender       
Male 0.55 (0.2, 0.91) 1.74 (1.22, 2.48) 0.002 
Site of index event       
Proximal DVT 1.65 (0.64, 2.66) 5.19 (1.89, 14.24) 0.001 
PE 1.68 (0.66, 2.7) 5.38 (1.94, 14.92) 0.001 
D-dimer (Log) 0.31 (-0.86, 1.49) 1.37 (0.42, 4.45) 0.601 
Lag time in days (Log) -1.02 (-3.23, 1.18) 0.36 (0.04, 3.27) 0.364 
D-dimer x Lag time 
interaction term 




Allowing for time-dependent predictor effects might improve the performance of the model 
if it better fits the underlying data. Non-proportional hazards can be a sign of a time-
dependent effect and as such including time-dependent effects can account for departures 
from the proportional hazards assumption. The validity of the proportional hazards 
assumption was assessed for predictors above (see section 0), and the assumption was 
considered appropriate for all predictors. It was therefore not expected that any time-
dependent effects would be found to significantly improve the performance of either final 
model. 
To further check this, a procedure proposed by Royston and Lambert (46) was used to 
identify potential time-dependent effects. The procedure first identifies the p-value 
associated with including each predictor in the model as a time-dependent effect using a 
likelihood-ratio test. A time-dependent effect is included for the predictor with the smallest 
p-value, providing the p-value is less than a pre-defined alpha significance level. The process 
is repeated until no time-dependent effects are significant at the chosen alpha level. 
A 1% significance level was selected to test for time-dependent effects so as to account for 
multiple testing. The baseline spline function for the post D-dimer model used 3d.f. (see 
section 0) and therefore 3d.f. were used for the time-dependent effects to allow more 
flexibility. After one cycle of the procedure no predictors in the post D-dimer model were 
found to be significantly time-dependent at the 1% level, though log D-dimer was close to 
significance with a p-value from the likelihood-ratio test of 0.02 (see Table 0.7). Given the 
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lack of formal significance, and the aim for a more parsimonious model, the time-dependent 
effect was excluded. 






Age 2.49 0.477 
Gender (Male) 4.491 0.213 
Site of index event (Proximal 
DVT) 0.658 0.883 
Site of index event (PE) 2.495 0.476 
Log D-dimer 9.68 0.022 
Log lag time 3.98 0.264 
 
Multiple imputation of missing data 
 
As the RVTE dataset used for model development included some missing data for some of 
the potential predictors, a complete case analysis was perform for model development, 
excluding any patient with missing data from the analysis. Sensitivity analysis was performed 
using multiple imputation, to evaluate how model estimates compared to those from the 
complete case analysis.  
Of the included predictors only D-dimer and lag time had missing values, with 15% and 
11.4% incomplete data respectively, across the whole dataset of six trials (see Table 0.3). It 
was therefore possible to consider multiple imputation for these two factors within the post 
D-dimer model. As the RVTE dataset consisted of multiple trial populations for development 
of the post D-dimer model it was important to account for this clustering when imputing 
missing observations; imputation across trials can lead to bias where the association 
between  factors differs by trial (211). As such missing data for lag time which was 100% 
incomplete within the Baglin trial (198) could not be imputed (see Table 0.3), and so the 
same set of six trials (excluding Baglin) were used as in the complete data analysis for the 
post D-dimer model. 
Imputation models were selected to include all included predictors from the final post D-
dimer model as well as predictors for the observed recurrences (event indicator) and the 
baseline hazard to account for the time-to-event outcome (57); imputation was performed 
within trial populations. The largest proportion of incomplete data observed within 
individual trial populations was 48.1% missing D-dimer observations within the Poli trial 
(214), therefore 50 imputed datasets were created to provide the greatest reproducibility 
(57). Imputation was performed for ten cycles within each of the 50 imputed datasets to 
stabilise the results. 
Box plots were used to check that the distributions of the observed and imputed data 
broadly matched, large differences could indicate an inappropriate imputation model (57). 
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On inspection the imputed distributions for both D-dimer and lag time (see Figure 0.30 and 
Figure 0.31) appeared to be very similar to the corresponding observed distributions 
(indicated as zero on the box plots). Therefore the imputation process appeared to be 
appropriate.  
The model including all predictors identified as important in the complete case analysis (age, 
site of index event, gender, D-dimer and lag time) was fitted to the 50 imputed datasets and 
the coefficients of each were combined using Rubins rules (56) (see Table 0.8). In 
comparison with the specification of the post D-dimer model under a complete case analysis 
(see Table 0.8) the estimated hazard ratios after imputation were reasonably similar. The 
effect of each factor within the model did not have a dramatically different interpretation 
between the complete case and multiple imputation models. In particular the effects of D-
dimer and lag time are relatively unchanged with hazard ratios of 1.93 and 0.74 compared to 
2.01 and 0.75 for the complete case model. In general the 95% confidence intervals were 
similar with the exception of site of index event where the multiple imputation model 
estimated slightly smaller 95% confidence intervals, showing greater precision, likely due to 
the increased number of observations. The effect of age and lag time were borderline 
significantly different from null in the complete case model, but appeared to be significant in 
the multiple imputation model. This adds further weight to the inclusion of age and lag time 
factors in the prognostic model.  
The inclusion of treatment duration as a predictor in the multiple imputation model was 
investigated given the increased complete patient data; treatment duration did not reach 
significance within the imputation model with a hazard ratio of 1.07 (95% CI: 0.85, 1.35), and 
p-value of 0.574 providing confirmatory evidence toward the exclusion of treatment 
duration within the complete case post D-dimer model. 
Table 0.8 - The post D-dimer model specification following imputation of missing variable data. P=P-value. 
Predictor 
Imputation model Original model 









Gender          
Male 0.666 (0.352, 0.98) 
<0.00
1 
0.55 (0.19, 0.89) 
0.002 
0.007 
Site of index event          
Proximal DVT 1.662 (0.627, 2.697) 0.001 1.74 (0.67, 2.79) 0.001 0.001 
PE 1.639 (0.596, 2.683) 0.002 1.76 (0.68, 2.83) 0.001 0.002 
Log D-dimer 0.657 (0.485, 0.829) 
<0.00
1 
0.7 (0.51, 0.89) <0.00
1 
0.169 






* FMI = Fraction of Missing Information = B /(W + B); where B is the between-imputations variance, 
and W is the within imputation variance 
 
 
Figure 0.30 - Comparison of observed and imputed data for log D-dimer (The post D-dimer model) 
 
Figure 0.31 - Comparison of observed and imputed data for log lag time (The post D-dimer model) 
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Regarding the reproducibility of the multiple imputation results to check that similar 
conclusions could be drawn from an identical imputation approach, the MC error of each 
estimated hazard ratio and the corresponding standard errors was checked. The MC error 
was measured as a percentage of the standard error of the estimated hazard ratio, where an 
MC error lower than 10% of the standard error was considered appropriate. The MC errors 
observed from the imputation procedure used were all lower than 10%, with the greatest 
being 5.74% for D-dimer, meaning that it is highly likely that the results of multiple 
imputation procedure would lead to consistent conclusions across the imputed datasets (see 
Table 0.9). 
Table 0.9 - Monte Carlo error acceptability for analysis based on 50 imputed datasets 





Age 0.98 0.005 0.001 0.97 0.99 0.03 
MC error 0.00 6.90E-07 0.000 1.26E-04 1.21E-04 0.01 
% of s.e. 2.50% 0.01%         
Gender (Male) 1.95 0.302 0.000 1.43 2.64 0.01 
MC error 0.00 0.0003 0.000 0.003 0.005 0.00 
% of s.e. 1.16% 0.12%         
Site (Proximal 
DVT) 5.27 2.694 0.001 1.93 14.37 0.00 
MC error 0.01 0.003 0.000 0.01 0.04 0.00 
% of s.e. 0.54% 0.12%         
Site (PE) 5.15 2.653 0.002 1.87 14.15 0.00 
MC error 0.01 0.003 0.000 0.01 0.04 0.00 
% of s.e. 0.56% 0.13%         
Log D-dimer 1.93 0.180 0.000 1.61 2.32 0.17 
MC error 0.01 0.001 0.000 0.01 0.02 0.03 
% of s.e. 5.74% 0.78%         
Log lag time 0.74 0.110 0.044 0.56 0.99 0.17 
MC error 0.01 0.002 0.006 0.006 0.009 0.03 
% of s.e. 5.70% 1.37%         
* FMI = Fraction of Missing Information = B /(W + B); where B is the between-imputations variance, 
and W is the within imputation variance 
 
APPENDIX B4: Model checking results: Post D-dimer model 
Proportional hazards assumption 
A scatter plot of the scaled Schoenfeld residuals against log time, with a lowess smoother, 
was used to check the proportional hazards assumption for factors in the post D-dimer 
model as described previously (see section 3.2.6). Plots for log D-dimer (see Figure 0.32) and 
log lag time (see Figure 0.33) show that the proportional hazards assumption is valid for the 
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post D-dimer model; the lowess smoothed line roughly follows the reference line for each 
covariates log hazard ratio, indicating proportionality. Similar plots testing the proportional 
hazards assumption were inspected for the remaining covariates in the post D-dimer model, 
the proportional hazards assumption was valid for all predictors. 
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To check that continuous predictors were included in the model with appropriate functional 
form, scatter plots of Martingale residuals against the predictors with a lowess smoother 
applied were inspected.  Patient age, log D-dimer and lag time were the only continuous 
predictors included in the post D-dimer model and the functional form of these covariates 
was checked using Martingale residuals. Figure 0.34 and Figure 0.35 show a lowess 
smoother applied to a scatter of martingale residuals against log D-dimer and log lag time, 
respectively.  In both cases the smoother appears to follow a linear trend over the covariate 




















Ln(Years from cessation of therapy)
Testing proportional hazards assumptions




Figure 0.34 - Scatter plot of martingale residuals against log D-dimer (The post D-dimer model) 
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As seen for the pre D-dimer model, plots of the deviance residuals against a patient indicator 
(see Figure 0.36) and against time (see Figure 0.37) indicate some outlying individuals. Figure 
0.36 illustrates a scatter of the deviance residuals for the post D-dimer model, they clearly 
do not follow a normal distribution and this may again be due to heavy censoring in the 
dataset, a small number of individuals fall above the 1.96 critical Z value. 
A plot of the deviance residuals against years from cessation of therapy allows investigation 
of any trend in the deviance residuals. In Figure 0.37 for the post D-dimer model there is 
again a trend in the deviance residuals over time based on the cumulative hazard at the 
event time (or censoring time). The deviance residuals which lie in the top left of the plot 
are, as for the pre D-dimer model, likely to be those individuals who had a recurrence early 
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Figure 0.36 - Scatter plot of deviance residuals vs. patient ID (The post D-dimer model) 
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To check the influence of individuals on the parameter estimates, leverage can be assessed 
using delta-beta changes for each covariate as seen in the pre D-dimer model. Scatter plots 
of delta-betas for log D-dimer (see Figure 0.38) and log lag time (see Figure 0.39) show that 
even individuals with the greatest leverage on these parameter estimates, have very small 
effects on the log hazard ratio as seen for the pre D-dimer model. Similar, small delta-beta 
changes were observed for the other covariates included in the post D-dimer model. 
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APPENDIX B5: Pre D-dimer model validation performance 
Model validation 
The final step of the IECV approach (see section 3.2.7) is to assess model performance within 
the validation trial, at each cycle of the IECV approach. As the validation trial was excluded 
from model development the performance of the model within this dataset can be deemed 
as external validation. Model performance is now assessed in terms of both discrimination 
and calibration (see section 3.2.7).  
Discrimination and calibration results for each cycle of the IECV for the pre D-dimer model 
are presented in Table 0.10, under a random-effects assumption on the baseline hazard. C-
statistic estimates for the developed model range from 0.47 in the Tait (218) trial, to 0.58 in 
both the Palareti 2006 (204) and Poli (214) trials. A random-effects meta-analysis of the C-
statistics from each validated model (each cycle of the IECV) provides a pooled estimate of 
the performance across all developed models (see Figure 0.40). The pooled C-statistic of 0.56 
(95% CI: 0.51, 0.6) represents the overall weighted average C-statistic from all validation 
trials, showing poor discriminatory ability of the models developed in the cycles of the IECV 
approach. However, as this is a weighted average of the performance within each validation 
trial, it is expected that the discrimination would average out to that of a model built using 
the whole dataset. In this case it is of more interest to examine the heterogeneity across the 
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for interpreting the potential range of performance of the new model in a new setting 
(where the model will be applied), by accounting for the uncertainty in the pooled estimate, 
the heterogeneity between trials and the between trial standard deviation (113). The 
interval suggests that the C-statistic for the model used in a new setting could vary 
anywhere between 0.49 and 0.62, which represents a potentially broad range of 
performance from awful discrimination to a higher but still quite poor level. The 
heterogeneity, or variability, across the trial populations appears to be minimal (I-squared 
statistic = 0), indicating that the discrimination of the model appears consistent in new 
populations, and that any variation is due to chance (113). However, as this zero 
heterogeneity is only an estimate, its uncertainty is propagated in the 95% prediction 
interval, which is why the prediction interval is so wide. The prediction interval for the 
pooled C-statistic is entirely below the estimated prediction interval for the post D-dimer 
model, indicating that the pre D-dimer model may be inferior in all other possible settings.  
 
Figure 0.40 - Random-effects meta-analysis of C-statistic estimates obtained from each external validation of the Pre D-
dimer models from the IECV cycle 
 
Calibration is examined visually across all time-points in Figure 0.41. It is then quantified 
further in Table 0.10 at four time points: six months, one year, two years and three years 
after cessation of therapy. The model appears to be well calibrated (see Table 0.10), with 
expected minus observed, S(t) – Ŝ(t), probabilities with a recurrence very close to zero, and 
95% confidence intervals including zero across all cycles of the IECV. Plots of the observed 
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probability of recurrence (based on the Kaplan-Meier survival estimates) compared to the 
expected probability of recurrence (based on the predictions of the model) are presented for 
each validation trial in Figure 0.41. A perfectly calibrated model would give a predicted curve 
very similar to the observed Kaplan-Meier curve, which can be seen for validation trials 
Palareti 2003 (217) and Poli (214). Within the remaining validation trials the developed 
model either over, or under predicted the probability of recurrence, compared to the 
observed probabilities within the validation trial. For example over prediction can be seen in 
the Palareti 2006 (204) trial beyond six months post cessation of therapy (see Figure 0.41). 
Plots of the S(t) – Ŝ(t) statistic and 95% confidence intervals for each validation trial can be 
seen in Figure 0.42, showing the difference in proportion survived remains close to zero over 
time from cessation of therapy. 
 
 
Figure 0.41 - Observed vs. Expected recurrence probabilities over time, obtained from each external validation of the Pre 
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Figure 0.42 - Expected minus Observed probabilities with a recurrence for each validation trial for the pre D-dimer model 
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Table 0.10 - Summary statistics for discrimination and calibration of the pre D-dimer model 
 
External validation trial 
Estimate (95% CI) 
 Palareti 03 Palareti 06 Poli Tait Baglin Shrivastava 
Recurrences/Total patients 31/280 38/434 26/156 17/99 40/175 9/91 
C-statistic 0.56 (0.44, 0.65) 0.58 (0.50, 0.67) 0.58 (0.43, 0.72) 0.47 (0.31, 0.61) 0.57 (0.48, 0.65) 0.52 (0.34, 0.69) 
S(t) – Ŝ(t) statistic (6 
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Figure 0.43 - Random-effects meta-analysis of calibration performance (at 1 year post therapy) estimates from each 
external validation trial in the IECV cycles for the pre D-dimer model 
 
Figure 0.44 - Random-effects meta-analysis of calibration performance (at 2 years post therapy) estimates from each 
external validation trial in the IECV cycles for the pre D-dimer model 
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The pooled calibration from a random-effects meta-analysis gives an overall S(t) – Ŝ(t) 
statistic of zero (95% CI: -0.03, 0.03) at one year post cessation of therapy (see Figure 0.43), 
showing excellent calibration on average. However there appears to be large heterogeneity 
across trials, with an I-squared statistic of 71.5% suggesting that the calibration of the model 
is not consistent in all populations. Indeed, the 95% prediction interval ranges from 0.1 to -
0.09, indicating that the discrepancy in the predicted and true observed S(t) could range 
from 0.1 to -0.09, in a particular population. The wide confidence interval is also a reflection 
of uncertainty in the heterogeneity estimate. Similar results can be seen for a random-
effects meta-analysis of calibration statistics at two years post cessation of therapy (see 
Figure 0.44) showing consistent agreement on average in the validation trials at two years. 
In summary, discrimination of the model developed is generally poor with C statistics 
ranging from 0.47 to 0.58 (see Table 0.10 and Figure 0.40); other published clinical 
prediction models have shown stronger discriminatory ability (24). Furthermore, although 
on average across all trials calibration appears good, there is a large amount of 
heterogeneity in calibration performance across the different trial populations.  
In particular the post D-dimer model showed stronger discriminatory performance, with the 
prediction interval for the post D-dimer model entirely above the performance indicated for 
the pre D-dimer model, as such the pre D-dimer model in its current form should not be 
considered useful for estimating patient’s risk of recurrence. Despite the short-comings of 
the current model, there would be a distinct benefit to making predictions at the time of 
stopping OAC therapy, and so future work could aim to enhance the pre D-dimer model. Of 
interest would be the performance of the pre D-dimer model should on treatment D-dimer 
measurements be included as an additional factor. To aid in such potential future work, the 
pre D-dimer is presented in full (similar to the post D-dimer model) in the appendix. In this 
way researchers could easily investigate the added value of updating the pre D-dimer model 
with predictors such as on therapy D-dimer measurements.  
APPENDIX B6: Final pre D-dimer model 
Although model performance was generally weak, it was considered important to present a 
final pre D-dimer model for future research to build on. The final model therefore used the 
data from all trials, and estimated predictor effects and the baseline hazard, with a random-
effect on the baseline hazard to allow for trial differences. 
A description, performance and sensitivity analyses of the final model are now presented.  
Specification and parameter estimates 
The pre D-dimer model was fitted to the whole dataset, with the candidate predictors for 
patient age, gender, treatment duration and site of index event (distal DVT, proximal DVT 
and PE) considered. A random-effects model on the baseline hazard was estimated using a 
FP model with 3d.f. on the proportional hazards scale. The MFP algorithm was used to 
perform predictor selection as described previously (see section 3.2.6); subsequently only 
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gender and site of index event were selected for inclusion in the final pre D-dimer model. 
The estimated hazard ratios for included predictors remained similar to those seen 
throughout the IECV cycles as expected (see Table 0.11). Patient’s gender and site of index 
event had large hazard ratios consistent with the literature (40, 196, 272). Male gender was 
associated with an almost 80% increase in recurrence rate compared to females (HR=1.79, 
95% CI: 1.33, 2.41), while proximal DVT and PE were associated with around a six-fold 
increase in recurrence rate compared to patients with a first distal DVT (see Table 0.11). 
Table 0.11 - Final specification and estimates for the pre D-dimer model after fitted to all trial data, with a random effect 
on the baseline hazard 
Predictor 
Beta coefficient (95% 
CI) 
Hazard ratio (95% 
CI) 
P-value 
Gender       
Male 0.58 (0.29, 0.88) 1.79 (1.33, 2.41) < 0.001 
Site of index 
event       
Proximal DVT 1.82 (0.76, 2.88) 6.17 (2.13, 17.86) 0.001 
PE 1.71 (0.64, 2.79) 5.55 (1.9, 16.23) 0.002 
 
To make predictions from the model, the following equation is required 
Equation 0.1 - Equation to predict probability of recurrence free survival at time t  
1()  1*()234(£B) 
where for the pre D-dimer model,  within Equation 0.1 is the risk score which is equal to 
Equation 0.2 - Risk score equation for the pre D-dimer model 
  (0.58	 × e98/9S		gR!9) + (1.82	 × 19		SjR!	klm) + (1.71	 × 19		Z) 
and where S0(t) is the average baseline survival function at a specific time t, which is shown 
below in Figure 0.45 up to four years post cessation of therapy. Values of S0(t) can be read 
from the Kaplan-Meier plot at specific time points (see Figure 0.45), as presented in Table 
0.12 for six months, one, two and three years post cessation of therapy. 
Equation 0.1 allows the prediction of a recurrence free survival probability at a particular 
time point after cessation of therapy, meaning that the probability of recurrence by a 
specific time point, R(t), is equal to; 
p() = 1 − 1() 
Table 0.12 - Baseline (recurrence free) survival at particular time points to combine with patient specific predictor values 
for individual risk prediction (Pre D-dimer model) 
Model 
predictor 
Time from cessation of therapy 
6 months 1 year 2 years 3 years 





Figure 0.45 - Average baseline (recurrence free) survival function (S0(t)) for the pre D-dimer model 
The apparent calibration of the predicted probability of recurrence to the observed 
probabilities (Kaplan-Meier estimates) within this whole trial dataset appeared under visual 
inspection to calibrate well up to four years from cessation of therapy (see Figure 0.46). This 
is expected, as the model is estimated on the same dataset, so the apparent calibration is 
naturally a good fit. 
The probability of recurrence over time from cessation of therapy varies across the risk 
spectrum, illustrating what happens to individuals at the edges of the risk spectrum (46). It 
can be seen that individuals in the 90th centile of the distribution of the prognostic index 
having higher probability of recurrence compared to those in the 10th centile of the 
prognostic index (see Figure 0.47). However, the range of discrimination for the model 
appears to be limited, with little gap between some centiles, which corresponds with the 
discrimination statistics observed during model development (see section 0).  This is 
expected, as the IECV showed the discrimination is low, with the average C-statistic of 0.56 
across all cycles (see Figure 0.40). The superior discrimination in the post D-dimer model 
compared to the pre D-dimer model is illustrated by far larger separation in the centiles of 




Figure 0.46 - Calibration of the pre D-dimer model fit to all trial data 
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Model checking & sensitivity analyses 
The final model above was checked in terms of proportional hazards assumptions, functional 
form of continuous predictors (non-linear trends), outliers, leverage, interactions and time-
dependent effects. There was no evidence of any concerns, and no indication that the model 
could be improved or modified in regard these aspects. None of the predictors had missing 
observations (see Table 0.3), and as such a sensitivity analysis using multiple imputation was 
not required. Sensitivity analyses showed no requirement for the addition of interaction or 
time dependent effects to the model. 
Summary 
The final pre D-dimer model proposed in the appendix contained site of index event and 
gender as predictors. It forms a starting point for individual recurrence risk prediction at the 
time of stopping therapy, to help inform immediate decisions on the need for extended 
therapy. However throughout the IECV approach and through external validation of the final 
model, the performance of the model was rather poor in terms of discrimination and there 
was heterogeneity in calibration performance across populations. Thus the pre D-dimer 
model should not currently be recommended for use in practice, and needs improving. One 
way the model performance may be improved is through the inclusion of more candidate 
predictors, which may better explain individuals risk and the variation between patients. As 
such future work may look to investigate the addition of D-dimer measurements taken on 
therapy as an additional predictor. D-dimer has been shown to be predictive of recurrence 




APPENDIX B7: Sensitivity analysis on D-dimer assays 
A small sensitivity analysis was conducted to crudely assess the impact of differences in the 
continuous scale of D-dimer assays on the predicted risk of recurrent VTE from the post D-
dimer model. Assuming that there could be a potential discrepancy of up to 10% in D-dimer 
values across assays, the change in predicted risk of recurrence was assessed using example 
patients with true D-dimer values at the 25th, 50th and 75th percentiles of the distribution 
of D-dimer values within the RVTE population. All other predictor values were forced to be 
constant in the model for the predictions. These were varied by 10% either greater or lower, 
and the resulting predicted survival probabilities were plotted over time (see Table 0.13 and 
Figure 0.48 and Figure 0.49 and Figure 0.50). The figures show very little difference in 
predicted recurrence free survival, indicating that in practice a similar treatment decision 
would be made regardless of such a discrepancy in D-dimer measurements.  
Table 0.13 - Values of log D-dimer used in post D-dimer model to assess 10% change in D-dimer value 
Values of Log(D-dimer) used in the post D-
dimer model 
Percentile of the 
dataset 
25th 50th 75th 
D-dimer 10% lower 247.5 375.75 672.3 
Log (D-dimer) 10% lower 5.51 5.93 6.51 
D-dimer 275 417.5 747 
Log (D-dimer) 5.55 6.03 6.62 
 D-dimer 10% higher 302.5 459.25 821.7 





Figure 0.48 - Predicted recurrence free survival for the 25th percentile of D-dimer values & 10% change in D-dimer values 
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APPENDIX C: Chapter 4 Appendices 
APPENDIX C1: Validation performance 
Performance of developed model in validation studies 
Discrimination performance 
Forest plots showing the meta-analysis of the developed models performance across the 












Forest plots showing the meta-analysis of the developed models performance across the 
validations studies is presented below for the Expected minus Observed statistic at time 
points including 6 months, and 1 to 6 years from surgery. The expected values describe the 
predicted survival probabilities from the model, while the observed values give the true 













Performance of recalibrated model 
Random effects meta-analysis plots are given below showing model performance at external 




Figure 0.51 - Random effects meta-analysis of discrimination performance (C-statistics) of the model in all validation 




Figure 0.52 - Random effects meta-analysis of calibration performance (E-O at 3 years post-surgery) of the model in all 




APPENDIX C2: Stata code 
Code for recalibration methods 
The below is an excerpt of Stata 14 code showing how the model was fitted and then 
recalibrated for each method, it does not detail the process of calculating the performance 
statistics and 95% confidence intervals relating to each method as this was done using 
standard bootstrapping methods, looping across all validation studies (labo==`j' ). 
// load and set up data and run developed model 
clear 
use BCdata, replace 
// drop out unknown aduj trt patients, & T4 tumour sizes 
 
drop if adjuv==1 
drop if pt==4 
 
// set up data as time-to-event 
stset dfs, f(dfsi==1) scale(12) exit(time 72) 
 
// Developed model in rotterdam derivation data 
xi: stpm2 age i.pt i.np i.post2 i.adjuv if labo==1,  all df(3) 
scale(h) eform 
 
// predict the linear predictor (for method 3) 
predict LP, xbnobaseline 
 
*************************************************** ***************** 
// save knots to ensure the same in model on extern al data 
global bhknots `e(bhknots)' 
global boundknots `e(boundary_knots)' 
 
// build up constraints 
local consval 1 
foreach v in `e(varlist)' { 
 constraint `consval' _b[`v'] = `=_b[`v']' 
 local ++consval 
} 
 
foreach v in `e(rcsterms_base)' { 
 constraint `consval' _b[`v'] = `=_b[`v']' 
 local ++consval 
} 
 
constraint `consval' _b[_cons] = `=_b[_cons]' 
 








// make model predictions directly from fitted deve lopment model 
above 
predict xb_mean`j' if labo==`j', meansurv 
 
*************************************************** ***************** 
// METHOD 1 
 
// fit model allowing intercept to be re-estimated 
qui stpm2 age _Ipt_2 _Ipt_3 _Inp_1 _Inp_2 _Inp_3 _I post2_1 _Iadjuv_2  
if labo==`j', all /// 





// METHOD 2 
 
// fit model allowing intercept & baseline hazard s hape to be re-
estimated 
qui stpm2 age _Ipt_2 _Ipt_3 _Inp_1 _Inp_2 _Inp_3 _I post2_1 _Iadjuv_2  
if labo==`j', all /// 





// METHOD 3 
 
// fit model allowing intercept to be re-estimated and scaling the 
original LP 
qui stpm2 LP if labo==`j', all /// 





// METHOD 4 
 
// fit model allowing intercept and heterogeneous p redictors to be 
re-estimated 
qui stpm2 age _Ipt_2 _Ipt_3 _Inp_1 _Inp_2 _Inp_3 _I post2_1 _Iadjuv_2  
if labo==`j', all /// 






Code for meta-analysis of recalibration performance 
Example random-effects meta-analysis code in Stata version 14, for synthesising C-statistics 
and E-O statistics is presented below. In the following code fragment, cstat and EmO3, 
335 
 
refer to the average c-statistic and E-O statistic from 1000 bootstrap samples, and the lci 
and uci parameters refer to the 2.5th and 97.5th percentiles of the 1000 bootstrap 
estimates respectively. 
 
metan cstat clci cuci, random name(cstat_m2, replac e) scheme(sj) /// 
  lcols(Study) astext(40) texts(150) rfdist /// 
  title("Random-effects meta-analysis of C-statisti c" 
"(Recalibration method 2)", size(medsmall)) /// 
  graphr(col(white)) xlab(0,.25,.5,.75,1) null(.5) /// 
  nowt nowarning effect(C-statistic) boxsca(150) // / 
  xtitle("C-statistic", size(small)) 
 
metan EmO3 cal3lci cal3uci, random name(EmO3_m2, re place) /// 
  scheme(sj) /// 
  lcols(Study) astext(40) texts(150) rfdist /// 
  title("Random-effects meta-analysis of E-O at 3 y ears 
post surgery" "(Recalibration method 2)", size(meds mall)) /// 
  graphr(col(white)) xlab(-.5,0,.5) null(0) /// 
  nowt nowarning effect(E-O) boxsca(150) /// 
  xtitle("Difference in model predicted and observe d 
survival probabilities", size(small)) 
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APPENDIX D: Chapter 5 Appendices 
Stata code for MIDC method 
The following code fragment defines the MIDC program as described in section 5.3. 
clear 
capture program drop midc 
program define midc, rclass 
 
/* Syntax  
  STudyvar = Name of study indicator variable (can be a 
string or number eg.author ) 
  THresholdvar = Name of threshold indicator variab le (can 
be a string or number eg.threshold value) 
  SENSitivity = Name of sensitivity variable OR nam e of new 
variable to be created to hold sensitivity  
  SPECificity = Name of specificity variable OR nam e of new 
variable to be created to hold specificity 
  COVariance = Variance-covariance structure of the  random 
effects (see help xtmelogit for further details)  
      [NB: Should be specified when 
nometa option is omitted] 
*/ 
 syntax , STudyvar(string) THresholdvar(string) 
SENSitivity(string) /// 
    SPECificity(string) IMPutations(int) 
COVariance(string) 
     
/* Create a copy of the users dataset and then crea te a template 
dataset based on the number of studies 
 and thresholds input. Merge the user and template data 
together. (This will create any missing 
 threshold rows so that the program can look for mi ssing 
values)*/ 
 
timer on 1 
 
// If convert/logitscale option is not specified th en make "yes" the 
defualt to ensure these options are 'on' 
di _n "Note: Number of imputation datasets = `imput ations'" 
di  "Note: Bivariate random-effects model fitted wi th covariance 
structure = `covariance'" 
 
tempname st1 st2 th1 th2 
 
// Create study and threshold indicators from strin g (or numerical) 
variable user inputs 
egen `st1' = group(`studyvar')  
rename `studyvar' `studyvar'_`st2' 
rename `st1' `studyvar' 
egen `th1' = group(`thresholdvar') 
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rename `thresholdvar' `thresholdvar'_`th2' 
rename `th1' `thresholdvar' 
qui save userdata, replace 
 
// Calculate number of unique studies and threshold s from the 
corresponding user given variables 
qui unique `studyvar' 
local studies = r(sum) 
 
qui unique `thresholdvar' 
local thresholds = r(sum) 
 
// Set obs of template dataset 
clear 
local obs = `studies'*`thresholds' 
qui set obs `obs' 
   
gen idnum=_n 
 
// Create a study and threshold indicator in the te mplate dataset 
qui egen `studyvar' = seq(), b(`thresholds') 
qui egen `thresholdvar' = seq(), t(`thresholds') by (`studyvar') 
 
sort `studyvar' `thresholdvar'  
qui save template, replace  
   
// Merge user data into the template 
qui merge 1:1 `studyvar' `thresholdvar' using userd ata.dta 
sort `studyvar' `thresholdvar' 
 
 
/* If the convert option is on (default) then data is transformed 
from a 2x2 table format into sensitivity  
 and specificity, missing values are imputed and th en finally 
converted back to 2x2 table format*/  
  
 
// Generate a missing values indicator variable  
 qui gen missingind=0 
 qui replace missingind=1 if tp==. 
 qui gen impind=0 
   
// Create true diseased and true non-diseased varia bles and store 
them in a vector  
 qui gen td = tp+fn 
 qui gen tnd = fp+tn 
  
 local listD = "0" 
 local listND = "0" 
 local counter = 1 
  forvalues k=1/`studies' { 
   forvalues y=1/`thresholds' { 
    if missingind[`counter']==0 { 
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     local trueD`k' = td[`counter'] 
     local trueND`k' = tnd[`counter'] 
     } 
    local counter = `counter'+1   
    } 
   local listD = "`listD',`trueD`k''" 
   local listND = "`listND',`trueND`k''" 
   } 
    
   mat truedis=(`listD') 
   mat truenondis=(`listND') 
 
// Use the vector to replace any missing true disea sed/non-diseased 
with the values for that study 
 forvalues z=1/`studies' { 
  local zp=`z'+1 
  qui replace td=truedis[1,`zp'] if missingind==1 &  
`studyvar'==`z' 
  qui replace tnd=truenondis[1,`zp'] if missingind= =1 & 
`studyvar'==`z' 
  } 
  
 // Add continuity correction (0.5) to any threshol ds with zero 
values 
qui gen td2=. 
qui gen tnd2=. 
qui gen tp2=. 
qui gen fn2=. 
qui gen tn2=. 
qui gen fp2=. 
forvalues i=1/`obs' { 
 if tp[`i']==0 | fn[`i']==0 | tn[`i']==0 | fp[`i']= =0 { 
  qui replace tp2=tp+.5 if idnum==`i' 
  qui replace fn2=fn+.5 if idnum==`i' 
  qui replace tn2=tn+.5 if idnum==`i' 
  qui replace fp2=fp+.5 if idnum==`i' 
  qui replace td2=tp2+fn2 if idnum==`i' 
  qui replace tnd2=fp2+tn2 if idnum==`i' 
  } 
 } 
  
qui replace td2=td if td2==. 
qui replace tnd2=tnd if tnd2==. 
qui replace tp2=tp if tp2==. 
qui replace fn2=fn if fn2==. 
qui replace tn2=tn if tn2==. 
qui replace fp2=fp if fp2==. 
 
/* Generate the sensitivity and specificity using t he 2x2 table 
results with any continuity  
 correction values required*/ 
  
 qui gen `sensitivity'=tp2/td2 
339 
 




/* If the meta-analysis option is on (default) then  a meta-analysis 
is performed pre-imputation 
 so that comparison can be made between estimated p ooled sens 
and spec before and after imputation*/ 




qui postfile `metaAnalysis1' thresh original_num_th resh pre_imp_sens 
pre_sens_SE pre_imp_spec pre_spec_SE pre_logit_sens  pre_logit_spec 
using `MA1', replace 
 
 forvalues b=1/`thresholds' { 
  qui count if `thresholdvar'==`b' & tp!=. 
  local dometa = r(N) 
  if `dometa'>1 { 
   capture drop n true n1 n0 true1 true0 `studyvar'  
`sensitivity' `specificity' 
  
   //Reshape the data from wide to long format 
   qui gen long n1=tp+fn 
   qui gen long n0=fp+tn 
   qui gen long true1=tp 
   qui gen long true0=tn 
   qui gen long id0001= _n 
   qui reshape long n true, i(id0001) j(sens0001) 
   qui sort id0001 sens0001 
   qui gen byte spec0001=1-sens0001 
    
   if `dometa'>5 { 
    local dometa1=5  
    } 
    else { 
     local dometa1=`dometa' 
     } 
  
   //Perform meta-analysis where more than one stud y 
reports threshold results 
   qui xtmelogit true sens0001 spec0001 if 
`thresholdvar'==`b', nocons || `studyvar': sens0001  spec0001, /// 
    nocons cov("`covariance'") binomial(n)  
refineopts(iterate(3)) intpoints(`dometa1') varianc e 
     
   local sensB = _b[sens0001] 
   local specB = _b[spec0001] 
   local sensP = (exp(`sensB'))/(1+(exp(`sensB'))) 
   local specP = (exp(`specB'))/(1+(exp(`specB'))) 
   local se1 = _se[sens0001] 
   local se2 = _se[spec0001] 
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   } 
   else { 
    qui su sens if `thresholdvar'==`b' & tp!=. 
    local sensP = r(mean) 
    qui su spec if `thresholdvar'==`b' & tp!=. 
    local specP = r(mean) 
     
    local sensB = ln(`sensP'/(1-`sensP')) 
    local specB = ln(`specP'/(1-`specP')) 
     
    qui su td if `thresholdvar'==`b' & tp!=. 
    local tdP = r(mean) 
    local se1 = (1/(`tdP'*`sensP'*(1-`sensP')))^.5 
     
    qui su tnd if `thresholdvar'==`b' & tp!=. 
    local tndP = r(mean) 
    local se2 = (1/(`tndP'*`specP'*(1-
`specP')))^.5 
    } 
   
  post `metaAnalysis1' (`b') (`dometa') (`sensP') ( `se1') 
(`specP') (`se2') (`sensB') (`specB') 
  use orgdata123, replace 
  } 
 postclose `metaAnalysis1' 
 use `MA1', replace 
 qui save MApreimpdata, replace 
  
use orgdata123, replace 
 
 
qui drop td2 
qui drop tnd2 
qui drop tp2 
qui drop tn2 
qui drop fp2 
qui drop fn2 
qui drop `sensitivity' 
qui drop `specificity' 
 
    
/* Preserve the dataset so that we can drop out stu dy data in order 
to impute missing sensitivity and 
 specificity values*/ 
 preserve 
 qui save imputation_loop_data, replace 
 
  
local m = 1 
while `m'<=`imputations' { 
 di _n "Imputing dataset `m' " _continue 
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/* Loop through the studies, dropping out all but o ne study in each 
cycle to allow analysis  
 of each study individually*/ 
 
forvalues stud=1/`studies' { 
 qui drop if `studyvar'!=`stud' 
 
 local tminus=`thresholds'-1 
  
// Cycle through the thresholds looking for those w ithout data, 
which could be imputed 
  
forvalues i=2/`tminus' { 
 if missingind[`i']==1 & impind[`i']!=1 { 
   
  local down=`i'+1 
 
/* When a threshold with missing data is found then  the program will 
cycle down the list of thresholds 
 looking for the next threshold with data and store  this data*/ 
 
  forvalues j=`down'/`thresholds' { 
   if missingind[`j']==0 { 
    local DthreshNM= `j' 
    local DtpNM= tp[`j'] 
    local DfpNM= fp[`j'] 
    continue, break 
    } 
    else if `j'==`thresholds' { 
    local DtpNM= . 
    local DfpNM= . 
    } 
   } 
 
/* The program will then cycle up the list of thres holds from the 
missing threshold, looking for 
 the next threshold with data above it and store th is data*/ 
 
  qui save looking_for_higher_thresh, replace 
  qui drop if `thresholdvar'>`i' 
   
  forvalues k= 1/`i' { 
   local real_thresh=(`i'-`k') 
   if missingind[`real_thresh']==0 { 
    local UthreshNM= `real_thresh' 
    local UtpNM = tp[`real_thresh'] 
    local UfpNM = fp[`real_thresh'] 
    continue, break 
    } 
    else if `real_thresh'==1 { 
    local UtpNM = . 
    local UfpNM = . 
    } 
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   } 
    
/* Check if there are known bounding thresholds non -missing */ 
if `DtpNM'!=. & `UtpNM'!=. { 
 
/* Calculate the necessary parameters*/ 
 
 local num_miss = `DthreshNM'-`UthreshNM'-1 
  
 if `DtpNM'<=`UtpNM' { 
  local pot_tp = `UtpNM'-`DtpNM'+1 
  local pot_fp = `UfpNM'-`DfpNM'+1 
  } 
  else if `DtpNM'>=`UtpNM' { 
   local pot_tp = `DtpNM'-`UtpNM'+1 
   local pot_fp = `DfpNM'-`UfpNM'+1 
   } 
  
 // Calculate the number of possible combinations 
 local numer_tp = `pot_tp'+`num_miss'-1 
 local pot_comb_tp = comb(`numer_tp',`num_miss') 
 
 local numer_fp = `pot_fp'+`num_miss'-1 
 local pot_comb_fp = comb(`numer_fp',`num_miss') 
  
   
/* Create matrix of possible combinations and selec t one at random 
to impute the missing TP */ 
 
 use looking_for_higher_thresh, replace 
 
// calculate random number to select combination fr om all possible 
combinations with repitition 
 
 local rand = 1+int((`pot_comb_tp'-1+1)*runiform())  
 return scalar rand_tp_`m'=`rand' 
  
 local count=0 
 
// run combination calculator program to get select ed combination 
  
 /* 
 NT = number of missing thresholds 
 KT = number of possible numbers  
 ST = starting value (upper limit) 
 RT = random combination selected 
 */ 
  
 combswrep, nt(`num_miss') kt(`pot_tp') st(`UtpNM')  rt(`rand') 
  
  
 // which thresholds to impute to 
 local thresh_1_id=`i' 
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 if `num_miss'>1 { 
  local extra=2 
  forvalues f=1/`num_miss' { 
   local thresh_`extra'_id = `i'+`f' 
   local extra = `extra'+1 
   } 
  } 
  
 forvalues g=1/`num_miss' { 
   
  qui replace tp = `r(T`g')' if 
`thresholdvar'==`thresh_`g'_id' & missingind==1 
  di "." _continue 
   
  qui replace fn = td - tp if 
`thresholdvar'==`thresh_`g'_id' & missingind==1 
  qui replace impind=1 if `thresholdvar'==`thresh_` g'_id' 
  } 
   
  qui save looking_for_higher_thresh, replace 
   
 /* Create matrix of possible combinations and sele ct one at 
random to impute the missing fp */ 
  
 // calculate random number to select combination f rom all 
possible combinations with repitition 
 
 local rand = 1+int((`pot_comb_fp'-1+1)*runiform())  
 return scalar rand_fp_`m'=`rand' 
  
 local count=0 
 
// run combination calculator program to get select ed combination 
  
 /* 
 NT = number of missing thresholds 
 KT = number of possible numbers  
 ST = starting value (upper limit) 
 RT = random combination selected 
 */ 
  
 combswrep, nt(`num_miss') kt(`pot_fp') st(`UfpNM')  rt(`rand')  
  
// which thresholds to impute to 
 local thresh_1_id=`i' 
 if `num_miss'>1 { 
  local extra=2 
  forvalues f=1/`num_miss' { 
   local thresh_`extra'_id = `i'+`f' 
   local extra = `extra'+1 
   } 




 forvalues g=1/`num_miss' { 
   
  qui replace fp = `r(T`g')' if 
`thresholdvar'==`thresh_`g'_id' & missingind==1 
     
  qui replace tn = tnd - fp if 
`thresholdvar'==`thresh_`g'_id' & missingind==1 
  qui replace impind=1 if `thresholdvar'==`thresh_` g'_id' 
   
  } 
   
  qui save looking_for_higher_thresh, replace 
   
 } // from if statement to check we have non-missin g bounding 
thresholds 
   
  use looking_for_higher_thresh, replace 
   
   } // only perform this loop if the threshold we are 
on is missing 
  
  } // cycle thresholds looking for missing thresho lds 
   
/* Save the imputed data file for this study and th en restore all 
studies data from memory so that the  
 loop can continue by imputing data for the next st udy in the 
dataset*/ 
   
 qui save imputed_study_data`stud', replace 
 restore, preserve 
 } // cycle through isolating studies to look for m issing 
thresholds within studies 
 
/* When all the studies have been looped through an d their missing 
thresholds imputed, the dataset can 
 be restored and wiped from memory*/ 
restore, not 
 
/* Append all the imputed study data files into one  complete meta-
analytic dataset, with  
 all sensitivity and specificity imputed where poss ible*/ 
 
 use imputed_study_data1, replace 
  
 if `studies'>1 { 
  forvalues a=2/`studies' { 
   qui append using imputed_study_data`a' 
   qui save imputed_dataset_data, replace 
   } 
  } 
   
/* Look through the imputed 2x2 values and correct any where the 
value should be equal to the above 
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 and below thresholds because the two surrounding t hresholds are 
also equal (only if the convert 
 option is on (by default convert is set to on)*/ 
 
preserve 
forvalues j=1/`studies' { 
 qui drop if `studyvar'!=`j' 
  
 forvalues i=1/`thresholds' { 
  if missingind[`i']==1 { 
   local TPabove = tp[`i'-1] 
   local TPbelow = tp[`i'+1] 
   if `TPabove'==`TPbelow' { 
    qui replace tp = `TPabove' if 
`thresholdvar'==`i' & missingind==1 
    } 
   local FPabove = fp[`i'-1] 
   local FPbelow = fp[`i'+1] 
   if `FPabove'==`FPbelow' { 
    qui replace fp = `FPabove' if 
`thresholdvar'==`i' & missingind==1 
    } 
   local FNabove = fn[`i'-1] 
   local FNbelow = fn[`i'+1] 
   if `FNabove'==`FNbelow' { 
    qui replace fn = `FNabove' if 
`thresholdvar'==`i' & missingind==1 
    } 
   local TNabove = tn[`i'-1] 
   local TNbelow = tn[`i'+1] 
   if `TNabove'==`TNbelow' { 
    qui replace tn = `TNabove' if 
`thresholdvar'==`i' & missingind==1 
    } 
  } 
 } 
 qui save final_study_data`j', replace 




use final_study_data1, replace 
 
if `studies'>1 { 
  forvalues a=2/`studies' { 
   qui append using final_study_data`a' 
   qui save final_imputed_threshold_dataset`m', rep lace 
   } 
  } 
 
   
/* Now calculate the sens/spec from the imputed (an d original) data. 
 Allow for continuity corrections where necessary. */ 
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// Add continuity correction (0.5) to any threshold s with zero 
values 
qui gen td2=. 
qui gen tnd2=. 
qui gen tp2=. 
qui gen fn2=. 
qui gen tn2=. 
qui gen fp2=. 
forvalues i=1/`obs' { 
 if tp[`i']==0 | fn[`i']==0 | tn[`i']==0 | fp[`i']= =0 { 
  qui replace tp2=tp+.5 if idnum==`i' 
  qui replace fn2=fn+.5 if idnum==`i' 
  qui replace tn2=tn+.5 if idnum==`i' 
  qui replace fp2=fp+.5 if idnum==`i' 
  qui replace td2=tp2+fn2 if idnum==`i' 
  qui replace tnd2=fp2+tn2 if idnum==`i' 
  } 
 } 
  
qui replace td2=td if td2==. 
qui replace tnd2=tnd if tnd2==. 
qui replace tp2=tp if tp2==. 
qui replace fn2=fn if fn2==. 
qui replace tn2=tn if tn2==. 
qui replace fp2=fp if fp2==. 
 
/* Generate the sensitivity and specificity using t he 2x2 table 
results with any continuity  
 correction values required*/ 
  
 qui gen `sensitivity'=tp2/td2 
 qui gen `specificity'=tn2/tnd2 
 
// Finally, drop out unrequired variables from fina lly dataset 
qui drop _merge 
 
qui drop td2 
qui drop tnd2 
qui drop tp2 
qui drop tn2 
qui drop fp2 
qui drop fn2 
 
 
qui save final_imputed_threshold_dataset`m', replac e 
 
/* List out number of imputations performed*/ 
  
/* Create scalars representing the number of impute d values at each 
threshold, and the total number  




local imp = 0 
 
forvalues i=1/`thresholds' { 
 qui count if `thresholdvar'==`i' & missingind==1 &  
`sensitivity'!=. 
 local imp_`i' = r(N) 
 return scalar imp_`i' = `imp_`i'' 
 local imp = `imp'+`imp_`i'' 
 } 
di _n "Total thresholds imputed = `imp'" 
return scalar imp = `imp' 
 




qui postfile `metaAnalysis2' imp_dataset thresh num ber_imputed sens 
se1 lci1 uci1 spec se2 lci2 uci2 tau1 tau2 logit1 l ogit2 conv convFE 
using `MA2', replace 
 
 forvalues b=1/`thresholds' { 
  qui count if `thresholdvar'==`b' & `sensitivity'! =. 
  local dometa = r(N) 
  return scalar dometa_`b' = `dometa' 
  if `dometa'>1 { 
   capture drop n true n1 n0 true1 true0 `studyvar'  
`sensitivity' `specificity' 
  
   //Reshape the data from wide to long format 
   qui gen long n1=tp+fn 
   qui gen long n0=fp+tn 
   qui gen long true1=tp 
   qui gen long true0=tn 
   qui gen long id0001= _n 
   qui reshape long n true, i(id0001) j(sens0001) 
   qui sort id0001 sens0001 
   qui gen byte spec0001=1-sens0001 
    
   if `dometa'>5 { 
    local dometa1=5  
    } 
    else { 
     local dometa1=`dometa' 
     } 
  
   //Perform meta-analysis where more than one stud y 
reports threshold results 
   capture qui xtmelogit true sens0001 spec0001 if 
`thresholdvar'==`b', nocons || `studyvar': sens0001  spec0001, /// 
    nocons cov("`covariance'") binomial(n)  
refineopts(iterate(3)) intpoints(`dometa1') varianc e iterate(100) 
    
   if _rc==0 { 
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    local sensB = _b[sens0001] 
    local specB = _b[spec0001] 
    local sensP = 
(exp(`sensB'))/(1+(exp(`sensB'))) 
    local specP = 
(exp(`specB'))/(1+(exp(`specB'))) 
    local se1 = _se[sens0001] 
    local se2 = _se[spec0001] 
     
    local conv = e(converged)  
    local convFE = . 
    return scalar conv`b' = `conv' 
    return scalar convFE`b' = `convFE' 
    
    qui regsave using regs1, p ci replace 
    use regs1, replace 
    
    local lci1= ci_lower[1] 
     
    local uci1= ci_upper[1] 
     
    local lci2= ci_lower[2] 
     
    local uci2= ci_upper[2] 
     
    local tau1 = coef[3] 
    local tau2 = coef[4] 
    local tau1 = exp(`tau1') 
     
    local tau2 = exp(`tau2') 
     
    } 
    else { 
     qui capture glm true sens0001 spec0001 if 
`thresholdvar'==`b', nocons family(binomial n) link (logit) 
iterate(100) 
     
     local sensB = _b[sens0001] 
     local specB = _b[spec0001] 
     local sensP = 
(exp(`sensB'))/(1+(exp(`sensB'))) 
     local specP = 
(exp(`specB'))/(1+(exp(`specB'))) 
     local se1 = _se[sens0001] 
     local se2 = _se[spec0001] 
      
     local conv = . 
     local convFE = e(converged) 
    
     qui regsave using regs1, p ci replace 
     use regs1, replace 
     
     local lci1= ci_lower[1] 
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     local uci1= ci_upper[1] 
     local lci2= ci_lower[2] 
     local uci2= ci_upper[2] 
    
     local tau1 = . 
     local tau2 = . 
    
    } 
     
   } 
   else { 
     
    qui su sens if `thresholdvar'==`b' & tp!=. 
    local sensP = r(mean) 
    qui su spec if `thresholdvar'==`b' & tp!=. 
    local specP = r(mean) 
     
    local sensB = ln(`sensP'/(1-`sensP')) 
    local specB = ln(`specP'/(1-`specP')) 
     
    qui su td if `thresholdvar'==`b' & tp!=. 
    local tdP = r(mean) 
    local se1 = (1/(`tdP'*`sensP'*(1-`sensP')))^.5 
     
    local lci1 = `sensB'-(1.96*`se1') 
     
    local uci1 = `sensB'+(1.96*`se1') 
     
    qui su tnd if `thresholdvar'==`b' & tp!=. 
    local tndP = r(mean) 
    local se2 = (1/(`tndP'*`specP'*(1-
`specP')))^.5 
     
    local lci2 = `specB'-(1.96*`se2') 
     
    local uci2 = `specB'+(1.96*`se2') 
     
    local tau1 = . 
    local tau2 = . 
     
    local conv = .  
    local convFE = . 
    } 
   
  post `metaAnalysis2' (`m') (`b') (`dometa') (`sen sP') 
(`se1') (`lci1') (`uci1') (`specP') (`se2') (`lci2' ) (`uci2') 
(`tau1') (`tau2') (`sensB') (`specB') (`conv') (`co nvFE') 
  use final_imputed_threshold_dataset`m', replace 
  } 
   
 if _rc==0 { 
  postclose `metaAnalysis2' 
  use `MA2', replace 
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  qui save MApostimpdata_`m', replace 
  } 
  
  
 qui use imputation_loop_data, replace 
 preserve 
  
 local m = `m'+1 
  
      




/* Combine the pre-imputed results with the post-im putation combined 
results*/ 
 
 use MApostimpdata_1, replace 
 
 if `imputations'>1 { 
  forvalues m1=2/`imputations' { 
   qui append using MApostimpdata_`m1' 
   qui save all_MApostimpdata, replace 
   } 
  } 
  
 
/* Combine using rubins rules */ 
 
qui gen diff_sens = . 
qui gen diffsq_sens = . 
qui gen diff_spec = . 
qui gen diffsq_spec = . 
 
 forvalues h2=1/`thresholds' { 
  qui su sens if thresh==`h2' 
  local pooled_sens_`h2' = (1/`imputations')*(r(sum )) 
   
  qui su se1 if thresh==`h2' 
  local within_sens_var_`h2' = (1/`imputations')*(r (sum)) 
   
   
   
  qui su spec if thresh==`h2' 
  local pooled_spec_`h2' = (1/`imputations')*(r(sum )) 
   
  qui su se2 if thresh==`h2' 
  local within_spec_var_`h2' = (1/`imputations')*(r (sum))  
   
   
   




  qui replace diffsq_sens = diff_sens^2 if thresh== `h2' 
   
  qui su diffsq_sens if thresh==`h2' 
  local btwn_sens_var_`h2' = (1/(`imputations'-1))* (r(sum)) 
   
   
   
  qui replace diff_spec = spec-`pooled_spec_`h2'' i f 
thresh==`h2' 
  qui replace diffsq_spec = diff_spec^2 if thresh== `h2' 
   
  qui su diffsq_spec if thresh==`h2' 
  local btwn_spec_var_`h2' = (1/(`imputations'-1))* (r(sum)) 
   
   
   
  local pooled_sens_var_`h2' = 
`within_sens_var_`h2''+((1+(1/`imputations'))*`btwn _sens_var_`h2'') 
  local pooled_spec_var_`h2' = 
`within_spec_var_`h2''+((1+(1/`imputations'))*`btwn _spec_var_`h2'') 
 
 ************************************************** ************* 
   
  qui su logit1 if thresh==`h2' 
  local pooled_logit1_`h2' = (1/`imputations')*(r(s um)) 
   
  qui su logit2 if thresh==`h2' 
  local pooled_logit2_`h2' = (1/`imputations')*(r(s um)) 
   
  qui su tau1 if thresh==`h2' 
  local pooled_tau1_`h2' = (1/`imputations')*(r(sum )) 
   
  qui su tau2 if thresh==`h2' 
  local pooled_tau2_`h2' = (1/`imputations')*(r(sum )) 
   
  qui su lci1 if thresh==`h2' 
  local pooled_lci1_`h2' = (1/`imputations')*(r(sum )) 
   
  qui su uci1 if thresh==`h2' 
  local pooled_uci1_`h2' = (1/`imputations')*(r(sum )) 
   
  qui su lci2 if thresh==`h2' 
  local pooled_lci2_`h2' = (1/`imputations')*(r(sum )) 
   
  qui su uci2 if thresh==`h2' 
  local pooled_uci2_`h2' = (1/`imputations')*(r(sum )) 
   
  qui su number_imputed if thresh==`h2' 
  local pooled_studies_`h2' = (1/`imputations')*(r( sum)) 
   
  qui su conv if thresh==`h2' 
  local pooled_conv_`h2' = (1/`imputations')*(r(sum )) 
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  qui su convFE if thresh==`h2' 
  local pooled_convFE_`h2' = (1/`imputations')*(r(s um)) 
  } 
   




qui postfile `metaAnalysis3' thresh number_imputed psens pspec pse1 
pse2 plci1 puci1 plci2 puci2 plogit1 plogit2 ptau1 ptau2 pconv 
pconvFE using `MA3', replace 
 
 forvalues b=1/`thresholds' { 
  if  sens>=0 {        
    
   local sensP = `pooled_sens_`b'' 
   return scalar sens`b' = `sensP' 
    
   local specP = `pooled_spec_`b'' 
   return scalar spec`b' = `specP' 
    
   local sensB_se = `pooled_sens_var_`b'' 
   return scalar se1`b' = `sensB_se' 
    
   local specB_se = `pooled_spec_var_`b'' 
   return scalar se2`b' = `specB_se' 
    
   local sensB = `pooled_logit1_`b'' 
   return scalar logit1`b' = `sensB' 
    
   local specB = `pooled_logit2_`b'' 
   return scalar logit2`b' = `specB' 
    
   local tau1 = `pooled_tau1_`b'' 
   return scalar tau1`b' = `tau1' 
    
   local tau2 = `pooled_tau2_`b'' 
   return scalar tau2`b' = `tau2' 
    
   local lci1 =  `pooled_lci1_`b'' 
   return scalar lci1`b' = `lci1' 
    
   local uci1 =  `pooled_uci1_`b'' 
   return scalar uci1`b' = `uci1' 
    
   local lci2 =  `pooled_lci2_`b'' 
   return scalar lci2`b' = `lci2' 
    
   local uci2 =  `pooled_uci2_`b'' 
   return scalar uci2`b' = `uci2' 
    
   local pnumber_imputed = `pooled_studies_`b'' 
   return scalar studies`b' = `pnumber_imputed' 
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   local conv = `pooled_conv_`b'' 
   return scalar conv`b' = `conv' 
    
   local convFE = `pooled_convFE_`b'' 
   return scalar convFE`b' = `convFE' 
    
   } 
   else { 
    local sensP = . 
    local specP = . 
    local sensB_se = . 
    local specB_se = . 
    local sensB = . 
    local specB = . 
    local tau1 = . 
    local tau2 = . 
    local lci1 = . 
    local uci1 = . 
    local lci2 = . 
    local uci2 = . 
    local pnumber_imputed = . 
    local conv = . 
    local convFE = . 
    
   return scalar sens`b' = `sensP' 
   return scalar spec`b' = `specP' 
   return scalar se1`b' = `sensB_se' 
   return scalar se2`b' = `specB_se' 
   return scalar logit1`b' = `sensB' 
   return scalar logit2`b' = `specB' 
   return scalar tau1`b' = `tau1' 
   return scalar tau2`b' = `tau2' 
   return scalar lci1`b' = `lci1' 
   return scalar uci1`b' = `uci1' 
   return scalar lci2`b' = `lci2' 
   return scalar uci2`b' = `uci2' 
   return scalar studies`b' = `pnumber_imputed' 
   return scalar conv`b' = `conv' 
   return scalar convFE`b' = `convFE' 
    } 
   
  qui post `metaAnalysis3' (`b') (`pnumber_imputed' ) 
(`sensP') (`specP') (`sensB_se') (`specB_se') (`lci 1') (`uci1') 
(`lci2') (`uci2') (`sensB') (`specB') (`tau1') (`ta u2') (`conv') 
(`convFE') 
  use rubins_data, replace 
  } 
 postclose `metaAnalysis3' 
 use `MA3', replace 





 /* Combine the pre-imputed results with the post-i mputation 
combined results*/ 
 
 // Merge user data into the template 
 /*qui merge 1:1 thresh using MApreimpdata.dta 
 sort thresh 
 drop _merge 
 order thresh original_num_thresh number_imputed pr e_imp_sens 
pre_imp_spec post_imp_sens post_imp_spec post_sens_ se post_spec_se 
 */ 
 qui save pooled_ma_results, replace 
  
forvalues e=1/`studies' { 
 erase final_study_data`e'.dta 




if "`MA'"=="yes" { 
 erase MApreimpdata.dta 
  forvalues e1=1/`imputations' { 
   erase MApostimpdata_`e1'.dta  
   *erase final_imputed_threshold_dataset`e1'.dta  








timer off 1 
  
qui timer list  
local prog_time = r(t1) 
local onoffs = r(nt1) 
return scalar prog_time = `prog_time'  
return scalar timer_switch = `onoffs'  
 
di _n "Program took `prog_time' seconds, for each i mputed dataset"
  
  
qui save pooled_ma_results, replace 
 





APPENDIX E: Chapter 6 Appendices 
APPENDIX E1: Base case scenarios 
Scenario 1 
Table 0.14 - Results for summary sensitivity for scenario 1 
Method Threshold No. Studies* Sensitivity Bias SE MSE LCI UCI Coverage 
NI 1 5.12 0.95 -0.007 0.68 0.46 0.83 0.98 95.87 
NI 2 5.08 0.93 -0.008 0.61 0.37 0.82 0.97 95.07 
NI 3 4.92 0.92 -0.007 0.55 0.30 0.80 0.97 96.01 
NI 4 5.01 0.90 -0.005 0.50 0.25 0.78 0.95 95.87 
NI 5 5.03 0.87 -0.005 0.44 0.20 0.75 0.94 95.74 
NI 6 5.00 0.84 -0.003 0.39 0.15 0.71 0.91 96.40 
NI 7 5.03 0.80 -0.003 0.36 0.13 0.67 0.88 96.41 
NI 8 5.03 0.75 -0.003 0.33 0.11 0.62 0.85 95.73 
NI 9 5.00 0.70 -0.002 0.31 0.10 0.56 0.81 95.35 
NI 10 4.92 0.64 0.000 0.30 0.09 0.50 0.76 95.08 
NI 11 4.99 0.58 0.004 0.29 0.08 0.44 0.71 94.81 
SI 1 5.12 0.95 -0.007 0.68 0.46 0.83 0.98 95.87 
SI 2 7.60 0.93 -0.012 0.45 0.20 0.85 0.97 92.69 
SI 3 8.79 0.91 -0.014 0.36 0.13 0.83 0.95 92.15 
SI 4 9.38 0.89 -0.013 0.32 0.10 0.81 0.94 93.22 
SI 5 9.61 0.86 -0.012 0.29 0.08 0.78 0.92 94.15 
SI 6 9.70 0.83 -0.011 0.26 0.07 0.75 0.89 95.48 
SI 7 9.60 0.79 -0.010 0.24 0.06 0.71 0.86 94.68 
SI 8 9.32 0.75 -0.010 0.23 0.05 0.65 0.82 94.95 
SI 9 8.70 0.69 -0.009 0.22 0.05 0.60 0.78 94.41 
SI 10 7.46 0.63 -0.008 0.23 0.05 0.53 0.73 94.68 
SI 11 4.99 0.58 0.004 0.29 0.08 0.44 0.71 94.81 
MIDC 1 5.12 0.95 -0.009 0.68 0.46 0.83 0.98 95.74 
MIDC 2 7.60 0.93 -0.007 0.47 0.22 0.86 0.97 94.68 
MIDC 3 8.79 0.92 -0.008 0.38 0.14 0.84 0.96 95.61 
MIDC 4 9.38 0.89 -0.008 0.32 0.10 0.82 0.94 94.95 
MIDC 5 9.61 0.87 -0.008 0.29 0.08 0.79 0.92 96.14 
MIDC 6 9.70 0.83 -0.007 0.26 0.07 0.75 0.89 95.61 
MIDC 7 9.60 0.80 -0.006 0.24 0.06 0.71 0.86 95.88 
MIDC 8 9.32 0.75 -0.005 0.23 0.05 0.66 0.82 96.01 
MIDC 9 8.70 0.70 -0.003 0.22 0.05 0.60 0.78 95.61 
MIDC 10 7.46 0.64 -0.001 0.23 0.05 0.53 0.74 95.48 





Table 0.15 - Results for summary specificity for scenario 1 
Method Threshold No. Studies* Specificity Bias SE MSE LCI UCI Coverage 
NI 1 5.12 0.57 0.000 0.09 0.01 0.52 0.61 95.47 
NI 2 5.08 0.64 0.001 0.10 0.01 0.59 0.68 94.14 
NI 3 4.92 0.70 0.001 0.10 0.01 0.66 0.74 94.41 
NI 4 5.01 0.76 0.001 0.11 0.01 0.71 0.79 94.80 
NI 5 5.03 0.80 0.001 0.12 0.01 0.77 0.84 94.94 
NI 6 5.00 0.85 0.001 0.13 0.02 0.81 0.88 94.41 
NI 7 5.03 0.88 -0.001 0.14 0.02 0.85 0.90 93.35 
NI 8 5.03 0.91 0.000 0.16 0.03 0.88 0.93 94.27 
NI 9 5.00 0.93 0.000 0.18 0.03 0.90 0.95 94.81 
NI 10 4.92 0.95 0.001 0.21 0.04 0.92 0.96 94.81 
NI 11 4.99 0.96 0.001 0.24 0.06 0.94 0.97 95.74 
SI 1 5.12 0.57 0.000 0.09 0.01 0.52 0.61 95.47 
SI 2 7.60 0.64 -0.001 0.08 0.01 0.60 0.67 95.08 
SI 3 8.79 0.70 -0.001 0.07 0.01 0.67 0.73 95.35 
SI 4 9.38 0.75 -0.001 0.08 0.01 0.73 0.78 94.41 
SI 5 9.61 0.80 -0.001 0.08 0.01 0.78 0.83 94.81 
SI 6 9.70 0.84 -0.001 0.09 0.01 0.82 0.87 94.41 
SI 7 9.60 0.88 -0.001 0.10 0.01 0.86 0.90 92.95 
SI 8 9.32 0.91 0.000 0.11 0.01 0.89 0.92 94.41 
SI 9 8.70 0.93 0.000 0.13 0.02 0.91 0.94 94.68 
SI 10 7.46 0.95 0.001 0.16 0.03 0.93 0.96 94.55 
SI 11 4.99 0.96 0.001 0.24 0.06 0.94 0.97 95.74 
MIDC 1 5.12 0.57 -0.001 0.09 0.01 0.52 0.61 95.35 
MIDC 2 7.60 0.63 -0.001 0.08 0.01 0.60 0.67 94.55 
MIDC 3 8.79 0.70 -0.004 0.07 0.01 0.66 0.72 92.69 
MIDC 4 9.38 0.75 -0.005 0.07 0.01 0.72 0.78 92.02 
MIDC 5 9.61 0.80 -0.006 0.08 0.01 0.77 0.82 92.42 
MIDC 6 9.70 0.84 -0.006 0.09 0.01 0.82 0.86 92.29 
MIDC 7 9.60 0.87 -0.005 0.10 0.01 0.85 0.89 91.76 
MIDC 8 9.32 0.90 -0.004 0.11 0.01 0.88 0.92 92.55 
MIDC 9 8.70 0.93 -0.003 0.13 0.02 0.91 0.94 92.95 
MIDC 10 7.46 0.94 -0.001 0.16 0.03 0.93 0.96 93.62 













Sensitivity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.15 0.95 -0.005 0.83 0.68 0.80 0.98 96.09 0.25 0.00 
NI 2 5.13 0.94 -0.002 0.73 0.54 0.79 0.98 97.27 0.21 0.04 
NI 3 5.08 0.92 -0.001 0.66 0.43 0.78 0.97 96.61 0.22 0.03 
NI 4 4.97 0.90 -0.004 0.59 0.34 0.75 0.96 95.96 0.18 0.07 
NI 5 5.02 0.88 0.000 0.51 0.26 0.73 0.94 97.39 0.19 0.06 
NI 6 5.03 0.84 -0.004 0.45 0.20 0.69 0.92 96.61 0.18 0.07 
NI 7 4.97 0.80 -0.004 0.41 0.17 0.64 0.89 96.35 0.18 0.07 
NI 8 4.95 0.75 -0.002 0.39 0.15 0.60 0.86 97.13 0.17 0.08 
NI 9 4.93 0.70 -0.004 0.36 0.13 0.54 0.82 95.31 0.17 0.08 
NI 10 4.96 0.64 -0.005 0.34 0.11 0.48 0.76 95.18 0.15 0.10 
NI 11 4.90 0.57 -0.003 0.33 0.11 0.42 0.71 96.74 0.16 0.09 
SI 1 5.15 0.95 -0.005 0.83 0.68 0.80 0.98 96.09 0.25 0.00 
SI 2 7.62 0.93 -0.008 0.52 0.27 0.84 0.97 95.44 0.20 0.05 
SI 3 8.80 0.91 -0.010 0.42 0.17 0.83 0.96 94.27 0.18 0.07 
SI 4 9.37 0.89 -0.011 0.36 0.13 0.80 0.94 95.05 0.18 0.07 
SI 5 9.63 0.86 -0.011 0.32 0.10 0.77 0.92 95.57 0.19 0.06 
SI 6 9.67 0.83 -0.012 0.29 0.08 0.74 0.89 95.44 0.17 0.08 
SI 7 9.57 0.79 -0.013 0.27 0.07 0.69 0.86 95.18 0.18 0.07 
SI 8 9.27 0.74 -0.012 0.25 0.06 0.64 0.82 95.18 0.18 0.07 
SI 9 8.64 0.69 -0.013 0.25 0.06 0.58 0.78 94.01 0.17 0.08 
SI 10 7.44 0.63 -0.013 0.26 0.07 0.51 0.74 95.44 0.17 0.08 
SI 11 4.90 0.57 -0.003 0.33 0.11 0.42 0.71 96.74 0.16 0.09 
MIDC 1 5.15 0.95 -0.006 0.83 0.68 0.80 0.98 95.96 0.24 0.01 
MIDC 2 7.62 0.94 -0.003 0.55 0.30 0.84 0.97 96.88 0.22 0.03 
MIDC 3 8.80 0.92 -0.003 0.45 0.20 0.83 0.96 96.61 0.22 0.03 
MIDC 4 9.37 0.90 -0.005 0.38 0.14 0.81 0.95 96.61 0.22 0.03 
MIDC 5 9.63 0.87 -0.005 0.33 0.11 0.78 0.93 97.27 0.22 0.03 
MIDC 6 9.67 0.84 -0.006 0.30 0.09 0.74 0.90 97.40 0.22 0.03 
MIDC 7 9.57 0.80 -0.007 0.27 0.08 0.70 0.87 97.27 0.21 0.04 
MIDC 8 9.27 0.75 -0.006 0.26 0.07 0.64 0.83 97.14 0.20 0.05 
MIDC 9 8.64 0.70 -0.006 0.25 0.06 0.58 0.79 96.48 0.19 0.06 
MIDC 10 7.44 0.64 -0.006 0.26 0.07 0.51 0.74 96.09 0.17 0.08 











Specificity Bias SE MSE LCI UCI Coverage ¢ ¢ 
bias 
NI 1 5.15 0.57 -0.001 0.13 0.02 0.50 0.63 86.18 0.16 0.09 
NI 2 5.13 0.63 -0.001 0.13 0.02 0.57 0.69 88.80 0.16 0.09 
NI 3 5.08 0.70 0.000 0.14 0.02 0.64 0.75 90.49 0.16 0.09 
NI 4 4.97 0.76 0.000 0.15 0.02 0.70 0.80 89.19 0.15 0.10 
NI 5 5.02 0.80 -0.001 0.15 0.02 0.75 0.84 89.31 0.15 0.10 
NI 6 5.03 0.84 -0.002 0.16 0.03 0.80 0.88 89.18 0.14 0.11 
NI 7 4.97 0.88 0.000 0.18 0.03 0.84 0.91 91.13 0.14 0.11 
NI 8 4.95 0.91 0.000 0.19 0.04 0.87 0.93 92.70 0.13 0.12 
NI 9 4.93 0.93 0.000 0.22 0.05 0.89 0.95 93.10 0.13 0.12 
NI 10 4.96 0.94 0.000 0.24 0.06 0.91 0.96 93.36 0.14 0.11 
NI 11 4.90 0.96 0.000 0.28 0.08 0.93 0.97 93.47 0.14 0.11 
SI 1 5.15 0.57 -0.001 0.13 0.02 0.50 0.63 86.18 0.16 0.09 
SI 2 7.62 0.63 -0.002 0.11 0.01 0.58 0.68 90.76 0.18 0.07 
SI 3 8.80 0.70 -0.002 0.10 0.01 0.65 0.74 92.32 0.19 0.06 
SI 4 9.37 0.75 -0.002 0.10 0.01 0.71 0.79 92.32 0.19 0.06 
SI 5 9.63 0.80 -0.002 0.11 0.01 0.77 0.83 92.06 0.18 0.07 
SI 6 9.67 0.84 -0.001 0.11 0.01 0.81 0.87 93.10 0.17 0.08 
SI 7 9.57 0.88 -0.001 0.12 0.02 0.85 0.90 93.10 0.17 0.08 
SI 8 9.27 0.91 -0.001 0.14 0.02 0.88 0.93 93.36 0.16 0.09 
SI 9 8.64 0.93 0.000 0.16 0.02 0.90 0.95 93.23 0.16 0.09 
SI 10 7.44 0.94 0.000 0.19 0.04 0.92 0.96 93.62 0.16 0.09 
SI 11 4.90 0.96 0.000 0.28 0.08 0.93 0.97 93.47 0.14 0.11 
MIDC 1 5.15 0.57 -0.002 0.13 0.02 0.50 0.63 86.07 0.16 0.09 
MIDC 2 7.62 0.63 -0.003 0.12 0.01 0.58 0.68 92.19 0.20 0.05 
MIDC 3 8.80 0.70 -0.004 0.11 0.01 0.65 0.74 93.75 0.23 0.02 
MIDC 4 9.37 0.75 -0.005 0.11 0.01 0.71 0.79 93.75 0.23 0.02 
MIDC 5 9.63 0.80 -0.005 0.12 0.01 0.76 0.83 92.84 0.23 0.02 
MIDC 6 9.67 0.84 -0.005 0.12 0.02 0.81 0.87 92.06 0.23 0.02 
MIDC 7 9.57 0.87 -0.004 0.13 0.02 0.84 0.90 92.58 0.22 0.03 
MIDC 8 9.27 0.90 -0.004 0.14 0.02 0.88 0.92 92.97 0.21 0.04 
MIDC 9 8.64 0.93 -0.002 0.16 0.03 0.90 0.94 93.62 0.20 0.05 
MIDC 10 7.44 0.94 -0.001 0.19 0.04 0.92 0.96 93.36 0.18 0.07 













Sensitivity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.12 0.95 -0.006 0.84 0.70 0.79 0.98 96.16 0.26 0.24 
NI 2 5.09 0.93 -0.008 0.76 0.57 0.77 0.98 93.63 0.27 0.23 
NI 3 5.12 0.92 -0.007 0.66 0.44 0.76 0.97 95.76 0.27 0.23 
NI 4 5.00 0.89 -0.010 0.60 0.35 0.74 0.95 92.56 0.26 0.24 
NI 5 5.05 0.87 -0.009 0.54 0.29 0.71 0.94 92.97 0.28 0.22 
NI 6 4.99 0.83 -0.008 0.48 0.24 0.67 0.92 94.42 0.28 0.22 
NI 7 5.06 0.79 -0.007 0.46 0.21 0.62 0.89 92.72 0.32 0.18 
NI 8 5.03 0.75 -0.009 0.42 0.18 0.58 0.86 92.19 0.31 0.19 
NI 9 4.97 0.70 -0.007 0.40 0.16 0.52 0.82 92.58 0.31 0.19 
NI 10 4.90 0.63 -0.009 0.39 0.15 0.46 0.78 93.24 0.32 0.18 
NI 11 4.94 0.58 -0.002 0.37 0.14 0.41 0.73 91.11 0.29 0.21 
SI 1 5.12 0.95 -0.006 0.84 0.70 0.79 0.98 96.16 0.26 0.24 
SI 2 7.60 0.93 -0.012 0.53 0.28 0.83 0.97 92.85 0.24 0.26 
SI 3 8.81 0.91 -0.014 0.43 0.18 0.82 0.96 91.26 0.26 0.24 
SI 4 9.36 0.89 -0.017 0.37 0.14 0.79 0.94 89.14 0.27 0.23 
SI 5 9.60 0.86 -0.017 0.34 0.11 0.76 0.92 92.32 0.29 0.21 
SI 6 9.66 0.82 -0.017 0.31 0.10 0.72 0.89 90.86 0.32 0.18 
SI 7 9.59 0.79 -0.017 0.30 0.09 0.67 0.86 91.92 0.34 0.16 
SI 8 9.32 0.74 -0.018 0.28 0.08 0.62 0.83 91.92 0.34 0.16 
SI 9 8.68 0.68 -0.017 0.28 0.08 0.56 0.79 92.32 0.35 0.15 
SI 10 7.41 0.63 -0.014 0.30 0.09 0.49 0.75 92.05 0.34 0.16 
SI 11 4.94 0.58 -0.002 0.37 0.14 0.41 0.73 91.11 0.29 0.21 
MIDC 1 5.12 0.95 -0.006 0.84 0.70 0.79 0.98 96.16 0.26 0.24 
MIDC 2 7.60 0.93 -0.006 0.57 0.32 0.83 0.97 96.29 0.28 0.22 
MIDC 3 8.81 0.92 -0.007 0.46 0.21 0.82 0.96 94.57 0.31 0.19 
MIDC 4 9.36 0.89 -0.009 0.40 0.16 0.80 0.94 94.44 0.32 0.18 
MIDC 5 9.60 0.87 -0.009 0.36 0.13 0.77 0.92 93.64 0.33 0.17 
MIDC 6 9.66 0.83 -0.010 0.33 0.11 0.73 0.90 94.17 0.35 0.15 
MIDC 7 9.59 0.79 -0.010 0.31 0.09 0.68 0.87 94.44 0.36 0.14 
MIDC 8 9.32 0.75 -0.010 0.29 0.08 0.63 0.83 94.30 0.36 0.14 
MIDC 9 8.68 0.69 -0.009 0.29 0.08 0.57 0.79 94.44 0.36 0.14 
MIDC 10 7.41 0.63 -0.007 0.30 0.09 0.49 0.75 93.51 0.35 0.15 











Specificity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.12 0.57 -0.001 0.21 0.04 0.47 0.66 83.84 0.39 0.11 
NI 2 5.09 0.63 -0.002 0.21 0.04 0.54 0.72 83.80 0.38 0.12 
NI 3 5.12 0.69 -0.004 0.21 0.04 0.60 0.77 83.82 0.37 0.13 
NI 4 5.00 0.75 -0.004 0.21 0.05 0.67 0.82 83.67 0.36 0.14 
NI 5 5.05 0.80 -0.003 0.22 0.05 0.72 0.86 86.47 0.38 0.12 
NI 6 4.99 0.84 -0.003 0.23 0.05 0.77 0.89 84.86 0.35 0.15 
NI 7 5.06 0.88 -0.002 0.24 0.06 0.82 0.92 86.62 0.35 0.15 
NI 8 5.03 0.90 -0.002 0.25 0.06 0.85 0.94 85.83 0.33 0.17 
NI 9 4.97 0.93 -0.002 0.27 0.07 0.88 0.95 85.83 0.32 0.18 
NI 10 4.90 0.94 -0.002 0.29 0.09 0.90 0.96 88.33 0.30 0.20 
NI 11 4.94 0.96 -0.002 0.35 0.12 0.92 0.97 90.58 0.45 0.05 
SI 1 5.12 0.57 -0.001 0.21 0.04 0.47 0.66 83.84 0.39 0.11 
SI 2 7.60 0.63 -0.002 0.18 0.03 0.55 0.71 87.81 0.43 0.07 
SI 3 8.81 0.70 -0.003 0.17 0.03 0.62 0.76 88.21 0.44 0.06 
SI 4 9.36 0.75 -0.003 0.17 0.03 0.69 0.81 88.61 0.44 0.06 
SI 5 9.60 0.80 -0.003 0.17 0.03 0.74 0.85 89.01 0.44 0.06 
SI 6 9.66 0.84 -0.002 0.17 0.03 0.79 0.88 89.01 0.43 0.07 
SI 7 9.59 0.88 -0.002 0.18 0.03 0.83 0.91 88.34 0.42 0.08 
SI 8 9.32 0.90 -0.002 0.19 0.04 0.87 0.93 90.20 0.41 0.09 
SI 9 8.68 0.93 -0.002 0.21 0.04 0.89 0.95 88.34 0.39 0.11 
SI 10 7.41 0.94 -0.002 0.24 0.06 0.91 0.96 90.07 0.36 0.14 
SI 11 4.94 0.96 -0.002 0.35 0.12 0.92 0.97 90.58 0.45 0.05 
MIDC 1 5.12 0.57 -0.001 0.21 0.04 0.47 0.66 83.84 0.38 0.12 
MIDC 2 7.60 0.63 -0.002 0.18 0.03 0.55 0.71 88.87 0.43 0.07 
MIDC 3 8.81 0.69 -0.005 0.17 0.03 0.62 0.76 89.27 0.45 0.05 
MIDC 4 9.36 0.75 -0.006 0.17 0.03 0.68 0.81 90.07 0.45 0.05 
MIDC 5 9.60 0.80 -0.006 0.17 0.03 0.74 0.85 90.60 0.45 0.05 
MIDC 6 9.66 0.84 -0.006 0.18 0.03 0.79 0.88 89.93 0.46 0.04 
MIDC 7 9.59 0.87 -0.005 0.19 0.03 0.83 0.91 89.93 0.45 0.05 
MIDC 8 9.32 0.90 -0.005 0.19 0.04 0.86 0.93 90.46 0.44 0.06 
MIDC 9 8.68 0.92 -0.004 0.21 0.04 0.89 0.95 89.93 0.42 0.08 
MIDC 10 7.41 0.94 -0.003 0.24 0.06 0.91 0.96 90.73 0.37 0.13 




APPENDIX E2: Missing not at random 
Scenario 7 
Table 0.20 - Results for summary sensitivity for scenario 7 
Method Threshold No. Studies* Sensitivity Bias SE MSE LCI UCI Coverage 
NI 1 5.20 0.95 -0.005 0.67 0.46 0.84 0.98 96.66 
NI 2 5.19 0.94 -0.005 0.61 0.37 0.83 0.98 96.27 
NI 3 5.44 0.92 0.001 0.54 0.29 0.82 0.97 97.69 
NI 4 6.26 0.91 0.012 0.46 0.22 0.82 0.96 96.53 
NI 5 6.95 0.90 0.022 0.40 0.16 0.81 0.95 94.86 
NI 6 7.30 0.87 0.023 0.34 0.11 0.77 0.92 93.06 
NI 7 7.27 0.83 0.028 0.31 0.09 0.73 0.90 90.62 
NI 8 6.96 0.79 0.033 0.29 0.08 0.68 0.86 88.95 
NI 9 6.52 0.74 0.034 0.28 0.08 0.62 0.82 89.33 
NI 10 6.06 0.67 0.029 0.27 0.08 0.55 0.77 90.73 
NI 11 5.67 0.60 0.026 0.27 0.07 0.48 0.72 93.06 
SI 1 5.20 0.95 -0.005 0.67 0.46 0.84 0.98 96.66 
SI 2 7.69 0.93 -0.009 0.45 0.20 0.85 0.97 93.96 
SI 3 8.97 0.92 -0.007 0.37 0.14 0.84 0.96 94.60 
SI 4 9.61 0.90 -0.003 0.33 0.11 0.83 0.94 95.12 
SI 5 9.82 0.87 -0.001 0.29 0.08 0.80 0.92 94.73 
SI 6 9.87 0.84 -0.001 0.26 0.07 0.76 0.90 93.32 
SI 7 9.83 0.80 0.000 0.24 0.06 0.72 0.87 93.06 
SI 8 9.60 0.76 0.002 0.23 0.05 0.67 0.83 92.42 
SI 9 9.13 0.70 0.003 0.22 0.05 0.61 0.78 93.83 
SI 10 8.05 0.65 0.007 0.22 0.05 0.55 0.74 93.44 
SI 11 5.67 0.60 0.026 0.27 0.07 0.48 0.72 93.06 
MIDC 1 5.20 0.95 -0.005 0.67 0.46 0.84 0.98 96.66 
MIDC 2 7.69 0.94 -0.004 0.47 0.22 0.86 0.97 97.30 
MIDC 3 8.97 0.92 -0.003 0.38 0.15 0.85 0.96 96.66 
MIDC 4 9.61 0.90 -0.001 0.33 0.11 0.83 0.94 96.14 
MIDC 5 9.82 0.88 0.001 0.29 0.09 0.80 0.92 94.47 
MIDC 6 9.87 0.84 0.001 0.26 0.07 0.76 0.90 94.09 
MIDC 7 9.83 0.80 0.002 0.24 0.06 0.72 0.87 93.83 
MIDC 8 9.60 0.76 0.004 0.23 0.05 0.67 0.83 93.70 
MIDC 9 9.13 0.71 0.007 0.22 0.05 0.61 0.79 93.96 
MIDC 10 8.05 0.65 0.011 0.22 0.05 0.55 0.74 93.83 






Table 0.21 - Results for summary specificity for scenario 7 
Method Threshold No. Studies* Specificity Bias SE MSE LCI UCI Coverage 
NI 1 5.20 0.57 0.001 0.09 0.01 0.52 0.61 94.73 
NI 2 5.19 0.64 0.000 0.10 0.01 0.59 0.68 94.86 
NI 3 5.44 0.70 0.005 0.10 0.01 0.66 0.74 93.06 
NI 4 6.26 0.76 0.007 0.10 0.01 0.73 0.79 92.93 
NI 5 6.95 0.81 0.005 0.10 0.01 0.78 0.84 93.96 
NI 6 7.30 0.85 0.002 0.10 0.01 0.82 0.87 94.60 
NI 7 7.27 0.88 0.001 0.12 0.01 0.85 0.90 95.12 
NI 8 6.96 0.91 0.002 0.13 0.02 0.88 0.93 94.99 
NI 9 6.52 0.93 0.001 0.16 0.02 0.91 0.95 95.24 
NI 10 6.06 0.95 0.001 0.19 0.03 0.92 0.96 95.50 
NI 11 5.67 0.96 0.000 0.22 0.05 0.94 0.97 95.63 
SI 1 5.20 0.57 0.001 0.09 0.01 0.52 0.61 94.73 
SI 2 7.69 0.63 -0.001 0.07 0.01 0.60 0.67 95.12 
SI 3 8.97 0.70 0.000 0.07 0.01 0.67 0.73 95.37 
SI 4 9.61 0.76 0.000 0.07 0.01 0.73 0.78 95.37 
SI 5 9.82 0.80 0.000 0.08 0.01 0.78 0.83 94.86 
SI 6 9.87 0.85 0.000 0.09 0.01 0.82 0.87 95.63 
SI 7 9.83 0.88 0.000 0.10 0.01 0.86 0.90 95.50 
SI 8 9.60 0.91 0.000 0.11 0.01 0.89 0.92 95.76 
SI 9 9.13 0.93 0.000 0.13 0.02 0.91 0.94 95.37 
SI 10 8.05 0.94 0.000 0.16 0.02 0.93 0.96 95.12 
SI 11 5.67 0.96 0.000 0.22 0.05 0.94 0.97 95.63 
MIDC 1 5.20 0.57 0.001 0.09 0.01 0.52 0.61 94.73 
MIDC 2 7.69 0.63 -0.001 0.07 0.01 0.60 0.67 94.34 
MIDC 3 8.97 0.70 -0.001 0.07 0.01 0.67 0.73 93.70 
MIDC 4 9.61 0.75 -0.002 0.07 0.01 0.73 0.78 93.32 
MIDC 5 9.82 0.80 -0.002 0.08 0.01 0.78 0.83 93.44 
MIDC 6 9.87 0.84 -0.002 0.09 0.01 0.82 0.86 94.99 
MIDC 7 9.83 0.88 -0.002 0.10 0.01 0.86 0.90 94.60 
MIDC 8 9.60 0.90 -0.002 0.11 0.01 0.88 0.92 94.34 
MIDC 9 9.13 0.93 -0.002 0.13 0.02 0.91 0.94 94.73 
MIDC 10 8.05 0.94 -0.001 0.15 0.02 0.93 0.96 94.86 














Sensitivity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.20 0.95 -0.002 0.86 0.75 0.80 0.99 97.69 0.27 -0.02 
NI 2 5.28 0.94 0.001 0.74 0.55 0.80 0.98 97.05 0.22 0.03 
NI 3 5.74 0.93 0.006 0.65 0.42 0.80 0.97 97.30 0.24 0.01 
NI 4 6.28 0.92 0.015 0.57 0.33 0.79 0.96 97.56 0.28 -0.03 
NI 5 6.84 0.90 0.022 0.47 0.22 0.78 0.95 97.05 0.24 0.01 
NI 6 7.20 0.87 0.026 0.40 0.16 0.75 0.93 96.02 0.22 0.03 
NI 7 7.16 0.83 0.031 0.36 0.13 0.71 0.91 93.58 0.22 0.03 
NI 8 6.94 0.79 0.035 0.34 0.12 0.66 0.87 92.94 0.21 0.04 
NI 9 6.59 0.74 0.035 0.33 0.11 0.60 0.84 92.04 0.22 0.03 
NI 10 6.06 0.68 0.037 0.33 0.11 0.53 0.79 91.91 0.22 0.03 
NI 11 5.72 0.61 0.031 0.32 0.10 0.46 0.74 92.17 0.22 0.03 
SI 1 5.20 0.95 -0.002 0.86 0.75 0.80 0.99 97.69 0.27 -0.02 
SI 2 7.73 0.94 -0.005 0.54 0.29 0.84 0.97 95.25 0.23 0.02 
SI 3 9.00 0.92 -0.004 0.44 0.19 0.83 0.96 95.38 0.23 0.02 
SI 4 9.54 0.90 -0.001 0.39 0.15 0.81 0.95 95.64 0.25 0.00 
SI 5 9.78 0.87 0.000 0.34 0.12 0.78 0.93 96.28 0.24 0.01 
SI 6 9.84 0.84 0.000 0.31 0.09 0.75 0.90 95.51 0.24 0.01 
SI 7 9.79 0.80 0.001 0.28 0.08 0.70 0.87 96.28 0.23 0.02 
SI 8 9.59 0.76 0.001 0.26 0.07 0.65 0.84 95.64 0.22 0.03 
SI 9 9.09 0.71 0.003 0.25 0.06 0.59 0.79 94.61 0.21 0.04 
SI 10 7.97 0.65 0.010 0.26 0.07 0.53 0.76 94.09 0.21 0.04 
SI 11 5.72 0.61 0.031 0.32 0.10 0.46 0.74 92.17 0.22 0.03 
MIDC 1 5.20 0.95 -0.003 0.86 0.74 0.80 0.99 97.56 0.27 -0.02 
MIDC 2 7.73 0.94 0.000 0.57 0.32 0.84 0.98 97.56 0.24 0.01 
MIDC 3 9.00 0.92 0.001 0.46 0.21 0.84 0.96 96.79 0.25 0.00 
MIDC 4 9.54 0.90 0.002 0.40 0.16 0.82 0.95 97.30 0.27 -0.02 
MIDC 5 9.78 0.88 0.002 0.35 0.12 0.79 0.93 96.92 0.24 0.01 
MIDC 6 9.84 0.84 0.002 0.31 0.09 0.75 0.91 96.66 0.23 0.02 
MIDC 7 9.79 0.81 0.004 0.28 0.08 0.71 0.88 96.28 0.22 0.03 
MIDC 8 9.59 0.76 0.005 0.26 0.07 0.66 0.84 96.15 0.21 0.04 
MIDC 9 9.09 0.71 0.007 0.25 0.06 0.60 0.80 95.51 0.21 0.04 
MIDC 10 7.97 0.66 0.014 0.26 0.07 0.53 0.76 94.87 0.21 0.04 












Specificity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.20 0.57 0.002 0.13 0.02 0.51 0.63 88.43 0.18 0.07 
NI 2 5.28 0.64 0.007 0.14 0.02 0.58 0.70 90.24 0.19 0.06 
NI 3 5.74 0.71 0.010 0.14 0.02 0.65 0.76 86.65 0.19 0.06 
NI 4 6.28 0.77 0.012 0.13 0.02 0.72 0.81 88.45 0.18 0.07 
NI 5 6.84 0.81 0.010 0.13 0.02 0.77 0.85 88.58 0.16 0.09 
NI 6 7.20 0.85 0.007 0.14 0.02 0.81 0.88 90.50 0.17 0.08 
NI 7 7.16 0.88 0.004 0.15 0.02 0.85 0.91 91.66 0.17 0.08 
NI 8 6.94 0.91 0.003 0.16 0.03 0.88 0.93 93.32 0.16 0.09 
NI 9 6.59 0.93 0.002 0.19 0.03 0.90 0.95 92.94 0.16 0.09 
NI 10 6.06 0.95 0.001 0.22 0.05 0.92 0.96 93.84 0.15 0.10 
NI 11 5.72 0.96 0.001 0.26 0.07 0.93 0.97 95.12 0.15 0.10 
SI 1 5.20 0.57 0.002 0.13 0.02 0.51 0.63 88.43 0.18 0.07 
SI 2 7.73 0.64 0.002 0.11 0.01 0.59 0.69 91.01 0.20 0.05 
SI 3 9.00 0.70 0.001 0.11 0.01 0.65 0.74 90.76 0.20 0.05 
SI 4 9.54 0.76 0.001 0.11 0.01 0.72 0.79 91.78 0.20 0.05 
SI 5 9.78 0.81 0.001 0.11 0.01 0.77 0.84 92.81 0.19 0.06 
SI 6 9.84 0.85 0.001 0.12 0.01 0.81 0.87 93.58 0.19 0.06 
SI 7 9.79 0.88 0.000 0.13 0.02 0.85 0.90 94.09 0.19 0.06 
SI 8 9.59 0.91 0.000 0.14 0.02 0.88 0.93 93.58 0.18 0.07 
SI 9 9.09 0.93 0.000 0.15 0.02 0.91 0.95 94.99 0.17 0.08 
SI 10 7.97 0.95 0.000 0.19 0.03 0.92 0.96 94.74 0.16 0.09 
SI 11 5.72 0.96 0.001 0.26 0.07 0.93 0.97 95.12 0.15 0.10 
MIDC 1 5.20 0.57 0.002 0.13 0.02 0.51 0.63 88.32 0.17 0.08 
MIDC 2 7.73 0.64 0.002 0.12 0.01 0.58 0.69 92.30 0.22 0.03 
MIDC 3 9.00 0.70 0.001 0.11 0.01 0.65 0.74 92.43 0.23 0.02 
MIDC 4 9.54 0.76 0.000 0.11 0.01 0.71 0.79 93.32 0.23 0.02 
MIDC 5 9.78 0.80 0.000 0.12 0.01 0.77 0.84 93.45 0.22 0.03 
MIDC 6 9.84 0.84 -0.001 0.12 0.01 0.81 0.87 93.84 0.22 0.03 
MIDC 7 9.79 0.88 -0.001 0.13 0.02 0.85 0.90 94.61 0.22 0.03 
MIDC 8 9.59 0.91 -0.001 0.14 0.02 0.88 0.93 94.61 0.21 0.04 
MIDC 9 9.09 0.93 -0.001 0.16 0.03 0.90 0.95 95.25 0.20 0.05 
MIDC 10 7.97 0.94 0.000 0.19 0.03 0.92 0.96 95.12 0.18 0.07 












Sensitivity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.32 0.95 -0.005 0.84 0.71 0.79 0.98 95.07 0.28 0.22 
NI 2 5.53 0.94 -0.003 0.76 0.57 0.79 0.98 95.20 0.32 0.18 
NI 3 5.96 0.93 0.002 0.66 0.44 0.79 0.97 96.37 0.32 0.18 
NI 4 6.35 0.91 0.007 0.57 0.32 0.78 0.96 96.37 0.33 0.17 
NI 5 6.71 0.89 0.014 0.49 0.24 0.76 0.95 95.73 0.34 0.16 
NI 6 6.95 0.86 0.023 0.45 0.20 0.73 0.93 95.08 0.35 0.15 
NI 7 7.00 0.83 0.026 0.40 0.16 0.69 0.91 94.43 0.36 0.14 
NI 8 6.86 0.79 0.035 0.38 0.15 0.65 0.88 93.52 0.37 0.13 
NI 9 6.62 0.74 0.038 0.37 0.14 0.59 0.85 90.03 0.38 0.12 
NI 10 6.24 0.68 0.038 0.36 0.13 0.52 0.80 88.47 0.39 0.11 
NI 11 5.85 0.62 0.038 0.38 0.14 0.44 0.76 90.28 0.42 0.08 
SI 1 5.32 0.95 -0.005 0.84 0.71 0.79 0.98 95.07 0.28 0.22 
SI 2 7.86 0.93 -0.009 0.55 0.30 0.83 0.97 92.75 0.29 0.21 
SI 3 9.01 0.91 -0.010 0.45 0.20 0.82 0.96 91.19 0.32 0.18 
SI 4 9.54 0.89 -0.010 0.40 0.16 0.80 0.94 92.62 0.35 0.15 
SI 5 9.77 0.87 -0.009 0.36 0.13 0.77 0.92 91.97 0.35 0.15 
SI 6 9.84 0.83 -0.008 0.33 0.11 0.73 0.90 92.23 0.38 0.12 
SI 7 9.78 0.80 -0.007 0.31 0.10 0.68 0.87 93.01 0.40 0.10 
SI 8 9.59 0.75 -0.005 0.30 0.09 0.63 0.84 91.71 0.40 0.10 
SI 9 9.18 0.70 -0.003 0.29 0.08 0.57 0.80 92.75 0.40 0.10 
SI 10 8.14 0.65 0.006 0.30 0.09 0.51 0.76 92.36 0.41 0.09 
SI 11 5.85 0.62 0.038 0.38 0.14 0.44 0.76 90.28 0.42 0.08 
MIDC 1 5.32 0.95 -0.006 0.84 0.71 0.79 0.98 94.95 0.28 0.22 
MIDC 2 7.86 0.94 -0.004 0.58 0.34 0.83 0.97 96.11 0.32 0.18 
MIDC 3 9.01 0.92 -0.005 0.48 0.23 0.82 0.96 95.21 0.35 0.15 
MIDC 4 9.54 0.90 -0.005 0.41 0.17 0.80 0.95 94.82 0.36 0.14 
MIDC 5 9.77 0.87 -0.006 0.36 0.13 0.77 0.93 93.78 0.37 0.13 
MIDC 6 9.84 0.84 -0.006 0.33 0.11 0.73 0.90 93.78 0.38 0.12 
MIDC 7 9.78 0.80 -0.004 0.31 0.10 0.69 0.88 94.43 0.39 0.11 
MIDC 8 9.59 0.75 -0.001 0.30 0.09 0.64 0.84 93.91 0.39 0.11 
MIDC 9 9.18 0.70 0.003 0.29 0.08 0.58 0.80 94.30 0.39 0.11 
MIDC 10 8.14 0.65 0.011 0.30 0.09 0.51 0.77 93.26 0.40 0.10 











Specificity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.32 0.57 0.007 0.22 0.05 0.47 0.67 84.05 0.42 0.08 
NI 2 5.53 0.65 0.017 0.22 0.05 0.55 0.74 85.08 0.43 0.07 
NI 3 5.96 0.72 0.018 0.21 0.05 0.63 0.79 85.49 0.43 0.07 
NI 4 6.35 0.77 0.018 0.20 0.04 0.70 0.83 83.94 0.41 0.09 
NI 5 6.71 0.82 0.013 0.20 0.04 0.75 0.87 85.23 0.40 0.10 
NI 6 6.95 0.85 0.009 0.20 0.04 0.80 0.90 87.05 0.39 0.11 
NI 7 7.00 0.88 0.005 0.21 0.04 0.83 0.92 89.25 0.39 0.11 
NI 8 6.86 0.91 0.003 0.22 0.05 0.87 0.94 88.34 0.36 0.14 
NI 9 6.62 0.93 0.001 0.24 0.06 0.89 0.95 89.64 0.36 0.14 
NI 10 6.24 0.94 0.000 0.26 0.07 0.91 0.97 91.58 0.34 0.16 
NI 11 5.85 0.96 0.000 0.30 0.09 0.93 0.97 91.19 0.32 0.18 
SI 1 5.32 0.57 0.007 0.22 0.05 0.47 0.67 84.05 0.42 0.08 
SI 2 7.86 0.64 0.003 0.18 0.03 0.55 0.72 89.25 0.45 0.05 
SI 3 9.01 0.70 -0.001 0.17 0.03 0.62 0.76 90.41 0.45 0.05 
SI 4 9.54 0.75 -0.002 0.17 0.03 0.69 0.81 90.54 0.45 0.05 
SI 5 9.77 0.80 -0.002 0.17 0.03 0.74 0.85 89.77 0.44 0.06 
SI 6 9.84 0.84 -0.002 0.17 0.03 0.79 0.88 90.80 0.44 0.06 
SI 7 9.78 0.88 -0.002 0.18 0.03 0.83 0.91 90.16 0.43 0.07 
SI 8 9.59 0.90 -0.002 0.19 0.04 0.87 0.93 89.12 0.42 0.08 
SI 9 9.18 0.93 -0.001 0.20 0.04 0.89 0.95 89.12 0.40 0.10 
SI 10 8.14 0.94 -0.001 0.23 0.05 0.92 0.96 89.12 0.37 0.13 
SI 11 5.85 0.96 0.000 0.30 0.09 0.93 0.97 91.19 0.32 0.18 
MIDC 1 5.32 0.57 0.006 0.22 0.05 0.47 0.67 83.94 0.41 0.09 
MIDC 2 7.86 0.64 0.003 0.19 0.03 0.55 0.72 89.64 0.45 0.05 
MIDC 3 9.01 0.70 -0.001 0.18 0.03 0.62 0.77 90.54 0.46 0.04 
MIDC 4 9.54 0.75 -0.003 0.17 0.03 0.68 0.81 91.32 0.46 0.04 
MIDC 5 9.77 0.80 -0.003 0.18 0.03 0.74 0.85 90.54 0.46 0.04 
MIDC 6 9.84 0.84 -0.004 0.18 0.03 0.79 0.88 90.16 0.46 0.04 
MIDC 7 9.78 0.88 -0.004 0.18 0.03 0.83 0.91 90.54 0.45 0.05 
MIDC 8 9.59 0.90 -0.003 0.19 0.04 0.86 0.93 90.28 0.44 0.06 
MIDC 9 9.18 0.93 -0.002 0.21 0.04 0.89 0.95 90.03 0.42 0.08 
MIDC 10 8.14 0.94 -0.001 0.23 0.05 0.91 0.96 89.51 0.39 0.11 







APPENDIX E3: Unequal threshold spacing 
Scenario 12 




Sensitivity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.03 0.95 -0.011 0.86 0.73 0.79 0.99 93.58 0.22 0.28 
NI 2 5.03 0.95 -0.013 0.78 0.61 0.80 0.98 93.23 0.19 0.31 
NI 3 5.09 0.94 -0.012 0.80 0.64 0.79 0.98 92.69 0.26 0.24 
NI 4 4.97 0.93 -0.013 0.73 0.53 0.79 0.98 93.93 0.27 0.23 
NI 5 5.01 0.93 -0.010 0.70 0.49 0.77 0.97 95.01 0.26 0.24 
NI 6 5.03 0.91 -0.010 0.66 0.43 0.76 0.97 94.83 0.26 0.24 
NI 7 5.09 0.90 -0.009 0.61 0.38 0.75 0.96 93.40 0.28 0.22 
NI 8 5.00 0.88 -0.011 0.56 0.32 0.72 0.95 93.76 0.30 0.20 
NI 9 5.07 0.85 -0.009 0.51 0.26 0.70 0.93 91.62 0.27 0.23 
NI 10 5.09 0.82 -0.014 0.46 0.21 0.66 0.91 93.40 0.25 0.25 
NI 11 4.93 0.78 -0.008 0.47 0.22 0.61 0.88 92.86 0.28 0.22 
SI 1 5.03 0.95 -0.011 0.86 0.73 0.79 0.99 93.58 0.22 0.28 
SI 2 7.50 0.94 -0.016 0.57 0.33 0.85 0.98 88.24 0.18 0.32 
SI 3 8.72 0.94 -0.018 0.49 0.24 0.85 0.97 86.10 0.20 0.30 
SI 4 9.30 0.93 -0.019 0.45 0.20 0.85 0.97 85.92 0.22 0.28 
SI 5 9.57 0.92 -0.018 0.42 0.18 0.84 0.96 86.63 0.23 0.27 
SI 6 9.66 0.91 -0.018 0.40 0.16 0.82 0.95 90.37 0.26 0.24 
SI 7 9.61 0.89 -0.019 0.37 0.14 0.80 0.94 90.37 0.29 0.21 
SI 8 9.32 0.87 -0.019 0.35 0.12 0.77 0.93 91.09 0.30 0.20 
SI 9 8.75 0.84 -0.018 0.34 0.12 0.74 0.91 91.98 0.29 0.21 
SI 10 7.50 0.81 -0.015 0.36 0.13 0.69 0.89 92.51 0.29 0.21 
SI 11 4.93 0.78 -0.008 0.47 0.22 0.61 0.88 92.86 0.28 0.22 
MIDC 1 5.03 0.95 -0.011 0.86 0.73 0.79 0.99 93.58 0.22 0.28 
MIDC 2 7.50 0.95 -0.011 0.62 0.39 0.85 0.98 91.98 0.22 0.28 
MIDC 3 8.72 0.94 -0.011 0.54 0.29 0.86 0.98 91.98 0.26 0.24 
MIDC 4 9.30 0.94 -0.011 0.50 0.24 0.85 0.97 93.05 0.27 0.23 
MIDC 5 9.57 0.93 -0.011 0.46 0.21 0.84 0.97 93.58 0.29 0.21 
MIDC 6 9.66 0.91 -0.011 0.43 0.18 0.83 0.96 94.65 0.31 0.19 
MIDC 7 9.61 0.90 -0.012 0.40 0.16 0.80 0.95 94.12 0.33 0.17 
MIDC 8 9.32 0.88 -0.013 0.37 0.14 0.78 0.93 94.12 0.33 0.17 
MIDC 9 8.75 0.85 -0.012 0.35 0.12 0.74 0.92 93.58 0.31 0.19 
MIDC 10 7.50 0.82 -0.010 0.36 0.13 0.70 0.90 93.58 0.30 0.20 










Specificity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.03 0.51 0.001 0.21 0.04 0.41 0.61 86.45 0.38 0.12 
NI 2 5.03 0.54 -0.001 0.21 0.04 0.44 0.63 82.17 0.38 0.12 
NI 3 5.09 0.57 -0.002 0.21 0.04 0.47 0.66 84.85 0.39 0.11 
NI 4 4.97 0.61 0.003 0.21 0.04 0.51 0.70 84.82 0.37 0.13 
NI 5 5.01 0.65 -0.004 0.21 0.05 0.55 0.73 83.24 0.38 0.12 
NI 6 5.03 0.69 -0.003 0.21 0.05 0.60 0.77 83.24 0.38 0.12 
NI 7 5.09 0.74 0.000 0.22 0.05 0.65 0.81 86.45 0.39 0.11 
NI 8 5.00 0.78 -0.003 0.22 0.05 0.70 0.84 85.74 0.37 0.13 
NI 9 5.07 0.82 -0.003 0.23 0.05 0.74 0.87 85.20 0.38 0.12 
NI 10 5.09 0.86 -0.002 0.24 0.06 0.79 0.90 84.67 0.35 0.15 
NI 11 4.93 0.89 -0.002 0.25 0.06 0.83 0.92 86.43 0.34 0.16 
SI 1 5.03 0.51 0.001 0.21 0.04 0.41 0.61 86.45 0.38 0.12 
SI 2 7.50 0.54 0.001 0.18 0.03 0.45 0.62 88.24 0.43 0.07 
SI 3 8.72 0.57 0.000 0.17 0.03 0.49 0.65 91.80 0.45 0.05 
SI 4 9.30 0.61 0.000 0.17 0.03 0.53 0.68 90.73 0.45 0.05 
SI 5 9.57 0.65 0.000 0.16 0.03 0.58 0.72 91.44 0.45 0.05 
SI 6 9.66 0.69 0.000 0.17 0.03 0.62 0.76 91.09 0.45 0.05 
SI 7 9.61 0.74 -0.001 0.17 0.03 0.67 0.80 91.62 0.44 0.06 
SI 8 9.32 0.78 -0.001 0.17 0.03 0.72 0.83 91.62 0.44 0.06 
SI 9 8.75 0.82 -0.001 0.18 0.03 0.76 0.87 91.27 0.43 0.07 
SI 10 7.50 0.86 -0.001 0.20 0.04 0.80 0.90 88.24 0.40 0.10 
SI 11 4.93 0.89 -0.002 0.25 0.06 0.83 0.92 86.43 0.34 0.16 
MIDC 1 5.03 0.51 0.001 0.21 0.04 0.41 0.61 86.45 0.38 0.12 
MIDC 2 7.50 0.54 0.003 0.18 0.03 0.45 0.63 87.88 0.43 0.07 
MIDC 3 8.72 0.57 0.002 0.17 0.03 0.49 0.65 91.62 0.45 0.05 
MIDC 4 9.30 0.61 0.002 0.17 0.03 0.53 0.68 91.09 0.45 0.05 
MIDC 5 9.57 0.65 0.001 0.17 0.03 0.58 0.72 91.27 0.45 0.05 
MIDC 6 9.66 0.69 0.000 0.17 0.03 0.62 0.76 92.51 0.45 0.05 
MIDC 7 9.61 0.74 -0.002 0.17 0.03 0.67 0.80 93.94 0.45 0.05 
MIDC 8 9.32 0.78 -0.003 0.17 0.03 0.72 0.83 92.34 0.45 0.05 
MIDC 9 8.75 0.82 -0.003 0.18 0.03 0.76 0.87 91.44 0.44 0.06 
MIDC 10 7.50 0.86 -0.002 0.20 0.04 0.80 0.90 89.66 0.41 0.09 








APPENDIX E4: Extreme threshold spacing 
Scenario 15 




Sensitivity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.11 0.95 -0.009 0.85 0.72 0.81 0.99 94.92 0.24 0.26 
NI 2 4.97 0.95 -0.011 0.80 0.64 0.80 0.98 93.45 0.23 0.27 
NI 3 5.14 0.94 -0.009 0.81 0.65 0.79 0.98 94.60 0.25 0.25 
NI 4 5.00 0.93 -0.008 0.73 0.54 0.77 0.97 93.78 0.29 0.21 
NI 5 5.13 0.92 -0.009 0.68 0.46 0.76 0.97 96.40 0.32 0.18 
NI 6 4.95 0.73 -0.010 0.42 0.18 0.55 0.84 92.79 0.31 0.19 
NI 7 5.00 0.71 -0.010 0.39 0.15 0.54 0.83 91.64 0.28 0.22 
NI 8 4.94 0.68 -0.013 0.40 0.16 0.50 0.81 90.66 0.30 0.20 
NI 9 4.99 0.66 -0.012 0.39 0.15 0.48 0.79 92.62 0.32 0.18 
NI 10 4.91 0.62 -0.013 0.37 0.14 0.45 0.76 90.83 0.28 0.22 
NI 11 4.97 0.59 -0.008 0.37 0.14 0.42 0.73 91.49 0.31 0.19 
SI 1 5.11 0.95 -0.009 0.85 0.72 0.81 0.99 94.92 0.24 0.26 
SI 2 7.50 0.94 -0.014 0.59 0.35 0.85 0.98 89.85 0.23 0.27 
SI 3 8.76 0.93 -0.019 0.49 0.24 0.85 0.97 83.80 0.23 0.27 
SI 4 9.29 0.91 -0.023 0.42 0.18 0.82 0.96 82.98 0.28 0.22 
SI 5 9.56 0.88 -0.048 0.37 0.13 0.78 0.93 63.01 0.36 0.14 
SI 6 9.65 0.77 0.029 0.29 0.08 0.65 0.85 92.31 0.36 0.14 
SI 7 9.57 0.72 0.000 0.27 0.07 0.60 0.81 92.80 0.35 0.15 
SI 8 9.32 0.68 -0.011 0.27 0.07 0.56 0.78 92.80 0.36 0.14 
SI 9 8.74 0.65 -0.016 0.28 0.08 0.52 0.76 91.98 0.36 0.14 
SI 10 7.47 0.62 -0.016 0.29 0.09 0.48 0.74 90.67 0.34 0.16 
SI 11 4.97 0.59 -0.008 0.37 0.14 0.42 0.73 91.49 0.31 0.19 
MIDC 1 5.11 0.95 -0.011 0.85 0.72 0.81 0.99 94.76 0.23 0.27 
MIDC 2 7.50 0.95 -0.010 0.62 0.39 0.85 0.98 94.44 0.24 0.26 
MIDC 3 8.76 0.94 -0.013 0.54 0.29 0.85 0.97 90.02 0.30 0.20 
MIDC 4 9.29 0.92 -0.017 0.47 0.22 0.82 0.96 89.85 0.41 0.09 
MIDC 5 9.56 0.88 -0.042 0.41 0.17 0.78 0.94 73.81 0.49 0.01 
MIDC 6 9.65 0.77 0.034 0.31 0.10 0.65 0.86 93.45 0.43 0.07 
MIDC 7 9.57 0.72 0.006 0.28 0.08 0.60 0.81 94.93 0.37 0.13 
MIDC 8 9.32 0.69 -0.005 0.27 0.07 0.57 0.79 93.78 0.36 0.14 
MIDC 9 8.74 0.66 -0.009 0.27 0.08 0.53 0.76 93.13 0.35 0.15 
MIDC 10 7.47 0.62 -0.011 0.29 0.09 0.49 0.74 91.16 0.34 0.16 










Specificity Bias SE MSE LCI UCI Coverage ¢ ¢ bias 
NI 1 5.11 0.50 -0.005 0.20 0.04 0.41 0.60 82.62 0.37 0.13 
NI 2 4.97 0.54 0.000 0.21 0.05 0.44 0.64 85.92 0.39 0.11 
NI 3 5.14 0.58 -0.001 0.20 0.04 0.48 0.67 81.67 0.37 0.13 
NI 4 5.00 0.66 0.000 0.21 0.04 0.57 0.74 81.18 0.36 0.14 
NI 5 5.13 0.70 -0.001 0.21 0.04 0.60 0.77 83.80 0.37 0.13 
NI 6 4.95 0.91 -0.001 0.26 0.07 0.86 0.94 85.25 0.32 0.18 
NI 7 5.00 0.92 -0.003 0.27 0.07 0.87 0.95 87.21 0.34 0.16 
NI 8 4.94 0.93 -0.004 0.27 0.07 0.88 0.95 87.87 0.32 0.18 
NI 9 4.99 0.94 -0.003 0.28 0.08 0.90 0.96 86.89 0.30 0.20 
NI 10 4.91 0.94 -0.003 0.30 0.09 0.90 0.97 89.20 0.32 0.18 
NI 11 4.97 0.95 -0.002 0.31 0.10 0.92 0.97 89.03 0.31 0.19 
SI 1 5.11 0.50 -0.005 0.20 0.04 0.41 0.60 82.62 0.37 0.13 
SI 2 7.50 0.54 0.003 0.18 0.03 0.46 0.63 88.05 0.42 0.08 
SI 3 8.76 0.59 0.014 0.17 0.03 0.51 0.67 86.91 0.45 0.05 
SI 4 9.29 0.67 0.010 0.17 0.03 0.59 0.74 88.22 0.47 0.03 
SI 5 9.56 0.75 0.054 0.20 0.04 0.67 0.81 65.79 0.54 -0.04 
SI 6 9.65 0.88 -0.036 0.22 0.05 0.83 0.92 57.94 0.57 -0.07 
SI 7 9.57 0.91 -0.012 0.20 0.04 0.87 0.94 82.32 0.47 0.03 
SI 8 9.32 0.93 -0.005 0.20 0.04 0.89 0.95 88.05 0.42 0.08 
SI 9 8.74 0.94 -0.002 0.21 0.05 0.91 0.96 88.05 0.39 0.11 
SI 10 7.47 0.95 -0.002 0.24 0.06 0.92 0.96 91.65 0.37 0.13 
SI 11 4.97 0.95 -0.002 0.31 0.10 0.92 0.97 89.03 0.31 0.19 
MIDC 1 5.11 0.50 -0.006 0.20 0.04 0.41 0.60 82.49 0.36 0.14 
MIDC 2 7.50 0.54 0.003 0.18 0.03 0.46 0.63 89.20 0.43 0.07 
MIDC 3 8.76 0.59 0.011 0.17 0.03 0.51 0.67 89.53 0.45 0.05 
MIDC 4 9.29 0.66 0.001 0.18 0.03 0.58 0.73 91.16 0.47 0.03 
MIDC 5 9.56 0.73 0.038 0.20 0.04 0.65 0.80 81.34 0.54 -0.04 
MIDC 6 9.65 0.87 -0.045 0.25 0.06 0.80 0.92 56.63 0.69 -0.19 
MIDC 7 9.57 0.91 -0.016 0.23 0.05 0.86 0.94 81.51 0.56 -0.06 
MIDC 8 9.32 0.92 -0.007 0.21 0.05 0.89 0.95 88.38 0.46 0.04 
MIDC 9 8.74 0.94 -0.003 0.22 0.05 0.90 0.96 89.85 0.41 0.09 
MIDC 10 7.47 0.94 -0.002 0.24 0.06 0.91 0.96 91.98 0.38 0.12 








APPENDIX E5: Extensions 
Fewer studies - Scenario 1 




Sensitivity Bias SE MSE LCI UCI Coverage 
NI 1 2.65 0.93 -0.023 0.86 0.74 0.73 0.98 0.94 
NI 2 2.67 0.92 -0.017 0.81 0.66 0.73 0.98 0.95 
NI 3 2.53 0.90 -0.025 0.77 0.59 0.69 0.97 0.93 
NI 4 2.60 0.89 -0.016 0.69 0.48 0.69 0.96 0.95 
NI 5 2.62 0.86 -0.015 0.65 0.42 0.65 0.95 0.96 
NI 6 2.59 0.83 -0.008 0.58 0.34 0.63 0.93 0.96 
NI 7 2.55 0.79 -0.010 0.55 0.30 0.59 0.90 0.97 
NI 8 2.63 0.75 -0.011 0.50 0.25 0.54 0.87 0.96 
NI 9 2.54 0.69 -0.008 0.49 0.24 0.49 0.84 0.94 
NI 10 2.57 0.63 -0.010 0.45 0.20 0.43 0.79 0.95 
NI 11 2.56 0.58 0.005 0.44 0.19 0.39 0.75 0.98 
SI 1 2.65 0.93 -0.023 0.86 0.74 0.73 0.98 0.94 
SI 2 3.87 0.92 -0.018 0.62 0.38 0.79 0.97 0.94 
SI 3 4.40 0.90 -0.019 0.51 0.26 0.78 0.96 0.92 
SI 4 4.70 0.88 -0.017 0.45 0.20 0.77 0.95 0.94 
SI 5 4.81 0.86 -0.018 0.40 0.16 0.74 0.93 0.93 
SI 6 4.86 0.82 -0.017 0.36 0.13 0.70 0.90 0.94 
SI 7 4.84 0.79 -0.016 0.34 0.11 0.66 0.87 0.95 
SI 8 4.74 0.74 -0.017 0.32 0.10 0.61 0.84 0.95 
SI 9 4.40 0.69 -0.015 0.31 0.10 0.55 0.80 0.95 
SI 10 3.80 0.63 -0.013 0.33 0.11 0.48 0.76 0.96 
SI 11 2.56 0.58 0.005 0.44 0.19 0.39 0.75 0.98 
MIDC 1 2.65 0.93 -0.023 0.86 0.74 0.73 0.98 0.94 
MIDC 2 3.87 0.93 -0.014 0.63 0.40 0.80 0.97 0.95 
MIDC 3 4.40 0.91 -0.014 0.53 0.28 0.79 0.96 0.94 
MIDC 4 4.70 0.89 -0.014 0.45 0.21 0.77 0.95 0.96 
MIDC 5 4.81 0.86 -0.013 0.40 0.16 0.74 0.93 0.96 
MIDC 6 4.86 0.83 -0.014 0.36 0.13 0.71 0.91 0.96 
MIDC 7 4.84 0.79 -0.013 0.34 0.11 0.66 0.88 0.97 
MIDC 8 4.74 0.74 -0.012 0.32 0.10 0.61 0.84 0.95 
MIDC 9 4.40 0.69 -0.008 0.31 0.10 0.55 0.80 0.95 
MIDC 10 3.80 0.63 -0.008 0.33 0.11 0.48 0.76 0.96 









Specificity Bias SE MSE LCI UCI Coverage 
NI 1 2.65 0.57 0.001 0.14 0.02 0.50 0.63 0.96 
NI 2 2.67 0.63 -0.001 0.14 0.02 0.57 0.69 0.96 
NI 3 2.53 0.70 0.002 0.15 0.02 0.64 0.76 0.95 
NI 4 2.60 0.76 0.000 0.16 0.02 0.69 0.81 0.95 
NI 5 2.62 0.80 -0.002 0.17 0.03 0.74 0.85 0.97 
NI 6 2.59 0.84 -0.002 0.19 0.03 0.79 0.88 0.94 
NI 7 2.55 0.88 -0.001 0.21 0.04 0.83 0.91 0.94 
NI 8 2.63 0.90 -0.001 0.24 0.06 0.86 0.94 0.96 
NI 9 2.54 0.93 -0.002 0.27 0.07 0.88 0.95 0.94 
NI 10 2.57 0.94 0.000 0.31 0.09 0.90 0.97 0.96 
NI 11 2.56 0.96 -0.001 0.35 0.13 0.92 0.98 0.95 
SI 1 2.65 0.57 0.001 0.14 0.02 0.50 0.63 0.96 
SI 2 3.87 0.64 -0.001 0.11 0.01 0.59 0.68 0.94 
SI 3 4.40 0.70 0.000 0.10 0.01 0.65 0.74 0.95 
SI 4 4.70 0.75 -0.001 0.11 0.01 0.71 0.79 0.93 
SI 5 4.81 0.80 -0.001 0.11 0.01 0.77 0.84 0.96 
SI 6 4.86 0.84 -0.001 0.12 0.02 0.81 0.87 0.95 
SI 7 4.84 0.88 -0.001 0.14 0.02 0.85 0.90 0.94 
SI 8 4.74 0.91 -0.001 0.16 0.02 0.88 0.93 0.95 
SI 9 4.40 0.93 0.000 0.19 0.03 0.90 0.95 0.95 
SI 10 3.80 0.94 0.000 0.23 0.06 0.92 0.96 0.95 
SI 11 2.56 0.96 -0.001 0.35 0.13 0.92 0.98 0.95 
MIDC 1 2.65 0.57 0.001 0.14 0.02 0.50 0.63 0.96 
MIDC 2 3.87 0.64 -0.001 0.11 0.01 0.59 0.68 0.95 
MIDC 3 4.40 0.70 -0.003 0.10 0.01 0.65 0.74 0.93 
MIDC 4 4.70 0.75 -0.005 0.11 0.01 0.71 0.79 0.91 
MIDC 5 4.81 0.80 -0.006 0.11 0.01 0.76 0.83 0.92 
MIDC 6 4.86 0.84 -0.006 0.12 0.01 0.81 0.87 0.92 
MIDC 7 4.84 0.87 -0.005 0.14 0.02 0.84 0.90 0.91 
MIDC 8 4.74 0.90 -0.005 0.15 0.02 0.87 0.93 0.91 
MIDC 9 4.40 0.92 -0.003 0.18 0.03 0.90 0.95 0.94 
MIDC 10 3.80 0.94 -0.001 0.23 0.05 0.91 0.96 0.95 








Fewer studies - Scenario 2 




Sensitivity Bias SE MSE LCI UCI Coverage Tau 
Tau 
bias 
NI 1 2.78 0.94 -0.017 0.89 0.80 0.75 0.98 0.85 0.46 -0.21 
NI 2 2.85 0.93 -0.010 0.81 0.65 0.75 0.98 0.93 0.11 0.14 
NI 3 3.00 0.91 -0.013 0.72 0.51 0.73 0.97 0.93 0.13 0.12 
NI 4 3.07 0.89 -0.012 0.66 0.43 0.71 0.96 0.90 0.10 0.15 
NI 5 2.93 0.85 -0.021 0.62 0.38 0.65 0.94 0.92 0.17 0.08 
NI 6 3.08 0.83 -0.009 0.52 0.27 0.65 0.92 0.95 0.11 0.14 
NI 7 2.98 0.79 -0.012 0.53 0.28 0.59 0.90 0.95 0.17 0.08 
NI 8 2.86 0.73 -0.027 0.46 0.21 0.53 0.86 0.97 0.14 0.11 
NI 9 2.85 0.68 -0.024 0.42 0.18 0.49 0.82 0.97 0.11 0.14 
NI 10 2.90 0.62 -0.019 0.43 0.18 0.43 0.78 0.98 0.17 0.08 
NI 11 2.66 0.57 -0.009 0.42 0.18 0.37 0.74 0.95 0.12 0.13 
SI 1 2.78 0.94 -0.017 0.89 0.80 0.75 0.98 0.85 0.46 -0.21 
SI 2 3.98 0.93 -0.010 0.69 0.48 0.79 0.98 0.92 0.14 0.11 
SI 3 4.58 0.91 -0.014 0.58 0.34 0.78 0.96 0.92 0.16 0.09 
SI 4 4.83 0.89 -0.016 0.47 0.22 0.76 0.95 0.85 0.13 0.12 
SI 5 4.88 0.86 -0.018 0.43 0.18 0.73 0.93 0.92 0.15 0.10 
SI 6 4.97 0.83 -0.014 0.40 0.16 0.69 0.91 0.90 0.15 0.10 
SI 7 4.93 0.79 -0.016 0.37 0.14 0.65 0.88 0.92 0.15 0.10 
SI 8 4.83 0.74 -0.018 0.34 0.12 0.59 0.84 0.93 0.16 0.09 
SI 9 4.63 0.68 -0.019 0.34 0.11 0.53 0.80 0.93 0.16 0.09 
SI 10 4.00 0.62 -0.017 0.34 0.12 0.47 0.76 0.93 0.13 0.12 
SI 11 2.66 0.57 -0.009 0.42 0.18 0.37 0.74 0.95 0.12 0.13 
MIDC 1 2.78 0.94 -0.017 0.89 0.80 0.75 0.98 0.85 0.46 -0.21 
MIDC 2 3.98 0.93 -0.009 0.67 0.44 0.80 0.98 0.95 0.12 0.13 
MIDC 3 4.58 0.91 -0.009 0.56 0.31 0.79 0.97 0.93 0.13 0.12 
MIDC 4 4.83 0.89 -0.011 0.49 0.24 0.76 0.95 0.90 0.16 0.09 
MIDC 5 4.88 0.86 -0.014 0.44 0.19 0.73 0.93 0.93 0.16 0.09 
MIDC 6 4.97 0.83 -0.012 0.40 0.16 0.70 0.91 0.93 0.16 0.09 
MIDC 7 4.93 0.79 -0.010 0.37 0.14 0.65 0.88 0.95 0.16 0.09 
MIDC 8 4.83 0.74 -0.015 0.34 0.12 0.60 0.84 0.97 0.16 0.09 
MIDC 9 4.63 0.69 -0.016 0.34 0.11 0.53 0.80 0.97 0.17 0.08 
MIDC 10 4.00 0.63 -0.013 0.34 0.11 0.47 0.76 0.93 0.13 0.12 












Specificity Bias SE MSE LCI UCI Coverage Tau 
Tau 
bias 
NI 1 2.78 0.57 0.005 0.16 0.03 0.50 0.64 0.83 0.11 0.14 
NI 2 2.85 0.63 -0.004 0.15 0.02 0.56 0.69 0.86 0.07 0.18 
NI 3 3.00 0.70 0.003 0.16 0.03 0.63 0.76 0.86 0.11 0.14 
NI 4 3.07 0.76 0.006 0.17 0.03 0.70 0.82 0.92 0.12 0.13 
NI 5 2.93 0.80 0.000 0.19 0.04 0.74 0.85 0.90 0.12 0.13 
NI 6 3.08 0.84 -0.002 0.21 0.04 0.78 0.89 0.88 0.15 0.10 
NI 7 2.98 0.88 -0.001 0.23 0.05 0.82 0.92 0.92 0.13 0.12 
NI 8 2.86 0.90 -0.003 0.24 0.06 0.85 0.93 0.83 0.09 0.16 
NI 9 2.85 0.93 0.000 0.27 0.07 0.88 0.95 0.88 0.08 0.17 
NI 10 2.90 0.94 -0.001 0.29 0.08 0.90 0.97 0.92 0.09 0.16 
NI 11 2.66 0.96 0.002 0.38 0.15 0.92 0.98 0.93 0.13 0.12 
SI 1 2.78 0.57 0.005 0.16 0.03 0.50 0.64 0.83 0.11 0.14 
SI 2 3.98 0.64 0.002 0.13 0.02 0.58 0.69 0.92 0.12 0.13 
SI 3 4.58 0.70 0.000 0.13 0.02 0.64 0.75 0.85 0.14 0.11 
SI 4 4.83 0.76 0.000 0.14 0.02 0.70 0.80 0.92 0.17 0.08 
SI 5 4.88 0.80 -0.001 0.15 0.02 0.75 0.84 0.92 0.16 0.09 
SI 6 4.97 0.84 -0.001 0.16 0.02 0.80 0.88 0.86 0.16 0.09 
SI 7 4.93 0.88 0.000 0.17 0.03 0.84 0.91 0.92 0.16 0.09 
SI 8 4.83 0.90 -0.001 0.18 0.03 0.87 0.93 0.90 0.14 0.11 
SI 9 4.63 0.93 -0.001 0.21 0.04 0.90 0.95 0.95 0.14 0.11 
SI 10 4.00 0.94 -0.001 0.24 0.06 0.91 0.96 0.95 0.11 0.14 
SI 11 2.66 0.96 0.002 0.38 0.15 0.92 0.98 0.93 0.13 0.12 
MIDC 1 2.78 0.57 0.005 0.16 0.03 0.50 0.64 0.83 0.11 0.14 
MIDC 2 3.98 0.64 0.001 0.14 0.02 0.57 0.70 0.92 0.13 0.12 
MIDC 3 4.58 0.70 -0.001 0.14 0.02 0.64 0.75 0.88 0.15 0.10 
MIDC 4 4.83 0.75 -0.002 0.14 0.02 0.70 0.80 0.92 0.18 0.07 
MIDC 5 4.88 0.80 -0.004 0.15 0.02 0.75 0.84 0.93 0.18 0.07 
MIDC 6 4.97 0.84 -0.005 0.16 0.03 0.79 0.88 0.83 0.17 0.08 
MIDC 7 4.93 0.88 -0.003 0.17 0.03 0.83 0.91 0.90 0.17 0.08 
MIDC 8 4.83 0.90 -0.004 0.19 0.04 0.87 0.93 0.92 0.17 0.08 
MIDC 9 4.63 0.93 -0.002 0.21 0.05 0.89 0.95 0.95 0.17 0.08 
MIDC 10 4.00 0.94 -0.002 0.24 0.06 0.91 0.96 0.93 0.12 0.13 






Fewer studies - Scenario 3 




Sensitivity Bias SE MSE LCI UCI Coverage Tau 
Tau 
bias 
NI 1 3.15 0.92 -0.029 0.86 0.74 0.73 0.98 0.91 0.15 0.35 
NI 2 2.93 0.91 -0.028 0.79 0.62 0.71 0.97 0.93 0.13 0.37 
NI 3 2.89 0.90 -0.020 0.87 0.75 0.66 0.97 0.98 0.25 0.25 
NI 4 3.19 0.87 -0.029 0.62 0.38 0.68 0.95 0.89 0.13 0.37 
NI 5 3.20 0.84 -0.037 0.57 0.33 0.65 0.93 0.91 0.13 0.37 
NI 6 2.98 0.81 -0.033 0.55 0.30 0.60 0.92 0.93 0.14 0.36 
NI 7 2.94 0.77 -0.028 0.57 0.33 0.55 0.90 0.91 0.23 0.27 
NI 8 2.76 0.71 -0.049 0.58 0.33 0.48 0.85 0.83 0.24 0.26 
NI 9 3.13 0.67 -0.034 0.45 0.20 0.47 0.82 0.91 0.14 0.36 
NI 10 3.04 0.62 -0.024 0.46 0.21 0.41 0.79 0.94 0.21 0.29 
NI 11 2.85 0.53 -0.045 0.50 0.24 0.32 0.73 0.85 0.25 0.25 
SI 1 3.15 0.92 -0.029 0.86 0.74 0.73 0.98 0.91 0.15 0.35 
SI 2 4.17 0.91 -0.028 0.67 0.44 0.76 0.97 0.89 0.15 0.35 
SI 3 4.69 0.89 -0.029 0.56 0.31 0.75 0.96 0.96 0.17 0.33 
SI 4 4.91 0.87 -0.033 0.47 0.22 0.73 0.94 0.81 0.14 0.36 
SI 5 4.94 0.84 -0.036 0.43 0.18 0.70 0.92 0.87 0.14 0.36 
SI 6 4.98 0.80 -0.043 0.39 0.15 0.65 0.89 0.81 0.16 0.34 
SI 7 4.96 0.76 -0.046 0.38 0.14 0.60 0.86 0.89 0.22 0.28 
SI 8 4.83 0.72 -0.040 0.40 0.16 0.54 0.83 0.89 0.31 0.19 
SI 9 4.70 0.65 -0.049 0.37 0.13 0.48 0.79 0.91 0.28 0.22 
SI 10 4.20 0.60 -0.043 0.38 0.15 0.42 0.75 0.89 0.26 0.24 
SI 11 2.85 0.53 -0.045 0.50 0.24 0.32 0.73 0.85 0.25 0.25 
MIDC 1 3.15 0.92 -0.029 0.86 0.74 0.73 0.98 0.91 0.15 0.35 
MIDC 2 4.17 0.91 -0.026 0.66 0.44 0.76 0.97 0.89 0.14 0.36 
MIDC 3 4.69 0.90 -0.028 0.55 0.30 0.76 0.96 0.94 0.17 0.33 
MIDC 4 4.91 0.87 -0.031 0.48 0.23 0.73 0.94 0.87 0.16 0.34 
MIDC 5 4.94 0.84 -0.032 0.45 0.20 0.70 0.92 0.89 0.19 0.31 
MIDC 6 4.98 0.81 -0.036 0.41 0.17 0.66 0.90 0.87 0.19 0.31 
MIDC 7 4.96 0.77 -0.035 0.40 0.16 0.61 0.87 0.93 0.26 0.24 
MIDC 8 4.83 0.72 -0.033 0.40 0.16 0.55 0.84 0.93 0.30 0.20 
MIDC 9 4.70 0.66 -0.041 0.37 0.14 0.49 0.80 0.91 0.27 0.23 
MIDC 10 4.20 0.61 -0.036 0.39 0.15 0.43 0.76 0.93 0.27 0.23 











Specificity Bias SE MSE LCI UCI Coverage Tau 
Tau 
bias 
NI 1 3.15 0.56 -0.013 0.23 0.05 0.45 0.66 0.72 0.30 0.20 
NI 2 2.93 0.62 -0.013 0.23 0.05 0.52 0.71 0.57 0.25 0.25 
NI 3 2.89 0.68 -0.021 0.25 0.06 0.57 0.76 0.72 0.28 0.22 
NI 4 3.19 0.74 -0.011 0.24 0.06 0.65 0.82 0.74 0.28 0.22 
NI 5 3.20 0.79 -0.018 0.25 0.06 0.69 0.85 0.74 0.29 0.21 
NI 6 2.98 0.83 -0.018 0.26 0.07 0.74 0.88 0.72 0.25 0.25 
NI 7 2.94 0.86 -0.015 0.27 0.07 0.79 0.91 0.74 0.23 0.27 
NI 8 2.76 0.90 -0.007 0.34 0.12 0.83 0.94 0.74 0.27 0.23 
NI 9 3.13 0.92 -0.012 0.31 0.10 0.86 0.95 0.76 0.22 0.28 
NI 10 3.04 0.94 -0.008 0.37 0.13 0.88 0.96 0.78 0.21 0.29 
NI 11 2.85 0.96 -0.001 0.46 0.21 0.90 0.98 0.91 0.31 0.19 
SI 1 3.15 0.56 -0.013 0.23 0.05 0.45 0.66 0.72 0.30 0.20 
SI 2 4.17 0.62 -0.017 0.22 0.05 0.52 0.71 0.63 0.35 0.15 
SI 3 4.69 0.68 -0.020 0.21 0.04 0.58 0.76 0.78 0.37 0.13 
SI 4 4.91 0.74 -0.020 0.21 0.04 0.65 0.81 0.80 0.37 0.13 
SI 5 4.94 0.79 -0.016 0.22 0.05 0.71 0.85 0.80 0.36 0.14 
SI 6 4.98 0.83 -0.013 0.23 0.05 0.76 0.88 0.80 0.37 0.13 
SI 7 4.96 0.87 -0.011 0.24 0.06 0.81 0.91 0.78 0.36 0.14 
SI 8 4.83 0.90 -0.008 0.26 0.07 0.84 0.93 0.83 0.35 0.15 
SI 9 4.70 0.92 -0.008 0.27 0.08 0.87 0.95 0.80 0.32 0.18 
SI 10 4.20 0.94 -0.006 0.32 0.10 0.89 0.96 0.83 0.29 0.21 
SI 11 2.85 0.96 -0.001 0.46 0.21 0.90 0.98 0.91 0.31 0.19 
MIDC 1 3.15 0.56 -0.013 0.23 0.05 0.45 0.66 0.72 0.30 0.20 
MIDC 2 4.17 0.62 -0.015 0.22 0.05 0.52 0.71 0.67 0.35 0.15 
MIDC 3 4.69 0.68 -0.021 0.22 0.05 0.58 0.76 0.81 0.37 0.13 
MIDC 4 4.91 0.73 -0.021 0.22 0.05 0.64 0.81 0.78 0.38 0.12 
MIDC 5 4.94 0.79 -0.019 0.22 0.05 0.70 0.85 0.80 0.38 0.12 
MIDC 6 4.98 0.83 -0.017 0.23 0.05 0.76 0.88 0.78 0.39 0.11 
MIDC 7 4.96 0.87 -0.014 0.24 0.06 0.80 0.91 0.83 0.37 0.13 
MIDC 8 4.83 0.90 -0.010 0.27 0.07 0.84 0.93 0.80 0.38 0.12 
MIDC 9 4.70 0.92 -0.009 0.28 0.08 0.87 0.95 0.78 0.34 0.16 
MIDC 10 4.20 0.94 -0.007 0.33 0.11 0.89 0.96 0.81 0.32 0.18 






Increased number of MIDC imputations - Scenario 1 




Sensitivity Bias SE MSE LCI UCI Coverage 
NI 1 5.23 0.95 -0.007 0.67 0.45 0.84 0.98 0.96 
NI 2 5.03 0.93 -0.006 0.61 0.38 0.82 0.98 0.96 
NI 3 5.17 0.92 -0.006 0.53 0.28 0.81 0.97 0.96 
NI 4 5.01 0.90 -0.004 0.49 0.24 0.78 0.95 0.97 
NI 5 5.04 0.87 -0.001 0.45 0.20 0.75 0.94 0.97 
NI 6 4.96 0.84 -0.002 0.40 0.16 0.71 0.92 0.96 
NI 7 5.01 0.80 -0.003 0.36 0.13 0.67 0.88 0.96 
NI 8 4.94 0.75 -0.002 0.34 0.12 0.62 0.85 0.95 
NI 9 4.93 0.70 -0.005 0.32 0.10 0.56 0.81 0.95 
NI 10 4.97 0.64 -0.003 0.30 0.09 0.50 0.76 0.95 
NI 11 4.94 0.57 -0.004 0.29 0.08 0.44 0.70 0.95 
SI 1 5.23 0.95 -0.007 0.67 0.45 0.84 0.98 0.96 
SI 2 7.59 0.93 -0.010 0.45 0.20 0.85 0.97 0.93 
SI 3 8.83 0.91 -0.012 0.37 0.13 0.84 0.95 0.93 
SI 4 9.35 0.89 -0.012 0.32 0.10 0.82 0.94 0.92 
SI 5 9.62 0.86 -0.010 0.29 0.08 0.79 0.92 0.94 
SI 6 9.69 0.83 -0.012 0.26 0.07 0.75 0.89 0.93 
SI 7 9.56 0.79 -0.012 0.24 0.06 0.70 0.86 0.95 
SI 8 9.27 0.74 -0.013 0.23 0.05 0.65 0.82 0.94 
SI 9 8.66 0.69 -0.013 0.22 0.05 0.59 0.77 0.94 
SI 10 7.45 0.63 -0.010 0.23 0.05 0.52 0.73 0.94 
SI 11 4.94 0.57 -0.004 0.29 0.08 0.44 0.70 0.95 
MIDC 1 5.23 0.95 -0.007 0.67 0.45 0.84 0.98 0.96 
MIDC 2 7.59 0.93 -0.006 0.46 0.22 0.86 0.97 0.95 
MIDC 3 8.83 0.92 -0.007 0.38 0.14 0.84 0.96 0.95 
MIDC 4 9.35 0.89 -0.007 0.32 0.10 0.82 0.94 0.96 
MIDC 5 9.62 0.87 -0.007 0.29 0.08 0.79 0.92 0.96 
MIDC 6 9.69 0.83 -0.008 0.26 0.07 0.75 0.89 0.96 
MIDC 7 9.56 0.79 -0.008 0.24 0.06 0.71 0.86 0.97 
MIDC 8 9.27 0.75 -0.008 0.23 0.05 0.66 0.82 0.96 
MIDC 9 8.66 0.70 -0.007 0.22 0.05 0.60 0.78 0.95 
MIDC 10 7.45 0.64 -0.004 0.23 0.05 0.53 0.73 0.95 










Specificity Bias SE MSE LCI UCI Coverage 
NI 1 5.23 0.57 -0.001 0.09 0.01 0.52 0.61 0.95 
NI 2 5.03 0.63 -0.002 0.10 0.01 0.59 0.68 0.96 
NI 3 5.17 0.70 -0.001 0.10 0.01 0.66 0.74 0.95 
NI 4 5.01 0.75 -0.001 0.11 0.01 0.71 0.79 0.95 
NI 5 5.04 0.80 -0.002 0.12 0.01 0.76 0.84 0.94 
NI 6 4.96 0.85 0.000 0.13 0.02 0.81 0.88 0.96 
NI 7 5.01 0.88 0.000 0.14 0.02 0.85 0.91 0.94 
NI 8 4.94 0.91 0.000 0.16 0.03 0.88 0.93 0.94 
NI 9 4.93 0.93 0.000 0.18 0.03 0.90 0.95 0.94 
NI 10 4.97 0.94 0.000 0.21 0.04 0.92 0.96 0.95 
NI 11 4.94 0.96 0.000 0.24 0.06 0.93 0.97 0.96 
SI 1 5.23 0.57 -0.001 0.09 0.01 0.52 0.61 0.95 
SI 2 7.59 0.63 -0.003 0.07 0.01 0.60 0.67 0.97 
SI 3 8.83 0.70 -0.003 0.07 0.01 0.67 0.73 0.96 
SI 4 9.35 0.75 -0.002 0.07 0.01 0.73 0.78 0.96 
SI 5 9.62 0.80 -0.002 0.08 0.01 0.78 0.83 0.95 
SI 6 9.69 0.84 -0.002 0.09 0.01 0.82 0.86 0.95 
SI 7 9.56 0.88 -0.001 0.10 0.01 0.86 0.90 0.94 
SI 8 9.27 0.91 0.000 0.11 0.01 0.89 0.92 0.94 
SI 9 8.66 0.93 0.000 0.13 0.02 0.91 0.94 0.94 
SI 10 7.45 0.94 0.000 0.16 0.03 0.93 0.96 0.95 
SI 11 4.94 0.96 0.000 0.24 0.06 0.93 0.97 0.96 
MIDC 1 5.23 0.57 -0.001 0.09 0.01 0.52 0.61 0.95 
MIDC 2 7.59 0.63 -0.003 0.07 0.01 0.60 0.67 0.96 
MIDC 3 8.83 0.69 -0.005 0.07 0.01 0.66 0.72 0.95 
MIDC 4 9.35 0.75 -0.006 0.07 0.01 0.72 0.78 0.94 
MIDC 5 9.62 0.80 -0.007 0.08 0.01 0.77 0.82 0.91 
MIDC 6 9.69 0.84 -0.007 0.09 0.01 0.81 0.86 0.90 
MIDC 7 9.56 0.87 -0.006 0.10 0.01 0.85 0.89 0.91 
MIDC 8 9.27 0.90 -0.004 0.11 0.01 0.88 0.92 0.91 
MIDC 9 8.66 0.93 -0.003 0.13 0.02 0.91 0.94 0.93 
MIDC 10 7.45 0.94 -0.001 0.16 0.03 0.92 0.96 0.95 








Increased number of MIDC imputations - Scenario 2 




Sensitivity Bias SE MSE LCI UCI Coverage Tau 
Tau 
bias 
NI 1 5.23 0.95 -0.006 0.81 0.65 0.80 0.98 0.96 0.23 0.02 
NI 2 5.21 0.94 -0.003 0.74 0.54 0.79 0.98 0.97 0.22 0.03 
NI 3 5.11 0.92 -0.002 0.64 0.42 0.78 0.97 0.96 0.20 0.05 
NI 4 5.07 0.90 -0.005 0.57 0.33 0.75 0.96 0.94 0.20 0.05 
NI 5 5.03 0.87 -0.002 0.53 0.28 0.72 0.94 0.97 0.21 0.04 
NI 6 4.99 0.84 -0.003 0.45 0.21 0.69 0.92 0.96 0.17 0.08 
NI 7 5.02 0.80 -0.001 0.42 0.18 0.65 0.89 0.94 0.18 0.07 
NI 8 5.01 0.75 -0.001 0.38 0.14 0.60 0.86 0.95 0.16 0.09 
NI 9 5.05 0.70 -0.003 0.36 0.13 0.54 0.82 0.95 0.17 0.08 
NI 10 5.06 0.64 -0.004 0.33 0.11 0.49 0.76 0.97 0.15 0.10 
NI 11 4.95 0.58 -0.001 0.33 0.11 0.42 0.72 0.95 0.18 0.07 
SI 1 5.23 0.95 -0.006 0.81 0.65 0.80 0.98 0.96 0.23 0.02 
SI 2 7.71 0.93 -0.009 0.54 0.29 0.83 0.97 0.93 0.21 0.04 
SI 3 8.84 0.91 -0.011 0.41 0.17 0.83 0.96 0.94 0.17 0.08 
SI 4 9.38 0.89 -0.012 0.36 0.13 0.80 0.94 0.93 0.18 0.07 
SI 5 9.64 0.86 -0.013 0.32 0.10 0.77 0.92 0.93 0.18 0.07 
SI 6 9.70 0.83 -0.013 0.29 0.08 0.74 0.89 0.95 0.18 0.07 
SI 7 9.61 0.79 -0.012 0.27 0.07 0.69 0.86 0.93 0.18 0.07 
SI 8 9.36 0.74 -0.013 0.25 0.06 0.64 0.82 0.92 0.17 0.08 
SI 9 8.78 0.69 -0.012 0.25 0.06 0.58 0.78 0.94 0.17 0.08 
SI 10 7.48 0.63 -0.010 0.26 0.07 0.51 0.74 0.96 0.16 0.09 
SI 11 4.95 0.58 -0.001 0.33 0.11 0.42 0.72 0.95 0.18 0.07 
MIDC 1 5.23 0.95 -0.006 0.81 0.65 0.80 0.98 0.96 0.23 0.02 
MIDC 2 7.71 0.94 -0.004 0.56 0.31 0.84 0.97 0.97 0.23 0.02 
MIDC 3 8.84 0.92 -0.005 0.44 0.19 0.83 0.96 0.96 0.21 0.04 
MIDC 4 9.38 0.90 -0.006 0.38 0.14 0.81 0.94 0.95 0.21 0.04 
MIDC 5 9.64 0.87 -0.007 0.33 0.11 0.78 0.92 0.95 0.21 0.04 
MIDC 6 9.70 0.83 -0.007 0.30 0.09 0.74 0.90 0.96 0.21 0.04 
MIDC 7 9.61 0.80 -0.007 0.28 0.08 0.70 0.87 0.96 0.20 0.05 
MIDC 8 9.36 0.75 -0.006 0.26 0.07 0.65 0.83 0.96 0.19 0.06 
MIDC 9 8.78 0.70 -0.005 0.25 0.06 0.59 0.79 0.95 0.18 0.07 
MIDC 10 7.48 0.64 -0.004 0.26 0.07 0.52 0.74 0.96 0.17 0.08 









Specificity Bias SE MSE LCI UCI Coverage Tau 
Tau 
bias 
NI 1 5.23 0.57 -0.001 0.13 0.02 0.50 0.63 0.90 0.17 0.08 
NI 2 5.21 0.64 -0.001 0.13 0.02 0.57 0.69 0.88 0.16 0.09 
NI 3 5.11 0.70 -0.001 0.14 0.02 0.64 0.75 0.88 0.16 0.09 
NI 4 5.07 0.76 0.001 0.14 0.02 0.70 0.80 0.89 0.16 0.09 
NI 5 5.03 0.80 -0.001 0.15 0.02 0.75 0.84 0.86 0.14 0.11 
NI 6 4.99 0.85 0.000 0.17 0.03 0.80 0.88 0.88 0.15 0.10 
NI 7 5.02 0.88 -0.001 0.18 0.03 0.84 0.91 0.90 0.15 0.10 
NI 8 5.01 0.91 -0.001 0.19 0.04 0.87 0.93 0.91 0.14 0.11 
NI 9 5.05 0.93 0.000 0.22 0.05 0.89 0.95 0.94 0.15 0.10 
NI 10 5.06 0.94 0.000 0.24 0.06 0.91 0.96 0.93 0.14 0.11 
NI 11 4.95 0.96 0.000 0.28 0.08 0.93 0.97 0.96 0.16 0.09 
SI 1 5.23 0.57 -0.001 0.13 0.02 0.50 0.63 0.90 0.17 0.08 
SI 2 7.71 0.63 -0.002 0.11 0.01 0.58 0.68 0.90 0.19 0.06 
SI 3 8.84 0.70 -0.001 0.11 0.01 0.65 0.74 0.89 0.19 0.06 
SI 4 9.38 0.75 -0.001 0.11 0.01 0.71 0.79 0.90 0.19 0.06 
SI 5 9.64 0.80 -0.001 0.11 0.01 0.77 0.83 0.88 0.19 0.06 
SI 6 9.70 0.84 -0.001 0.12 0.01 0.81 0.87 0.91 0.19 0.06 
SI 7 9.61 0.88 -0.001 0.12 0.02 0.85 0.90 0.91 0.18 0.07 
SI 8 9.36 0.91 -0.001 0.14 0.02 0.88 0.93 0.92 0.17 0.08 
SI 9 8.78 0.93 0.000 0.16 0.02 0.90 0.95 0.93 0.17 0.08 
SI 10 7.48 0.94 0.000 0.19 0.04 0.92 0.96 0.94 0.16 0.09 
SI 11 4.95 0.96 0.000 0.28 0.08 0.93 0.97 0.96 0.16 0.09 
MIDC 1 5.23 0.57 -0.001 0.13 0.02 0.50 0.63 0.90 0.17 0.08 
MIDC 2 7.71 0.63 -0.002 0.12 0.01 0.58 0.68 0.92 0.21 0.04 
MIDC 3 8.84 0.70 -0.003 0.11 0.01 0.65 0.74 0.92 0.23 0.02 
MIDC 4 9.38 0.75 -0.004 0.12 0.01 0.71 0.79 0.92 0.23 0.02 
MIDC 5 9.64 0.80 -0.005 0.12 0.01 0.76 0.83 0.91 0.23 0.02 
MIDC 6 9.70 0.84 -0.005 0.13 0.02 0.80 0.87 0.91 0.24 0.01 
MIDC 7 9.61 0.87 -0.005 0.13 0.02 0.84 0.90 0.93 0.23 0.02 
MIDC 8 9.36 0.90 -0.004 0.14 0.02 0.88 0.92 0.92 0.22 0.03 
MIDC 9 8.78 0.93 -0.002 0.16 0.03 0.90 0.94 0.94 0.21 0.04 
MIDC 10 7.48 0.94 -0.001 0.19 0.04 0.92 0.96 0.94 0.18 0.07 








Increased number of MIDC imputations - Scenario 3 




Sensitivity Bias SE MSE LCI UCI Coverage Tau 
Tau 
bias 
NI 1 5.21 0.95 -0.007 0.84 0.70 0.79 0.98 0.93 0.30 0.20 
NI 2 5.04 0.93 -0.006 0.76 0.58 0.78 0.98 0.95 0.26 0.24 
NI 3 5.05 0.92 -0.007 0.66 0.43 0.77 0.97 0.95 0.25 0.25 
NI 4 5.09 0.89 -0.008 0.62 0.38 0.73 0.96 0.94 0.30 0.20 
NI 5 5.01 0.87 -0.009 0.54 0.29 0.71 0.94 0.95 0.28 0.22 
NI 6 4.95 0.84 -0.007 0.51 0.26 0.67 0.92 0.92 0.30 0.20 
NI 7 4.95 0.79 -0.008 0.45 0.20 0.63 0.89 0.93 0.30 0.20 
NI 8 5.00 0.75 -0.006 0.43 0.18 0.57 0.86 0.92 0.30 0.20 
NI 9 5.08 0.70 -0.007 0.39 0.15 0.53 0.82 0.93 0.30 0.20 
NI 10 4.99 0.63 -0.010 0.38 0.14 0.46 0.77 0.90 0.30 0.20 
NI 11 4.85 0.57 -0.007 0.37 0.13 0.40 0.72 0.90 0.28 0.22 
SI 1 5.21 0.95 -0.007 0.84 0.70 0.79 0.98 0.93 0.30 0.20 
SI 2 7.61 0.93 -0.012 0.53 0.28 0.83 0.97 0.91 0.25 0.25 
SI 3 8.82 0.91 -0.015 0.43 0.18 0.82 0.95 0.91 0.25 0.25 
SI 4 9.39 0.89 -0.015 0.38 0.14 0.79 0.94 0.93 0.29 0.21 
SI 5 9.65 0.86 -0.016 0.34 0.12 0.76 0.92 0.91 0.32 0.18 
SI 6 9.73 0.82 -0.018 0.32 0.10 0.72 0.89 0.90 0.35 0.15 
SI 7 9.62 0.78 -0.018 0.30 0.09 0.67 0.86 0.91 0.35 0.15 
SI 8 9.33 0.74 -0.018 0.29 0.08 0.62 0.83 0.91 0.36 0.14 
SI 9 8.69 0.68 -0.017 0.29 0.08 0.56 0.79 0.91 0.37 0.13 
SI 10 7.41 0.62 -0.018 0.30 0.09 0.49 0.74 0.91 0.34 0.16 
SI 11 4.85 0.57 -0.007 0.37 0.13 0.40 0.72 0.90 0.28 0.22 
MIDC 1 5.21 0.95 -0.007 0.84 0.70 0.79 0.98 0.93 0.30 0.20 
MIDC 2 7.61 0.93 -0.007 0.57 0.33 0.83 0.97 0.95 0.29 0.21 
MIDC 3 8.82 0.92 -0.008 0.46 0.21 0.82 0.96 0.94 0.30 0.20 
MIDC 4 9.39 0.89 -0.009 0.40 0.16 0.80 0.94 0.96 0.33 0.17 
MIDC 5 9.65 0.86 -0.010 0.36 0.13 0.77 0.92 0.95 0.35 0.15 
MIDC 6 9.73 0.83 -0.011 0.33 0.11 0.73 0.90 0.93 0.37 0.13 
MIDC 7 9.62 0.79 -0.011 0.30 0.09 0.68 0.87 0.93 0.37 0.13 
MIDC 8 9.33 0.75 -0.011 0.29 0.08 0.63 0.83 0.92 0.37 0.13 
MIDC 9 8.69 0.69 -0.010 0.29 0.08 0.56 0.79 0.92 0.37 0.13 
MIDC 10 7.41 0.63 -0.011 0.30 0.09 0.49 0.75 0.92 0.34 0.16 









Specificity Bias SE MSE LCI UCI Coverage Tau 
Tau 
bias 
NI 1 5.21 0.57 0.001 0.21 0.04 0.47 0.66 0.84 0.38 0.12 
NI 2 5.04 0.63 -0.003 0.21 0.04 0.53 0.72 0.82 0.38 0.12 
NI 3 5.05 0.69 -0.005 0.21 0.04 0.60 0.77 0.83 0.37 0.13 
NI 4 5.09 0.75 -0.004 0.22 0.05 0.67 0.82 0.83 0.37 0.13 
NI 5 5.01 0.80 -0.003 0.22 0.05 0.72 0.86 0.84 0.36 0.14 
NI 6 4.95 0.84 -0.003 0.23 0.05 0.77 0.89 0.85 0.35 0.15 
NI 7 4.95 0.88 -0.003 0.24 0.06 0.82 0.92 0.85 0.35 0.15 
NI 8 5.00 0.90 -0.001 0.25 0.06 0.85 0.94 0.86 0.33 0.17 
NI 9 5.08 0.93 -0.001 0.27 0.07 0.88 0.95 0.88 0.32 0.18 
NI 10 4.99 0.94 -0.002 0.29 0.08 0.90 0.96 0.86 0.30 0.20 
NI 11 4.85 0.96 -0.002 0.31 0.10 0.92 0.97 0.89 0.28 0.22 
SI 1 5.21 0.57 0.001 0.21 0.04 0.47 0.66 0.84 0.38 0.12 
SI 2 7.61 0.63 -0.002 0.18 0.03 0.55 0.71 0.86 0.42 0.08 
SI 3 8.82 0.70 -0.004 0.17 0.03 0.62 0.76 0.88 0.43 0.07 
SI 4 9.39 0.75 -0.003 0.17 0.03 0.69 0.81 0.89 0.43 0.07 
SI 5 9.65 0.80 -0.003 0.17 0.03 0.74 0.85 0.90 0.43 0.07 
SI 6 9.73 0.84 -0.003 0.17 0.03 0.79 0.88 0.90 0.43 0.07 
SI 7 9.62 0.88 -0.002 0.18 0.03 0.83 0.91 0.90 0.41 0.09 
SI 8 9.33 0.90 -0.002 0.19 0.04 0.87 0.93 0.89 0.40 0.10 
SI 9 8.69 0.93 -0.002 0.20 0.04 0.89 0.95 0.87 0.38 0.12 
SI 10 7.41 0.94 -0.001 0.24 0.06 0.91 0.96 0.90 0.36 0.14 
SI 11 4.85 0.96 -0.002 0.31 0.10 0.92 0.97 0.89 0.28 0.22 
MIDC 1 5.21 0.57 0.001 0.21 0.04 0.47 0.66 0.84 0.38 0.12 
MIDC 2 7.61 0.63 -0.002 0.18 0.03 0.55 0.71 0.88 0.43 0.07 
MIDC 3 8.82 0.69 -0.005 0.17 0.03 0.62 0.76 0.89 0.44 0.06 
MIDC 4 9.39 0.75 -0.006 0.17 0.03 0.68 0.81 0.91 0.45 0.05 
MIDC 5 9.65 0.80 -0.006 0.17 0.03 0.74 0.85 0.90 0.45 0.05 
MIDC 6 9.73 0.84 -0.006 0.18 0.03 0.79 0.88 0.90 0.45 0.05 
MIDC 7 9.62 0.87 -0.006 0.18 0.03 0.83 0.91 0.90 0.44 0.06 
MIDC 8 9.33 0.90 -0.005 0.19 0.04 0.86 0.93 0.89 0.43 0.07 
MIDC 9 8.69 0.92 -0.004 0.21 0.04 0.89 0.95 0.89 0.40 0.10 
MIDC 10 7.41 0.94 -0.002 0.24 0.06 0.91 0.96 0.90 0.37 0.13 
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